No., subject, TM-score, RMSD, Sequence Identity, Subject length, Aligned length, Description
1, 3r83A, 1.0000, 0.00, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-92
2, 3r7yA, 0.9959, 0.40, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-88
3, 3r1yA, 0.9945, 0.47, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-134
4, 4kd1A, 0.9943, 0.48, 0.993, 298, 294, CDK2 IN COMPLEX WITH DINACICLIB
5, 3r71A, 0.9942, 0.48, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-162
6, 3qx2A, 0.9942, 0.49, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-190
7, 3rpoA, 0.9936, 0.51, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-156
8, 1pxiA, 0.9935, 0.51, 1.000, 294, 294, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-(25-DICHLORO-THIOPHEN-3-YL)-PYRIMIDIN-2- YLAMINE
9, 3r8pA, 0.9933, 0.52, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC1-6
10, 1hclA, 0.9929, 0.54, 1.000, 294, 294, HUMAN CYCLIN-DEPENDENT KINASE 2
11, 1pw2A, 0.9928, 0.54, 1.000, 294, 294, APO STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2
12, 2exmA, 0.9927, 0.55, 0.993, 298, 294, HUMAN CDK2 IN COMPLEX WITH ISOPENTENYLADENINE
13, 5aneA, 0.9920, 0.57, 1.000, 294, 294, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 6-METHOXY-7H- PURINE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
14, 3r7eA, 0.9918, 0.58, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-67
15, 3qxoA, 0.9917, 0.58, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-84
16, 2b53A, 0.9917, 0.61, 1.000, 294, 294, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DIN- 234325
17, 1hckA, 0.9916, 0.59, 1.000, 294, 294, HUMAN CYCLIN-DEPENDENT KINASE 2
18, 3r7vA, 0.9912, 0.61, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-9
19, 3qqlA, 0.9911, 0.65, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR L3
20, 3qx4A, 0.9906, 0.62, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-78
21, 1pxjA, 0.9906, 0.62, 1.000, 294, 294, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YLAMINE
22, 3rm7A, 0.9905, 0.63, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-91
23, 3raiA, 0.9903, 0.63, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-160
24, 3qwjA, 0.9903, 0.63, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-142
25, 3qqfA, 0.9899, 0.65, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR L1
26, 3r1sA, 0.9895, 0.66, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-127
27, 2b54A, 0.9890, 0.69, 0.997, 298, 294, HUMAN CYCLIN DEPENDENT KINASE 2 (CKD2)COMPLEXED WITH DIN- 232305
28, 3qzhA, 0.9888, 0.69, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-124
29, 3pxrA, 0.9885, 0.71, 1.000, 294, 294, APO CDK2 CRYSTALLIZED FROM JEFFAMINE
30, 2a0cX, 0.9885, 0.69, 1.000, 294, 294, HUMAN CDK2 IN COMPLEX WITH OLOMOUCINE II A NOVEL 269- TRISUBSTITUTED PURINE CYCLIN-DEPENDENT KINASE INHIBITOR
31, 3r6xA, 0.9884, 0.71, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-158
32, 3qzfA, 0.9876, 0.72, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-52
33, 3r73A, 0.9874, 0.74, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-164
34, 3r1qA, 0.9872, 0.76, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-102
35, 1ykrA, 0.9870, 0.74, 0.997, 298, 294, CRYSTAL STRUCTURE OF CDK2 WITH AN AMINOIMIDAZO PYRIDINE INHIBITOR
36, 2clxA, 0.9869, 0.64, 0.997, 293, 293, 4-ARYLAZO-35-DIAMINO-1H-PYRAZOLE CDK INHIBITORS: SAR STUDY CRYSTAL STRUCTURE IN COMPLEX WITH CDK2 SELECTIVITY AND CELLULAR EFFECTS
37, 3qziA, 0.9868, 0.77, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-126
38, 3r8uA, 0.9862, 0.76, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR RC-1-132
39, 3royA, 0.9860, 0.80, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-154
40, 3r28A, 0.9857, 0.79, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-140
41, 2xmyA, 0.9850, 0.79, 0.993, 295, 294, DISCOVERY AND CHARACTERISATION OF 2-ANILINO-4-(THIAZOL-5-YL) PYRIMIDINE TRANSCRIPTIONAL CDK INHIBITORS AS ANTICANCER AGENTS
42, 3rm6A, 0.9845, 0.76, 1.000, 293, 293, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-80
43, 1y8yA, 0.9845, 0.60, 0.997, 292, 292, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1 5-A]PYRIMIDINE INHIBITOR
44, 3s00A, 0.9843, 0.81, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR L4-14
45, 2c69A, 0.9842, 0.61, 0.997, 292, 292, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
46, 3r8lA, 0.9841, 0.81, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR L3-4
47, 3qwkA, 0.9837, 0.87, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-150
48, 1pxpA, 0.9837, 0.83, 1.000, 294, 294, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR N-[4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]- N N -DIMETHYL-BENZENE-14-DIAMINE
49, 3ql8A, 0.9836, 0.83, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-260
50, 2v0dA, 0.9836, 0.63, 0.997, 292, 292, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
51, 3lfsA, 0.9826, 0.39, 1.000, 290, 290, CRYSTAL STRUCTURE OF CDK2 WITH SAR37 AN AMINOINDAZOLE TYPE INHIBITOR
52, 2c6kA, 0.9822, 0.68, 0.997, 292, 292, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
53, 3rk7A, 0.9818, 0.90, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR RC-2-71
54, 3qrtA, 0.9818, 0.92, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC2-55
55, 1pxoA, 0.9816, 0.90, 1.000, 294, 294, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(2-AMINO-4-METHYL-THIAZOL-5-YL)-PYRIMIDIN-2- YL]-(3-NITRO-PHENYL)-AMINE
56, 3tiyA, 0.9806, 0.84, 1.000, 293, 293, CDK2 IN COMPLEX WITH NSC 35676
57, 4fklA, 0.9804, 0.49, 1.000, 290, 290, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
58, 2vtlA, 0.9804, 0.49, 1.000, 290, 290, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
59, 3rk9A, 0.9803, 0.93, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR RC-2-74
60, 2c6lA, 0.9803, 0.63, 1.000, 291, 291, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
61, 3r8vA, 0.9802, 0.92, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR RC-1-135
62, 2r3fA, 0.9801, 0.51, 1.000, 290, 290, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
63, 2r3rA, 0.9800, 0.51, 1.000, 290, 290, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
64, 1gz8A, 0.9799, 0.51, 1.000, 290, 290, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 2-AMINO-6-(3 -METHYL-2 -OXO)BUTOXYPURINE
65, 1b38A, 0.9798, 0.52, 1.000, 290, 290, HUMAN CYCLIN-DEPENDENT KINASE 2
66, 3iggA, 0.9797, 0.52, 1.000, 290, 290, NOVEL CDK-5 INHIBITORS - CRYSTAL STRUCTURE OF INHIBITOR EFQ WITH CDK-2
67, 3qu0A, 0.9796, 0.95, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR RC-2-38
68, 3lfqA, 0.9794, 0.39, 1.000, 289, 289, CRYSTAL STRUCTURE OF CDK2 WITH SAR60 AN AMINOINDAZOLE TYPE INHIBITOR
69, 1w8cA, 0.9793, 0.54, 1.000, 290, 290, CO-CRYSTAL STRUCTURE OF 6-CYCLOHEXYLMETHOXY-8-ISOPROPYL-9H- PURIN-2-YLAMINE AND MONOMERIC CDK2
70, 3tizA, 0.9792, 0.86, 0.997, 293, 293, CDK2 IN COMPLEX WITH NSC 111848
71, 3qzgA, 0.9791, 0.95, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-76
72, 3r9hA, 0.9790, 0.96, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR RC-2-142
73, 3qtqA, 0.9790, 0.96, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR RC-1-137
74, 2ds1A, 0.9790, 0.55, 0.990, 290, 290, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
75, 2vtmA, 0.9789, 0.55, 1.000, 290, 290, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
76, 4ek5A, 0.9786, 0.42, 1.000, 289, 289, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
77, 3rk5A, 0.9785, 0.98, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR RC-2-72
78, 1b39A, 0.9783, 0.58, 1.000, 290, 290, HUMAN CYCLIN-DEPENDENT KINASE 2 PHOSPHORYLATED ON THR 160
79, 2c6iA, 0.9782, 0.80, 0.997, 292, 292, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
80, 2c5yA, 0.9779, 0.59, 1.000, 290, 290, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
81, 3qqjA, 0.9776, 0.99, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR L2
82, 3qruA, 0.9775, 1.01, 1.000, 295, 294, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC1-12
83, 5osjA, 0.9774, 0.73, 0.997, 292, 291, CDK2(WT) WITH COVALENT ADDUCT AT C177
84, 2c68A, 0.9774, 0.61, 0.997, 290, 290, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
85, 2vtrA, 0.9771, 0.62, 1.000, 290, 290, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
86, 3qqgA, 0.9767, 1.00, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR L2-5
87, 3ns9A, 0.9766, 0.51, 1.000, 289, 289, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR BS-194
88, 2r3pA, 0.9761, 0.53, 1.000, 289, 289, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
89, 2r3oA, 0.9761, 0.53, 1.000, 289, 289, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
90, 2xnbA, 0.9760, 1.02, 0.993, 296, 294, DISCOVERY AND CHARACTERISATION OF 2-ANILINO-4-(THIAZOL-5-YL) PYRIMIDINE TRANSCRIPTIONAL CDK INHIBITORS AS ANTICANCER AGENTS
91, 3r9dA, 0.9756, 1.04, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR RC-2-135
92, 2r3hA, 0.9756, 0.55, 1.000, 289, 289, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
93, 2r3iA, 0.9754, 0.56, 1.000, 289, 289, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
94, 1e1xA, 0.9752, 0.68, 1.000, 290, 290, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU6027
95, 3qtwA, 0.9749, 1.15, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR RC-2-13
96, 3rjcA, 0.9748, 1.07, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR L4-12
97, 3qqkA, 0.9745, 1.07, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR L4
98, 3qqhA, 0.9744, 1.04, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR L2-2
99, 2c6oA, 0.9743, 0.71, 0.997, 290, 290, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
100, 3qtuA, 0.9742, 1.09, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR RC-2-132
101, 3ti1A, 0.9741, 1.08, 1.000, 294, 294, CDK2 IN COMPLEX WITH SUNITINIB
102, 3rniA, 0.9740, 1.18, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR RC-3-86
103, 3qtxA, 0.9739, 1.07, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR RC-2-35
104, 2c6mA, 0.9737, 0.74, 0.997, 290, 290, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
105, 1pxlA, 0.9737, 0.73, 1.000, 290, 290, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]- (4-TRIFLUOROMETHYL-PHENYL)-AMINE
106, 1pxnA, 0.9735, 1.07, 1.000, 294, 294, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-[4-(4-METHYL-2-METHYLAMINO-THIAZOL-5-YL)- PYRIMIDIN-2-YLAMINO]-PHENOL
107, 3rpvA, 0.9733, 1.09, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR RC-2-88
108, 1pxkA, 0.9732, 0.75, 1.000, 290, 290, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR N-[4-(24-DIMETHYL-THIAZOL-5-YL)PYRIMIDIN-2-YL]- N -HYDROXYIMINOFORMAMIDE
109, 1e1vA, 0.9732, 0.74, 1.000, 290, 290, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU2058
110, 3rkbA, 0.9731, 1.18, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR RC-2-73
111, 1h0vA, 0.9731, 0.52, 1.000, 288, 288, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 2-AMINO-6-[(R)-PYRROLIDINO-5 -YL]METHOXYPURINE
112, 3pxyA, 0.9729, 1.08, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR JWS648
113, 3unkA, 0.9728, 1.09, 1.000, 295, 294, CDK2 IN COMPLEX WITH INHIBITOR YL5-083
114, 3qxpA, 0.9725, 1.18, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR RC-3-89
115, 2uzoA, 0.9725, 0.77, 0.997, 290, 290, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
116, 4ez3A, 0.9724, 1.14, 1.000, 294, 294, CDK2 IN COMPLEX WITH NSC 134199
117, 4ek4A, 0.9724, 0.39, 1.000, 287, 287, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
118, 5osmA, 0.9723, 0.55, 0.990, 292, 288, CDK2(F80C C177A) WITH COVALENT ADDUCT AT C80
119, 1jsvA, 0.9718, 0.42, 1.000, 287, 287, THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4-[(6-AMINO-4-PYRIMIDINYL) AMINO]BENZENESULFONAMIDE
120, 3qtzA, 0.9717, 1.12, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR RC-2-36
121, 3py0A, 0.9716, 1.11, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR SU9516
122, 3s0oA, 0.9713, 0.98, 0.997, 293, 292, CDK2 IN COMPLEX WITH INHIBITOR RC-1-138
123, 4fkiA, 0.9711, 0.46, 1.000, 287, 287, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
124, 4ek3A, 0.9711, 0.46, 1.000, 287, 287, CRYSTAL STRUCTURE OF APO CDK2
125, 5oo0A, 0.9708, 0.61, 1.000, 288, 288, CDK2(WT) COVALENT ADDUCT WITH D28 AT C177
126, 5mhqA, 0.9707, 0.61, 0.997, 291, 288, CCT068127 IN COMPLEX WITH CDK2
127, 5jq5A, 0.9707, 0.48, 1.000, 287, 287, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR ICEC0942
128, 2r3gA, 0.9706, 0.48, 1.000, 287, 287, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
129, 4rj3A, 0.9705, 0.51, 0.997, 287, 287, CDK2 WITH EGFR INHIBITOR COMPOUND 8
130, 1pxmA, 0.9699, 0.84, 1.000, 290, 290, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 3-[4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2- YLAMINO]-PHENOL
131, 4fkgA, 0.9678, 0.45, 1.000, 286, 286, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
132, 2a4lA, 0.9678, 0.46, 1.000, 286, 286, HUMAN CYCLIN-DEPENDENT KINASE 2 IN COMPLEX WITH ROSCOVITINE
133, 5anjA, 0.9675, 0.61, 1.000, 291, 287, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH N-(9H-PURIN-6-YL) THIOPHENE-2-CARBOXAMIDE  PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
134, 2r3qA, 0.9668, 0.50, 1.000, 286, 286, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
135, 3unjA, 0.9664, 1.22, 1.000, 294, 294, CDK2 IN COMPLEX WITH INHIBITOR YL1-038-31
136, 3r8zA, 0.9663, 0.95, 1.000, 290, 290, CDK2 IN COMPLEX WITH INHIBITOR RC-1-136
137, 4erwA, 0.9662, 1.19, 0.997, 292, 292, CDK2 IN COMPLEX WITH STAUROSPORINE
138, 1oirA, 0.9658, 0.56, 0.997, 286, 286, IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
139, 1h01A, 0.9657, 0.56, 1.000, 286, 286, CDK2 IN COMPLEX WITH A DISUBSTITUTED 2 4-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
140, 4fkuA, 0.9611, 1.32, 0.979, 293, 292, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
141, 1h07A, 0.9605, 0.61, 1.000, 285, 285, CDK2 IN COMPLEX WITH A DISUBSTITUTED 4 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
142, 1y91A, 0.9597, 0.76, 0.997, 286, 286, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1 5-A]PYRIMIDINE INHIBITOR
143, 3pj8A, 0.9596, 0.76, 0.993, 288, 286, STRUCTURE OF CDK2 IN COMPLEX WITH A PYRAZOLO[43-D]PYRIMIDINE BIOISOSTERE OF ROSCOVITINE.
144, 3le6A, 0.9574, 0.47, 1.000, 283, 283, THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH A PYRAZOLOBENZODIAZEPINE INHIBITOR
145, 3sqqA, 0.9572, 1.01, 0.986, 288, 288, CDK2 IN COMPLEX WITH INHIBITOR RC-3-96
146, 3lfnA, 0.9570, 0.72, 1.000, 285, 285, CRYSTAL STRUCTURE OF CDK2 WITH SAR57 AN AMINOINDAZOLE TYPE INHIBITOR
147, 3fz1A, 0.9566, 0.63, 1.000, 284, 284, CRYSTAL STRUCTURE OF A BENZTHIOPHENE INHIBITOR BOUND TO HUMAN CYCLIN-DEPENDENT KINASE-2 (CDK-2)
148, 1pf8A, 0.9561, 1.72, 0.935, 298, 293, CRYSTAL STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH A NUCLEOSIDE INHIBITOR
149, 2vtoA, 0.9548, 0.57, 1.000, 283, 283, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
150, 1wccA, 0.9542, 0.59, 1.000, 283, 283, SCREENING FOR FRAGMENT BINDING BY X-RAY CRYSTALLOGRAPHY
151, 5ieyA, 0.9541, 0.92, 0.997, 286, 286, CRYSTAL STRUCTURE OF A CDK INHIBITOR BOUND TO CDK2
152, 4fkoA, 0.9527, 1.58, 0.997, 291, 291, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
153, 1buhA, 0.9524, 1.06, 0.990, 287, 287, CRYSTAL STRUCTURE OF THE HUMAN CDK2 KINASE COMPLEX WITH CELL CYCLE-REGULATORY PROTEIN CKSHS1
154, 3wblA, 0.9517, 0.69, 0.996, 283, 283, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH PYRAZOLOPYRIMIDINE INHIBITOR
155, 2vtsA, 0.9516, 0.57, 1.000, 282, 282, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
156, 4lynA, 0.9513, 0.70, 0.993, 287, 283, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2-WT) COMPLEX WITH (2S)-N-(5-(((5-TERT-BUTYL-13-OXAZOL-2-YL)METHYL)SULFANYL)-13- THIAZOL-2-YL)-2-PHENYLPROPANAMIDE
157, 3uliA, 0.9513, 0.99, 0.993, 286, 286, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) BOUND TO AZABENZIMIDAZOLE DERIVATIVE
158, 4gcjA, 0.9511, 1.65, 0.938, 304, 292, CDK2 IN COMPLEX WITH INHIBITOR RC-3-89
159, 3r7iA, 0.9507, 0.63, 1.000, 282, 282, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-74
160, 5iexA, 0.9499, 0.96, 0.996, 285, 285, CRYSTAL STRUCTURE OF (RS)-S-{4-[(5-BROMO-4-{[(2R3R)-2-HYDROXY-1- METHYLPROPYL]OXY}- PYRIMIDIN-2-YL)AMINO]PHENYL}-S- CYCLOPROPYLSULFOXIMIDE BOUND TO CDK2
161, 1h08A, 0.9499, 0.74, 1.000, 283, 283, CDK2 IN COMPLEX WITH A DISUBSTITUTED 2 4-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
162, 3r7uA, 0.9498, 0.65, 1.000, 282, 282, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-75
163, 4fkqA, 0.9495, 0.77, 0.996, 283, 283, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
164, 2w06A, 0.9491, 0.66, 1.000, 282, 282, STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE COMPOUND 5C
165, 1fvtA, 0.9490, 0.66, 1.000, 282, 282, THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH AN OXINDOLE INHIBITOR
166, 4fkvA, 0.9488, 0.67, 0.996, 282, 282, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
167, 1h0wA, 0.9482, 0.87, 1.000, 283, 283, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 2-AMINO-6-[CYCLOHEX-3-ENYL]METHOXYPURINE
168, 1ke8A, 0.9473, 0.72, 1.000, 282, 282, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 4-{[(2-OXO- 12-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO}-N-(13- THIAZOL-2-YL)BENZENESULFONAMIDE
169, 2vtpA, 0.9472, 0.60, 1.000, 281, 281, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
170, 4fkrA, 0.9471, 0.73, 0.996, 282, 282, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
171, 2b52A, 0.9461, 0.86, 0.996, 283, 283, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DPH- 042562
172, 5ievA, 0.9460, 0.95, 0.996, 284, 284, CRYSTAL STRUCTURE OF BAY 1000394 (RONICICLIB) BOUND TO CDK2
173, 5aniA, 0.9459, 0.52, 1.000, 280, 280, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 6-CHLORO-7H- PURINE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
174, 1di8A, 0.9452, 0.88, 1.000, 283, 283, THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4-[3-HYDROXYANILINO]-67-DIMETHOXYQUINAZOLINE
175, 5k4jA, 0.9450, 0.69, 1.000, 282, 281, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH COMPOUND 22
176, 1ke7A, 0.9447, 0.69, 1.000, 281, 281, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[(22- DIOXIDO-13-DIHYDRO-2-BENZOTHIEN-5-YL)AMINO]METHYLENE}-5- (13-OXAZOL-5-YL)-13-DIHYDRO-2H-INDOL-2-ONE
177, 4ek8A, 0.9442, 0.59, 1.000, 280, 280, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
178, 3qtsA, 0.9440, 0.82, 1.000, 282, 282, CDK2 IN COMPLEX WITH INHIBITOR RC-2-12
179, 3rahA, 0.9438, 0.83, 1.000, 282, 282, CDK2 IN COMPLEX WITH INHIBITOR RC-2-22
180, 3rprA, 0.9436, 0.83, 1.000, 282, 282, CDK2 IN COMPLEX WITH INHIBITOR RC-2-49
181, 2w1hA, 0.9435, 0.92, 1.000, 283, 283, FRAGMENT-BASED DISCOVERY OF THE PYRAZOL-4-YL UREA (AT9283) A MULTI-TARGETED KINASE INHIBITOR WITH POTENT AURORA KINASE ACTIVITY
182, 1ke5A, 0.9430, 0.75, 1.000, 281, 281, CDK2 COMPLEXED WITH N-METHYL-4-{[(2-OXO-12-DIHYDRO-3H- INDOL-3-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE
183, 3r9nA, 0.9428, 0.85, 1.000, 282, 282, CDK2 IN COMPLEX WITH INHIBITOR RC-2-21
184, 1ckpA, 0.9425, 0.53, 1.000, 279, 279, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR PURVALANOL B
185, 3s2pA, 0.9423, 0.53, 1.000, 279, 279, CRYSTAL STRUCTURE OF CDK2 WITH A 2-AMINOPYRIMIDINE COMPOUND
186, 1vyzA, 0.9421, 0.54, 1.000, 279, 279, STRUCTURE OF CDK2 COMPLEXED WITH PNU-181227
187, 1ke9A, 0.9420, 0.78, 1.000, 281, 281, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[4- ({[AMINO(IMINO)METHYL]AMINOSULFONYL)ANILINO]METHYLENE}-2- OXO-23-DIHYDRO-1H-INDOLE
188, 2r64A, 0.9412, 0.58, 1.000, 279, 279, CRYSTAL STRUCTURE OF A 3-AMINOINDAZOLE COMPOUND WITH CDK2
189, 4fkpA, 0.9410, 0.58, 1.000, 279, 279, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
190, 2vtiA, 0.9409, 0.70, 1.000, 280, 280, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
191, 3r8mA, 0.9406, 1.26, 0.972, 286, 285, CDK2 IN COMPLEX WITH INHIBITOR L3-3
192, 1ke6A, 0.9405, 0.72, 1.000, 280, 280, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH N-METHYL-{4- [2-(7-OXO-67-DIHYDRO-8H-[13]THIAZOLO[54-E]INDOL-8- YLIDENE)HYDRAZINO]PHENYL}METHANESULFONAMIDE
193, 4ek6A, 0.9404, 0.47, 1.000, 278, 278, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
194, 4fkjA, 0.9401, 0.48, 1.000, 278, 278, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
195, 2uznA, 0.9398, 0.63, 1.000, 279, 279, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
196, 3r9oA, 0.9382, 1.00, 0.996, 282, 282, CDK2 IN COMPLEX WITH INHIBITOR RC-2-143
197, 4fktA, 0.9379, 0.57, 1.000, 278, 278, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
198, 1w0xC, 0.9375, 0.81, 1.000, 280, 280, CRYSTAL STRUCTURE OF HUMAN CDK2 IN COMPLEX WITH THE INHIBITOR OLOMOUCINE.
199, 2r3mA, 0.9374, 0.59, 1.000, 278, 278, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
200, 3ig7A, 0.9363, 0.63, 1.000, 278, 278, NOVEL CDK-5 INHIBITORS - CRYSTAL STRUCTURE OF INHIBITOR EFP WITH CDK-2
201, 2vthA, 0.9362, 0.64, 1.000, 278, 278, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN
202, 2vtaA, 0.9360, 0.65, 1.000, 278, 278, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
203, 5jq8A, 0.9359, 0.65, 1.000, 278, 278, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR ICEC0943
204, 1h00A, 0.9356, 0.66, 1.000, 278, 278, CDK2 IN COMPLEX WITH A DISUBSTITUTED 4 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
205, 4fkwA, 0.9353, 0.88, 0.993, 280, 280, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
206, 3pxfA, 0.9351, 1.92, 0.942, 302, 292, CDK2 IN COMPLEX WITH TWO MOLECULES OF 8-ANILINO-1-NAPHTHALENE SULFONATE
207, 2r3jA, 0.9349, 0.68, 1.000, 278, 278, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
208, 3qtrA, 0.9346, 1.12, 0.996, 282, 282, CDK2 IN COMPLEX WITH INHIBITOR RC-1-148
209, 4ez7A, 0.9345, 1.90, 0.924, 302, 291, CDK2 IN COMPLEX WITH STAUROSPORINE AND 2 MOLECULES OF 8-ANILINO-1- NAPHTHALENE SULFONIC ACID
210, 1giiA, 0.9344, 0.80, 0.989, 279, 279, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
211, 2vu3A, 0.9339, 1.45, 0.965, 285, 283, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
212, 3sw4A, 0.9336, 0.84, 1.000, 279, 279, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
213, 3pxzA, 0.9334, 2.05, 0.956, 302, 293, CDK2 TERNARY COMPLEX WITH JWS648 AND ANS
214, 2r3kA, 0.9332, 0.62, 1.000, 277, 277, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
215, 2vv9A, 0.9323, 0.88, 0.986, 279, 279, CDK2 IN COMPLEX WITH AN IMIDAZOLE PIPERAZINE
216, 5anoA, 0.9321, 0.66, 1.000, 277, 277, CRYSTAL STRUCTURE OF CDK2 PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
217, 3pxqA, 0.9320, 1.83, 0.934, 298, 290, CDK2 IN COMPLEX WITH 3 MOLECULES OF 8-ANILINO-1-NAPHTHALENE SULFONATE
218, 3rzbA, 0.9305, 1.23, 0.996, 282, 282, CDK2 IN COMPLEX WITH INHIBITOR RC-2-23
219, 4acmA, 0.9300, 0.73, 1.000, 277, 277, CDK2 IN COMPLEX WITH 3-AMINO-6-(4-{[2-(DIMETHYLAMINO)ETHYL] SULFAMOYL}-PHENYL)-N-PYRIDIN-3-YLPYRAZINE-2-CARBOXAMIDE
220, 1aq1A, 0.9298, 0.74, 1.000, 277, 277, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR STAUROSPORINE
221, 2vtjA, 0.9291, 0.65, 1.000, 276, 276, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
222, 2w17A, 0.9288, 0.89, 0.982, 278, 278, CDK2 IN COMPLEX WITH THE IMIDAZOLE PYRIMIDINE AMIDE COMPOUND (S)-8B
223, 3sw7A, 0.9284, 0.89, 0.986, 278, 278, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
224, 2fvdA, 0.9284, 1.48, 0.957, 284, 282, CYCLIN DEPENDENT KINASE 2 (CDK2) WITH DIAMINOPYRIMIDINE INHIBITOR
225, 2w05A, 0.9281, 0.69, 0.989, 276, 276, STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE COMPOUND 5B
226, 3ezvA, 0.9274, 0.82, 0.993, 277, 277, CDK-2 WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
227, 4nj3A, 0.9273, 0.85, 0.986, 277, 277, MODULATING THE INTERACTION BETWEEN CDK2 AND CYCLIN A WITH A QUINOLINE- BASED INHIBITOR
228, 2btrA, 0.9273, 0.59, 1.000, 275, 275, STRUCTURE OF CDK2 COMPLEXED WITH PNU-198873
229, 1v1kA, 0.9269, 0.83, 0.996, 277, 277, CDK2 IN COMPLEX WITH A DISUBSTITUTED 4 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
230, 3rmfA, 0.9263, 0.94, 0.986, 278, 278, CDK2 IN COMPLEX WITH INHIBITOR RC-2-33
231, 4fksA, 0.9253, 0.67, 1.000, 275, 275, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
232, 3py1A, 0.9248, 2.06, 0.925, 302, 292, CDK2 TERNARY COMPLEX WITH SU9516 AND ANS
233, 2r3nA, 0.9242, 0.70, 0.993, 275, 275, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
234, 4bzdA, 0.9239, 0.92, 0.964, 277, 277, STRUCTURE OF CDK2 IN COMPLEX WITH A BENZIMIDAZOPYRIMIDINE
235, 3s1hA, 0.9239, 0.91, 0.989, 277, 277, CDK2 IN COMPLEX WITH INHIBITOR RC-2-39
236, 2r3lA, 0.9233, 0.73, 1.000, 275, 275, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
237, 2btsA, 0.9233, 0.63, 0.993, 274, 274, STRUCTURE OF CDK2 COMPLEXED WITH PNU-230032
238, 3rakA, 0.9229, 0.94, 0.989, 277, 277, CDK2 IN COMPLEX WITH INHIBITOR RC-2-32
239, 2j9mA, 0.9228, 0.75, 0.993, 275, 275, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH MACROCYCLIC AMINOPYRIMIDINE
240, 1gihA, 0.9227, 0.85, 1.000, 276, 276, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
241, 3rpyA, 0.9223, 0.95, 0.989, 277, 277, CDK2 IN COMPLEX WITH INHIBITOR RC-2-40
242, 1v0bA, 0.9221, 1.26, 0.621, 286, 280, CRYSTAL STRUCTURE OF THE T198A MUTANT OF PFPK5
243, 2b55A, 0.9219, 0.87, 0.996, 276, 276, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH INDENOPYRAXOLE DIN-101312
244, 5andA, 0.9217, 0.54, 1.000, 273, 273, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 2-IMIDAZOL-1-YL-1H- BENZIMIDAZOLE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
245, 1oitA, 0.9212, 0.57, 0.996, 273, 273, IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
246, 2vtqA, 0.9211, 0.70, 0.996, 274, 274, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
247, 1g5sA, 0.9209, 0.81, 0.993, 275, 275, CRYSTAL STRUCTURE OF HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH THE INHIBITOR H717
248, 1dm2A, 0.9206, 0.71, 0.993, 274, 274, HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR HYMENIALDISINE
249, 2bheA, 0.9205, 0.72, 0.993, 274, 274, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 5-BROMO-INDIRUBINE
250, 2bhhA, 0.9202, 0.73, 0.993, 274, 274, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 4-HYDROXYPIPERINDINESULFONYL-INDIRUBINE
251, 5ankA, 0.9199, 0.61, 1.000, 273, 273, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 246-TRIOXO-1- PHENYL-HEXAHYDROPYRIMIDINE-5-CARBOXAMIDE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
252, 2vtnA, 0.9199, 0.73, 0.996, 274, 274, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
253, 3ralA, 0.9198, 1.02, 0.989, 277, 277, CDK2 IN COMPLEX WITH INHIBITOR RC-2-34
254, 1urwA, 0.9195, 0.76, 0.978, 274, 274, CDK2 IN COMPLEX WITH AN IMIDAZO[12-B]PYRIDAZINE
255, 4d1xA, 0.9184, 0.79, 0.996, 274, 274, CDK2 IN COMPLEX WITH LUCIFERIN
256, 4bghA, 0.9183, 0.89, 1.000, 275, 275, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH PAN-CDK INHIBITOR
257, 3ezrA, 0.9182, 0.68, 1.000, 273, 273, CDK-2 WITH INDAZOLE INHIBITOR 17 BOUND AT ITS ACTIVE SITE
258, 2duvA, 0.9177, 0.57, 1.000, 272, 272, STRUCTURE OF CDK2 WITH A 3-HYDROXYCHROMONES
259, 2vttA, 0.9117, 0.83, 0.993, 272, 272, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
260, 1gijA, 0.9105, 0.92, 0.989, 273, 273, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
261, 1r78A, 0.9103, 0.92, 0.996, 273, 273, CDK2 COMPLEX WITH A 4-ALKYNYL OXINDOLE INHIBITOR
262, 4yc6E, 0.9097, 1.58, 0.661, 285, 280, CDK1/CKS1
263, 4yc6C, 0.9088, 1.59, 0.661, 285, 280, CDK1/CKS1
264, 4yc6A, 0.9087, 1.59, 0.661, 285, 280, CDK1/CKS1
265, 5fp6A, 0.9086, 1.07, 0.974, 278, 274, STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH SMALL-MOLECULE LIGAND 3-(47-DICHLORO-1H-INDOL-3-YL)PROP-2-YN-1-OL (AT17833) IN AN ALTERNATE BINDING SITE.
266, 1fvvA, 0.9063, 2.15, 0.944, 298, 287, THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLE INHIBITOR
267, 1p2aA, 0.9056, 0.87, 0.978, 271, 271, THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH A TRISUBSTITUTED NAPHTHOSTYRIL INHIBITOR
268, 4yc6G, 0.9052, 1.67, 0.661, 285, 280, CDK1/CKS1
269, 4fx3A, 0.9051, 2.16, 0.934, 298, 287, CRYSTAL STRUCTURE OF THE CDK2/CYCLIN A COMPLEX WITH OXINDOLE INHIBITOR
270, 1v0pA, 0.9051, 1.11, 0.626, 277, 273, STRUCTURE OF P. FALCIPARUM PFPK5-PURVALANOL B LIGAND COMPLEX
271, 1ob3A, 0.9047, 1.12, 0.626, 277, 273, STRUCTURE OF P. FALCIPARUM PFPK5
272, 5if1A, 0.9038, 2.31, 0.941, 298, 288, CRYSTAL STRUCTURE APO CDK2/CYCLIN A
273, 2wxvA, 0.9029, 2.32, 0.944, 302, 288, STRUCTURE OF CDK2-CYCLIN A WITH A PYRAZOLO(43-H) QUINAZOLINE-3-CARBOXAMIDE INHIBITOR
274, 4fx3C, 0.9028, 2.34, 0.931, 298, 288, CRYSTAL STRUCTURE OF THE CDK2/CYCLIN A COMPLEX WITH OXINDOLE INHIBITOR
275, 3qhwC, 0.9011, 2.08, 0.951, 297, 284, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
276, 3qhwA, 0.9007, 2.09, 0.951, 297, 284, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
277, 3qhrC, 0.9005, 2.09, 0.951, 297, 284, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
278, 3qhrA, 0.9003, 2.10, 0.951, 297, 284, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
279, 3ej1A, 0.9002, 2.42, 0.979, 295, 288, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
280, 3eocA, 0.8999, 2.44, 0.979, 295, 288, CDK2/CYCLINA COMPLEXED WITH A IMIDAZO TRIAZIN-2-AMINE
281, 2wihA, 0.8995, 2.35, 0.944, 302, 288, STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125
282, 4cfxC, 0.8993, 2.24, 0.986, 298, 286, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
283, 1finA, 0.8990, 2.25, 0.944, 298, 287, CYCLIN A-CYCLIN-DEPENDENT KINASE 2 COMPLEX
284, 5angA, 0.8989, 0.77, 0.989, 268, 268, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 7-HYDROXY-4-( MORPHOLINOMETHYL)CHROMEN-2-ONE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
285, 2cchC, 0.8986, 2.13, 0.940, 296, 284, THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA- LINKED ATP ANALOGUE
286, 1vywA, 0.8986, 2.39, 0.944, 302, 288, STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137
287, 1pyeA, 0.8974, 0.57, 1.000, 266, 266, CRYSTAL STRUCTURE OF CDK2 WITH INHIBITOR
288, 4ii5A, 0.8969, 2.16, 0.951, 295, 284, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 1 MAGNESIUM ION
289, 4ii5C, 0.8967, 2.16, 0.951, 295, 284, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 1 MAGNESIUM ION
290, 2wpaA, 0.8962, 2.45, 0.979, 302, 288, OPTIMISATION OF 66-DIMETHYL PYRROLO 34-C PYRAZOLES: IDENTIFICATION OF PHA-793887 A POTENT CDK INHIBITOR SUITABLE FOR INTRAVENOUS DOSING
291, 1jvpP, 0.8961, 0.85, 1.000, 268, 268, CRYSTAL STRUCTURE OF HUMAN CDK2 (UNPHOSPHORYLATED) IN COMPLEX WITH PKF049-365
292, 4i3zA, 0.8958, 2.17, 0.951, 295, 284, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 2 MAGNESIUM IONS
293, 2i40A, 0.8954, 2.30, 0.989, 291, 285, CDK2/CYCLIN A COMPLEXED WITH A THIOPHENE CARBOXAMIDE INHIBITOR
294, 5cyiA, 0.8953, 2.28, 0.976, 298, 286, CDK2/CYCLIN A COVALENT COMPLEX WITH 6-(CYCLOHEXYLMETHOXY)-N-(4- (VINYLSULFONYL)PHENYL)-9H-PURIN-2-AMINE (NU6300)
295, 4i3zC, 0.8953, 2.18, 0.951, 295, 284, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 2 MAGNESIUM IONS
296, 2bpmA, 0.8953, 2.41, 0.944, 302, 288, STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529
297, 2uzdA, 0.8951, 2.17, 0.951, 295, 284, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
298, 1h1pA, 0.8946, 2.17, 0.940, 296, 284, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058
299, 3eidA, 0.8945, 2.45, 0.983, 292, 286, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
300, 5hq0A, 0.8942, 1.72, 0.606, 292, 279, TERNARY COMPLEX OF HUMAN PROTEINS CDK1 CYCLIN B AND CKS2 BOUND TO AN INHIBITOR
301, 4y72A, 0.8942, 1.72, 0.606, 292, 279, HUMAN CDK1/CYCLINB1/CKS2 WITH INHIBITOR
302, 1h1sC, 0.8941, 2.18, 0.940, 296, 284, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102
303, 5cyiC, 0.8938, 2.21, 0.986, 296, 284, CDK2/CYCLIN A COVALENT COMPLEX WITH 6-(CYCLOHEXYLMETHOXY)-N-(4- (VINYLSULFONYL)PHENYL)-9H-PURIN-2-AMINE (NU6300)
304, 4eokA, 0.8933, 2.28, 0.975, 293, 285, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
305, 2bkzA, 0.8933, 2.52, 0.941, 302, 288, STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611
306, 1oiyC, 0.8933, 2.24, 0.982, 296, 284, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
307, 4eonC, 0.8930, 2.26, 0.930, 298, 285, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
308, 2iw8A, 0.8930, 2.26, 0.979, 297, 285, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H-L83V- H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR
309, 2cchA, 0.8924, 2.22, 0.940, 296, 284, THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA- LINKED ATP ANALOGUE
310, 4eolA, 0.8923, 2.22, 0.930, 294, 284, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
311, 4bcoA, 0.8921, 2.33, 0.983, 298, 286, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
312, 2uzlC, 0.8921, 2.23, 0.951, 295, 284, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
313, 2uzeC, 0.8920, 2.22, 0.940, 295, 284, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
314, 4bcnA, 0.8919, 2.35, 0.979, 296, 286, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
315, 1jstC, 0.8919, 2.38, 0.983, 297, 286, PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A
316, 4bcpA, 0.8917, 2.34, 0.983, 298, 286, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
317, 3f5xC, 0.8914, 2.50, 0.979, 298, 288, CDK-2-CYCLIN COMPLEX WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
318, 1h1pC, 0.8914, 2.21, 0.940, 296, 284, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058
319, 2uzlA, 0.8913, 2.24, 0.951, 295, 284, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
320, 2c6tA, 0.8913, 2.23, 0.951, 295, 284, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
321, 2c4gC, 0.8913, 2.55, 0.941, 300, 288, STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514
322, 4cfxA, 0.8912, 2.36, 0.969, 298, 286, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
323, 3ddpC, 0.8912, 2.31, 0.955, 298, 286, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR CR8
324, 3bhuA, 0.8912, 2.33, 0.990, 297, 286, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 5
325, 1h1qC, 0.8911, 2.25, 0.982, 296, 284, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094
326, 1qmzC, 0.8910, 2.24, 0.951, 296, 284, PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX
327, 1qmzA, 0.8909, 2.25, 0.951, 296, 284, PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX
328, 3bhtA, 0.8908, 2.34, 0.983, 297, 286, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 3
329, 2uzeA, 0.8908, 2.23, 0.951, 295, 284, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
330, 2iw6C, 0.8908, 2.17, 0.947, 295, 283, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
331, 1oi9C, 0.8908, 2.23, 0.982, 296, 284, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
332, 3dogA, 0.8907, 2.35, 0.979, 297, 286, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR N-&-N1
333, 1gy3C, 0.8907, 2.23, 0.951, 295, 284, PCDK2/CYCLIN A IN COMPLEX WITH MGADP NITRATE AND PEPTIDE SUBSTRATE
334, 2g9xA, 0.8906, 2.35, 0.979, 298, 286, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR NU6271
335, 1h1rC, 0.8905, 2.23, 0.940, 296, 284, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086
336, 4eoiC, 0.8904, 2.24, 0.933, 296, 284, THR 160 PHOSPHORYLATED CDK2 K89D Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
337, 2cciC, 0.8904, 2.29, 0.989, 296, 284, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6
338, 4eopC, 0.8903, 2.27, 0.982, 296, 284, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
339, 4cfwC, 0.8903, 2.28, 0.986, 297, 284, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
340, 3ddpA, 0.8902, 2.30, 0.989, 297, 285, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR CR8
341, 4eonA, 0.8901, 2.38, 0.941, 299, 286, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
342, 2c4gA, 0.8901, 2.33, 0.941, 301, 286, STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514
343, 1ua2A, 0.8900, 2.15, 0.440, 286, 282, CRYSTAL STRUCTURE OF HUMAN CDK7
344, 1gy3A, 0.8900, 2.25, 0.951, 295, 284, PCDK2/CYCLIN A IN COMPLEX WITH MGADP NITRATE AND PEPTIDE SUBSTRATE
345, 5d1jA, 0.8899, 0.73, 0.996, 265, 265, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2-WT) COMPLEX WITH N-[5-[[[5-(11-DIMETHYLETHYL)-2-OXAZOLYL] METHYL]THIO]-2-THIAZOLYL]- 4-PIPERIDINECARBOXAMIDE (BMS-387032)
346, 2c5vC, 0.8897, 2.31, 0.982, 296, 285, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
347, 2c5nA, 0.8897, 2.34, 0.979, 296, 285, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
348, 1h1sA, 0.8896, 2.27, 0.979, 296, 284, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102
349, 3f5xA, 0.8895, 2.50, 0.983, 297, 287, CDK-2-CYCLIN COMPLEX WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
350, 2wxvC, 0.8894, 2.55, 0.941, 299, 288, STRUCTURE OF CDK2-CYCLIN A WITH A PYRAZOLO(43-H) QUINAZOLINE-3-CARBOXAMIDE INHIBITOR
351, 3gc0A, 0.8892, 1.68, 0.567, 278, 275, STRUCTURE OF THE CMGC CDK KINASE FROM GIARDIA LAMBLIA IN COMPLEX WITH AMP
352, 2c5nC, 0.8892, 2.34, 0.982, 296, 285, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
353, 5nevA, 0.8890, 2.26, 0.989, 295, 283, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
354, 4eolC, 0.8890, 2.29, 0.930, 299, 285, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
355, 2wevC, 0.8889, 2.32, 0.982, 296, 285, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
356, 5lmkA, 0.8888, 2.39, 0.979, 296, 286, STRUCTURE OF PHOPSHO-CDK2-CYCLIN A IN COMPLEX WITH AN ATP-COMPETITIVE INHIBITOR
357, 2bkzC, 0.8888, 2.55, 0.941, 298, 287, STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611
358, 1oiuA, 0.8888, 2.33, 0.989, 296, 285, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
359, 1h1qA, 0.8888, 2.29, 0.979, 296, 284, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094
360, 1oiqA, 0.8887, 0.66, 1.000, 264, 264, IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
361, 1oi9A, 0.8887, 2.30, 0.979, 295, 284, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
362, 1h1rA, 0.8887, 2.29, 0.979, 296, 284, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086
363, 2iw9A, 0.8886, 2.33, 0.982, 293, 285, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
364, 4eosC, 0.8885, 2.27, 0.951, 296, 284, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
365, 1ol1C, 0.8884, 2.32, 0.982, 296, 285, CYCLIN A BINDING GROOVE INHIBITOR H-CIT-CIT-LEU-ILE-(P-F-PHE)-NH2
366, 1ol2C, 0.8883, 2.34, 0.982, 296, 285, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ASN-(P-F-PHE)-NH2
367, 1oiyA, 0.8883, 2.31, 0.979, 293, 284, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
368, 4eooC, 0.8881, 2.30, 0.982, 297, 284, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
369, 2c5vA, 0.8878, 2.35, 0.982, 296, 285, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
370, 4cfmA, 0.8877, 2.32, 0.979, 296, 284, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
371, 3ddqA, 0.8877, 2.39, 0.979, 296, 286, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR ROSCOVITINE
372, 2c5oA, 0.8874, 2.37, 0.982, 296, 285, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
373, 1oguA, 0.8874, 2.37, 0.979, 296, 285, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR
374, 1fvvC, 0.8874, 2.55, 0.937, 298, 288, THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLE INHIBITOR
375, 5lqeA, 0.8873, 2.30, 0.979, 295, 283, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
376, 3bhvA, 0.8873, 2.39, 0.983, 297, 286, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR VARIOLIN B
377, 1urcC, 0.8873, 2.52, 0.972, 296, 286, CYCLIN A BINDING GROOVE INHIBITOR ACE-ARG-LYS-LEU-PHE-GLY
378, 1ua2D, 0.8872, 2.27, 0.447, 286, 282, CRYSTAL STRUCTURE OF HUMAN CDK7
379, 2wmbA, 0.8871, 2.33, 0.979, 296, 284, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
380, 2c5oC, 0.8871, 2.37, 0.982, 296, 285, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
381, 1fq1B, 0.8871, 2.49, 0.979, 295, 287, CRYSTAL STRUCTURE OF KINASE ASSOCIATED PHOSPHATASE (KAP) IN COMPLEX WITH PHOSPHO-CDK2
382, 2cciA, 0.8868, 2.32, 0.989, 296, 284, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6
383, 4eojA, 0.8867, 2.43, 0.976, 295, 286, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH ATP
384, 2v22C, 0.8867, 2.38, 0.982, 296, 285, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
385, 4cfwA, 0.8866, 2.42, 0.969, 299, 286, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
386, 2iw6A, 0.8866, 2.29, 0.975, 292, 283, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
387, 3my5A, 0.8865, 2.41, 0.990, 296, 286, CDK2/CYCLINA IN COMPLEX WITH DRB
388, 4eoiA, 0.8863, 2.43, 0.979, 294, 286, THR 160 PHOSPHORYLATED CDK2 K89D Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
389, 4cfvA, 0.8863, 2.40, 0.983, 300, 286, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
390, 2wfyC, 0.8862, 2.40, 0.982, 296, 285, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
391, 2uzbA, 0.8862, 2.33, 0.989, 295, 284, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
392, 4bcnC, 0.8861, 2.25, 0.982, 295, 282, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
393, 1vywC, 0.8860, 2.62, 0.979, 299, 288, STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137
394, 4cfnA, 0.8858, 2.38, 0.989, 296, 285, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
395, 1okwC, 0.8858, 2.29, 0.989, 296, 284, CYCLIN A BINDING GROOVE INHIBITOR AC-ARG-ARG-LEU-ASN-(M-CL-PHE)-NH2
396, 2x1nC, 0.8857, 2.52, 0.979, 296, 286, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
397, 1ua2B, 0.8857, 2.29, 0.443, 286, 282, CRYSTAL STRUCTURE OF HUMAN CDK7
398, 5nevC, 0.8856, 2.31, 0.989, 296, 284, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
399, 4eopA, 0.8856, 2.38, 0.986, 297, 285, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
400, 4bcmA, 0.8856, 2.36, 0.979, 295, 284, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
401, 2x1nA, 0.8856, 2.41, 0.982, 296, 285, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
402, 2c5xC, 0.8856, 2.27, 0.989, 296, 284, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
403, 4eokC, 0.8854, 2.33, 0.930, 299, 285, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
404, 4cfuA, 0.8854, 2.42, 0.990, 299, 286, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
405, 2wpaC, 0.8854, 2.64, 0.976, 299, 288, OPTIMISATION OF 66-DIMETHYL PYRROLO 34-C PYRAZOLES: IDENTIFICATION OF PHA-793887 A POTENT CDK INHIBITOR SUITABLE FOR INTRAVENOUS DOSING
406, 2c5xA, 0.8854, 2.38, 0.982, 296, 285, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
407, 4eorA, 0.8853, 2.41, 0.975, 293, 285, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
408, 4eooA, 0.8853, 2.40, 0.972, 294, 285, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
409, 2wevA, 0.8853, 2.38, 0.979, 296, 285, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
410, 4eomA, 0.8852, 2.39, 0.972, 296, 285, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
411, 1okvC, 0.8852, 2.30, 0.989, 296, 284, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ILE-PHE-NH2
412, 2uzbC, 0.8851, 2.30, 0.951, 292, 284, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
413, 2wihC, 0.8850, 2.59, 0.941, 299, 288, STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125
414, 1urcA, 0.8850, 2.56, 0.979, 296, 286, CYCLIN A BINDING GROOVE INHIBITOR ACE-ARG-LYS-LEU-PHE-GLY
415, 3tnwA, 0.8849, 2.44, 0.979, 295, 286, STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH CAN508
416, 5if1C, 0.8847, 2.49, 0.944, 296, 286, CRYSTAL STRUCTURE APO CDK2/CYCLIN A
417, 2uueC, 0.8846, 2.41, 0.982, 296, 285, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
418, 1ua2C, 0.8846, 2.17, 0.423, 286, 281, CRYSTAL STRUCTURE OF HUMAN CDK7
419, 4eosA, 0.8845, 2.40, 0.986, 296, 285, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
420, 1h28A, 0.8843, 2.33, 0.951, 296, 284, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107
421, 1pkdA, 0.8842, 2.37, 0.979, 296, 284, THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO- CDK2/CYCLIN A
422, 2wipA, 0.8841, 2.36, 0.943, 297, 283, STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1- METHYL-45-DIHYDRO-1H-PYRAZOLO[43-H] QUINAZOLINE-3- CARBOXYLIC ACID
423, 1h26A, 0.8841, 2.37, 0.979, 296, 284, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53
424, 2whbA, 0.8840, 2.43, 0.982, 296, 285, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
425, 4bcmC, 0.8838, 2.29, 0.986, 294, 282, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
426, 2v22A, 0.8836, 2.42, 0.982, 296, 285, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
427, 4eoqA, 0.8835, 2.41, 0.989, 295, 285, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH ATP
428, 1h28C, 0.8835, 2.35, 0.951, 296, 284, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107
429, 5lqeC, 0.8832, 2.39, 0.979, 296, 284, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
430, 2uueA, 0.8832, 2.44, 0.982, 296, 285, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
431, 3eocC, 0.8829, 2.58, 0.979, 293, 286, CDK2/CYCLINA COMPLEXED WITH A IMIDAZO TRIAZIN-2-AMINE
432, 4cfnC, 0.8827, 2.29, 0.986, 296, 282, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
433, 1f5qA, 0.8826, 2.46, 0.951, 296, 288, CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDENT KINASE 2
434, 1e9hC, 0.8826, 2.36, 0.979, 296, 284, THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5-SULPHONATE BOUND
435, 1ol2A, 0.8822, 2.59, 0.976, 296, 286, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ASN-(P-F-PHE)-NH2
436, 5uq2A, 0.8821, 2.51, 0.979, 296, 285, CRYSTAL STRUCTURE OF HUMAN CDK2-SPY1 COMPLEX
437, 5lqfA, 0.8819, 1.64, 0.613, 287, 274, CDK1/CYCLINB1/CKS2 IN COMPLEX WITH NU6102
438, 2whbC, 0.8817, 2.45, 0.982, 296, 285, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
439, 2c6tC, 0.8813, 2.35, 0.951, 295, 284, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
440, 1ol1A, 0.8813, 2.60, 0.976, 296, 286, CYCLIN A BINDING GROOVE INHIBITOR H-CIT-CIT-LEU-ILE-(P-F-PHE)-NH2
441, 3ej1C, 0.8809, 2.61, 0.979, 294, 287, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
442, 2bpmC, 0.8809, 2.65, 0.941, 299, 288, STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529
443, 1okwA, 0.8809, 2.46, 0.982, 296, 285, CYCLIN A BINDING GROOVE INHIBITOR AC-ARG-ARG-LEU-ASN-(M-CL-PHE)-NH2
444, 2i40C, 0.8807, 2.46, 0.979, 296, 285, CDK2/CYCLIN A COMPLEXED WITH A THIOPHENE CARBOXAMIDE INHIBITOR
445, 3gbzA, 0.8806, 1.65, 0.566, 274, 272, STRUCTURE OF THE CMGC CDK KINASE FROM GIARDIA LAMBLIA
446, 2wfyA, 0.8803, 2.43, 0.982, 295, 284, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
447, 5fp5A, 0.8802, 0.93, 0.989, 264, 264, STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH SMALL-MOLECULE LIGAND 4-FLUOROBENZOIC ACID (AT222) IN AN ALTERNATE BINDING SITE.
448, 1h27A, 0.8802, 2.42, 0.979, 296, 284, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27
449, 1e9hA, 0.8801, 2.41, 0.989, 295, 284, THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5-SULPHONATE BOUND
450, 2uzdC, 0.8800, 2.40, 0.989, 295, 284, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
451, 2wmaA, 0.8797, 2.40, 0.940, 296, 284, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
452, 1p5eA, 0.8796, 2.45, 0.989, 296, 284, THE STRUCTURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMOBENZOTRIAZOLE (TBS)
453, 1finC, 0.8790, 2.53, 0.930, 298, 287, CYCLIN A-CYCLIN-DEPENDENT KINASE 2 COMPLEX
454, 5xs2A, 0.8778, 2.39, 0.380, 366, 287, CDK8-CYCC IN COMPLEX WITH COMPOUND 17:3-CHLORO-4-(4-PYRIDYL)-1H- PYRROLE-2-CARBOXAMIDE
455, 1pkdC, 0.8769, 2.43, 0.989, 296, 284, THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO- CDK2/CYCLIN A
456, 5lqfD, 0.8766, 1.68, 0.615, 285, 273, CDK1/CYCLINB1/CKS2 IN COMPLEX WITH NU6102
457, 4bckA, 0.8756, 2.54, 0.975, 298, 285, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
458, 3tnwC, 0.8756, 2.30, 0.979, 291, 280, STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH CAN508
459, 1p5eC, 0.8753, 2.46, 0.940, 296, 284, THE STRUCTURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMOBENZOTRIAZOLE (TBS)
460, 1jstA, 0.8752, 2.59, 0.983, 297, 286, PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A
461, 2wipC, 0.8751, 2.47, 0.940, 292, 281, STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1- METHYL-45-DIHYDRO-1H-PYRAZOLO[43-H] QUINAZOLINE-3- CARBOXYLIC ACID
462, 5hbhA, 0.8750, 2.21, 0.389, 336, 283, CDK8-CYCC IN COMPLEX WITH 5-{5-CHLORO-4-[1-(2-METHOXY-ETHYL)-18- DIAZA-SPIRO[4.5]DEC-8-YL]-PYRIDIN-3-YL}-1-METHYL-13-DIHYDRO- BENZO[C]ISOTHIAZOLE 22-DIOXIDE
463, 4yc3A, 0.8749, 2.09, 0.644, 295, 278, CDK1/CYCLINB1/CKS2 APO
464, 1okvA, 0.8742, 2.63, 0.975, 295, 285, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ILE-PHE-NH2
465, 4crlA, 0.8733, 2.62, 0.387, 339, 287, CRYSTAL STRUCTURE OF HUMAN CDK8-CYCLIN C IN COMPLEX WITH CORTISTATIN A
466, 1h25A, 0.8728, 2.41, 0.979, 293, 281, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM RETINOBLASTOMA-ASSOCIATED PROTEIN
467, 4ec8A, 0.8725, 2.53, 0.407, 325, 285, STRUCTURE OF FULL LENGTH CDK9 IN COMPLEX WITH CYCLINT AND DRB
468, 2cjmC, 0.8716, 2.45, 0.982, 294, 283, MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE
469, 5uq1A, 0.8698, 2.36, 0.950, 288, 278, CRYSTAL STRUCTURE OF HUMAN CDK2-SPY1 COMPLEX
470, 5uq1C, 0.8696, 2.24, 0.982, 289, 277, CRYSTAL STRUCTURE OF HUMAN CDK2-SPY1 COMPLEX
471, 1h24A, 0.8696, 2.45, 0.979, 293, 281, CDK2/CYCLIN A IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F
472, 4or5A, 0.8690, 2.70, 0.404, 319, 285, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB AND AFF4
473, 3eidC, 0.8688, 2.72, 0.979, 290, 285, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
474, 1v0bB, 0.8687, 1.00, 0.628, 261, 261, CRYSTAL STRUCTURE OF THE T198A MUTANT OF PFPK5
475, 5l2wA, 0.8674, 2.38, 0.982, 297, 278, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK2/CYCLINE AND DINACICLIB.
476, 5a14A, 0.8674, 2.57, 0.950, 284, 282, HUMAN CDK2 WITH TYPE II INHIBITOR
477, 5hbjA, 0.8672, 2.57, 0.368, 342, 285, CDK8-CYCC IN COMPLEX WITH 8-[2-AMINO-3-CHLORO-5-(1-METHYL-1H-INDAZOL- 5-YL)-PYRIDIN-4-YL]-28-DIAZA-SPIRO[4.5]DECAN-1-ONE
478, 4or5F, 0.8672, 2.73, 0.407, 324, 285, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB AND AFF4
479, 4bcqC, 0.8672, 2.42, 0.975, 292, 280, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
480, 5ceiA, 0.8668, 2.68, 0.376, 345, 287, CRYSTAL STRUCTURE OF CDK8:CYCLIN C COMPLEX WITH COMPOUND 22
481, 5icpA, 0.8660, 2.75, 0.389, 343, 288, CDK8-CYCC IN COMPLEX WITH [(S)-2-(4-CHLORO-PHENYL)-PYRROLIDIN-1-YL]- (5-METHYL-IMIDAZO[51-B][134]THIADIAZOL-2-YL)-METHANONE
482, 1f5qC, 0.8657, 2.28, 0.957, 288, 279, CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDENT KINASE 2
483, 4bckC, 0.8656, 2.44, 0.975, 293, 280, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
484, 2w99B, 0.8654, 2.24, 0.458, 291, 277, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
485, 5idpA, 0.8649, 2.67, 0.381, 342, 286, CDK8-CYCC IN COMPLEX WITH (3-AMINO-1H-INDAZOL-5-YL)-[(S)-2-(4-FLUORO- PHENYL)-PIPERIDIN-1-YL]-METHANONE
486, 4bcgA, 0.8643, 2.58, 0.403, 312, 283, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
487, 4bchA, 0.8642, 2.58, 0.406, 308, 283, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
488, 4ogrI, 0.8638, 2.70, 0.407, 318, 285, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
489, 5hbeA, 0.8632, 2.72, 0.387, 344, 287, CDK8-CYCC IN COMPLEX WITH 8-[3-CHLORO-5-(1-METHYL-22-DIOXO-2 3- DIHYDRO-1H-2L6-BENZO[C]ISOTHIAZOL-5-YL)-PYRIDIN- 4-YL]-1-OXA-38- DIAZA-SPIRO[4.5]DECAN-2-ONE
490, 3mi9A, 0.8629, 2.79, 0.404, 328, 285, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB
491, 3my1A, 0.8628, 2.58, 0.403, 314, 283, STRUCTURE OF CDK9/CYCLINT1 IN COMPLEX WITH DRB
492, 1unlB, 0.8628, 2.37, 0.552, 292, 277, STRUCTURAL MECHANISM FOR THE INHIBITION OF CD5-P25 FROM THE ROSCOVITINE ALOISINE AND INDIRUBIN.
493, 4f7sA, 0.8627, 2.75, 0.376, 339, 287, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN THE DMG-IN CONFORMATION
494, 3miaA, 0.8627, 2.74, 0.387, 324, 284, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH ATP-BOUND HUMAN P-TEFB
495, 4ogrA, 0.8620, 2.76, 0.407, 314, 285, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
496, 5hnbA, 0.8617, 2.79, 0.385, 342, 286, CDK8-CYCC IN COMPLEX WITH [6-HYDROXY-3-(3-METHYL-BENZYL)-1H-INDAZOL-5- YL]-((S)-3-HYDROXY-PYRROLIDIN-1-YL)-METHANONE
497, 2w9zB, 0.8615, 2.18, 0.464, 287, 274, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
498, 1h24C, 0.8615, 2.51, 0.940, 293, 281, CDK2/CYCLIN A IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F
499, 2jgzA, 0.8613, 2.31, 0.938, 288, 276, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 IN COMPLEX WITH CYCLIN B
500, 6b3eA, 0.8612, 2.74, 0.421, 309, 285, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLINK IN COMPLEX WITH AN INHIBITOR
501, 4d1zA, 0.8612, 0.91, 0.969, 258, 258, CDK2 IN COMPLEX WITH A LUCIFERIN DERIVATE
502, 1blxA, 0.8612, 2.52, 0.461, 305, 282, P19INK4D/CDK6 COMPLEX
503, 3nizA, 0.8608, 2.49, 0.579, 288, 278, CRYPTOSPORIDIUM PARVUM CYCLIN-DEPENDENT KINASE CGD5_2510 WITH ADP BOUND.
504, 5i5zA, 0.8606, 2.73, 0.385, 345, 286, CDK8-CYCC IN COMPLEX WITH 8-(1-METHYL-22-DIOXO-23-DIHYDRO-1H-2L6- BENZO[C]ISOTHIAZOL-5-YL)-[16]NAPHTHYRIDINE-2-CARBOXYLIC ACID METHYLAMIDE
505, 3g33A, 0.8606, 2.22, 0.465, 291, 275, CRYSTAL STRUCTURE OF CDK4/CYCLIN D3
506, 5xqxA, 0.8605, 2.32, 0.379, 340, 280, HUMAN CDK8-CYCC IN COMPLEX WITH COMPOUND 4: N-METHYL-4-(4-PYRIDYL)-1H- PYRROLE-2-CARBOXAMIDE
507, 1h27C, 0.8605, 2.45, 0.978, 291, 279, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27
508, 6b3eC, 0.8603, 2.74, 0.421, 307, 285, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLINK IN COMPLEX WITH AN INHIBITOR
509, 5idnA, 0.8603, 2.40, 0.377, 336, 281, CDK8-CYCC IN COMPLEX WITH [(S)-2-(4-CHLORO-PHENYL)-PYRROLIDIN-1-YL]- (3-METHYL-1H-PYRAZOLO[34-B]PYRIDIN-5-YL)-METHANONE
510, 4bcfA, 0.8598, 2.62, 0.415, 307, 282, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
511, 4j71A, 0.8596, 2.55, 0.332, 347, 280, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 1R
512, 4cxaA, 0.8594, 2.72, 0.412, 329, 284, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLIN K COMPLEX BOUND TO AMPPNP
513, 4bcjA, 0.8594, 2.62, 0.404, 309, 282, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
514, 2cjmA, 0.8592, 2.43, 0.986, 285, 278, MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE
515, 1w98A, 0.8592, 2.51, 0.950, 297, 278, THE STRUCTURAL BASIS OF CDK2 ACTIVATION BY CYCLIN E
516, 4imyE, 0.8588, 2.72, 0.408, 313, 284, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
517, 4j1rC, 0.8585, 2.57, 0.329, 344, 280, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
518, 4j1rA, 0.8585, 2.57, 0.329, 343, 280, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
519, 4j1rD, 0.8583, 2.57, 0.329, 345, 280, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
520, 3g33C, 0.8577, 2.32, 0.462, 291, 275, CRYSTAL STRUCTURE OF CDK4/CYCLIN D3
521, 4ogrE, 0.8574, 2.64, 0.399, 310, 281, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
522, 5bnjA, 0.8572, 2.68, 0.386, 343, 285, CDK8/CYCC IN COMPLEX WITH 8-{3-CHLORO-5-[4-(1-METHYL-1H-PYRAZOL-4-YL)- PHENYL]-PYRIDIN- 4-YL}-28-DIAZA-SPIRO[4.5]DECAN-1-ONE
523, 5hlnB, 0.8569, 2.57, 0.319, 346, 279, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH CHIR99021
524, 1v0oA, 0.8569, 1.98, 0.601, 276, 271, STRUCTURE OF P. FALCIPARUM PFPK5-INDIRUBIN-5-SULPHONATE LIGAND COMPLEX
525, 5hvyA, 0.8567, 2.43, 0.370, 335, 281, CDK8/CYCC IN COMPLEX WITH COMPOUND 20
526, 5l1zA, 0.8565, 2.65, 0.399, 310, 281, TAR COMPLEX WITH HIV-1 TAT-AFF4-P-TEFB
527, 3lq5A, 0.8563, 2.62, 0.399, 307, 281, STRUCTURE OF CDK9/CYCLINT IN COMPLEX WITH S-CR8
528, 4imyA, 0.8557, 2.79, 0.394, 314, 284, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
529, 4g6lA, 0.8557, 2.72, 0.384, 336, 284, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN THE DMG-IN CONFORMATION
530, 4bciA, 0.8555, 2.62, 0.406, 308, 281, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
531, 4f7nA, 0.8554, 2.36, 0.382, 334, 280, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 11 (1- [3-TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]-3-(5- HYDROXYPENTYL)UREA)
532, 5oy4B, 0.8551, 2.61, 0.329, 353, 280, GSK3BETA COMPLEX WITH N-(6-(34-DIHYDROXYPHENYL)-1H-PYRAZOLO[34- B]PYRIDIN-3-YL)ACETAMIDE
533, 4j71B, 0.8550, 2.63, 0.329, 347, 280, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 1R
534, 2o5kA, 0.8547, 2.56, 0.325, 350, 280, CRYSTAL STRUCTURE OF GSK3BETA IN COMPLEX WITH A BENZOIMIDAZOL INHIBITOR
535, 3zrkB, 0.8545, 2.65, 0.329, 348, 280, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
536, 3i4bB, 0.8544, 2.59, 0.332, 347, 280, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH A PYRIMIDYLPYRROLE INHIBITOR
537, 5f94A, 0.8543, 2.69, 0.335, 346, 281, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 15: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-METHOXYPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
538, 3sayB, 0.8543, 2.66, 0.332, 347, 280, CRYSTAL STRUCTURE OF HUMAN GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH INHIBITOR 142
539, 1v0pB, 0.8543, 1.11, 0.628, 258, 258, STRUCTURE OF P. FALCIPARUM PFPK5-PURVALANOL B LIGAND COMPLEX
540, 5fgkA, 0.8541, 2.33, 0.382, 331, 280, CDK8-CYCC IN COMPLEX WITH 8-[3-(3-AMINO-1H-INDAZOL-6-YL)-5-CHLORO- PYRIDINE-4-YL]-28-DIAZA-SPIRO[4.5]DECAN-1-ONE
541, 4pteB, 0.8539, 2.72, 0.331, 347, 281, STRUCTURE OF A CARVOXAMIDE COMPOUND (15) (N-[4-(ISOQUINOLIN-7-YL) PYRIDIN-2-YL]CYCLOPROPANECARBOXAMIDE) TO GSK3B
542, 3zrmB, 0.8539, 2.66, 0.329, 347, 280, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK- 3BETA INHIBITORS
543, 3zdiA, 0.8539, 2.65, 0.332, 348, 280, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH AXIN PEPTIDE AND INHIBITOR 7D
544, 3zrlB, 0.8538, 2.66, 0.329, 347, 280, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
545, 5f94B, 0.8537, 2.70, 0.331, 349, 281, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 15: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-METHOXYPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
546, 4ptcA, 0.8537, 2.69, 0.335, 342, 281, STRUCTURE OF A CARBOXAMIDE COMPOUND (3) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-OXO-4H-1LAMBDA~4~3-THIAZOLE-5-CARBOXAMIDE) TO GSK3B
547, 3gc8A, 0.8537, 2.52, 0.357, 347, 280, THE STRUCTURE OF P38BETA C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE
548, 1ob3B, 0.8535, 1.13, 0.628, 258, 258, STRUCTURE OF P. FALCIPARUM PFPK5
549, 4krcA, 0.8533, 2.70, 0.556, 297, 279, CRYSTAL STRUCTURE OF PHO85-PCL10-ATP-GAMMA-S COMPLEX
550, 4f6uA, 0.8533, 2.40, 0.382, 334, 280, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 5 (1-[3- TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]-3-[3-(MORPHOLIN-4-YL) PROPYL]UREA)
551, 3i4bA, 0.8533, 2.69, 0.335, 359, 281, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH A PYRIMIDYLPYRROLE INHIBITOR
552, 5kpmA, 0.8532, 2.66, 0.332, 344, 280, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH BRD3731
553, 3sd0B, 0.8530, 2.72, 0.335, 349, 281, IDENTIFICATION OF A GLYCOGEN SYNTHASE KINASE-3B INHIBITOR THAT ATTENUATES HYPERACTIVITY IN CLOCK MUTANT MICE
554, 4bcqA, 0.8526, 2.56, 0.975, 292, 278, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
555, 5hlnA, 0.8524, 2.69, 0.332, 346, 280, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH CHIR99021
556, 4ptcB, 0.8524, 2.73, 0.335, 347, 281, STRUCTURE OF A CARBOXAMIDE COMPOUND (3) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-OXO-4H-1LAMBDA~4~3-THIAZOLE-5-CARBOXAMIDE) TO GSK3B
557, 3sayA, 0.8523, 2.57, 0.335, 347, 278, CRYSTAL STRUCTURE OF HUMAN GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH INHIBITOR 142
558, 4nu1A, 0.8521, 2.78, 0.335, 356, 281, CRYSTAL STRUCTURE OF A TRANSITION STATE MIMIC OF THE GSK-3/AXIN COMPLEX BOUND TO PHOSPHORYLATED N-TERMINAL AUTO-INHIBITORY PS9 PEPTIDE
559, 4j1rB, 0.8521, 2.57, 0.331, 346, 278, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
560, 5kpkB, 0.8517, 2.67, 0.336, 344, 280, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH BRD0209
561, 4nm0A, 0.8517, 2.75, 0.331, 356, 281, CRYSTAL STRUCTURE OF PEPTIDE INHIBITOR-FREE GSK-3/AXIN COMPLEX
562, 1v0oB, 0.8516, 1.92, 0.599, 274, 269, STRUCTURE OF P. FALCIPARUM PFPK5-INDIRUBIN-5-SULPHONATE LIGAND COMPLEX
563, 1j1bB, 0.8516, 2.70, 0.335, 364, 281, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH AMPPNP
564, 1j1bA, 0.8514, 2.73, 0.331, 354, 281, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH AMPPNP
565, 6b8jA, 0.8512, 2.77, 0.332, 344, 280, CO-STRUCTURE OF HUMAN GLYCOGEN SYNTHASE KINASE BETA WITH A SELECTIVE (5-IMIDAZOL-2-YL-4-PHENYLPYRIMIDIN-2-YL)[2-(2-PYRIDYLAMINO) ETHYL]AMINE INHIBITOR
566, 4f6wA, 0.8512, 2.35, 0.376, 330, 279, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 1 (N-[3- TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]-4-[2-({[3-TERT-BUTYL- 1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]CARBAMOYL}AMINO)ETHYL]PIPERAZINE- 1-CARBOXAMIDE)
567, 5acbC, 0.8508, 2.90, 0.425, 324, 285, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
568, 4pteA, 0.8508, 2.67, 0.337, 341, 279, STRUCTURE OF A CARVOXAMIDE COMPOUND (15) (N-[4-(ISOQUINOLIN-7-YL) PYRIDIN-2-YL]CYCLOPROPANECARBOXAMIDE) TO GSK3B
569, 3zrkA, 0.8508, 2.65, 0.330, 345, 279, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
570, 3m1sB, 0.8506, 2.68, 0.336, 349, 280, STRUCTURE OF RUTHENIUM HALF-SANDWICH COMPLEX BOUND TO GLYCOGEN SYNTHASE KINASE 3
571, 3f88A, 0.8506, 2.58, 0.335, 340, 278, GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR COMPLEX
572, 3f88B, 0.8505, 2.61, 0.331, 340, 278, GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR COMPLEX
573, 4krdA, 0.8504, 2.65, 0.560, 294, 277, CRYSTAL STRUCTURE OF PHO85-PCL10 COMPLEX
574, 3tn8A, 0.8504, 2.63, 0.407, 304, 280, CDK9/CYCLIN T IN COMPLEX WITH CAN508
575, 4nstC, 0.8503, 2.86, 0.412, 317, 284, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
576, 1h8fB, 0.8503, 2.74, 0.331, 350, 281, GLYCOGEN SYNTHASE KINASE 3 BETA.
577, 1j1cB, 0.8502, 2.72, 0.335, 364, 281, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH ADP
578, 5oy4A, 0.8501, 2.70, 0.332, 349, 280, GSK3BETA COMPLEX WITH N-(6-(34-DIHYDROXYPHENYL)-1H-PYRAZOLO[34- B]PYRIDIN-3-YL)ACETAMIDE
579, 1h8fA, 0.8501, 2.74, 0.331, 352, 281, GLYCOGEN SYNTHASE KINASE 3 BETA.
580, 4nstA, 0.8499, 2.86, 0.408, 322, 284, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
581, 1j1cA, 0.8498, 2.74, 0.331, 354, 281, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH ADP
582, 1gngB, 0.8498, 2.67, 0.336, 355, 280, GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3) COMPLEX WITH FRATTIDE PEPTIDE
583, 5kpmB, 0.8496, 2.71, 0.336, 345, 280, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH BRD3731
584, 3zrmA, 0.8496, 2.66, 0.330, 344, 279, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK- 3BETA INHIBITORS
585, 4imyC, 0.8495, 2.74, 0.409, 310, 281, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
586, 1q41B, 0.8495, 2.75, 0.331, 343, 281, GSK-3 BETA COMPLEXED WITH INDIRUBIN-3 -MONOXIME
587, 3sd0A, 0.8493, 2.77, 0.331, 350, 281, IDENTIFICATION OF A GLYCOGEN SYNTHASE KINASE-3B INHIBITOR THAT ATTENUATES HYPERACTIVITY IN CLOCK MUTANT MICE
588, 4nm3A, 0.8492, 2.84, 0.331, 357, 281, CRYSTAL STRUCTURE OF GSK-3/AXIN COMPLEX BOUND TO PHOSPHORYLATED N- TERMINAL AUTO-INHIBITORY PS9 PEPTIDE
589, 1uv5A, 0.8492, 2.73, 0.335, 348, 281, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH 6-BROMOINDIRUBIN-3 -OXIME
590, 3gb2A, 0.8491, 2.59, 0.336, 340, 277, GSK3BETA INHIBITOR COMPLEX
591, 5kpkA, 0.8489, 2.70, 0.332, 346, 280, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH BRD0209
592, 3zrlA, 0.8488, 2.68, 0.330, 345, 279, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
593, 2pk9A, 0.8486, 2.35, 0.553, 287, 273, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE-RESPONSIVE SIGNAL TRANSDUCTION PATHWAY
594, 3gc8B, 0.8485, 2.58, 0.336, 346, 280, THE STRUCTURE OF P38BETA C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE
595, 3eb0A, 0.8485, 2.57, 0.353, 311, 275, CRYSTAL STRUCTURE OF CGD4_240 FROM CRYPTOSPORIDIUM PARVUM IN COMPLEX WITH INDIRUBIN E804
596, 1o9uA, 0.8483, 2.76, 0.339, 349, 280, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH AXIN PEPTIDE
597, 4achB, 0.8480, 2.77, 0.331, 350, 281, GSK3B IN COMPLEX WITH INHIBITOR
598, 4acgA, 0.8480, 2.78, 0.335, 350, 281, GSK3B IN COMPLEX WITH INHIBITOR
599, 4nm7A, 0.8476, 2.89, 0.331, 355, 281, CRYSTAL STRUCTURE OF GSK-3/AXIN COMPLEX BOUND TO PHOSPHORYLATED WNT RECEPTOR LRP6 E-MOTIF
600, 4b7tA, 0.8475, 2.82, 0.335, 350, 281, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH AXIN PEPTIDE AND LEUCETTINE L4
601, 4acdA, 0.8471, 2.79, 0.335, 350, 281, GSK3B IN COMPLEX WITH INHIBITOR
602, 4acgB, 0.8468, 2.79, 0.335, 350, 281, GSK3B IN COMPLEX WITH INHIBITOR
603, 4nm5A, 0.8467, 2.87, 0.331, 361, 281, CRYSTAL STRUCTURE OF GSK-3/AXIN COMPLEX BOUND TO PHOSPHORYLATED WNT RECEPTOR LRP6 C-MOTIF
604, 3rgfA, 0.8466, 2.36, 0.365, 321, 277, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC
605, 2jldB, 0.8466, 2.73, 0.336, 349, 280, EXTREMELY TIGHT BINDING OF RUTHENIUM COMPLEX TO GLYCOGEN SYNTHASE KINASE 3
606, 2ow3A, 0.8465, 2.76, 0.336, 346, 280, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH BIS- (INDOLE)MALEIMIDE PYRIDINOPHANE INHIBITOR
607, 4achA, 0.8464, 2.78, 0.335, 350, 281, GSK3B IN COMPLEX WITH INHIBITOR
608, 3m1sA, 0.8464, 2.73, 0.341, 348, 279, STRUCTURE OF RUTHENIUM HALF-SANDWICH COMPLEX BOUND TO GLYCOGEN SYNTHASE KINASE 3
609, 4f6sA, 0.8462, 2.48, 0.380, 328, 279, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 7 (1-[3- TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]UREA)
610, 5efqC, 0.8461, 2.94, 0.419, 325, 284, CRYSTAL STRUCTURE OF HUMAN CDK13/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
611, 2ow3B, 0.8460, 2.79, 0.332, 351, 280, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH BIS- (INDOLE)MALEIMIDE PYRIDINOPHANE INHIBITOR
612, 4afjB, 0.8459, 2.60, 0.333, 346, 276, 5-ARYL-4-CARBOXAMIDE-13-OXAZOLES: POTENT AND SELECTIVE GSK-3 INHIBITORS
613, 4afjA, 0.8459, 2.59, 0.333, 342, 276, 5-ARYL-4-CARBOXAMIDE-13-OXAZOLES: POTENT AND SELECTIVE GSK-3 INHIBITORS
614, 4un0C, 0.8458, 2.87, 0.413, 308, 283, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
615, 3pupB, 0.8458, 2.78, 0.343, 347, 280, STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OS1)
616, 4accA, 0.8457, 2.78, 0.335, 350, 281, GSK3B IN COMPLEX WITH INHIBITOR
617, 2jldA, 0.8457, 2.76, 0.339, 349, 280, EXTREMELY TIGHT BINDING OF RUTHENIUM COMPLEX TO GLYCOGEN SYNTHASE KINASE 3
618, 5acbD, 0.8456, 2.97, 0.428, 319, 285, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
619, 4f7lA, 0.8455, 2.36, 0.379, 328, 277, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 2 (TERT- BUTYL [3-({[3-TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5- YL]CARBAMOYL}AMINO)PROPYL]CARBAMATE)
620, 3pupA, 0.8455, 2.66, 0.341, 346, 279, STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OS1)
621, 6gn1A, 0.8454, 2.64, 0.336, 339, 277, CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3B) IN COMPLEX WITH PIK-75 
622, 5efqA, 0.8454, 2.96, 0.419, 321, 284, CRYSTAL STRUCTURE OF HUMAN CDK13/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
623, 6gn1B, 0.8452, 2.65, 0.336, 339, 277, CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3B) IN COMPLEX WITH PIK-75 
624, 1q5kA, 0.8452, 2.72, 0.335, 345, 278, CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 IN COMPLEXED WITH INHIBITOR
625, 4acdB, 0.8449, 2.80, 0.338, 350, 281, GSK3B IN COMPLEX WITH INHIBITOR
626, 3eb0C, 0.8443, 2.59, 0.350, 310, 274, CRYSTAL STRUCTURE OF CGD4_240 FROM CRYPTOSPORIDIUM PARVUM IN COMPLEX WITH INDIRUBIN E804
627, 1r0eB, 0.8443, 2.82, 0.335, 344, 281, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH 3-INDOLYL-4- ARYLMALEIMIDE INHIBITOR
628, 4i5hA, 0.8442, 2.38, 0.356, 335, 275, CRYSTAL STRUCTURE OF A DOUBLE MUTANT RAT ERK2 COMPLEXED WITH A TYPE II QUINAZOLINE INHIBITOR
629, 3f7zB, 0.8442, 2.62, 0.330, 339, 276, X-RAY CO-CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3BETA IN COMPLEX WITH AN INHIBITOR
630, 1gngA, 0.8442, 2.67, 0.333, 348, 279, GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3) COMPLEX WITH FRATTIDE PEPTIDE
631, 1r0eA, 0.8439, 2.82, 0.335, 344, 281, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH 3-INDOLYL-4- ARYLMALEIMIDE INHIBITOR
632, 4qp8B, 0.8438, 2.29, 0.341, 337, 273, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-7- (PYRIDIN-3-YL)-5H-PYRROLO[23-B]PYRAZINE
633, 4accB, 0.8438, 2.82, 0.335, 350, 281, GSK3B IN COMPLEX WITH INHIBITOR
634, 5airA, 0.8436, 2.74, 0.344, 353, 279, STRUCTURAL ANALYSIS OF MOUSE GSK3BETA FUSED WITH LRP6 PEPTIDE.
635, 4au8B, 0.8436, 2.41, 0.599, 277, 272, CRYSTAL STRUCTURE OF COMPOUND 4A IN COMPLEX WITH CDK5 SHOWING AN UNUSUAL BINDING MODE TO THE HINGE REGION VIA A WATER MOLECULE
636, 4nifE, 0.8435, 2.51, 0.361, 348, 277, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
637, 4f70A, 0.8435, 2.47, 0.383, 327, 277, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 4 (1-[3- TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]-3-[2-(MORPHOLIN-4-YL) ETHYL]UREA)
638, 4mq2A, 0.8434, 2.54, 0.337, 343, 273, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
639, 4iz5D, 0.8434, 2.52, 0.350, 347, 277, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
640, 4iz5B, 0.8434, 2.52, 0.350, 347, 277, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
641, 4iz5A, 0.8433, 2.52, 0.350, 347, 277, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
642, 4iz5C, 0.8432, 2.52, 0.350, 347, 277, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
643, 4bbmA, 0.8431, 2.69, 0.394, 314, 279, CRYSTAL STRUCTURE OF THE HUMAN CDKL2 KINASE DOMAIN WITH BOUND TCS 2312
644, 4nifB, 0.8430, 2.52, 0.357, 349, 277, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
645, 4f7jA, 0.8430, 2.40, 0.383, 326, 277, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 3 (1-[3- TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]-3-(2-HYDROXYETHYL) UREA)
646, 4qp9A, 0.8429, 2.28, 0.341, 335, 273, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-PROPYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
647, 4qp7A, 0.8429, 2.32, 0.341, 337, 273, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-5H- PYRROLO[23-B]PYRAZINE
648, 4fmqA, 0.8429, 2.56, 0.359, 350, 276, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
649, 2fysA, 0.8429, 2.51, 0.361, 348, 277, CRYSTAL STRUCTURE OF ERK2 COMPLEX WITH KIM PEPTIDE DERIVED FROM MKP3
650, 4e7wA, 0.8428, 2.74, 0.369, 359, 279, STRUCTURE OF GSK3 FROM USTILAGO MAYDIS
651, 5f95A, 0.8426, 2.58, 0.343, 345, 277, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 18: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-PHENYLPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
652, 4qp4A, 0.8426, 2.31, 0.341, 337, 273, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
653, 5hlpA, 0.8425, 2.66, 0.341, 337, 276, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH BRD3937
654, 4ec9A, 0.8425, 2.70, 0.406, 306, 278, CRYSTAL STRUCTURE OF FULL-LENGTH CDK9 IN COMPLEX WITH CYCLIN T
655, 4yljA, 0.8422, 2.55, 0.333, 346, 273, CRYSTAL STRUCTURE OF DYRK1A IN COMPLEX WITH 10-IODO-SUBSTITUTED 11H- INDOLO[32-C]QUINOLINE-6-CARBOXYLIC ACID INHIBITOR 5J
656, 4yu2A, 0.8421, 2.60, 0.332, 348, 274, CRYSTAL STRUCTURE OF DYRK1A WITH HARMINE-DERIVATIZED ANNH-75 INHIBITOR
657, 2vx3A, 0.8417, 2.55, 0.337, 346, 273, CRYSTAL STRUCTURE OF THE HUMAN DUAL SPECIFICITY TYROSINE- PHOSPHORYLATION-REGULATED KINASE 1A
658, 1pyxA, 0.8416, 2.70, 0.339, 343, 277, GSK-3 BETA COMPLEXED WITH AMP-PNP
659, 5airB, 0.8415, 2.78, 0.337, 361, 279, STRUCTURAL ANALYSIS OF MOUSE GSK3BETA FUSED WITH LRP6 PEPTIDE.
660, 4h3qA, 0.8414, 2.61, 0.361, 352, 277, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
661, 5lxdB, 0.8410, 2.57, 0.310, 385, 274, CRYSTAL STRUCTURE OF DYRK2 IN COMPLEX WITH EHT 1610 (COMPOUND 2)
662, 5lxdA, 0.8408, 2.57, 0.310, 385, 274, CRYSTAL STRUCTURE OF DYRK2 IN COMPLEX WITH EHT 1610 (COMPOUND 2)
663, 4yljC, 0.8407, 2.56, 0.333, 346, 273, CRYSTAL STRUCTURE OF DYRK1A IN COMPLEX WITH 10-IODO-SUBSTITUTED 11H- INDOLO[32-C]QUINOLINE-6-CARBOXYLIC ACID INHIBITOR 5J
664, 3fwqB, 0.8407, 2.63, 0.310, 334, 277, INACTIVE CONFORMATION OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
665, 2gphA, 0.8404, 2.55, 0.366, 345, 276, DOCKING MOTIF INTERACTIONS IN THE MAP KINASE ERK2
666, 1unlA, 0.8404, 2.67, 0.585, 292, 277, STRUCTURAL MECHANISM FOR THE INHIBITION OF CD5-P25 FROM THE ROSCOVITINE ALOISINE AND INDIRUBIN.
667, 4yljD, 0.8400, 2.56, 0.333, 347, 273, CRYSTAL STRUCTURE OF DYRK1A IN COMPLEX WITH 10-IODO-SUBSTITUTED 11H- INDOLO[32-C]QUINOLINE-6-CARBOXYLIC ACID INHIBITOR 5J
668, 3tniA, 0.8397, 2.57, 0.407, 297, 275, STRUCTURE OF CDK9/CYCLIN T F241L
669, 2y9qA, 0.8397, 2.54, 0.342, 349, 275, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
670, 4yu2B, 0.8396, 2.58, 0.333, 347, 273, CRYSTAL STRUCTURE OF DYRK1A WITH HARMINE-DERIVATIZED ANNH-75 INHIBITOR
671, 5cqwA, 0.8395, 2.59, 0.310, 331, 274, TETRAGONAL COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
672, 3u9cA, 0.8395, 2.54, 0.315, 331, 273, STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE ATP-COMPETITIVE INHIBITOR RESORUFIN
673, 3blrA, 0.8395, 2.66, 0.404, 300, 277, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1 IN COMPLEX WITH FLAVOPIRIDOL
674, 5ztnA, 0.8394, 2.50, 0.312, 395, 272, THE CRYSTAL STRUCTURE OF HUMAN DYRK2 IN COMPLEX WITH CURCUMIN 
675, 3h30B, 0.8394, 2.73, 0.310, 333, 277, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2 WITH 56-DICHLORO-1-BETA-D- RIBOFURANOSYLBENZIMIDAZOLE
676, 3u9cB, 0.8392, 2.54, 0.315, 331, 273, STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE ATP-COMPETITIVE INHIBITOR RESORUFIN
677, 5ztnB, 0.8390, 2.52, 0.316, 395, 272, THE CRYSTAL STRUCTURE OF HUMAN DYRK2 IN COMPLEX WITH CURCUMIN 
678, 4yljB, 0.8390, 2.58, 0.333, 347, 273, CRYSTAL STRUCTURE OF DYRK1A IN COMPLEX WITH 10-IODO-SUBSTITUTED 11H- INDOLO[32-C]QUINOLINE-6-CARBOXYLIC ACID INHIBITOR 5J
679, 4md7H, 0.8390, 2.54, 0.315, 330, 273, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
680, 5nqcA, 0.8389, 2.73, 0.310, 331, 277, CK2ALPHA IN COMPLEX WITH NMR154
681, 4au8A, 0.8388, 2.15, 0.578, 276, 268, CRYSTAL STRUCTURE OF COMPOUND 4A IN COMPLEX WITH CDK5 SHOWING AN UNUSUAL BINDING MODE TO THE HINGE REGION VIA A WATER MOLECULE
682, 5v61A, 0.8385, 2.41, 0.357, 348, 272, PHOSPHO-ERK2 BOUND TO BIVALENT INHIBITOR SBP2
683, 3q9xB, 0.8385, 2.54, 0.315, 330, 273, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 6.5
684, 3juhA, 0.8385, 2.69, 0.318, 334, 277, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PROTEIN KINASE CK2ALPHA WITH ALTERED COSUBSTRATE SPECIFICITY
685, 5h8bA, 0.8384, 2.58, 0.310, 331, 274, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 2
686, 3kvwA, 0.8384, 2.46, 0.312, 403, 272, CRYSTAL STRUCTURE OF DUAL-SPECIFICITY TYROSINE PHOSPHORYLATION REGULATED KINASE 2 (DYRK2) IN COMPLEX WITH AN INDIRUBIN LIGAND
687, 1pyxB, 0.8384, 2.67, 0.342, 338, 275, GSK-3 BETA COMPLEXED WITH AMP-PNP
688, 5cqwB, 0.8382, 2.60, 0.310, 331, 274, TETRAGONAL COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
689, 4md7E, 0.8382, 2.55, 0.315, 332, 273, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
690, 3q3bA, 0.8382, 2.75, 0.343, 344, 277, 6-AMINO-4-(PYRIMIDIN-4-YL)PYRIDONES: NOVEL GLYCOGEN SYNTHASE KINASE-3 INHIBITORS
691, 5oniB, 0.8381, 2.55, 0.310, 334, 274, LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
692, 2h96B, 0.8381, 2.44, 0.337, 357, 273, DISCOVERY OF POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PYRIDINE CARBOXAMIDE C-JUN NH2-TERMINAL KINASE INHIBITORS
693, 4yu2D, 0.8380, 2.59, 0.333, 346, 273, CRYSTAL STRUCTURE OF DYRK1A WITH HARMINE-DERIVATIZED ANNH-75 INHIBITOR
694, 3ngaB, 0.8380, 2.60, 0.310, 331, 274, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH CX-4945
695, 4md7F, 0.8379, 2.55, 0.315, 332, 273, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
696, 4yu2C, 0.8378, 2.61, 0.333, 346, 273, CRYSTAL STRUCTURE OF DYRK1A WITH HARMINE-DERIVATIZED ANNH-75 INHIBITOR
697, 3zu7A, 0.8378, 2.67, 0.371, 344, 278, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE MAP KINASE ERK2
698, 5h8eA, 0.8377, 2.59, 0.310, 331, 274, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7H
699, 5k5nA, 0.8376, 2.54, 0.338, 331, 272, CRYSTAL STRUCTURE OF GSK-3BETA COMPLEXED WITH PF-04802367 A HIGHLY SELECTIVE BRAIN-PENETRANT KINASE INHIBITOR
700, 4md7G, 0.8376, 2.57, 0.315, 332, 273, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
701, 4azfA, 0.8376, 2.57, 0.312, 404, 272, HUMAN DYRK2 IN COMPLEX WITH LEUCETTINE L41
702, 3rpsA, 0.8376, 2.50, 0.315, 334, 273, STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 3-(4567-TETRABROMO-1H-BENZOTRIAZOL-1-YL)PROPAN-1-OL
703, 1q3wB, 0.8376, 2.72, 0.337, 341, 276, GSK-3 BETA COMPLEXED WITH ALSTERPAULLONE
704, 3od6X, 0.8375, 2.37, 0.359, 344, 270, CRYSTAL STRUCTURE OF P38ALPHA Y323T ACTIVE MUTANT
705, 3ngaA, 0.8375, 2.61, 0.310, 331, 274, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH CX-4945
706, 4kwpA, 0.8374, 2.64, 0.310, 329, 274, CRYSTAL STRUCTURE OF HUMAN CK2-ALPHA IN COMPLEX WITH A BENZIMIDAZOLE INHIBITOR (K164) AT 1.25 A RESOLUTION
707, 3q9zA, 0.8374, 2.62, 0.310, 332, 274, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 6.5
708, 3be9A, 0.8374, 2.61, 0.310, 327, 274, STRUCTURE-BASED DESIGN AND SYNTHESIS OF NOVEL MACROCYCLIC PYRAZOLO[15-A] [135]TRIAZINE COMPOUNDS AS POTENT INHIBITORS OF PROTEIN KINASE CK2 AND THEIR ANTICANCER ACTIVITIES
709, 5ooiB, 0.8373, 2.65, 0.320, 325, 275, STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
710, 3ofmA, 0.8373, 2.60, 0.321, 325, 274, STRUCTURE OF A HUMAN CK2ALPHA PRIME THE PARALOG ISOFORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM HOMO SAPIENS
711, 1q3wA, 0.8373, 2.79, 0.343, 344, 277, GSK-3 BETA COMPLEXED WITH ALSTERPAULLONE
712, 5v62A, 0.8372, 2.55, 0.359, 349, 273, PHOSPHO-ERK2 BOUND TO BIVALENT INHIBITOR SBP3
713, 5kwhA, 0.8372, 2.62, 0.310, 331, 274, CRYSTAL STRUCTURE OF CK2
714, 4ubaA, 0.8371, 2.52, 0.308, 333, 273, LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26)
715, 5kwhB, 0.8370, 2.62, 0.310, 331, 274, CRYSTAL STRUCTURE OF CK2
716, 4mq1A, 0.8370, 2.52, 0.339, 345, 271, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
717, 5m56A, 0.8369, 2.61, 0.321, 331, 274, MONOCLINIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
718, 3q9zB, 0.8369, 2.54, 0.315, 332, 273, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 6.5
719, 4mq2D, 0.8367, 2.60, 0.338, 329, 272, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
720, 2vx3B, 0.8367, 2.57, 0.338, 340, 272, CRYSTAL STRUCTURE OF THE HUMAN DUAL SPECIFICITY TYROSINE- PHOSPHORYLATION-REGULATED KINASE 1A
721, 5ooiA, 0.8366, 2.62, 0.318, 329, 274, STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
722, 4gubA, 0.8366, 2.52, 0.311, 329, 273, CASEIN KINASE II BOUND TO INHIBITOR
723, 3o2mB, 0.8366, 2.43, 0.337, 358, 273, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM COMPLEX WITH A BIARYL TETRAZOL (A-82118)
724, 3du8A, 0.8366, 2.69, 0.338, 336, 275, CRYSTAL STRUCTURE OF GSK-3 BETA IN COMPLEX WITH NMS-869553A
725, 3q9xA, 0.8365, 2.63, 0.310, 330, 274, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 6.5
726, 4azeC, 0.8364, 2.63, 0.337, 348, 273, HUMAN DYRK1A IN COMPLEX WITH LEUCETTINE L41
727, 4azeB, 0.8364, 2.63, 0.337, 345, 273, HUMAN DYRK1A IN COMPLEX WITH LEUCETTINE L41
728, 4azeA, 0.8364, 2.63, 0.337, 348, 273, HUMAN DYRK1A IN COMPLEX WITH LEUCETTINE L41
729, 3qa0B, 0.8364, 2.57, 0.315, 330, 273, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 6.5
730, 5omyA, 0.8363, 2.53, 0.315, 332, 273, HIGH-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
731, 4md8F, 0.8363, 2.68, 0.309, 332, 275, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
732, 4md8E, 0.8363, 2.70, 0.309, 332, 275, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
733, 4fbxA, 0.8363, 2.52, 0.315, 333, 273, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT CRYSTALLIZED IN THE PRESENCE OF A BISUBSTRATE INHIBITOR
734, 3h30A, 0.8363, 2.75, 0.310, 333, 277, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2 WITH 56-DICHLORO-1-BETA-D- RIBOFURANOSYLBENZIMIDAZOLE
735, 3u87A, 0.8362, 2.61, 0.310, 329, 274, STRUCTURE OF A CHIMERIC CONSTRUCT OF HUMAN CK2ALPHA AND HUMAN CK2ALPHA  IN COMPLEX WITH A NON-HYDROLYSABLE ATP-ANALOGUE
736, 3q04A, 0.8362, 2.55, 0.311, 328, 273, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 8.5
737, 3juhB, 0.8362, 2.73, 0.318, 334, 277, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PROTEIN KINASE CK2ALPHA WITH ALTERED COSUBSTRATE SPECIFICITY
738, 5t1hA, 0.8361, 2.61, 0.310, 331, 274, CRYSTAL STRUCTURE OF CK2
739, 5owhA, 0.8361, 2.52, 0.315, 334, 273, HIGH SALT STRUCTURE OF HUMAN PROTEIN KINASE CK2ALPHA IN COMPLEX WITH 3-AMINOPROPYL-4;5;6;7-TETRABROMOBENZIMIDAZOL 
740, 5h8eB, 0.8361, 2.63, 0.310, 331, 274, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7H
741, 2wo6B, 0.8361, 2.56, 0.338, 339, 272, HUMAN DUAL-SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 1A IN COMPLEX WITH A CONSENSUS SUBSTRATE PEPTIDE
742, 4md8G, 0.8360, 2.61, 0.307, 332, 274, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
743, 4ib5A, 0.8360, 2.64, 0.318, 331, 274, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
744, 5cquA, 0.8359, 2.53, 0.311, 328, 273, MONOCLINIC COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
745, 4mq2C, 0.8359, 2.61, 0.338, 339, 272, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
746, 3qa0A, 0.8358, 2.64, 0.310, 330, 274, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 6.5
747, 2vx3C, 0.8358, 2.59, 0.338, 338, 272, CRYSTAL STRUCTURE OF THE HUMAN DUAL SPECIFICITY TYROSINE- PHOSPHORYLATION-REGULATED KINASE 1A
748, 5h8bB, 0.8357, 2.64, 0.310, 331, 274, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 2
749, 5cu2A, 0.8357, 2.61, 0.314, 328, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND (METHYL 4-((3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)AMINO)-4- OXOBUTANOAT BOUND
750, 4qnyA, 0.8357, 2.58, 0.307, 333, 277, CRYSTAL STRUCTURE OF MAPK FROM LEISHMANIA DONOVANI LDBPK_331470
751, 4nh1A, 0.8357, 2.64, 0.307, 330, 274, CRYSTAL STRUCTURE OF A HETEROTETRAMERIC CK2 HOLOENZYME COMPLEX CARRYING THE ANDANTE-MUTATION IN CK2BETA AND CONSISTENT WITH PROPOSED MODELS OF AUTOINHIBITION AND TRANS-AUTOPHOSPHORYLATION
752, 3u87B, 0.8357, 2.69, 0.313, 329, 275, STRUCTURE OF A CHIMERIC CONSTRUCT OF HUMAN CK2ALPHA AND HUMAN CK2ALPHA  IN COMPLEX WITH A NON-HYDROLYSABLE ATP-ANALOGUE
753, 3q3bB, 0.8357, 2.73, 0.337, 341, 276, 6-AMINO-4-(PYRIMIDIN-4-YL)PYRIDONES: NOVEL GLYCOGEN SYNTHASE KINASE-3 INHIBITORS
754, 2pvmA, 0.8357, 2.64, 0.310, 327, 274, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
755, 2pvkA, 0.8357, 2.64, 0.310, 327, 274, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
756, 5n1vB, 0.8356, 2.63, 0.310, 331, 274, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH PYRAZOLO-PYRIMIDINE MACROCYCLIC LIGAND
757, 5lxcB, 0.8356, 2.72, 0.318, 385, 274, CRYSTAL STRUCTURE OF DYRK2 IN COMPLEX WITH EHT 5372 (COMPOUND 1)
758, 4rlkA, 0.8356, 2.62, 0.314, 327, 274, CRYSTAL STRUCTURE OF Z. MAYS CK2ALPHA IN COMPLEX WITH THE ATP- COMPETITIVE INHIBITOR 4-[(E)-(FLUOREN-9-YLIDENEHYDRAZINYLIDENE)- METHYL] BENZOATE
759, 3o17B, 0.8356, 2.44, 0.342, 357, 272, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM
760, 3k2lA, 0.8355, 2.58, 0.312, 402, 272, CRYSTAL STRUCTURE OF DUAL-SPECIFICITY TYROSINE PHOSPHORYLATION REGULATED KINASE 2 (DYRK2)
761, 2vx3D, 0.8355, 2.58, 0.338, 342, 272, CRYSTAL STRUCTURE OF THE HUMAN DUAL SPECIFICITY TYROSINE- PHOSPHORYLATION-REGULATED KINASE 1A
762, 4nh1B, 0.8354, 2.69, 0.313, 332, 275, CRYSTAL STRUCTURE OF A HETEROTETRAMERIC CK2 HOLOENZYME COMPLEX CARRYING THE ANDANTE-MUTATION IN CK2BETA AND CONSISTENT WITH PROPOSED MODELS OF AUTOINHIBITION AND TRANS-AUTOPHOSPHORYLATION
763, 4md8H, 0.8354, 2.70, 0.313, 331, 275, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
764, 3q9wA, 0.8354, 2.67, 0.318, 328, 274, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 8.5
765, 1ds5A, 0.8354, 2.69, 0.316, 328, 275, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
766, 5cu0A, 0.8353, 2.54, 0.311, 327, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND N-(3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)ACETAMIDE BOUND
767, 3wowA, 0.8353, 2.60, 0.307, 334, 274, CRYSTAL STRUCTURE OF HUMAN CK2A WITH AMPPNP
768, 3c13A, 0.8353, 2.59, 0.319, 328, 273, LOW PH-VALUE CRYSTAL STRUCTURE OF EMODIN IN COMPLEX WITH THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
769, 2pvjA, 0.8353, 2.65, 0.310, 326, 274, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
770, 1jamA, 0.8353, 2.70, 0.316, 327, 275, CRYSTAL STRUCTURE OF APO-FORM OF Z. MAYS CK2 PROTEIN KINASE ALPHA SUBUNIT
771, 1ds5C, 0.8353, 2.68, 0.316, 328, 275, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
772, 5owlB, 0.8352, 2.63, 0.310, 332, 274, LOW SALT STRUCTURE OF HUMAN PROTEIN KINASE CK2ALPHA IN COMPLEX WITH 3- AMINOPROPYL-4;5;6;7-TETRABROMOBENZIMIDAZOL 
773, 5oniA, 0.8352, 2.61, 0.310, 334, 274, LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
774, 5ku8B, 0.8352, 2.65, 0.310, 331, 274, CRYSTAL STRUCTURE OF CK2
775, 1i09B, 0.8352, 2.75, 0.337, 341, 276, STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 (GSK3B)
776, 3pzhA, 0.8351, 2.68, 0.316, 327, 275, CRYSTAL STRUCTURE OF MAIZE CK2 ALPHA IN COMPLEX WITH EMODIN AT 1.92 A RESOLUTION
777, 1lpuA, 0.8351, 2.69, 0.316, 327, 275, LOW TEMPERATURE CRYSTAL STRUCTURE OF THE APO-FORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM ZEA MAYS
778, 4qteA, 0.8350, 2.50, 0.359, 348, 273, STRUCTURE OF ERK2 IN COMPLEX WITH VTX-11E 4-{2-[(2-CHLORO-4- FLUOROPHENYL)AMINO]-5-METHYLPYRIMIDIN-4-YL}-N-[(1S)-1-(3- CHLOROPHENYL)-2-HYDROXYETHYL]-1H-PYRROLE-2-CARBOXAMIDE
779, 3pvgA, 0.8349, 2.69, 0.316, 326, 275, CRYSTAL STRUCTURE OF Z. MAYS CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMO-1-CARBOXYMETHYLBENZIMIDAZOLE (K68)
780, 3fl5A, 0.8349, 2.63, 0.314, 324, 274, PROTEIN KINASE CK2 IN COMPLEX WITH THE INHIBITOR QUINALIZARIN
781, 2pvhA, 0.8349, 2.70, 0.313, 327, 275, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
782, 5n1vA, 0.8348, 2.63, 0.310, 331, 274, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH PYRAZOLO-PYRIMIDINE MACROCYCLIC LIGAND
783, 4mq1B, 0.8348, 2.56, 0.339, 340, 271, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
784, 2pvnA, 0.8348, 2.70, 0.313, 327, 275, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
785, 1ds5D, 0.8348, 2.70, 0.316, 328, 275, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
786, 5t1hB, 0.8347, 2.66, 0.310, 331, 274, CRYSTAL STRUCTURE OF CK2
787, 4lfiA, 0.8347, 2.73, 0.287, 370, 275, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
788, 5cx9A, 0.8346, 2.64, 0.314, 328, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH (METHYL 4-((3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)AMINO)-4-OXOBUTANOATE BOUND
789, 5ctpB, 0.8346, 2.65, 0.314, 327, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)ACETAMIDE BOUND
790, 4md9F, 0.8346, 2.61, 0.310, 327, 274, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
791, 4lfiB, 0.8346, 2.73, 0.287, 371, 275, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
792, 1q99A, 0.8346, 2.78, 0.300, 354, 277, CRYSTAL STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINSAE SKY1P COMPLEXED WITH THE NON-HYDROLYZABLE ATP ANALOGUE AMP-PNP
793, 1ds5B, 0.8346, 2.70, 0.316, 328, 275, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
794, 5n9lA, 0.8345, 2.67, 0.310, 329, 274, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE DIBENZOFURAN INHIBITOR TF (4B)
795, 5lw1B, 0.8345, 2.68, 0.341, 355, 279, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_232_11_D12 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
796, 4mq2B, 0.8345, 2.73, 0.338, 338, 272, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
797, 3w55A, 0.8345, 2.30, 0.344, 335, 270, THE STRUCTURE OF ERK2 IN COMPLEX WITH FR148083
798, 3du8B, 0.8345, 2.72, 0.345, 339, 275, CRYSTAL STRUCTURE OF GSK-3 BETA IN COMPLEX WITH NMS-869553A
799, 5kplB, 0.8344, 2.71, 0.338, 339, 275, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH BRD0705
800, 4md9E, 0.8344, 2.72, 0.309, 329, 275, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
801, 3bqcA, 0.8344, 2.61, 0.319, 328, 273, HIGH PH-VALUE CRYSTAL STRUCTURE OF EMODIN IN COMPLEX WITH THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
802, 2zjwA, 0.8344, 2.60, 0.314, 332, 274, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA COMPLEXED WITH ELLAGIC ACID
803, 2jd5A, 0.8344, 2.66, 0.305, 353, 275, SKY1P BOUND TO NPL3P-DERIVED SUBSTRATE PEPTIDE
804, 5ct0A, 0.8343, 2.55, 0.311, 326, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH 3-(3-CHLORO-4-(PHENYL)BENZYLAMINO) PROPAN-1-OL BOUND
805, 5v60A, 0.8342, 2.47, 0.364, 347, 272, PHOSPHO-ERK2 BOUND TO AMP-PCP
806, 5moeA, 0.8342, 2.53, 0.312, 325, 272, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
807, 5mmrA, 0.8342, 2.55, 0.311, 326, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-((2-CHLORO-[11 -BIPHENYL]-4-YL) METHYL)BUTANE-14-DIAMINE BOUND
808, 3kxgA, 0.8342, 2.71, 0.316, 326, 275, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR 34567-PENTABROMO-1H-INDAZOLE (K64)
809, 3f7zA, 0.8342, 2.62, 0.330, 339, 273, X-RAY CO-CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3BETA IN COMPLEX WITH AN INHIBITOR
810, 5cu0B, 0.8341, 2.57, 0.311, 325, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND N-(3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)ACETAMIDE BOUND
811, 4md9K, 0.8341, 2.71, 0.309, 328, 275, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
812, 1q8zA, 0.8341, 2.79, 0.303, 354, 277, THE APOENZYME STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P
813, 5t31B, 0.8340, 2.63, 0.341, 333, 273, EXPLOITING AN ASP-GLU SWITCH IN GLYCOGEN SYNTHASE KINASE 3 TO DESIGN PARALOG SELECTIVE INHIBITORS FOR USE IN ACUTE MYELOID LEUKEMIA
814, 5clpB, 0.8340, 2.63, 0.314, 327, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH 34-DICHLOROPHENETHYLAMINE BOUND
815, 4ib5C, 0.8340, 2.72, 0.313, 332, 275, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
816, 1lr4A, 0.8340, 2.71, 0.316, 327, 275, ROOM TEMPERATURE CRYSTAL STRUCTURE OF THE APO-FORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM ZEA MAYS
817, 5nhjA, 0.8339, 2.50, 0.355, 345, 273, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
818, 5lw1E, 0.8339, 2.83, 0.352, 355, 281, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_232_11_D12 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
819, 4qnyB, 0.8339, 2.61, 0.310, 339, 277, CRYSTAL STRUCTURE OF MAPK FROM LEISHMANIA DONOVANI LDBPK_331470
820, 4md9P, 0.8339, 2.72, 0.309, 328, 275, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
821, 4md9G, 0.8339, 2.62, 0.310, 329, 274, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
822, 3o0gA, 0.8339, 2.68, 0.589, 289, 275, CRYSTAL STRUCTURE OF CDK5:P25 IN COMPLEX WITH AN ATP ANALOGUE
823, 2pvlA, 0.8339, 2.67, 0.310, 327, 274, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
824, 1zohA, 0.8339, 2.71, 0.316, 326, 275, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES INHIBITORS
825, 5y86A, 0.8338, 2.70, 0.311, 391, 273, CRYSTAL STRUCTURE OF KINASE 
826, 5hlpB, 0.8338, 2.65, 0.341, 335, 273, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH BRD3937
827, 3nieA, 0.8338, 2.66, 0.384, 369, 276, CRYSTAL STRUCTURE OF PF11_0147
828, 4md9H, 0.8337, 2.73, 0.309, 328, 275, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
829, 4anmA, 0.8337, 2.72, 0.316, 328, 275, COMPLEX OF CK2 WITH A CDC7 INHIBITOR
830, 3at2A, 0.8337, 2.64, 0.307, 334, 274, CRYSTAL STRUCTURE OF CK2ALPHA
831, 5oueA, 0.8336, 2.65, 0.314, 328, 274, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 20
832, 5mmfA, 0.8336, 2.57, 0.311, 326, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 7 BOUND
833, 4dgmA, 0.8336, 2.72, 0.316, 326, 275, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH THE INHIBITOR APIGENIN
834, 5modA, 0.8335, 2.57, 0.311, 327, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
835, 4md9M, 0.8335, 2.73, 0.309, 331, 275, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
836, 3wilA, 0.8335, 2.55, 0.311, 331, 273, CRYSTAL STRUCTURE OF THE CK2ALPHA/COMPOUND3 COMPLEX
837, 3r0tA, 0.8335, 2.65, 0.314, 327, 274, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR CX-5279
838, 3o2mA, 0.8334, 2.46, 0.337, 358, 273, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM COMPLEX WITH A BIARYL TETRAZOL (A-82118)
839, 5lw1H, 0.8333, 2.65, 0.356, 355, 278, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_232_11_D12 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
840, 5buiA, 0.8333, 2.23, 0.353, 338, 269, ERK2 COMPLEXED WITH 2-PYRIDIYL TETRAHYDROAZAINDAZOLE
841, 4izaA, 0.8333, 2.57, 0.364, 346, 275, STRUCTURE OF DUALLY PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
842, 3rpsB, 0.8333, 2.49, 0.312, 334, 272, STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 3-(4567-TETRABROMO-1H-BENZOTRIAZOL-1-YL)PROPAN-1-OL
843, 5m4uA, 0.8332, 2.59, 0.322, 332, 273, ORTHORHOMBIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
844, 5ku8A, 0.8332, 2.64, 0.311, 328, 273, CRYSTAL STRUCTURE OF CK2
845, 3warA, 0.8332, 2.65, 0.307, 334, 274, CRYSTAL STRUCTURE OF HUMAN CK2A
846, 3owlA, 0.8332, 2.74, 0.313, 330, 275, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A BENZOPYRIDOINDOLE DERIVATIVE INHIBITOR
847, 3kxmA, 0.8332, 2.73, 0.316, 326, 275, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR K74
848, 1zoeA, 0.8332, 2.73, 0.316, 325, 275, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES INHIBITORS
849, 1di9A, 0.8332, 2.68, 0.357, 348, 277, THE STRUCTURE OF P38 MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH 4-[3-METHYLSULFANYLANILINO]-67- DIMETHOXYQUINAZOLINE
850, 5csvA, 0.8331, 2.62, 0.319, 327, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 6 BOUND
851, 5cspA, 0.8331, 2.61, 0.319, 327, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 5 BOUND
852, 4md9L, 0.8331, 2.76, 0.309, 328, 275, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
853, 1m2qA, 0.8331, 2.76, 0.316, 327, 275, CRYSTAL STRUCTURE OF 18-DI-HYDROXY-4-NITRO-XANTEN-9- ONE/CK2 KINASE COMPLEX
854, 1dayA, 0.8331, 2.64, 0.314, 327, 274, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF PROTEIN KINASE CK2 (ALPHA-SUBUNIT) AND MG-GMPPNP
855, 6g97A, 0.8330, 2.48, 0.360, 344, 272, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
856, 4cxaC, 0.8330, 2.91, 0.419, 330, 279, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLIN K COMPLEX BOUND TO AMPPNP
857, 3pe2A, 0.8330, 2.65, 0.314, 327, 274, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 IN COMPLEX WITH THE INHIBITOR CX-5011
858, 1om1A, 0.8330, 2.72, 0.316, 325, 275, CRYSTAL STRUCTURE OF MAIZE CK2 ALPHA IN COMPLEX WITH IQA
859, 1m2pA, 0.8330, 2.73, 0.316, 325, 275, CRYSTAL STRUCTURE OF 18-DI-HYDROXY-4-NITRO- ANTHRAQUINONE/CK2 KINASE COMPLEX
860, 4dgnA, 0.8329, 2.72, 0.316, 325, 275, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH THE INHIBITOR LUTEOLIN
861, 3kxnA, 0.8329, 2.72, 0.316, 327, 275, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR TETRAIODOBENZIMIDAZOLE (K88)
862, 3at3A, 0.8329, 2.58, 0.311, 332, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH PYRADINE DERIVATIVE
863, 1j91B, 0.8329, 2.81, 0.315, 327, 276, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 4567- TETRABROMOBENZOTRIAZOLE
864, 1dawA, 0.8329, 2.72, 0.316, 327, 275, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF PROTEIN KINASE CK2 (ALPHA-SUBUNIT) AND MG-AMPPNP
865, 6gmdB, 0.8328, 2.58, 0.311, 326, 273, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 3 
866, 5ts8A, 0.8328, 2.64, 0.321, 332, 274, Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 56-DIBROMOBENZOTRIAZOLE
867, 5ot5A, 0.8328, 2.59, 0.311, 326, 273, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 24
868, 4rllA, 0.8328, 2.66, 0.314, 329, 274, CRYSTAL STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP- COMPETITIVE INHIBITOR 4-[(E)-(FLUOREN-9-YLIDENEHYDRAZINYLIDENE)- METHYL] BENZOATE
869, 1xo2B, 0.8328, 2.42, 0.469, 289, 271, CRYSTAL STRUCTURE OF A HUMAN CYCLIN-DEPENDENT KINASE 6 COMPLEX WITH A FLAVONOL INHIBITOR FISETIN
870, 1jwhB, 0.8328, 2.76, 0.313, 335, 275, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 HOLOENZYME
871, 5otzA, 0.8327, 2.67, 0.314, 327, 274, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 1
872, 5os7A, 0.8327, 2.58, 0.311, 326, 273, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 4
873, 5mpjA, 0.8327, 2.61, 0.311, 326, 273, 1-(2-CHLORO-[11 -BIPHENYL]-4-YL)-N-METHYLETHANAMINE
874, 3wikA, 0.8327, 2.64, 0.307, 334, 274, CRYSTAL STRUCTURE OF THE CK2ALPHA/COMPOUND10 COMPLEX
875, 3owkA, 0.8327, 2.75, 0.313, 330, 275, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A BENZOPYRIDOINDOLE DERIVATIVE INHIBITOR
876, 5mohA, 0.8326, 2.57, 0.316, 326, 272, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0583 BOUND.
877, 3owjA, 0.8326, 2.76, 0.313, 328, 275, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A PYRIDOCARBAZOLE DERIVATIVE INHIBITOR
878, 1lp4A, 0.8326, 2.72, 0.316, 327, 275, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 WITH MG-AMPPNP
879, 5u6iA, 0.8325, 2.49, 0.357, 339, 272, DISCOVERY OF MLI-2 AN ORALLY AVAILABLE AND SELECTIVE LRRK2 INHIBITOR THAT REDUCES BRAIN KINASE ACTIVITY
880, 5mp8A, 0.8324, 2.56, 0.312, 325, 272, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
881, 5lxcA, 0.8324, 2.68, 0.316, 383, 272, CRYSTAL STRUCTURE OF DYRK2 IN COMPLEX WITH EHT 5372 (COMPOUND 1)
882, 4mwhA, 0.8324, 2.75, 0.287, 371, 275, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH ATP
883, 4dgoA, 0.8324, 2.73, 0.316, 325, 275, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH TYRPHOSTIN AG99
884, 3pe1A, 0.8324, 2.66, 0.314, 327, 274, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR CX-4945
885, 3at4A, 0.8324, 2.59, 0.311, 331, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH PYRADINE DERIVERTIVE
886, 5nhhA, 0.8323, 2.53, 0.359, 348, 273, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
887, 5motA, 0.8323, 2.64, 0.319, 328, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0627 BOUND
888, 4fi1A, 0.8323, 2.75, 0.287, 371, 275, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH ATP
889, 3q9yA, 0.8323, 2.69, 0.314, 327, 274, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 8.5
890, 5otlB, 0.8322, 2.60, 0.311, 326, 273, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 29
891, 5mo7A, 0.8322, 2.59, 0.311, 327, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
892, 2pvrA, 0.8322, 2.67, 0.314, 328, 274, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 (C- TERMINAL DELETION MUTANT 1-335) IN COMPLEX WITH TWO SULFATE IONS
893, 5oslA, 0.8321, 2.66, 0.314, 328, 274, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 7
894, 5orjA, 0.8321, 2.56, 0.312, 325, 272, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 3
895, 3nieB, 0.8321, 2.69, 0.384, 367, 276, CRYSTAL STRUCTURE OF PF11_0147
896, 1pjkA, 0.8321, 2.65, 0.314, 331, 274, CRYSTAL STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
897, 4ptgA, 0.8320, 2.68, 0.352, 333, 273, STRUCTURE OF A CARBOXAMINE COMPOUND (26) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-METHOXYPYRIMIDINE-5-CARBOXAMIDE) TO GSK3B
898, 2qc6A, 0.8320, 2.73, 0.316, 326, 275, PROTEIN KINASE CK2 IN COMPLEX WITH DBC
899, 2oxxA, 0.8320, 2.75, 0.316, 325, 275, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
900, 1wbwA, 0.8320, 2.68, 0.361, 351, 277, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
901, 5mo5A, 0.8319, 2.55, 0.312, 326, 272, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
902, 4mygA, 0.8319, 2.68, 0.380, 335, 274, MAPK13 ACTIVE FORM
903, 3blqA, 0.8319, 2.68, 0.411, 295, 275, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1 IN COMPLEX WITH ATP
904, 1na7A, 0.8319, 2.64, 0.314, 326, 274, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2
905, 1f0qA, 0.8319, 2.74, 0.316, 329, 275, CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT OF PROTEIN KINASE CK2 IN COMPLEX WITH THE NUCLEOTIDE COMPETITIVE INHIBITOR EMODIN
906, 4ubaB, 0.8318, 2.65, 0.310, 333, 274, LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26)
907, 3mb6A, 0.8318, 2.66, 0.319, 329, 273, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A DIFURANE DERIVATIVE INHIBITOR (CPA)
908, 3gc9A, 0.8318, 2.26, 0.361, 335, 269, THE STRUCTURE OF P38BETA C119S C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE INHIBITOR
909, 1q41A, 0.8317, 2.73, 0.343, 339, 274, GSK-3 BETA COMPLEXED WITH INDIRUBIN-3 -MONOXIME
910, 6gmdA, 0.8316, 2.58, 0.309, 325, 272, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 3 
911, 5os8A, 0.8316, 2.68, 0.314, 327, 274, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 11
912, 5orjB, 0.8316, 2.59, 0.312, 324, 272, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 3
913, 5orhB, 0.8316, 2.57, 0.312, 325, 272, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 2
914, 4grbA, 0.8316, 2.56, 0.309, 327, 272, CASEIN KINASE 2 (CK2) BOUND TO INHIBITOR
915, 3zduA, 0.8316, 2.69, 0.349, 297, 275, CRYSTAL STRUCTURE OF THE HUMAN CDKL3 KINASE DOMAIN
916, 5nhoA, 0.8315, 2.53, 0.355, 343, 273, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
917, 5cu6A, 0.8315, 2.72, 0.314, 327, 274, CRYSTAL STRUCTURE OF CK2ALPHA
918, 3kxhA, 0.8315, 2.74, 0.316, 326, 275, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR (2-DYMETHYLAMMINO-4567-TETRABROMOBENZOIMIDAZOL-1YL- ACETIC ACID (K66)
919, 6ehkA, 0.8314, 2.70, 0.314, 327, 274, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH CAM4712 AND COMPOUND 37
920, 5oumA, 0.8314, 2.60, 0.311, 326, 273, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 21
921, 5othA, 0.8314, 2.61, 0.311, 326, 273, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 26
922, 5os7B, 0.8314, 2.59, 0.309, 325, 272, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 4
923, 3axwA, 0.8314, 2.68, 0.310, 329, 274, CRYSTAL STRUCTURE OF HUMAN CK2ALPHA COMPLEXED WITH A POTENT INHIBITOR
924, 1zogA, 0.8314, 2.73, 0.316, 325, 275, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES
925, 5otrA, 0.8313, 2.73, 0.314, 327, 274, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 14
926, 3fwqA, 0.8313, 2.80, 0.310, 334, 277, INACTIVE CONFORMATION OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
927, 5owlA, 0.8312, 2.74, 0.310, 331, 274, LOW SALT STRUCTURE OF HUMAN PROTEIN KINASE CK2ALPHA IN COMPLEX WITH 3- AMINOPROPYL-4;5;6;7-TETRABROMOBENZIMIDAZOL 
928, 5k5nB, 0.8312, 2.48, 0.338, 334, 269, CRYSTAL STRUCTURE OF GSK-3BETA COMPLEXED WITH PF-04802367 A HIGHLY SELECTIVE BRAIN-PENETRANT KINASE INHIBITOR
929, 5cu2B, 0.8312, 2.58, 0.312, 325, 272, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND (METHYL 4-((3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)AMINO)-4- OXOBUTANOAT BOUND
930, 4kinB, 0.8312, 2.41, 0.375, 341, 272, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
931, 2oxdA, 0.8312, 2.75, 0.316, 325, 275, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE K17 K22 AND K32 INHIBITORS
932, 1h4lA, 0.8312, 2.36, 0.569, 278, 267, STRUCTURE AND REGULATION OF THE CDK5-P25(NCK5A) COMPLEX
933, 5n9nA, 0.8311, 2.68, 0.314, 329, 274, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE TIGHT-BINDING DIBENZOFURAN INHIBITOR TF85 (4A)
934, 5cvhA, 0.8311, 2.63, 0.311, 327, 273, CRYSTAL STRUCTURE OF CK2ALPHA
935, 5oulA, 0.8310, 2.72, 0.314, 327, 274, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 9
936, 5otyA, 0.8310, 2.71, 0.314, 327, 274, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH CAM4712
937, 5ot6B, 0.8310, 2.58, 0.312, 326, 272, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 19
938, 5cshA, 0.8310, 2.59, 0.312, 324, 272, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 4 BOUND
939, 4kipB, 0.8310, 2.34, 0.378, 338, 270, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 2-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-13-THIAZOLE-5-CARBOXAMIDE
940, 5orkA, 0.8309, 2.60, 0.312, 324, 272, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 6
941, 5mo6B, 0.8309, 2.58, 0.312, 324, 272, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
942, 3gc9B, 0.8309, 2.34, 0.343, 339, 271, THE STRUCTURE OF P38BETA C119S C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE INHIBITOR
943, 5otoA, 0.8308, 2.63, 0.311, 327, 273, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 30
944, 5mo8A, 0.8308, 2.61, 0.311, 325, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
945, 5mmfB, 0.8308, 2.58, 0.312, 325, 272, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 7 BOUND
946, 5b0xA, 0.8308, 2.68, 0.310, 329, 274, CRYSTAL STRUCTURE OF THE CK2A/BENZOIC ACID DERIVATIVE COMPLEX
947, 5mmrB, 0.8307, 2.57, 0.312, 325, 272, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-((2-CHLORO-[11 -BIPHENYL]-4-YL) METHYL)BUTANE-14-DIAMINE BOUND
948, 5n9kA, 0.8306, 2.68, 0.314, 329, 274, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE TIGHT-BINDING DIBENZOFURAN INHIBITOR TF107 (5)
949, 5mpjB, 0.8306, 2.59, 0.312, 324, 272, 1-(2-CHLORO-[11 -BIPHENYL]-4-YL)-N-METHYLETHANAMINE
950, 5cu4A, 0.8306, 2.67, 0.314, 327, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
951, 2zoqB, 0.8306, 2.35, 0.370, 351, 270, STRUCTURAL DISSECTION OF HUMAN MITOGEN-ACTIVATED KINASE ERK1
952, 2wo6A, 0.8306, 2.85, 0.337, 344, 273, HUMAN DUAL-SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 1A IN COMPLEX WITH A CONSENSUS SUBSTRATE PEPTIDE
953, 1q99B, 0.8306, 2.69, 0.296, 364, 277, CRYSTAL STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINSAE SKY1P COMPLEXED WITH THE NON-HYDROLYZABLE ATP ANALOGUE AMP-PNP
954, 5otdA, 0.8305, 2.63, 0.311, 327, 273, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 25
955, 5orhA, 0.8305, 2.60, 0.312, 324, 272, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 2
956, 5mo7B, 0.8305, 2.57, 0.312, 325, 272, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
957, 5mo5B, 0.8305, 2.59, 0.312, 325, 272, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
958, 5cx9B, 0.8305, 2.59, 0.312, 325, 272, CRYSTAL STRUCTURE OF CK2ALPHA WITH (METHYL 4-((3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)AMINO)-4-OXOBUTANOATE BOUND
959, 1q5kB, 0.8305, 2.79, 0.338, 344, 275, CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 IN COMPLEXED WITH INHIBITOR
960, 6ehuB, 0.8304, 2.77, 0.314, 327, 274, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 32
961, 5ot6A, 0.8304, 2.63, 0.311, 327, 273, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 19
962, 5ot5B, 0.8304, 2.60, 0.312, 325, 272, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 24
963, 5mo6A, 0.8304, 2.57, 0.312, 325, 272, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
964, 5kplA, 0.8304, 2.66, 0.337, 339, 273, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH BRD0705
965, 4jqeA, 0.8304, 2.80, 0.287, 369, 275, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH AMPPN
966, 3zuvC, 0.8303, 2.69, 0.380, 357, 274, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE PHOSPHORYLATED MAP KINASE ERK2
967, 2h96A, 0.8303, 2.59, 0.355, 358, 273, DISCOVERY OF POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PYRIDINE CARBOXAMIDE C-JUN NH2-TERMINAL KINASE INHIBITORS
968, 5otiA, 0.8302, 2.74, 0.314, 327, 274, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 27
969, 5moeB, 0.8302, 2.54, 0.310, 323, 271, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
970, 5l2sA, 0.8302, 1.62, 0.512, 263, 258, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK6 AND ABEMACICLIB.
971, 3pwdA, 0.8302, 2.77, 0.316, 327, 275, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH NBC (Z1)
972, 3mb7A, 0.8302, 2.80, 0.313, 330, 275, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A DIFURANE DERIVATIVE INHIBITOR (AMR)
973, 1w82A, 0.8302, 2.73, 0.359, 351, 276, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
974, 5oueB, 0.8301, 2.60, 0.312, 326, 272, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 20
975, 5oquA, 0.8301, 2.61, 0.312, 324, 272, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 5
976, 5movA, 0.8301, 2.60, 0.312, 325, 272, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0633 BOUND
977, 5cvfA, 0.8301, 2.61, 0.320, 325, 272, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 5 BOUND
978, 3u4uA, 0.8301, 2.56, 0.309, 327, 272, CASEIN KINASE 2 IN COMPLEX WITH AZ-INHIBITOR
979, 3e3bX, 0.8301, 2.77, 0.320, 334, 275, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2ALPHA PRIME WITH A POTENT INDAZOLE-DERIVATIVE INHIBITOR
980, 1wboA, 0.8301, 2.71, 0.361, 351, 277, FRAGMENT BASED P38 INHIBITORS
981, 1j91A, 0.8301, 2.78, 0.316, 327, 275, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 4567- TETRABROMOBENZOTRIAZOLE
982, 5m4cA, 0.8300, 2.73, 0.313, 329, 275, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A THIENO[23-D]PYRIMIDIN INHIBITOR CRYSTALLIZED UNDER LOW-SALT CONDITIONS
983, 5ctpA, 0.8300, 2.59, 0.312, 324, 272, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)ACETAMIDE BOUND
984, 3zuvA, 0.8300, 2.71, 0.376, 357, 274, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE PHOSPHORYLATED MAP KINASE ERK2
985, 3w8lB, 0.8300, 2.66, 0.311, 326, 273, CRYSTAL STRUCTURE OF HUMAN CK2 IN COMPLEX WITH INOSITOL HEXAKISPHOSPHATE
986, 1q8zB, 0.8300, 2.84, 0.306, 364, 278, THE APOENZYME STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P
987, 5ct0B, 0.8299, 2.59, 0.312, 326, 272, CRYSTAL STRUCTURE OF CK2ALPHA WITH 3-(3-CHLORO-4-(PHENYL)BENZYLAMINO) PROPAN-1-OL BOUND
988, 4looA, 0.8299, 2.80, 0.371, 349, 280, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (MONOCLINIC CRYSTAL FORM)
989, 4aaaA, 0.8299, 2.28, 0.405, 295, 269, CRYSTAL STRUCTURE OF THE HUMAN CDKL2 KINASE DOMAIN
990, 1howA, 0.8299, 2.84, 0.314, 346, 277, THE X-RAY CRYSTAL STRUCTURE OF SKY1P AN SR PROTEIN KINASE IN YEAST
991, 4ewqA, 0.8298, 2.64, 0.355, 346, 276, HUMAN P38 ALPHA MAPK IN COMPLEX WITH A PYRIDAZINE BASED INHIBITOR
992, 1q4lA, 0.8298, 2.73, 0.343, 342, 274, GSK-3 BETA COMPLEXED WITH INHIBITOR I-5
993, 5t31A, 0.8297, 2.60, 0.339, 334, 271, EXPLOITING AN ASP-GLU SWITCH IN GLYCOGEN SYNTHASE KINASE 3 TO DESIGN PARALOG SELECTIVE INHIBITORS FOR USE IN ACUTE MYELOID LEUKEMIA
994, 5ouuB, 0.8297, 2.61, 0.312, 325, 272, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 22
995, 5oumB, 0.8297, 2.60, 0.312, 326, 272, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 21
996, 5oyfA, 0.8296, 2.77, 0.314, 327, 274, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 31
997, 4iq6B, 0.8296, 2.71, 0.344, 332, 273, GSK-3BETA WITH INHIBITOR 6-CHLORO-N-CYCLOHEXYL-4-(1H-PYRROLO[23- B]PYRIDIN-3-YL)PYRIDIN-2-AMINE
998, 3o17A, 0.8296, 2.52, 0.342, 357, 272, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM
999, 3mvlB, 0.8296, 2.35, 0.374, 339, 270, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7K
1000, 3anrA, 0.8296, 2.64, 0.338, 342, 272, HUMAN DYRK1A/HARMINE COMPLEX
1001, 3d7zA, 0.8295, 2.68, 0.373, 348, 276, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIPHENYL AMIDE INHIBITOR
1002, 4mq1C, 0.8294, 2.59, 0.341, 328, 270, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
1003, 3mtlA, 0.8294, 2.67, 0.504, 294, 276, CRYSTAL STRUCTURE OF THE PCTAIRE1 KINASE IN COMPLEX WITH INDIRUBIN E804
1004, 1ouyA, 0.8294, 2.73, 0.357, 350, 277, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A DIHYDROPYRIDO- PYRIMIDINE INHIBITOR
1005, 4ib5B, 0.8293, 2.75, 0.307, 329, 274, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
1006, 4f9bA, 0.8293, 2.32, 0.267, 318, 270, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND PHA767491
1007, 3nszA, 0.8293, 2.66, 0.311, 327, 273, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH AMPPN
1008, 2g01B, 0.8293, 2.62, 0.341, 356, 273, PYRAZOLOQUINOLONES AS NOVEL SELECTIVE JNK1 INHIBITORS
1009, 1jsuA, 0.8293, 2.87, 0.879, 285, 272, P27(KIP1)/CYCLIN A/CDK2 COMPLEX
1010, 6gihA, 0.8292, 2.62, 0.311, 324, 270, CRYSTAL STRUCTURE OF CK2ALPHA WITH CAM187 BOUND 
1011, 5cvhB, 0.8292, 2.62, 0.312, 324, 272, CRYSTAL STRUCTURE OF CK2ALPHA
1012, 5othB, 0.8291, 2.61, 0.312, 324, 272, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 26
1013, 5oquB, 0.8291, 2.62, 0.312, 324, 272, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 5
1014, 5mo8B, 0.8291, 2.61, 0.312, 324, 272, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1015, 5m56B, 0.8291, 2.77, 0.320, 328, 275, MONOCLINIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
1016, 5ke0A, 0.8291, 2.59, 0.355, 340, 273, DISCOVERY OF 1-1H-PYRAZOLO 43-C PYRIDINE-6-YL UREA INHIBITORS OF EXTRACELLULAR SIGNAL REGULATED KINASE ERK FOR THE TREATMENT OF CANCERS
1017, 4mygB, 0.8291, 2.59, 0.377, 335, 273, MAPK13 ACTIVE FORM
1018, 2b9iA, 0.8291, 2.63, 0.378, 338, 275, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM MSG5
1019, 4kiqA, 0.8290, 2.31, 0.375, 338, 269, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
1020, 3anqA, 0.8290, 2.64, 0.338, 342, 272, HUMAN DYRK1A/INHIBITOR COMPLEX
1021, 2pmiC, 0.8290, 2.46, 0.561, 285, 269, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE- RESPONSIVE SIGNAL TRANSDUCTION PATHWAY WITH BOUND ATP-GAMMA-S
1022, 5modB, 0.8289, 2.62, 0.312, 324, 272, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1023, 4mq1D, 0.8289, 2.65, 0.341, 336, 270, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
1024, 2qkrA, 0.8289, 2.26, 0.580, 273, 264, CRYPTOSPORIDIUM PARVUM CYCLIN-DEPENDENT KINASE CGD5_2510 WITH INDIRUBIN 3 -MONOXIME BOUND
1025, 4qtbA, 0.8288, 2.59, 0.371, 351, 272, STRUCTURE OF HUMAN ERK1 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
1026, 3dt1A, 0.8288, 2.73, 0.372, 356, 277, P38 COMPLEXED WITH A QUINAZOLINE INHIBITOR
1027, 3blhA, 0.8287, 2.65, 0.418, 291, 273, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1
1028, 5otdB, 0.8286, 2.62, 0.312, 324, 272, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 25
1029, 5mowA, 0.8286, 2.61, 0.312, 328, 272, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
1030, 2eu9A, 0.8286, 2.93, 0.285, 345, 277, CRYSTAL STRUCTURE OF CLK3
1031, 4fv6A, 0.8285, 2.22, 0.356, 332, 267, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E57
1032, 4dglD, 0.8285, 2.73, 0.310, 328, 274, CRYSTAL STRUCTURE OF THE CK2 TETRAMERIC HOLOENZYME
1033, 2zb0A, 0.8285, 2.69, 0.362, 349, 276, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH BIPHENYL AMIDE INHIBITOR
1034, 4f9bC, 0.8284, 2.51, 0.266, 316, 271, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND PHA767491
1035, 2oxyA, 0.8284, 2.77, 0.316, 327, 275, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
1036, 1q3dB, 0.8284, 2.78, 0.342, 339, 275, GSK-3 BETA COMPLEXED WITH STAUROSPORINE
1037, 5xyyA, 0.8283, 2.73, 0.361, 350, 277, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A TRIAZOL INHIBITOR
1038, 4f9aC, 0.8283, 2.50, 0.273, 317, 271, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND NUCLEOTIDE
1039, 3mvlA, 0.8283, 2.37, 0.378, 339, 270, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7K
1040, 3fmhA, 0.8283, 2.65, 0.367, 347, 275, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24-DIFLUORO-PHENOXY)- 8-METHYL-2-((R)-1-METHYL-2-TETRAZOL-2-YL-ETHYLAMINO)-8H-PYRIDO[23- D]PYRIMIDIN-7-ONE
1041, 2b9hA, 0.8283, 2.57, 0.358, 337, 274, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM STE7
1042, 1q97B, 0.8283, 2.86, 0.295, 361, 278, THE STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINASE SKY1P WITH BOUND ATP
1043, 1q97A, 0.8283, 2.70, 0.303, 351, 274, THE STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINASE SKY1P WITH BOUND ATP
1044, 1h4lB, 0.8283, 2.40, 0.569, 278, 267, STRUCTURE AND REGULATION OF THE CDK5-P25(NCK5A) COMPLEX
1045, 6fyrA, 0.8282, 2.93, 0.285, 355, 277, X-RAY STRUCTURE OF CLK3-KD(GP-[275-632]; NON-PHOS.)/CPD-2 AT 1.42A 
1046, 3w8lA, 0.8281, 2.70, 0.314, 326, 274, CRYSTAL STRUCTURE OF HUMAN CK2 IN COMPLEX WITH INOSITOL HEXAKISPHOSPHATE
1047, 2jd5B, 0.8281, 2.86, 0.295, 360, 278, SKY1P BOUND TO NPL3P-DERIVED SUBSTRATE PEPTIDE
1048, 2g01A, 0.8281, 2.55, 0.353, 355, 272, PYRAZOLOQUINOLONES AS NOVEL SELECTIVE JNK1 INHIBITORS
1049, 4aguC, 0.8280, 2.21, 0.387, 278, 266, CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
1050, 1oukA, 0.8280, 2.72, 0.357, 348, 277, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A PYRIDINYLIMIDAZOLE INHIBITOR
1051, 4aguA, 0.8279, 2.24, 0.383, 277, 266, CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
1052, 2zoqA, 0.8279, 2.47, 0.369, 351, 271, STRUCTURAL DISSECTION OF HUMAN MITOGEN-ACTIVATED KINASE ERK1
1053, 1wbsA, 0.8279, 2.80, 0.359, 351, 276, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
1054, 2erkA, 0.8278, 2.71, 0.380, 351, 274, PHOSPHORYLATED MAP KINASE ERK2
1055, 5otoB, 0.8277, 2.63, 0.312, 324, 272, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 30
1056, 4fv7A, 0.8277, 2.56, 0.353, 342, 272, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E94
1057, 3anrB, 0.8277, 2.67, 0.338, 342, 272, HUMAN DYRK1A/HARMINE COMPLEX
1058, 5m4fA, 0.8276, 2.76, 0.313, 330, 275, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO-FLAVONOL (FLC21) CRYSTALLIZED UNDER LOW-SALT CONDITIONS
1059, 4kiqC, 0.8276, 2.32, 0.375, 338, 269, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
1060, 4aguB, 0.8276, 2.23, 0.376, 276, 266, CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
1061, 3c9wA, 0.8276, 2.32, 0.364, 336, 269, CRYSTAL STRUCTURE OF ERK-2 WITH HYPOTHEMYCIN COVALENTLY BOUND
1062, 3anqB, 0.8276, 2.67, 0.338, 343, 272, HUMAN DYRK1A/INHIBITOR COMPLEX
1063, 2b9jA, 0.8276, 2.57, 0.358, 337, 274, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM FAR1
1064, 4h3pA, 0.8275, 2.56, 0.366, 342, 273, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
1065, 5mowB, 0.8274, 2.64, 0.312, 324, 272, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
1066, 4kipA, 0.8274, 2.34, 0.375, 337, 269, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 2-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-13-THIAZOLE-5-CARBOXAMIDE
1067, 2oxyB, 0.8274, 2.79, 0.316, 327, 275, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
1068, 5h8gA, 0.8273, 2.49, 0.307, 324, 270, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7B
1069, 5otqA, 0.8272, 2.80, 0.310, 327, 274, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 33
1070, 5k4iA, 0.8272, 2.32, 0.353, 336, 269, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH COMPOUND 22
1071, 1m2rA, 0.8271, 2.81, 0.316, 327, 275, CRYSTAL STRUCTURE OF 58-DI-AMINO-14-DI-HYDROXY- ANTHRAQUINONE/CK2 KINASE COMPLEX
1072, 5m4iA, 0.8269, 2.77, 0.310, 331, 274, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO-FLAVONOL (FLC21) CRYSTALLIZED UNDER HIGH-SALT CONDITIONS
1073, 4qtbB, 0.8269, 2.68, 0.366, 348, 273, STRUCTURE OF HUMAN ERK1 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
1074, 5oszA, 0.8268, 2.81, 0.314, 327, 274, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 23
1075, 6ehuA, 0.8267, 2.81, 0.314, 327, 274, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 32
1076, 1q8yA, 0.8267, 2.73, 0.303, 351, 274, THE STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P WITH BOUND ADP
1077, 5orkB, 0.8266, 2.63, 0.310, 323, 271, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 6
1078, 3c9wB, 0.8266, 2.37, 0.368, 336, 269, CRYSTAL STRUCTURE OF ERK-2 WITH HYPOTHEMYCIN COVALENTLY BOUND
1079, 2no3B, 0.8266, 2.58, 0.338, 357, 272, NOVEL 4-ANILINOPYRIMIDINES AS POTENT JNK1 INHIBITORS
1080, 1q3dA, 0.8266, 2.83, 0.342, 339, 275, GSK-3 BETA COMPLEXED WITH STAUROSPORINE
1081, 6fypA, 0.8265, 3.09, 0.285, 348, 277, X-RAY STRUCTURE OF CLK3-KD(GP-[275-632]; NON-PHOS.)/CX-4945 AT 2.29A 
1082, 2no3A, 0.8265, 2.59, 0.338, 357, 272, NOVEL 4-ANILINOPYRIMIDINES AS POTENT JNK1 INHIBITORS
1083, 5cu3B, 0.8264, 2.63, 0.312, 324, 272, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
1084, 3nnwA, 0.8263, 2.80, 0.359, 349, 276, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH DP802
1085, 5cu3A, 0.8262, 2.65, 0.312, 325, 272, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
1086, 6eiiB, 0.8261, 2.64, 0.312, 326, 272, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 18
1087, 5nhpA, 0.8261, 2.66, 0.370, 338, 273, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
1088, 4ub7A, 0.8261, 2.64, 0.309, 334, 272, HIGH-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26) SHOWING AN EXTREME DISTORTION OF THE ATP-BINDING LOOP COMBINED WITH A PI-HALOGEN BOND
1089, 2gmxA, 0.8261, 2.65, 0.355, 357, 273, SELECTIVE AMINOPYRIDINE-BASED C-JUN N-TERMINAL KINASE INHIBITORS WITH CELLULAR ACTIVITY
1090, 2b9fA, 0.8261, 2.68, 0.382, 337, 275, CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED FUS3
1091, 1r3cA, 0.8261, 2.79, 0.361, 349, 277, THE STRUCTURE OF P38ALPHA C162S MUTANT
1092, 5nhlA, 0.8260, 2.63, 0.366, 345, 273, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
1093, 5nhvA, 0.8259, 2.63, 0.352, 345, 273, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
1094, 5cs6A, 0.8259, 2.73, 0.311, 327, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 3 BOUND
1095, 4ux9D, 0.8259, 2.35, 0.332, 344, 268, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
1096, 4kiqB, 0.8259, 2.34, 0.375, 338, 269, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
1097, 4f9aA, 0.8258, 2.41, 0.274, 315, 270, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND NUCLEOTIDE
1098, 4ic7A, 0.8256, 2.62, 0.372, 355, 274, CRYSTAL STRUCTURE OF THE ERK5 KINASE DOMAIN IN COMPLEX WITH AN MKK5 BINDING FRAGMENT
1099, 1bl6A, 0.8256, 2.80, 0.365, 351, 277, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB216995
1100, 6eiiA, 0.8255, 2.65, 0.312, 326, 272, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 18
1101, 5mz3A, 0.8253, 2.90, 0.357, 350, 277, P38 ALPHA MUTANT C162S IN COMPLEX WITH CMPD2 [N-(4-METHYL-3-(4455- TETRAMETHYL-132-DIOXABOROLAN-2-YL)PHENYL)-3-(TRIFLUOROMETHYL) BENZAMIDE]
1102, 4f99A, 0.8252, 2.53, 0.266, 312, 271, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND NUCLEOTIDE
1103, 3s3iA, 0.8252, 2.79, 0.372, 349, 277, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1104, 3flyA, 0.8252, 2.64, 0.369, 347, 274, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24- DIFLUORO-PHENOXY)-2-ISOPROPYLAMINO-8-METHYL-8H-PYRIDO[23- D]PYRIMIDIN-7-ONE
1105, 3vuiA, 0.8251, 2.50, 0.339, 355, 271, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M2 IN MAP KINASE JNK1
1106, 1jwhA, 0.8250, 2.72, 0.307, 336, 274, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 HOLOENZYME
1107, 5bvdA, 0.8249, 2.12, 0.348, 330, 264, TETRAHYDROPYRROLO-DIAZEPENONES AS INHIBITORS OF ERK2 KINASE
1108, 1w84A, 0.8249, 2.75, 0.362, 351, 276, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1109, 1unhA, 0.8249, 2.37, 0.566, 276, 265, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
1110, 3py3A, 0.8248, 2.55, 0.364, 355, 272, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38ALPHA MAP KINASE
1111, 2r7iB, 0.8248, 2.54, 0.313, 322, 268, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
1112, 3n9xB, 0.8247, 2.71, 0.396, 374, 275, CRYSTAL STRUCTURE OF MAP KINASE FROM PLASMODIUM BERGHEI PB000659.00.0
1113, 5hd7A, 0.8246, 2.73, 0.363, 347, 273, DISSECTING THERAPEUTIC RESISTANCE TO ERK INHIBITION RAT MUTANT SCH772984 IN COMPLEX WITH (3R)-1-(2-OXO-2-{4-[4-(PYRIMIDIN-2-YL) PHENYL]PIPERAZIN-1-YL}ETHYL)-N-[3-(PYRIDIN-4-YL)-2H-INDAZOL-5- YL]PYRROLIDINE-3-CARBOXAMIDE
1114, 5bveA, 0.8246, 2.12, 0.348, 330, 264, TETRAHYDROPYRROLO-DIAZEPENONES AS INHIBITORS OF ERK2 KINASE
1115, 6g93A, 0.8245, 2.60, 0.349, 343, 272, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1116, 1wbtA, 0.8245, 2.89, 0.361, 351, 277, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
1117, 1q4lB, 0.8245, 2.72, 0.338, 337, 272, GSK-3 BETA COMPLEXED WITH INHIBITOR I-5
1118, 4kinA, 0.8244, 2.42, 0.378, 338, 270, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
1119, 5mp8B, 0.8243, 2.60, 0.311, 323, 270, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
1120, 3vugA, 0.8243, 2.64, 0.338, 356, 272, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M2 IN MAP KINASE JNK1
1121, 3mptA, 0.8242, 2.70, 0.367, 347, 275, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A PYRROLE-2- CARBOXAMIDE INHIBITOR
1122, 3flzA, 0.8242, 2.71, 0.367, 347, 275, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 8-METHYL-6-PHENOXY-2- (TETRAHYDRO-PYRAN-4-YLAMINO)-8H-PYRIDO[23-D]PYRIMIDIN-7-ONE
1123, 3vuhA, 0.8241, 2.66, 0.338, 355, 272, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M3 IN MAP KINASE JNK1
1124, 4f9cA, 0.8240, 2.42, 0.271, 306, 269, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND XL413
1125, 3vukA, 0.8240, 2.51, 0.339, 355, 271, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M5 IN MAP KINASE JNK1
1126, 3nnvA, 0.8240, 2.82, 0.359, 348, 276, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH DP437
1127, 3i60A, 0.8240, 2.24, 0.350, 335, 266, CRYSTAL STRUCTURE OF ERK2 BOUND TO (S)-4-(2-(2-CHLOROPHENYLAMINO)-5- METHYLPYRIMIDIN-4-YL)-N-(2-HYDROXY-1-PHENYLETHYL)-1H-PYRROLE-2- CARBOXAMIDE
1128, 3fklA, 0.8239, 2.68, 0.372, 344, 274, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO9552
1129, 2gmxB, 0.8239, 2.64, 0.355, 357, 273, SELECTIVE AMINOPYRIDINE-BASED C-JUN N-TERMINAL KINASE INHIBITORS WITH CELLULAR ACTIVITY
1130, 5cshB, 0.8238, 2.56, 0.316, 323, 269, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 4 BOUND
1131, 5a4eA, 0.8237, 2.66, 0.336, 341, 271, DYRK1A IN COMPLEX WITH METHOXY BENZOTHIAZOLE FRAGMENT
1132, 5ouuA, 0.8236, 2.59, 0.315, 324, 270, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 22
1133, 4kinD, 0.8236, 2.35, 0.373, 339, 268, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
1134, 3nnuA, 0.8236, 2.85, 0.359, 348, 276, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH DP1376
1135, 4fv8A, 0.8235, 2.25, 0.350, 333, 266, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E63
1136, 3vudA, 0.8235, 2.52, 0.339, 355, 271, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M1 IN MAP KINASE JNK1
1137, 2r7iD, 0.8235, 2.57, 0.313, 322, 268, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
1138, 6g9aA, 0.8234, 2.62, 0.353, 341, 272, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1139, 5y9mA, 0.8234, 2.59, 0.315, 320, 270, CRYSTAL STRUCTURE OF CK2A2 FORM 3 
1140, 5xvuB, 0.8234, 2.69, 0.308, 321, 273, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
1141, 4nctD, 0.8234, 2.67, 0.336, 331, 271, HUMAN DYRK1A IN COMPLEX WITH PKC412
1142, 3ds6D, 0.8234, 2.88, 0.363, 349, 278, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
1143, 1bl7A, 0.8234, 2.82, 0.365, 351, 277, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB220025
1144, 3ocgA, 0.8233, 2.30, 0.371, 336, 267, P38 ALPHA KINASE COMPLEXED WITH A 5-AMINO-PYRAZOLE BASED INHIBITOR
1145, 3nuxA, 0.8233, 1.68, 0.486, 261, 257, CDK6 (MONOMERIC) IN COMPLEX WITH INHIBITOR
1146, 3e92A, 0.8232, 2.83, 0.373, 348, 276, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIARYL AMIDE INHIBITOR
1147, 6fykA, 0.8231, 3.07, 0.279, 349, 276, X-RAY STRUCTURE OF CLK2-KD(136-496)/INDAZOLE1 AT 2.39A 
1148, 4iz7C, 0.8231, 2.58, 0.370, 340, 273, STRUCTURE OF NON-PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
1149, 3anqC, 0.8231, 2.71, 0.338, 340, 272, HUMAN DYRK1A/INHIBITOR COMPLEX
1150, 1g3nE, 0.8230, 2.68, 0.448, 293, 270, STRUCTURE OF A P18(INK4C)-CDK6-K-CYCLIN TERNARY COMPLEX
1151, 5a4lB, 0.8229, 2.66, 0.336, 339, 271, DYRK1A IN COMPLEX WITH FLUORO BENZOTHIAZOLE FRAGMENT
1152, 5a3xB, 0.8229, 2.71, 0.338, 340, 272, DYRK1A IN COMPLEX WITH HYDROXY BENZOTHIAZOLE FRAGMENT
1153, 3mvmA, 0.8229, 2.31, 0.372, 335, 266, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7V
1154, 1m7qA, 0.8229, 2.76, 0.359, 348, 276, CRYSTAL STRUCTURE OF P38 MAP KINASE IN COMPLEX WITH A DIHYDROQUINAZOLINONE INHIBITOR
1155, 5a4qB, 0.8228, 2.66, 0.336, 335, 271, DYRK1A IN COMPLEX WITH CHLORO BENZOTHIAZOLE FRAGMENT
1156, 1unhB, 0.8227, 2.40, 0.566, 276, 265, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
1157, 5bujA, 0.8224, 2.21, 0.351, 331, 265, ERK2 COMPLEXED WITH A N-H TETRAHYDROAZAINDAZOLE
1158, 3iphA, 0.8222, 2.64, 0.366, 345, 273, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH A BIPHENYLAMIDE INHIBITOR
1159, 5g6vA, 0.8221, 3.18, 0.512, 308, 283, CRYSTAL STRUCTURE OF THE PCTAIRE1 KINASE IN COMPLEX WITH INHIBITOR
1160, 5a54B, 0.8221, 2.68, 0.336, 339, 271, DYRK1A IN COMPLEX WITH NITRO BENZOTHIAZOLE FRAGMENT
1161, 2zb1A, 0.8218, 2.77, 0.358, 345, 274, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH BIPHENYL AMIDE INHIBITOR
1162, 1g3nA, 0.8218, 2.69, 0.448, 293, 270, STRUCTURE OF A P18(INK4C)-CDK6-K-CYCLIN TERNARY COMPLEX
1163, 5cvgA, 0.8217, 2.65, 0.314, 326, 271, CRYSTAL STRUCTURE OF CK2ALPHA WITH A NOVEL CLOSED CONFORMATION OF THE AD LOOP
1164, 5a3xA, 0.8217, 2.74, 0.338, 342, 272, DYRK1A IN COMPLEX WITH HYDROXY BENZOTHIAZOLE FRAGMENT
1165, 2lgcA, 0.8217, 2.93, 0.355, 359, 279, JOINT NMR AND X-RAY REFINEMENT REVEALS THE STRUCTURE OF A NOVEL DIBENZO[AD]CYCLOHEPTENONE INHIBITOR/P38 MAP KINASE COMPLEX IN SOLUTION
1166, 5a54A, 0.8216, 2.70, 0.336, 341, 271, DYRK1A IN COMPLEX WITH NITRO BENZOTHIAZOLE FRAGMENT
1167, 4kiqD, 0.8216, 2.44, 0.375, 338, 269, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
1168, 3anrC, 0.8216, 2.75, 0.338, 337, 272, HUMAN DYRK1A/HARMINE COMPLEX
1169, 1ungA, 0.8216, 2.75, 0.582, 288, 273, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
1170, 5hd4A, 0.8215, 2.74, 0.355, 347, 273, DISSECTING THERAPEUTIC RESISTANCE TO ERK INHIBITION RAT WILD TYPE SCH772984 IN COMPLEX WITH (3R)-1-(2-OXO-2-{4-[4-(PYRIMIDIN-2-YL) PHENYL]PIPERAZIN-1-YL}ETHYL)-N-[3-(PYRIDIN-4-YL)-2H-INDAZOL-5- YL]PYRROLIDINE-3-CARBOXAMIDE
1171, 1zz2A, 0.8215, 2.42, 0.375, 337, 269, TWO CLASSES OF P38ALPHA MAP KINASE INHIBITORS HAVING A COMMON DIPHENYLETHER CORE BUT EXHIBITING DIVERGENT BINDING MODES
1172, 4ic7D, 0.8214, 2.66, 0.372, 353, 274, CRYSTAL STRUCTURE OF THE ERK5 KINASE DOMAIN IN COMPLEX WITH AN MKK5 BINDING FRAGMENT
1173, 6fyoA, 0.8213, 3.12, 0.287, 331, 275, X-RAY STRUCTURE OF CLK1-KD(148-484)/CPD-2 AT 2.32A 
1174, 5xvuA, 0.8213, 2.72, 0.308, 321, 273, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
1175, 1bmkA, 0.8213, 2.87, 0.361, 351, 277, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB218655
1176, 6fykB, 0.8212, 3.10, 0.286, 349, 276, X-RAY STRUCTURE OF CLK2-KD(136-496)/INDAZOLE1 AT 2.39A 
1177, 5a4lA, 0.8212, 2.71, 0.336, 341, 271, DYRK1A IN COMPLEX WITH FLUORO BENZOTHIAZOLE FRAGMENT
1178, 5a3xD, 0.8212, 2.70, 0.339, 331, 271, DYRK1A IN COMPLEX WITH HYDROXY BENZOTHIAZOLE FRAGMENT
1179, 4nctA, 0.8211, 2.69, 0.339, 341, 271, HUMAN DYRK1A IN COMPLEX WITH PKC412
1180, 3e3pA, 0.8211, 2.73, 0.364, 337, 272, GLYCOGEN SYNTHASE KINASE FROM LEISHMANIA MAJOR
1181, 2yixA, 0.8211, 2.86, 0.357, 351, 277, TRIAZOLOPYRIDINE INHIBITORS OF P38
1182, 5m44A, 0.8210, 2.73, 0.312, 329, 272, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A THIENO[23-D]PYRIMIDIN INHIBITOR CRYSTALLIZED UNDER HIGH-SALT CONDITIONS
1183, 5l2iA, 0.8210, 1.67, 0.516, 260, 256, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK6 AND PALBOCICLIB.
1184, 1zzlA, 0.8210, 2.85, 0.357, 351, 277, CRYSTAL STRUCTURE OF P38 WITH TRIAZOLOPYRIDINE
1185, 5y9mX, 0.8208, 2.60, 0.316, 319, 269, CRYSTAL STRUCTURE OF CK2A2 FORM 3 
1186, 5aikC, 0.8208, 2.73, 0.338, 342, 272, HUMAN DYRK1A IN COMPLEX WITH LDN-211898
1187, 3n9xA, 0.8208, 2.71, 0.394, 374, 274, CRYSTAL STRUCTURE OF MAP KINASE FROM PLASMODIUM BERGHEI PB000659.00.0
1188, 3kq7A, 0.8208, 2.92, 0.362, 348, 276, STRUCTURE OF HUMAN P38ALPHA WITH N-[4-METHYL-3-(6-{[2-(1- METHYLPYRROLIDIN-2-YL)ETHYL]AMINO}PYRIDINE-3-AMIDO)PHENYL]- 2-(MORPHOLIN-4-YL)PYRIDINE-4-CARBOXAMIDE
1189, 2r7iA, 0.8208, 2.61, 0.310, 322, 268, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
1190, 4aa4A, 0.8207, 2.59, 0.379, 347, 272, P38ALPHA MAP KINASE BOUND TO CMPD 22
1191, 1w83A, 0.8207, 2.95, 0.357, 351, 277, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1192, 5xvuC, 0.8206, 2.73, 0.308, 321, 273, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
1193, 5x8iA, 0.8206, 3.05, 0.276, 328, 275, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH COMPOUND 25
1194, 4y46A, 0.8206, 2.90, 0.360, 340, 278, PYRIDOPYRIMIDINONE DERIVATIVES AS POTENT AND SELECTIVE C-JUN N- TERMINAL KINASE (JNK) INHIBITORS
1195, 3flwA, 0.8206, 2.71, 0.369, 345, 274, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH PAMAPIMOD
1196, 2ozaB, 0.8206, 2.48, 0.354, 340, 271, STRUCTURE OF P38ALPHA COMPLEX
1197, 5aikB, 0.8205, 2.74, 0.338, 342, 272, HUMAN DYRK1A IN COMPLEX WITH LDN-211898
1198, 5a4tB, 0.8205, 2.73, 0.336, 339, 271, DYRK1A IN COMPLEX WITH NITRILE BENZOTHIAZOLE FRAGMENT
1199, 5a4qA, 0.8205, 2.71, 0.336, 341, 271, DYRK1A IN COMPLEX WITH CHLORO BENZOTHIAZOLE FRAGMENT
1200, 5nzzE, 0.8204, 2.49, 0.351, 343, 268, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
1201, 4aa5A, 0.8204, 2.51, 0.378, 340, 270, P38ALPHA MAP KINASE BOUND TO CMPD 33
1202, 5x8iB, 0.8203, 3.05, 0.276, 327, 275, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH COMPOUND 25
1203, 3flsA, 0.8203, 2.53, 0.359, 343, 270, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24- DIFLUORO-PHENOXY)-2-((R)-2-METHANESULFONYL-1-METHYL- ETHYLAMINO)-8-METHYL-8H-PYRIDO[23-D]PYRIMIDIN-7-ONE
1204, 4qyyA, 0.8202, 2.76, 0.355, 337, 273, DISCOVERY OF NOVEL DUAL MECHANISM ERK INHIBITORS BY AFFINITY SELECTION SCREENING OF AN INACTIVE KINASE STATE
1205, 5larA, 0.8201, 2.90, 0.359, 350, 276, CRYSTAL STRUCTURE OF P38 ALPHA MAPK14 IN COMPLEX WITH VPC00628
1206, 1q8yB, 0.8201, 2.85, 0.295, 357, 275, THE STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P WITH BOUND ADP
1207, 1w7hA, 0.8200, 2.80, 0.353, 351, 275, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1208, 4nctB, 0.8199, 2.74, 0.339, 333, 271, HUMAN DYRK1A IN COMPLEX WITH PKC412
1209, 3v3vA, 0.8199, 2.55, 0.341, 351, 270, STRUCTURAL AND FUNCTIONAL ANALYSIS OF QUERCETAGETIN A NATURAL JNK1 INHIBITOR
1210, 2zdtA, 0.8199, 2.71, 0.345, 342, 275, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH AN ISOQUINOLONE INHIBITOR
1211, 1h25C, 0.8199, 2.47, 0.970, 278, 266, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM RETINOBLASTOMA-ASSOCIATED PROTEIN
1212, 6gdqA, 0.8198, 2.67, 0.349, 339, 272, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1213, 4lopD, 0.8198, 2.83, 0.365, 351, 277, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
1214, 3nwwA, 0.8198, 2.49, 0.374, 339, 270, P38 ALPHA KINASE COMPLEXED WITH A 2-AMINOTHIAZOL-5-YL-PYRIMIDINE BASED INHIBITOR
1215, 3gfeA, 0.8198, 2.87, 0.372, 352, 277, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A PYRAZOLOPYRIDINONE INHIBITOR
1216, 2zazA, 0.8198, 2.68, 0.355, 345, 273, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH 4-ANILINO QUINOLINE INHIBITOR
1217, 2wu6A, 0.8198, 3.10, 0.283, 350, 276, CRYSTAL STRUCTURE OF THE HUMAN CLK3 IN COMPLEX WITH DKI
1218, 4kinC, 0.8197, 2.52, 0.370, 338, 270, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
1219, 4aacA, 0.8197, 2.52, 0.378, 350, 270, P38ALPHA MAP KINASE BOUND TO CMPD 29
1220, 6ft7B, 0.8196, 3.12, 0.274, 356, 277, CRYSTAL STRUCTURE OF CLK3 IN COMPLEX WITH COMPOUND 8A 
1221, 5otlA, 0.8196, 2.58, 0.317, 320, 268, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 29
1222, 5a4tA, 0.8196, 2.72, 0.339, 341, 271, DYRK1A IN COMPLEX WITH NITRILE BENZOTHIAZOLE FRAGMENT
1223, 6fyvA, 0.8195, 3.00, 0.274, 329, 274, X-RAY STRUCTURE OF CLK4-KD(146-480)/CX-4945 AT 2.46A 
1224, 6fykC, 0.8195, 3.09, 0.284, 349, 275, X-RAY STRUCTURE OF CLK2-KD(136-496)/INDAZOLE1 AT 2.39A 
1225, 5aikA, 0.8195, 2.77, 0.338, 344, 272, HUMAN DYRK1A IN COMPLEX WITH LDN-211898
1226, 3teiA, 0.8194, 2.53, 0.370, 339, 270, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
1227, 3nr9A, 0.8194, 3.16, 0.286, 341, 276, STRUCTURE OF HUMAN CDC2-LIKE KINASE 2 (CLK2)
1228, 5clpA, 0.8192, 2.66, 0.316, 322, 269, CRYSTAL STRUCTURE OF CK2ALPHA WITH 34-DICHLOROPHENETHYLAMINE BOUND
1229, 4fv9A, 0.8192, 2.27, 0.355, 331, 265, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E71
1230, 5bueA, 0.8191, 2.26, 0.351, 329, 265, ERK2 COMPLEXED WITH N-BENZYLPYRIDONE TETRAHYDROAZAINDAZOLE
1231, 4y5hA, 0.8191, 2.91, 0.360, 349, 278, PYRIDOPYRIMIDINONE DERIVATIVES AS POTENT AND SELECTIVE C-JUN N- TERMINAL KINASE (JNK) INHIBITORS
1232, 4awiA, 0.8191, 2.73, 0.342, 352, 275, HUMAN JNK1ALPHA KINASE WITH 4-PHENYL-7-AZAINDOLE IKK2 INHIBITOR.
1233, 5l2tA, 0.8190, 1.71, 0.504, 261, 256, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK6 AND RIBOCICLIB.
1234, 5a4eB, 0.8190, 2.85, 0.343, 322, 271, DYRK1A IN COMPLEX WITH METHOXY BENZOTHIAZOLE FRAGMENT
1235, 5a4eD, 0.8189, 2.75, 0.339, 331, 271, DYRK1A IN COMPLEX WITH METHOXY BENZOTHIAZOLE FRAGMENT
1236, 3hllA, 0.8189, 2.43, 0.375, 337, 269, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH PH-797804
1237, 3gp0A, 0.8189, 2.47, 0.336, 333, 268, CRYSTAL STRUCTURE OF HUMAN MITOGEN ACTIVATED PROTEIN KINASE 11 (P38 BETA) IN COMPLEX WITH NILOTINIB
1238, 5nzzF, 0.8188, 2.47, 0.352, 341, 267, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
1239, 4qtdA, 0.8187, 2.82, 0.339, 355, 277, STRUCTURE OF HUMAN JNK1 IN COMPLEX WITH SCH772984 AND THE AMPPNP- HYDROLYSED TRIPHOSPHATE REVEALING THE SECOND TYPE-I BINDING MODE
1240, 3rawA, 0.8186, 3.17, 0.286, 351, 276, CRYSTAL STRUCTURE OF HUMAN CDC-LIKE KINASE 3 ISOFORM IN COMPLEX WITH LEUCETTINE L41
1241, 3anqD, 0.8185, 2.68, 0.341, 334, 270, HUMAN DYRK1A/INHIBITOR COMPLEX
1242, 5a3xC, 0.8184, 2.78, 0.338, 333, 272, DYRK1A IN COMPLEX WITH HYDROXY BENZOTHIAZOLE FRAGMENT
1243, 4jr7A, 0.8184, 2.78, 0.281, 367, 270, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
1244, 2r7iC, 0.8184, 2.60, 0.311, 321, 267, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
1245, 1wbnA, 0.8184, 3.01, 0.361, 351, 277, FRAGMENT BASED P38 INHIBITORS
1246, 2rg6A, 0.8183, 2.38, 0.372, 335, 266, PHENYLALANINE PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 11J
1247, 2g9xC, 0.8183, 2.30, 0.985, 274, 262, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR NU6271
1248, 1wbvA, 0.8183, 2.93, 0.362, 351, 276, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
1249, 5etaB, 0.8182, 2.32, 0.366, 335, 265, STRUCTURE OF MAPK14 WITH BOUND THE KIM DOMAIN OF THE TOXOPLASMA PROTEIN GRA24
1250, 1p38A, 0.8182, 2.93, 0.362, 351, 276, THE STRUCTURE OF THE MAP KINASE P38 AT 2.1 ANGSTOMS RESOLUTION
1251, 6g33B, 0.8181, 3.07, 0.291, 337, 275, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH 5-IODOTUBERCIDIN 
1252, 4eojC, 0.8181, 2.56, 0.918, 282, 267, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH ATP
1253, 3cgfA, 0.8181, 2.75, 0.364, 346, 275, IRAK-4 INHIBITORS (PART II)- A STRUCTURE BASED ASSESSMENT OF IMIDAZO[12 A]PYRIDINE BINDING
1254, 2f49A, 0.8181, 2.75, 0.361, 335, 274, CRYSTAL STRUCTURE OF FUS3 IN COMPLEX WITH A STE5 PEPTIDE
1255, 3tnhA, 0.8180, 2.65, 0.416, 288, 269, CDK9/CYCLIN T IN COMPLEX WITH CAN508
1256, 3rinA, 0.8180, 2.88, 0.372, 349, 277, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1257, 5yf9B, 0.8179, 2.59, 0.313, 319, 268, CRYSTAL STRUCTURE OF CK2A2 FORM-2 
1258, 4qp1B, 0.8179, 2.75, 0.364, 343, 272, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
1259, 5a4qD, 0.8178, 2.70, 0.341, 334, 270, DYRK1A IN COMPLEX WITH CHLORO BENZOTHIAZOLE FRAGMENT
1260, 3u8wA, 0.8177, 2.97, 0.371, 349, 278, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A TRIAZOLOPYRIDAZINONE INHIBITOR
1261, 3bx5A, 0.8177, 2.52, 0.378, 338, 270, P38 ALPHA MAP KINASE COMPLEXED WITH BMS-640994
1262, 1lewA, 0.8177, 2.53, 0.370, 341, 270, CRYSTAL STRUCTURE OF MAP KINASE P38 COMPLEXED TO THE DOCKING SITE ON ITS NUCLEAR SUBSTRATE MEF2A
1263, 5yf9X, 0.8175, 2.59, 0.317, 319, 268, CRYSTAL STRUCTURE OF CK2A2 FORM-2 
1264, 5aikD, 0.8175, 2.75, 0.339, 342, 271, HUMAN DYRK1A IN COMPLEX WITH LDN-211898
1265, 5a4tD, 0.8175, 2.71, 0.341, 332, 270, DYRK1A IN COMPLEX WITH NITRILE BENZOTHIAZOLE FRAGMENT
1266, 4ux9A, 0.8174, 2.52, 0.342, 343, 269, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
1267, 4kkhA, 0.8174, 2.91, 0.354, 351, 277, THE CRYSTAL STRUCTURE OF INHIBITOR-BOUND JNK3
1268, 3e3pB, 0.8174, 2.82, 0.355, 337, 273, GLYCOGEN SYNTHASE KINASE FROM LEISHMANIA MAJOR
1269, 2rg5A, 0.8174, 2.31, 0.377, 333, 265, PHENYLALANINE PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 11B
1270, 1lezA, 0.8174, 2.66, 0.368, 343, 272, CRYSTAL STRUCTURE OF MAP KINASE P38 COMPLEXED TO THE DOCKING SITE ON ITS ACTIVATOR MKK3B
1271, 3flqA, 0.8173, 2.68, 0.360, 345, 272, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24- DIFLUORO-PHENOXY)-2-((S)-2-METHANESULFONYL-1-METHYL- ETHYLAMINO)-8-METHYL-8H-PYRIDO[23-D]PYRIMIDIN
1272, 5a4lD, 0.8172, 2.71, 0.341, 334, 270, DYRK1A IN COMPLEX WITH FLUORO BENZOTHIAZOLE FRAGMENT
1273, 4ux9C, 0.8172, 2.62, 0.337, 333, 270, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
1274, 3nnxA, 0.8172, 2.50, 0.366, 336, 268, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38 ALPHA IN COMPLEX WITH DP802
1275, 3hl7A, 0.8171, 2.43, 0.375, 336, 269, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH SD-0006
1276, 4kkeA, 0.8170, 2.97, 0.360, 354, 278, THE CRYSTAL STRUCTURE OF AMP-BOUND JNK3
1277, 4w4wA, 0.8169, 2.95, 0.353, 349, 278, JNK2/3 IN COMPLEX WITH N-(2-METHYLPYRIDIN-4-YL)-3-{4- [(PHENYLCARBAMOYL)AMINO]-1H-PYRAZOL-1-YL}BENZAMIDE
1278, 2f9gA, 0.8169, 2.48, 0.364, 332, 269, CRYSTAL STRUCTURE OF FUS3 PHOSPHORYLATED ON TYR182
1279, 5nguA, 0.8168, 2.69, 0.360, 339, 272, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
1280, 5g6vB, 0.8167, 3.05, 0.522, 302, 278, CRYSTAL STRUCTURE OF THE PCTAIRE1 KINASE IN COMPLEX WITH INHIBITOR
1281, 3nr9C, 0.8166, 3.12, 0.287, 347, 275, STRUCTURE OF HUMAN CDC2-LIKE KINASE 2 (CLK2)
1282, 5bvfA, 0.8165, 2.09, 0.352, 327, 261, TETRAHYDROPYRROLO-DIAZEPENONES AS INHIBITORS OF ERK2 KINASE
1283, 5f95B, 0.8164, 2.67, 0.336, 338, 268, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 18: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-PHENYLPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
1284, 4ylkA, 0.8164, 2.90, 0.326, 341, 273, CRYSTAL STRUCTURE OF DYRK1A IN COMPLEX WITH 10-CHLORO-SUBSTITUTED 11H- INDOLO[32-C]QUINOLONE-6-CARBOXYLIC ACID INHIBITOR 5S
1285, 1z57A, 0.8164, 3.26, 0.290, 333, 276, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH 10Z-HYMENIALDISINE
1286, 4ptgB, 0.8163, 2.64, 0.337, 332, 267, STRUCTURE OF A CARBOXAMINE COMPOUND (26) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-METHOXYPYRIMIDINE-5-CARBOXAMIDE) TO GSK3B
1287, 4nctC, 0.8163, 2.74, 0.337, 339, 270, HUMAN DYRK1A IN COMPLEX WITH PKC412
1288, 3fmjA, 0.8163, 2.64, 0.365, 344, 271, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 4-(5-METHYL-3-PHENYL- ISOXAZOL-4-YL)-PYRIMIDIN-2-YLAMINE
1289, 3bv2A, 0.8163, 2.55, 0.362, 337, 268, MORPHOLINO PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 30
1290, 3anrD, 0.8163, 2.73, 0.341, 340, 270, HUMAN DYRK1A/HARMINE COMPLEX
1291, 5etcA, 0.8162, 2.84, 0.360, 355, 275, STRUCTURE OF INACTIVE MAPK14 WITH ORDERED ACTIVATION LOOP
1292, 3mvmB, 0.8162, 2.35, 0.377, 332, 265, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7V
1293, 1wzyA, 0.8162, 2.70, 0.348, 350, 273, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A PYRAZOLOPYRIDAZINE DERIVATIVE
1294, 3rocA, 0.8161, 2.47, 0.372, 337, 269, CRYSTAL STRUCTURE OF HUMAN P38 ALPHA COMPLEXED WITH A PYRIMIDINONE COMPOUND
1295, 3e93A, 0.8161, 2.88, 0.361, 346, 274, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIARYL AMIDE INHIBITOR
1296, 2wu7A, 0.8161, 3.22, 0.282, 348, 277, CRYSTAL STRUCTURE OF THE HUMAN CLK3 IN COMPLEX WITH V25
1297, 4yllA, 0.8160, 2.90, 0.326, 340, 273, CRYSTAL STRUCTURE OF DYRK1AA IN COMPLEX WITH 10-BROMO-SUBSTITUTED 11H- INDOLO[32-C]QUINOLONE-6-CARBOXYLIC ACID INHIBITOR 5T
1298, 2balA, 0.8160, 2.44, 0.377, 337, 268, P38ALPHA MAP KINASE BOUND TO PYRAZOLOAMINE
1299, 1jnkA, 0.8160, 2.79, 0.364, 346, 275, THE C-JUN N-TERMINAL KINASE (JNK3S) COMPLEXED WITH MGAMP-PNP
1300, 4ez5A, 0.8159, 1.65, 0.488, 258, 254, CDK6 (MONOMERIC) IN COMPLEX WITH INHIBITOR
1301, 1a9uA, 0.8159, 2.92, 0.342, 351, 275, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB203580
1302, 5a4qC, 0.8158, 2.74, 0.341, 332, 270, DYRK1A IN COMPLEX WITH CHLORO BENZOTHIAZOLE FRAGMENT
1303, 4iz7A, 0.8158, 2.82, 0.359, 344, 273, STRUCTURE OF NON-PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
1304, 6ft7A, 0.8157, 3.14, 0.271, 356, 277, CRYSTAL STRUCTURE OF CLK3 IN COMPLEX WITH COMPOUND 8A 
1305, 4lopB, 0.8157, 2.85, 0.357, 350, 277, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
1306, 3rawB, 0.8157, 3.12, 0.287, 349, 275, CRYSTAL STRUCTURE OF HUMAN CDC-LIKE KINASE 3 ISOFORM IN COMPLEX WITH LEUCETTINE L41
1307, 3o8uA, 0.8157, 2.32, 0.360, 332, 264, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
1308, 3bv3A, 0.8157, 2.67, 0.363, 338, 270, MORPHOLINO PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 2
1309, 5j1wA, 0.8156, 3.11, 0.288, 338, 274, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH PYRIDO[34- G]QUINAZOLINE DERIVATIVE ZW31 (COMPOUND 14)
1310, 3nr9B, 0.8156, 3.09, 0.285, 347, 274, STRUCTURE OF HUMAN CDC2-LIKE KINASE 2 (CLK2)
1311, 6ft9C, 0.8154, 3.02, 0.286, 337, 273, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH INHIBITOR 16 
1312, 3kf7A, 0.8154, 2.48, 0.375, 337, 269, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH A TRIAZOLOPYRIMIDINE COMPOUND
1313, 6ft9A, 0.8153, 3.20, 0.287, 336, 275, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH INHIBITOR 16 
1314, 4xj0A, 0.8153, 2.80, 0.364, 345, 272, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR 14K
1315, 4fv3A, 0.8153, 2.80, 0.360, 346, 272, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK6
1316, 3itzA, 0.8153, 2.90, 0.359, 357, 276, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A PYRAZOLOPYRIDAZINE INHIBITOR
1317, 3fknA, 0.8153, 2.77, 0.355, 346, 273, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO7125
1318, 6ft8A, 0.8152, 3.30, 0.290, 338, 276, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH INHIBITOR 8G 
1319, 5a54D, 0.8152, 2.75, 0.341, 334, 270, DYRK1A IN COMPLEX WITH NITRO BENZOTHIAZOLE FRAGMENT
1320, 5a54C, 0.8152, 2.74, 0.344, 332, 270, DYRK1A IN COMPLEX WITH NITRO BENZOTHIAZOLE FRAGMENT
1321, 3fmkA, 0.8152, 2.73, 0.370, 346, 273, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24-DIFLUORO-PHENOXY)- 8-METHYL-2-((S)-1-METHYL-2-TETRAZOL-2-YL-ETHYLAMINO)-8H-PYRIDO[23- D]PYRIMIDIN-7-ONE
1322, 5j1vA, 0.8151, 3.11, 0.288, 338, 274, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH PYRIDO[34- G]QUINAZOLINE DERIVATIVE ZW29 (COMPOUND 13)
1323, 4qp8A, 0.8151, 2.58, 0.346, 335, 272, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-7- (PYRIDIN-3-YL)-5H-PYRROLO[23-B]PYRAZINE
1324, 3cgoA, 0.8150, 2.81, 0.364, 332, 275, IRAK-4 INHIBITORS (PART II)- A STRUCTURE BASED ASSESSMENT OF IMIDAZO[12 A]PYRIDINE BINDING
1325, 2onlB, 0.8150, 2.53, 0.372, 339, 269, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
1326, 4o2zA, 0.8149, 2.66, 0.332, 363, 271, CRYSTAL STRUCTURE OF MPK3 FROM LEISHMANIA DONOVANI LDBPK_100540 IN THE PRESENCE OF NVP-BBT594
1327, 2pmiA, 0.8149, 2.45, 0.561, 284, 264, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE- RESPONSIVE SIGNAL TRANSDUCTION PATHWAY WITH BOUND ATP-GAMMA-S
1328, 2p33A, 0.8149, 2.80, 0.364, 332, 275, SYNTHESIS AND SAR OF AMINOPYRIMIDINES AS NOVEL C-JUN N- TERMINAL KINASE (JNK) INHIBITORS
1329, 4kkgA, 0.8148, 2.91, 0.350, 353, 277, CRYSTAL STRUCTURE OF APO AND AMP-BOUND JNK3
1330, 4fv4A, 0.8148, 2.21, 0.347, 329, 262, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK7
1331, 3hv4B, 0.8148, 2.68, 0.367, 338, 270, HUMAN P38 MAP KINASE IN COMPLEX WITH RL51
1332, 2ojgA, 0.8146, 2.81, 0.370, 337, 273, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH NN-DIMETHYL-4-(4- PHENYL-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
1333, 1oveA, 0.8145, 2.91, 0.338, 349, 275, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A DIHYDROQUINOLINONE
1334, 4dglC, 0.8144, 2.95, 0.309, 334, 275, CRYSTAL STRUCTURE OF THE CK2 TETRAMERIC HOLOENZYME
1335, 3ds6A, 0.8144, 2.70, 0.352, 343, 273, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
1336, 4o6eA, 0.8143, 2.50, 0.366, 328, 268, DISCOVERY OF 5678-TETRAHYDROPYRIDO[34-D]PYRIMIDINE INHIBITORS OF ERK2
1337, 3eljA, 0.8142, 2.74, 0.336, 347, 274, JNK1 COMPLEXED WITH A BIS-ANILINO-PYRROLOPYRIMIDINE INHIBITOR.
1338, 6g9hA, 0.8141, 2.81, 0.360, 343, 272, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1339, 5etiA, 0.8141, 2.93, 0.349, 355, 275, STRUCTURE OF DEAD KINASE MAPK14
1340, 4qp1A, 0.8141, 2.79, 0.364, 342, 272, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
1341, 2okrA, 0.8140, 2.55, 0.372, 339, 269, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
1342, 4qp7B, 0.8139, 2.54, 0.347, 335, 271, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-5H- PYRROLO[23-B]PYRAZINE
1343, 4qpaB, 0.8138, 2.81, 0.364, 345, 272, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-BENZYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
1344, 3e7oA, 0.8138, 3.05, 0.344, 342, 276, CRYSTAL STRUCTURE OF JNK2
1345, 6fylA, 0.8136, 3.05, 0.273, 340, 275, X-RAY STRUCTURE OF CLK2-KD(136-496)/CX-4945 AT 1.95A 
1346, 5unpA, 0.8136, 3.16, 0.287, 347, 275, STRUCTURE OF CDC2-LIKE KINASE 2 (CLK2) IN COMPLEX WITH COMPOUND T-025 [N2-METHYL-N4-(PYRIMIDIN-2-YLMETHYL)-5-(QUINOLIN-6-YL)-7H-PYRROLO[2; 3-D]PYRIMIDINE-2;4-DIAMINE] 
1347, 4ehvA, 0.8136, 2.63, 0.368, 337, 269, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F10 AND RL87
1348, 5unpB, 0.8135, 3.16, 0.287, 347, 275, STRUCTURE OF CDC2-LIKE KINASE 2 (CLK2) IN COMPLEX WITH COMPOUND T-025 [N2-METHYL-N4-(PYRIMIDIN-2-YLMETHYL)-5-(QUINOLIN-6-YL)-7H-PYRROLO[2; 3-D]PYRIMIDINE-2;4-DIAMINE] 
1349, 1oz1A, 0.8135, 2.75, 0.364, 344, 272, P38 MITOGEN-ACTIVATED KINASE IN COMPLEX WITH 4-AZAINDOLE INHIBITOR
1350, 2ojjA, 0.8133, 2.86, 0.352, 344, 273, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-N-(1-(3- CHLORO-4-FLUOROPHENYL)-2-HYDROXYETHYL)-4-(4-(3- CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
1351, 6g91A, 0.8132, 2.76, 0.349, 344, 272, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1352, 5etaA, 0.8132, 2.37, 0.366, 336, 265, STRUCTURE OF MAPK14 WITH BOUND THE KIM DOMAIN OF THE TOXOPLASMA PROTEIN GRA24
1353, 5byyA, 0.8132, 2.94, 0.374, 338, 273, ERK5 IN COMPLEX WITH SMALL MOLECULE
1354, 3ctqA, 0.8132, 2.55, 0.366, 336, 268, STRUCTURE OF MAP KINASE P38 IN COMPLEX WITH A 1-O-TOLYL-12 3-TRIAZOLE-4-CARBOXAMIDE
1355, 2fysB, 0.8132, 2.65, 0.348, 338, 273, CRYSTAL STRUCTURE OF ERK2 COMPLEX WITH KIM PEPTIDE DERIVED FROM MKP3
1356, 4lopA, 0.8131, 2.91, 0.365, 351, 277, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
1357, 4l7fA, 0.8130, 2.44, 0.352, 354, 267, CO-CRYSTAL STRUCTURE OF JNK1 AND AX13587
1358, 6g33C, 0.8129, 3.16, 0.288, 336, 274, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH 5-IODOTUBERCIDIN 
1359, 3fmmA, 0.8129, 2.80, 0.355, 346, 273, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO6226
1360, 6g33A, 0.8128, 3.11, 0.290, 335, 272, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH 5-IODOTUBERCIDIN 
1361, 5j1vB, 0.8128, 3.16, 0.285, 337, 274, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH PYRIDO[34- G]QUINAZOLINE DERIVATIVE ZW29 (COMPOUND 13)
1362, 5a4lC, 0.8127, 2.77, 0.341, 332, 270, DYRK1A IN COMPLEX WITH FLUORO BENZOTHIAZOLE FRAGMENT
1363, 4qp4B, 0.8126, 2.60, 0.346, 335, 272, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
1364, 2onlA, 0.8126, 2.52, 0.373, 338, 268, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
1365, 5nzzG, 0.8125, 2.60, 0.362, 342, 268, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
1366, 4xrlA, 0.8125, 2.74, 0.368, 337, 272, CRYSTAL STRUCTURE AT ROOM TEMPERATURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
1367, 4qtaA, 0.8125, 2.54, 0.364, 335, 269, STRUCTURE OF HUMAN ERK2 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
1368, 4loqD, 0.8125, 2.90, 0.354, 351, 277, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
1369, 3i5zA, 0.8125, 2.35, 0.351, 331, 265, CRYSTAL STRUCTURE OF ERK2 BOUND TO (S)-N-(2-HYDROXY-1-PHENYLETHYL)-4- (5-METHYL-2-(PHENYLAMINO)PYRIMIDIN-4-YL)-1H-PYRROLE-2-CARBOXAMIDE
1370, 2y8oA, 0.8125, 2.53, 0.369, 339, 268, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH A MAPK DOCKING PEPTIDE
1371, 2i6lA, 0.8124, 2.71, 0.331, 292, 269, CRYSTAL STRUCTURE OF HUMAN MITOGEN ACTIVATED PROTEIN KINASE 6 (MAPK6)
1372, 1zyjA, 0.8124, 2.29, 0.369, 331, 263, HUMAN P38 MAP KINASE IN COMPLEX WITH INHIBITOR 1A
1373, 4h3pD, 0.8123, 2.60, 0.372, 338, 269, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
1374, 4fv2A, 0.8123, 2.82, 0.364, 344, 272, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK5
1375, 3hv5B, 0.8122, 2.72, 0.367, 339, 270, HUMAN P38 MAP KINASE IN COMPLEX WITH RL24
1376, 3d83A, 0.8122, 3.01, 0.364, 347, 275, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIPHENYL AMIDE INHIBITOR
1377, 1yqjA, 0.8122, 2.87, 0.339, 356, 274, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH A SELECTIVE PYRIDAZINE INHIBITOR
1378, 4w4yA, 0.8121, 3.16, 0.354, 350, 280, JNK2/3 IN COMPLEX WITH 3-(4-{[(4-METHYLPHENYL)CARBAMOYL]AMINO}-1H- PYRAZOL-1-YL)-N-(2-METHYLPYRIDIN-4-YL)BENZAMIDE
1379, 4fa2A, 0.8120, 2.55, 0.361, 339, 269, HUMAN P38 ALPHA MITOGEN-ACTIVATED KINASE IN COMPLEX WITH SB239063
1380, 3mh0A, 0.8120, 2.35, 0.371, 332, 264, MUTAGENESIS OF P38 MAP KINASE ESHTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
1381, 3ttiA, 0.8119, 2.82, 0.364, 341, 275, CRYSTAL STRUCTURE OF JNK3 COMPLEXED WITH CC-930 AN ORALLY ACTIVE ANTI-FIBROTIC JNK INHIBITOR
1382, 1ywrA, 0.8119, 2.55, 0.379, 338, 269, CRYSTAL STRUCTURE ANALYSIS OF INACTIVE P38 KINASE DOMAIN IN COMPLEX WITH A MONOCYCLIC PYRAZOLONE INHIBITOR
1383, 6g8xA, 0.8118, 2.75, 0.347, 338, 271, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1384, 4fuxA, 0.8118, 2.78, 0.353, 342, 272, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E75
1385, 3g90X, 0.8118, 2.74, 0.352, 345, 273, JNK-3 BOUND TO (Z)-5-FLUORO-1-((6-FLUORO-4H-BENZO[D][13]DIOXIN-8-YL) METHYL)-3-(HYDROXYIMINO)INDOLIN-2-ONE
1386, 3lhjA, 0.8117, 2.83, 0.370, 341, 273, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A PYRAZOLOPYRIDINONE INHIBITOR.
1387, 3flnC, 0.8117, 2.66, 0.374, 343, 270, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH R1487
1388, 3erkA, 0.8117, 2.81, 0.359, 350, 273, THE COMPLEX STRUCTURE OF THE MAP KINASE ERK2/SB220025
1389, 2vagA, 0.8117, 3.19, 0.286, 330, 273, CRYSTAL STRUCTURE OF DI-PHOSPHORYLATED HUMAN CLK1 IN COMPLEX WITH A NOVEL SUBSTITUTED INDOLE INHIBITOR
1390, 2ojiA, 0.8117, 2.85, 0.366, 344, 273, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-BENZYL-4-(4-(3- CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
1391, 2ghmA, 0.8117, 2.47, 0.369, 336, 268, MUTATED MAP KINASE P38 (MUS MUSCULUS) IN COMPLEX WITH INHBITOR PG-895449
1392, 4ianA, 0.8116, 2.83, 0.306, 321, 271, CRYSTAL STRUCTURE OF APO HUMAN PRPF4B KINASE DOMAIN
1393, 5j1wB, 0.8115, 3.09, 0.289, 337, 273, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH PYRIDO[34- G]QUINAZOLINE DERIVATIVE ZW31 (COMPOUND 14)
1394, 4loqB, 0.8114, 2.93, 0.357, 351, 277, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
1395, 4fv1A, 0.8114, 2.83, 0.364, 342, 272, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK4
1396, 3g9nA, 0.8114, 2.81, 0.365, 346, 274, JNK3 BOUND TO (Z)-1-((6-FLUORO-4H-BENZO[D][13]DIOXIN-8-YL)METHYL)-3- (HYDROXYIMINO)-4-PHENYLINDOLIN-2-ONE
1397, 2o0uA, 0.8114, 2.85, 0.356, 331, 275, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH N-{3-CYANO-6-[3-(1- PIPERIDINYL)PROPANOYL]-4567-TETRAHYDROTHIENO[23-C]PYRIDIN-2-YL}- 1-NAPHTHALENECARBOXAMIDE
1398, 4w4vA, 0.8113, 3.18, 0.354, 342, 280, JNK2/3 IN COMPLEX WITH 3-(4-{[(2-CHLOROPHENYL)CARBAMOYL]AMINO}-1H- PYRAZOL-1-YL)-N-(2-METHYLPYRIDIN-4-YL)BENZAMIDE
1399, 5a4tC, 0.8112, 2.80, 0.341, 332, 270, DYRK1A IN COMPLEX WITH NITRILE BENZOTHIAZOLE FRAGMENT
1400, 4w4xA, 0.8112, 3.15, 0.354, 342, 280, JNK2/3 IN COMPLEX WITH 3-(4-{[(4-FLUOROPHENYL)CARBAMOYL]AMINO}-1H- PYRAZOL-1-YL)-N-(2-METHYLPYRIDIN-4-YL)BENZAMIDE
1401, 2zduA, 0.8111, 2.58, 0.358, 330, 268, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH AN ISOQUINOLONE INHIBITOR
1402, 3gcuB, 0.8110, 2.69, 0.364, 337, 269, HUMAN P38 MAP KINASE IN COMPLEX WITH RL48
1403, 1pmnA, 0.8110, 2.80, 0.358, 344, 274, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH AN IMIDAZOLE- PYRIMIDINE INHIBITOR
1404, 6dcgA, 0.8109, 2.70, 0.353, 326, 269, DISCOVERY OF MK-8353: AN ORALLY BIOAVAILABLE DUAL MECHANISM ERK INHIBITOR FOR ONCOLOGY 
1405, 4eh2A, 0.8108, 2.43, 0.372, 337, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F1 AND RL87
1406, 3oxiA, 0.8108, 2.33, 0.356, 322, 264, DESIGN AND SYNTHESIS OF DISUBSTITUTED THIOPHENE AND THIAZOLE BASED INHIBITORS OF JNK FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
1407, 4ux9B, 0.8107, 2.49, 0.338, 327, 266, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
1408, 3hv4A, 0.8107, 2.78, 0.367, 339, 270, HUMAN P38 MAP KINASE IN COMPLEX WITH RL51
1409, 5cs6B, 0.8106, 2.53, 0.318, 316, 264, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 3 BOUND
1410, 4ka3A, 0.8106, 2.54, 0.369, 340, 268, STRUCTURE OF MAP KINASE IN COMPLEX WITH A DOCKING PEPTIDE
1411, 5lcjA, 0.8105, 2.80, 0.360, 345, 272, IN-GEL ACTIVITY-BASED PROTEIN PROFILING OF A CLICKABLE COVALENT ERK 1/2 INHIBITOR
1412, 2fa2A, 0.8105, 2.85, 0.380, 333, 274, CRYSTAL STRUCTURE OF FUS3 WITHOUT A PEPTIDE FROM STE5
1413, 4f9yA, 0.8104, 2.63, 0.381, 339, 270, HUMAN P38 ALPHA MAPK IN COMPLEX WITH A NOVEL AND SELECTIVE SMALL MOLECULE INHIBITOR
1414, 6fyiA, 0.8103, 3.12, 0.276, 336, 275, X-RAY STRUCTURE OF CLK2-KD(130-496)/TG003 AT 2.6A 
1415, 1tvoA, 0.8103, 2.88, 0.363, 350, 273, THE STRUCTURE OF ERK2 IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
1416, 6ge0A, 0.8102, 2.78, 0.358, 343, 271, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1417, 6g9mA, 0.8102, 2.87, 0.360, 341, 272, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1418, 4b99A, 0.8101, 2.90, 0.379, 335, 272, CRYSTAL STRUCTURE OF MAPK7 (ERK5) WITH INHIBITOR
1419, 6g9dA, 0.8100, 2.82, 0.360, 345, 272, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1420, 2wajA, 0.8100, 2.88, 0.364, 348, 275, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH A 1-ARYL-34- DIHYDROISOQUINOLINE INHIBITOR
1421, 6eq9A, 0.8098, 2.85, 0.355, 350, 273, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH AMP-PCP 
1422, 4fv5A, 0.8097, 2.33, 0.345, 330, 264, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK9
1423, 3ptgA, 0.8097, 2.41, 0.365, 340, 266, DESIGN AND SYNTHESIS OF A NOVEL ORALLY EFFICACIOUS TRI-SUBSTITUTED THIOPHENE BASED JNK INHIBITOR
1424, 3p78A, 0.8094, 2.40, 0.360, 332, 264, P38 INHIBITOR-BOUND
1425, 6ft9B, 0.8092, 3.13, 0.286, 337, 273, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH INHIBITOR 16 
1426, 5ci6B, 0.8092, 2.61, 0.361, 350, 269, CRYSTAL STRUCTURE OF ARABIDOPSIS THALIANA MPK6
1427, 4loqA, 0.8092, 2.95, 0.354, 352, 277, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
1428, 4erkA, 0.8092, 2.84, 0.366, 350, 273, THE COMPLEX STRUCTURE OF THE MAP KINASE ERK2/OLOMOUCINE
1429, 2gfsA, 0.8090, 2.77, 0.354, 344, 271, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO3201195
1430, 4zzoA, 0.8089, 2.63, 0.368, 339, 269, HUMAN ERK2 IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR
1431, 4whzA, 0.8088, 2.86, 0.356, 342, 275, DESIGN AND SYNTHESIS OF HIGHLY POTENT AND ISOFORM SELECTIVE JNK3 INHIBITORS: SAR STUDIES ON AMINOPYRAZOLE DERIVATIVES
1432, 3l1sA, 0.8088, 2.64, 0.340, 336, 265, 3-ARYL-4-(ARYLHYDRAZONO)-1H-PYRAZOL-5-ONES: HIGHLY LIGAND EFFICIENT AND POTENT INHIBITORS OF GSK3
1433, 3fkoA, 0.8088, 2.76, 0.358, 343, 271, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO3668
1434, 4zthA, 0.8087, 2.56, 0.362, 339, 268, STRUCTURE OF HUMAN P38AMAPK-ARYLPYRIDAZINYLPYRIDINE FRAGMENT COMPLEX USED IN INHIBITOR DISCOVERY
1435, 3o71A, 0.8087, 2.93, 0.353, 340, 275, CRYSTAL STRUCTURE OF ERK2/DCC PEPTIDE COMPLEX
1436, 4ifcA, 0.8085, 2.88, 0.306, 327, 271, CRYSTAL STRUCTURE OF ADP-BOUND HUMAN PRPF4B KINASE DOMAIN
1437, 4auaA, 0.8085, 1.74, 0.474, 256, 253, LIGANDED X-RAY CRYSTAL STRUCTURE OF CYCLIN DEPENDENT KINASE 6 (CDK6)
1438, 1cm8B, 0.8085, 2.67, 0.342, 327, 266, PHOSPHORYLATED MAP KINASE P38-GAMMA
1439, 1cm8A, 0.8085, 2.67, 0.342, 327, 266, PHOSPHORYLATED MAP KINASE P38-GAMMA
1440, 4s33A, 0.8084, 2.89, 0.366, 347, 273, ERK2 R65S MUTANT COMPLEXED WITH AMP-PNP
1441, 3p7cA, 0.8084, 2.43, 0.356, 332, 264, P38 INHIBITOR-BOUND
1442, 3p5kA, 0.8084, 2.42, 0.360, 332, 264, P38 INHIBITOR-BOUND
1443, 2gtnA, 0.8084, 2.63, 0.358, 337, 268, MUTATED MAP KINASE P38 (MUS MUSCULUS) IN COMPLEX WITH INHBITOR PG-951717
1444, 4xp2A, 0.8083, 2.83, 0.364, 337, 272, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
1445, 5myvB, 0.8082, 3.02, 0.269, 349, 275, CRYSTAL STRUCTURE OF SRPK2 IN COMPLEX WITH COMPOUND 1
1446, 5mxxA, 0.8081, 2.99, 0.277, 361, 274, CRYSTAL STRUCTURE OF HUMAN SR PROTEIN KINASE 1 (SRPK1) IN COMPLEX WITH COMPOUND 1
1447, 4f9wA, 0.8081, 2.52, 0.373, 336, 268, HUMAN P38ALPHA MAPK IN COMPLEX WITH A NOVEL AND SELECTIVE SMALL MOLECULE INHIBITOR
1448, 3vulA, 0.8081, 2.40, 0.332, 344, 265, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M1 IN MAP KINASE JNK1
1449, 3p79A, 0.8081, 2.43, 0.360, 332, 264, P38 INHIBITOR-BOUND
1450, 2f49B, 0.8081, 2.86, 0.358, 337, 274, CRYSTAL STRUCTURE OF FUS3 IN COMPLEX WITH A STE5 PEPTIDE
1451, 3gc7A, 0.8080, 3.01, 0.332, 349, 274, THE STRUCTURE OF P38ALPHA IN COMPLEX WITH A DIHYDROQUINAZOLINONE
1452, 2okrD, 0.8080, 2.56, 0.367, 339, 267, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
1453, 5nhfA, 0.8079, 2.85, 0.349, 339, 272, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
1454, 4un0D, 0.8079, 2.82, 0.431, 276, 269, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
1455, 3gcvA, 0.8079, 2.70, 0.360, 338, 267, HUMAN P38 MAP KINASE IN COMPLEX WITH RL62
1456, 4bbmB, 0.8078, 2.59, 0.415, 292, 265, CRYSTAL STRUCTURE OF THE HUMAN CDKL2 KINASE DOMAIN WITH BOUND TCS 2312
1457, 3l1sB, 0.8078, 2.73, 0.346, 330, 266, 3-ARYL-4-(ARYLHYDRAZONO)-1H-PYRAZOL-5-ONES: HIGHLY LIGAND EFFICIENT AND POTENT INHIBITORS OF GSK3
1458, 3hp2A, 0.8078, 2.68, 0.364, 341, 269, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH A PYRIDINONE COMPOUND
1459, 6cpwA, 0.8076, 2.75, 0.353, 328, 269, DISCOVERY OF 3(S)-THIOMETHYL PYRROLIDINE ERK INHIBITORS FOR ONCOLOGY 
1460, 4bgqA, 0.8076, 2.40, 0.375, 276, 264, CRYSTAL STRUCTURE OF THE HUMAN CDKL5 KINASE DOMAIN
1461, 1golA, 0.8076, 2.91, 0.366, 357, 273, COORDINATES OF RAT MAP KINASE ERK2 WITH AN ARGININE MUTATION AT POSITION 52
1462, 4zznA, 0.8075, 2.85, 0.364, 338, 272, HUMAN ERK2 IN COMPLEX WITH AN INHIBITOR
1463, 3queA, 0.8075, 2.77, 0.359, 343, 270, HUMAN P38 MAP KINASE IN COMPLEX WITH SKEPINONE-L
1464, 4s34A, 0.8074, 2.88, 0.374, 343, 273, ERK2 (I84A) IN COMPLEX WITH AMP-PNP
1465, 4ifcB, 0.8074, 2.85, 0.304, 329, 270, CRYSTAL STRUCTURE OF ADP-BOUND HUMAN PRPF4B KINASE DOMAIN
1466, 4n4sA, 0.8073, 2.84, 0.354, 342, 274, A DOUBLE MUTANT RAT ERK2 IN COMPLEX WITH A PYRAZOLO[34-D]PYRIMIDINE INHIBITOR
1467, 1pmvA, 0.8073, 2.90, 0.364, 347, 275, THE STRUCTURE OF JNK3 IN COMPLEX WITH A DIHYDROANTHRAPYRAZOLE INHIBITOR
1468, 5umoA, 0.8072, 2.90, 0.370, 347, 273, STRUCTURE OF EXTRACELLULAR SIGNAL-REGULATED KINASE
1469, 2i0hA, 0.8072, 3.02, 0.328, 349, 274, THE STRUCTURE OF P38ALPHA IN COMPLEX WITH AN ARYLPYRIDAZINONE
1470, 6g9nA, 0.8071, 2.90, 0.360, 344, 272, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1471, 4qp3B, 0.8071, 2.56, 0.355, 331, 265, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-2-((9H-PURIN-6-YL) AMINO)-3-PHENYLPROPAN-1-OL
1472, 3fmlA, 0.8071, 2.76, 0.359, 342, 270, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO6224
1473, 3qudA, 0.8070, 2.85, 0.362, 345, 271, HUMAN P38 MAP KINASE IN COMPLEX WITH 2-AMINO-PHENYLAMINO-BENZOPHENONE
1474, 3ds6C, 0.8070, 3.03, 0.361, 349, 277, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
1475, 1yw2A, 0.8069, 2.74, 0.356, 341, 270, MUTATED MUS MUSCULUS P38 KINASE (MP38)
1476, 3p7bA, 0.8068, 2.44, 0.360, 332, 264, P38 INHIBITOR-BOUND
1477, 5lckA, 0.8067, 2.82, 0.362, 345, 271, A CLICKABLE COVALENT ERK 1/2 INHIBITOR
1478, 3p4kA, 0.8067, 2.56, 0.371, 338, 267, THE THIRD CONFORMATION OF P38A MAP KINASE OBSERVED IN PHOSPHORYLATED P38A AND IN SOLUTION
1479, 3kvxA, 0.8066, 2.49, 0.351, 327, 265, JNK3 BOUND TO AMINOPYRIMIDINE INHIBITOR SR-3562
1480, 3gcuA, 0.8066, 2.86, 0.370, 339, 270, HUMAN P38 MAP KINASE IN COMPLEX WITH RL48
1481, 2fa2B, 0.8066, 2.90, 0.330, 332, 273, CRYSTAL STRUCTURE OF FUS3 WITHOUT A PEPTIDE FROM STE5
1482, 1erkA, 0.8066, 2.93, 0.363, 357, 273, STRUCTURE OF SIGNAL-REGULATED KINASE
1483, 3o8tA, 0.8063, 2.45, 0.360, 332, 264, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG-MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
1484, 5myvC, 0.8062, 3.14, 0.268, 348, 276, CRYSTAL STRUCTURE OF SRPK2 IN COMPLEX WITH COMPOUND 1
1485, 5byzA, 0.8062, 2.86, 0.387, 348, 271, ERK5 IN COMPLEX WITH SMALL MOLECULE
1486, 4ianB, 0.8062, 2.90, 0.292, 319, 271, CRYSTAL STRUCTURE OF APO HUMAN PRPF4B KINASE DOMAIN
1487, 4xp3A, 0.8061, 2.68, 0.364, 339, 269, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
1488, 3newA, 0.8061, 2.49, 0.383, 334, 266, P38-ALPHA COMPLEXED WITH COMPOUND 10
1489, 3amyA, 0.8061, 2.61, 0.308, 318, 266, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA COMPLEXED WITH APIGENIN
1490, 4qp3A, 0.8060, 2.66, 0.367, 339, 267, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-2-((9H-PURIN-6-YL) AMINO)-3-PHENYLPROPAN-1-OL
1491, 3pzeA, 0.8060, 2.74, 0.339, 347, 271, JNK1 IN COMPLEX WITH INHIBITOR
1492, 3uvpA, 0.8059, 2.55, 0.366, 334, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH A BENZAMIDE SUBSTITUTED BENZOSUBERONE
1493, 3ds6B, 0.8059, 2.87, 0.372, 343, 274, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
1494, 6g92A, 0.8058, 2.89, 0.368, 343, 272, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1495, 4zzmA, 0.8058, 2.85, 0.347, 344, 271, HUMAN ERK2 IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR
1496, 4ijpB, 0.8058, 2.90, 0.295, 333, 271, CRYSTAL STRUCTURE OF HUMAN PRPF4B KINASE DOMAIN IN COMPLEX WITH 4-{5- [(2-CHLORO-PYRIDIN-4-YLMETHYL)-CARBAMOYL]-THIOPHEN-2-YL}- BENZO[B]THIOPHENE-2-CARBOXYLIC ACID AMINE
1497, 2z7lA, 0.8058, 2.81, 0.367, 329, 270, UNPHOSPHORYLATED MITOGEN ACTIVATED PROTEIN KINASE ERK2 IN COMPLEX WITH (4-{[5-CARBAMOYL-4-(3-METHYLANILINO)PYRIMIDIN 2-YL]AMINO}PHENYL)ACETIC ACID
1498, 4s32A, 0.8057, 2.94, 0.359, 346, 273, CRYSTAL STRUCTURE OF ERK2 AMP-PNP COMPLEX
1499, 3hv5A, 0.8055, 2.88, 0.370, 339, 270, HUMAN P38 MAP KINASE IN COMPLEX WITH RL24
1500, 5tbeA, 0.8054, 2.37, 0.361, 332, 263, HUMAN P38ALPHA MAP KINASE IN COMPLEX WITH DIBENZOSUBERONE COMPOUND 2
1501, 3fmnA, 0.8054, 2.68, 0.369, 341, 268, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO2530
1502, 4l8mA, 0.8053, 2.71, 0.364, 339, 269, HUMAN P38 MAP KINASE IN COMPLEX WITH A DIBENZOXEPINONE
1503, 4g6nA, 0.8053, 2.87, 0.360, 341, 272, CRYSTAL STRUCTURE OF THE ERK2
1504, 2eufB, 0.8053, 2.47, 0.506, 282, 261, X-RAY STRUCTURE OF HUMAN CDK6-VCYCLIN IN COMPLEX WITH THE INHIBITOR PD0332991
1505, 4lopC, 0.8052, 2.81, 0.371, 341, 272, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
1506, 4g6oA, 0.8052, 2.84, 0.359, 339, 270, CRYSTAL STRUCTURE OF THE ERK2
1507, 3lltA, 0.8052, 3.19, 0.271, 341, 273, CRYSTAL STRUCTURE OF PF14_0431 KINASE DOMAIN.
1508, 6g9kA, 0.8051, 2.86, 0.362, 343, 271, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1509, 5uojA, 0.8051, 2.87, 0.365, 343, 271, THE STRUCTURE OF THE MAP KINASE P38 AT 2.1 ANGSTROMS RESOLUTION
1510, 4eomC, 0.8051, 2.43, 0.965, 275, 260, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
1511, 4eh3A, 0.8051, 2.70, 0.362, 339, 268, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F2 AND RL87
1512, 4s2zA, 0.8050, 2.92, 0.374, 346, 273, ERK2 INTRINSICALLY ACTIVE MUTANT R65S
1513, 4eh7A, 0.8050, 2.55, 0.365, 337, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F6 AND RL87
1514, 3qywA, 0.8050, 2.68, 0.368, 340, 269, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
1515, 4s31A, 0.8049, 2.95, 0.359, 347, 273, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 1 WTERK2 AT 1.45A
1516, 3fv8A, 0.8049, 2.45, 0.358, 331, 265, JNK3 BOUND TO PIPERAZINE AMIDE INHIBITOR SR2774.
1517, 3fskA, 0.8049, 2.86, 0.368, 342, 272, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO6257
1518, 1r39A, 0.8049, 2.98, 0.363, 345, 273, THE STRUCTURE OF P38ALPHA
1519, 3begA, 0.8048, 2.87, 0.268, 348, 272, CRYSTAL STRUCTURE OF SR PROTEIN KINASE 1 COMPLEXED TO ITS SUBSTRATE ASF/SF2
1520, 4xneA, 0.8047, 2.88, 0.360, 344, 272, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
1521, 4e73A, 0.8047, 2.39, 0.341, 318, 264, CRYSTAL STRUCTURE OF JNK1BETA-JIP IN COMPLEX WITH AN AZAQUINOLONE INHBITOR
1522, 3odzX, 0.8047, 2.50, 0.373, 335, 263, CRYSTAL STRUCTURE OF P38ALPHA Y323R ACTIVE MUTANT
1523, 3mgyA, 0.8047, 2.35, 0.360, 329, 261, MUTAGENESIS OF P38 MAP KINASE ESHTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
1524, 3lffA, 0.8045, 2.64, 0.365, 335, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH RL166
1525, 1wfcA, 0.8045, 2.89, 0.365, 340, 271, STRUCTURE OF APO UNPHOSPHORYLATED P38 MITOGEN ACTIVATED PROTEIN KINASE P38 (P38 MAP KINASE) THE MAMMALIAN HOMOLOGUE OF THE YEAST HOG1 PROTEIN
1526, 6gdmA, 0.8044, 2.89, 0.365, 341, 271, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1527, 2xrwA, 0.8044, 2.33, 0.340, 348, 262, LINEAR BINDING MOTIFS FOR JNK AND FOR CALCINEURIN ANTAGONISTICALLY CONTROL THE NUCLEAR SHUTTLING OF NFAT4
1528, 1oguC, 0.8044, 2.34, 0.981, 272, 258, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR
1529, 4iq6A, 0.8043, 2.74, 0.347, 324, 265, GSK-3BETA WITH INHIBITOR 6-CHLORO-N-CYCLOHEXYL-4-(1H-PYRROLO[23- B]PYRIDIN-3-YL)PYRIDIN-2-AMINE
1530, 4eh8A, 0.8043, 2.49, 0.366, 336, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F7 AND RL87
1531, 3vumA, 0.8043, 2.45, 0.332, 347, 265, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M7 IN MAP KINASE JNK1
1532, 3uvqA, 0.8040, 2.42, 0.375, 333, 264, HUMAN P38 MAP KINASE IN COMPLEX WITH A DIBENZOSUBERONE DERIVATIVE
1533, 4ijpA, 0.8039, 2.94, 0.306, 330, 271, CRYSTAL STRUCTURE OF HUMAN PRPF4B KINASE DOMAIN IN COMPLEX WITH 4-{5- [(2-CHLORO-PYRIDIN-4-YLMETHYL)-CARBAMOYL]-THIOPHEN-2-YL}- BENZO[B]THIOPHENE-2-CARBOXYLIC ACID AMINE
1534, 6g9jA, 0.8038, 2.85, 0.356, 347, 270, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1535, 3v6sA, 0.8037, 2.74, 0.365, 349, 271, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
1536, 3bhuC, 0.8037, 2.36, 0.981, 271, 258, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 5
1537, 4qp6B, 0.8036, 2.61, 0.366, 334, 265, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 5H-PYRROLO[23-B]PYRAZINE
1538, 3v6rA, 0.8035, 2.75, 0.365, 349, 271, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
1539, 4qpaA, 0.8034, 2.64, 0.366, 331, 265, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-BENZYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
1540, 6ekdA, 0.8033, 2.44, 0.355, 325, 265, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH A PYRIDINYLIMIDAZOLE INHIBITOR 
1541, 3r63A, 0.8033, 2.96, 0.359, 347, 273, STRUCTURE OF ERK2 (SPE) MUTANT (S246E)
1542, 4izaC, 0.8031, 2.67, 0.364, 335, 269, STRUCTURE OF DUALLY PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
1543, 4gt3A, 0.8031, 2.92, 0.371, 347, 272, ATP-BOUND FORM OF THE ERK2 KINASE
1544, 3fl4A, 0.8030, 2.75, 0.362, 339, 268, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO5634
1545, 4eoqC, 0.8029, 2.46, 0.981, 275, 260, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH ATP
1546, 4eh6A, 0.8029, 2.47, 0.364, 335, 264, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F5 AND RL87
1547, 2gtmA, 0.8029, 2.83, 0.361, 341, 269, MUTATED MOUSE P38 MAP KINASE DOMAIN IN COMPLEX WITH INHIBITOR PG-892579
1548, 5etfA, 0.8027, 2.64, 0.367, 338, 267, STRUCTURE OF DEAD KINASE MAPK14 WITH BOUND THE KIM DOMAIN OF MKK6
1549, 4qp6A, 0.8027, 2.68, 0.363, 339, 267, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 5H-PYRROLO[23-B]PYRAZINE
1550, 4qp2B, 0.8026, 2.65, 0.381, 329, 265, CRYSTAL STRUCTURE OF ERKS IN COMPLEX WITH 5-CHLOROBENZO[D]OXAZOL-2- AMINE
1551, 4h36A, 0.8025, 3.22, 0.361, 353, 277, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH ATF2 PEPTIDE
1552, 4tyhB, 0.8024, 2.50, 0.357, 335, 266, TERNARY COMPLEX OF P38 AND MK2 WITH A P38 INHIBITOR
1553, 4iirB, 0.8023, 2.84, 0.306, 327, 268, CRYSTAL STRUCTURE OF AMPPNP-BOUND HUMAN PRPF4B KINASE DOMAIN
1554, 3bhtC, 0.8023, 2.38, 0.981, 270, 258, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 3
1555, 4iirA, 0.8022, 2.90, 0.309, 325, 269, CRYSTAL STRUCTURE OF AMPPNP-BOUND HUMAN PRPF4B KINASE DOMAIN
1556, 5nzzH, 0.8021, 2.55, 0.365, 335, 263, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
1557, 5j1wC, 0.8020, 2.83, 0.297, 316, 266, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH PYRIDO[34- G]QUINAZOLINE DERIVATIVE ZW31 (COMPOUND 14)
1558, 3c5uA, 0.8020, 2.65, 0.369, 338, 268, P38 ALPHA MAP KINASE COMPLEXED WITH A BENZOTHIAZOLE BASED INHIBITOR
1559, 4eorC, 0.8019, 2.36, 0.938, 270, 258, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
1560, 4bcoC, 0.8019, 2.34, 0.981, 269, 257, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
1561, 1i09A, 0.8019, 2.72, 0.347, 338, 265, STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 (GSK3B)
1562, 4xp0A, 0.8018, 2.83, 0.367, 336, 270, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
1563, 4g1wA, 0.8018, 2.44, 0.345, 322, 264, CRYSTAL STRUCTURE OF JNK1 IN COMPLEX WITH JIP1 PEPTIDE AND 7-FLUORO-3- [4-(2-HYDROXY-ETHANESULFONYL)-BENZYL]-4-OXO-1-PHENYL-14-DIHYDRO- QUINOLINE-2-CARBOXYLIC ACID METHYL ESTER
1564, 3hrbA, 0.8018, 2.89, 0.368, 344, 272, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1565, 2ghlA, 0.8017, 2.54, 0.372, 334, 266, MUTANT MUS MUSCULUS P38 KINASE DOMAIN IN COMPLEX WITH INHIBITOR PG-874743
1566, 1ungB, 0.8017, 2.37, 0.564, 268, 257, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
1567, 4yr8C, 0.8016, 2.34, 0.335, 318, 260, CRYSTAL STRUCTURE OF JNK IN COMPLEX WITH A REGULATOR PROTEIN
1568, 4h3bC, 0.8016, 3.06, 0.360, 351, 275, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH SAB PEPTIDE
1569, 4h3bA, 0.8016, 3.06, 0.360, 351, 275, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH SAB PEPTIDE
1570, 3obgA, 0.8015, 2.49, 0.371, 332, 264, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MUTANTS IN RESPONSE TO INHIBITOR BINDING
1571, 3fi4A, 0.8015, 2.63, 0.380, 339, 266, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO4499
1572, 4qp2A, 0.8014, 2.68, 0.363, 336, 267, CRYSTAL STRUCTURE OF ERKS IN COMPLEX WITH 5-CHLOROBENZO[D]OXAZOL-2- AMINE
1573, 2w96B, 0.8012, 2.24, 0.478, 267, 255, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
1574, 4xozA, 0.8010, 2.90, 0.375, 341, 272, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
1575, 4xj0B, 0.8010, 2.75, 0.360, 338, 267, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR 14K
1576, 3zyaA, 0.8010, 2.64, 0.369, 346, 268, HUMAN P38 MAP KINASE IN COMPLEX WITH 2-AMINO-PHENYLAMINO- DIBENZOSUBERONE
1577, 4r3cA, 0.8009, 2.57, 0.376, 335, 266, CRYSTAL STRUCTURE OF P38 ALPHA MAP KINASE IN COMPLEX WITH A NOVEL ISOFORM SELECTIVE DRUG CANDIDATE
1578, 5ax3A, 0.8006, 2.51, 0.356, 329, 264, CRYSTAL STRUCTURE OF ERK2 COMPLEXED WITH ALLOSTERIC AND ATP- COMPETITIVE INHIBITORS.
1579, 1pmeA, 0.8006, 2.81, 0.361, 333, 269, STRUCTURE OF PENTA MUTANT HUMAN ERK2 MAP KINASE COMPLEXED WITH A SPECIFIC INHIBITOR OF HUMAN P38 MAP KINASE
1580, 4zsjA, 0.8005, 2.91, 0.376, 344, 271, MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
1581, 4eh4A, 0.8005, 2.68, 0.365, 337, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F3 AND RL87
1582, 3uvrA, 0.8005, 2.67, 0.361, 331, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH KM064
1583, 3nupA, 0.8005, 1.56, 0.492, 252, 248, CDK6 (MONOMERIC) IN COMPLEX WITH INHIBITOR
1584, 4s30A, 0.8003, 2.93, 0.346, 342, 272, ERK2 INTRINSICALLY ACTIVE MUTANT (I84A)
1585, 3bhvC, 0.8003, 2.41, 0.981, 271, 258, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR VARIOLIN B
1586, 4ditA, 0.8002, 2.17, 0.335, 328, 257, CRYSTAL STRUCTURE OF GSK3BETA IN COMPLEX WITH A IMIDAZOPYRIDINE INHIBITOR
1587, 3o8pA, 0.8002, 2.80, 0.362, 336, 268, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
1588, 5uq3A, 0.8000, 2.79, 0.981, 270, 261, CRYSTAL STRUCTURE OF HUMAN CDK2-SPY1-P27 TERNARY COMPLEX
1589, 3p7aA, 0.8000, 2.55, 0.360, 332, 264, P38 INHIBITOR-BOUND
1590, 5n66A, 0.7999, 2.53, 0.364, 332, 264, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9J
1591, 5mtxA, 0.7999, 2.54, 0.367, 331, 264, DIBENZOOXEPINONE INHIBITOR 12B IN COMPLEX WITH P38 MAPK
1592, 3ttjA, 0.7999, 2.84, 0.358, 333, 271, CRYSTAL STRUCTURE OF JNK3 COMPLEXED WITH CC-359 A JNK INHIBITOR FOR THE PREVENTION OF ISCHEMIA-REPERFUSION INJURY
1593, 3o0gB, 0.7999, 2.13, 0.557, 264, 253, CRYSTAL STRUCTURE OF CDK5:P25 IN COMPLEX WITH AN ATP ANALOGUE
1594, 3mpaA, 0.7999, 2.39, 0.359, 331, 262, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
1595, 4cfuC, 0.7998, 2.42, 0.981, 272, 258, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
1596, 2x7gA, 0.7998, 3.23, 0.268, 344, 276, STRUCTURE OF HUMAN SERINE-ARGININE-RICH PROTEIN-SPECIFIC KINASE 2 (SRPK2) BOUND TO PURVALANOL B
1597, 2f2cB, 0.7998, 2.43, 0.479, 280, 259, X-RAY STRUCTURE OF HUMAN CDK6-VCYCLINWITH THE INHIBITOR AMINOPURVALANOL
1598, 4yr8A, 0.7997, 2.50, 0.350, 320, 263, CRYSTAL STRUCTURE OF JNK IN COMPLEX WITH A REGULATOR PROTEIN
1599, 3v6rB, 0.7994, 3.00, 0.349, 346, 272, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
1600, 3qyzA, 0.7994, 2.78, 0.361, 339, 269, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
1601, 2pk9C, 0.7993, 2.20, 0.567, 266, 254, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE-RESPONSIVE SIGNAL TRANSDUCTION PATHWAY
1602, 3hp5A, 0.7992, 2.47, 0.365, 330, 263, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH A PYRIMIDOPYRIDAZINONE COMPOUND
1603, 3hecA, 0.7991, 2.44, 0.352, 329, 261, P38 IN COMPLEX WITH IMATINIB
1604, 5o7iA, 0.7990, 2.84, 0.379, 340, 269, ERK5 IN COMPLEX WITH A PYRROLE INHIBITOR 
1605, 4zsgA, 0.7989, 2.93, 0.376, 347, 271, MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
1606, 4xrjA, 0.7987, 2.95, 0.360, 344, 272, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
1607, 4x21A, 0.7984, 2.67, 0.356, 336, 267, THE MAP KINASE JNK3 AS TARGET FOR HALOGEN BONDING
1608, 3npcA, 0.7983, 3.27, 0.330, 357, 276, CRYSTAL STRUCTURE OF JNK2 COMPLEXED WITH BIRB796
1609, 3mw1A, 0.7981, 2.95, 0.358, 342, 271, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1610, 3fsfA, 0.7980, 2.77, 0.360, 340, 267, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 3-(26- DICHLORO-PHENYL)-7-[4-(2-DIETHYLAMINO-ETHOXY)-PHENYLAMINO]- 1-METHYL-34-DIHYDRO-1H-PYRIMIDO[45-D]PYRIMIDIN-2-ONE
1611, 2xs0A, 0.7979, 2.68, 0.345, 346, 267, LINEAR BINDING MOTIFS FOR JNK AND FOR CALCINEURIN ANTAGONISTICALLY CONTROL THE NUCLEAR SHUTTLING OF NFAT4
1612, 2iw9C, 0.7978, 2.34, 0.977, 268, 256, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
1613, 4dljA, 0.7975, 2.60, 0.374, 336, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH RL163
1614, 1pmuA, 0.7974, 2.82, 0.358, 342, 271, THE CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH A PHENANTROLINE INHIBITOR
1615, 4fv0A, 0.7971, 2.92, 0.365, 341, 271, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK3
1616, 3pg1A, 0.7970, 2.81, 0.325, 341, 268, MAP KINASE LMAMPK10 FROM LEISHMANIA MAJOR (1.95 ANGS RESOLUTION)
1617, 5j1vC, 0.7969, 2.96, 0.298, 314, 265, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH PYRIDO[34- G]QUINAZOLINE DERIVATIVE ZW29 (COMPOUND 13)
1618, 4bcpC, 0.7968, 2.25, 0.965, 267, 254, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
1619, 5awmA, 0.7967, 2.92, 0.335, 345, 269, THE CRYSTAL STRUCTURE OF JNK FROM DROSOPHILA MELANOGASTER REVEALS AN EVOLUTIONARILY CONSERVED TOPOLOGY WITH THAT OF MAMMALIAN JNK PROTEINS.
1620, 4x21B, 0.7964, 2.59, 0.361, 336, 266, THE MAP KINASE JNK3 AS TARGET FOR HALOGEN BONDING
1621, 3hegA, 0.7963, 2.68, 0.362, 333, 265, P38 IN COMPLEX WITH SORAFENIB
1622, 3gi3A, 0.7963, 2.53, 0.359, 330, 262, CRYSTAL STRUCTURE OF A N-PHENYL-N -NAPHTHYLUREA ANALOG IN COMPLEX WITH P38 MAP KINASE
1623, 5ci6A, 0.7962, 2.64, 0.355, 335, 265, CRYSTAL STRUCTURE OF ARABIDOPSIS THALIANA MPK6
1624, 4gvaA, 0.7959, 3.00, 0.325, 345, 271, ADP-BOUND FORM OF THE ERK2 KINASE
1625, 3hv3A, 0.7956, 2.65, 0.366, 335, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH RL49
1626, 3oefX, 0.7955, 2.82, 0.361, 334, 266, CRYSTAL STRUCTURE OF Y323F INACTIVE MUTANT OF P38ALPHA MAP KINASE
1627, 2r9sB, 0.7953, 2.39, 0.352, 325, 261, C-JUN N-TERMINAL KINASE 3 WITH 35-DISUBSTITUTED QUINOLINE INHIBITOR
1628, 2r9sA, 0.7953, 2.40, 0.360, 325, 261, C-JUN N-TERMINAL KINASE 3 WITH 35-DISUBSTITUTED QUINOLINE INHIBITOR
1629, 4z9lA, 0.7952, 2.85, 0.359, 333, 270, THE STRUCTURE OF JNK3 IN COMPLEX WITH AN IMIDAZOLE-PYRIMIDINE INHIBITOR
1630, 3oz6B, 0.7952, 2.84, 0.373, 341, 268, CRYSTAL STRUCTURE OF MAPK FROM CRYPTOSPORIDIUM PARVUM CGD2_1960
1631, 4ynoA, 0.7951, 2.93, 0.342, 342, 269, CRYSTAL STRUCTURE OF MAPK13 AT INACTIVE FORM
1632, 4gsbA, 0.7951, 2.92, 0.361, 343, 269, MONOCLINIC CRYSTAL FORM OF THE APO-ERK2
1633, 5xyxA, 0.7950, 2.67, 0.364, 337, 264, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A TRIAZOL INHIBITOR
1634, 4fuyA, 0.7950, 2.90, 0.369, 329, 268, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK2
1635, 3gcqA, 0.7950, 2.66, 0.366, 337, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH RL45
1636, 4yr8E, 0.7948, 2.63, 0.345, 317, 264, CRYSTAL STRUCTURE OF JNK IN COMPLEX WITH A REGULATOR PROTEIN
1637, 4n0sA, 0.7948, 3.03, 0.365, 348, 271, COMPLEX OF ERK2 WITH CAFFEIC ACID
1638, 3vn9A, 0.7948, 2.66, 0.246, 291, 264, RIFINED CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED MAP2K6 IN A PUTATIVE AUTO-INHIBITION STATE
1639, 3mh1A, 0.7948, 2.77, 0.367, 337, 267, MUTAGENESIS OF P38 MAP KINASE ESTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
1640, 3l8xA, 0.7948, 2.24, 0.370, 326, 257, P38 ALPHA KINASE COMPLEXED WITH A PYRAZOLO-PYRIMIDINE BASED INHIBITOR
1641, 1wakA, 0.7948, 3.06, 0.277, 353, 271, X-RAY STRUCTURE OF SRPK1
1642, 1ukiA, 0.7948, 2.62, 0.340, 328, 265, STRUCTURAL BASIS FOR THE SELECTIVE INHIBITION OF JNK1 BY THE SCAFFOLDING PROTEIN JIP1 AND SP600125
1643, 4zslA, 0.7947, 2.96, 0.378, 341, 270, MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
1644, 4lmnA, 0.7947, 2.36, 0.270, 292, 259, CRYSTAL STRUCTURE OF MEK1 KINASE BOUND TO GDC0973
1645, 4eh9A, 0.7947, 2.68, 0.367, 334, 264, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F11 AND RL87
1646, 1kv1A, 0.7947, 2.53, 0.369, 331, 263, P38 MAP KINASE IN COMPLEX WITH INHIBITOR 1
1647, 4an2A, 0.7946, 2.38, 0.270, 282, 259, CRYSTAL STRUCTURES OF HUMAN MEK1 WITH CARBOXAMIDE-BASED ALLOSTERIC INHIBITOR XL518 (GDC-0973) OR RELATED ANALOGS.
1648, 3s4qA, 0.7944, 2.25, 0.377, 326, 257, P38 ALPHA KINASE COMPLEXED WITH A PYRAZOLO-TRIAZINE BASED INHIBITOR
1649, 4loqC, 0.7942, 2.91, 0.349, 337, 269, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
1650, 4izyA, 0.7942, 2.67, 0.340, 322, 265, CRYSTAL STRUCTURE OF JNK1 IN COMPLEX WITH JIP1 PEPTIDE AND 4-{4-[4-(4- METHANESULFONYL-PIPERIDIN-1-YL)-INDOL-1-YL]-PYRIMIDIN-2-YLAMINO}- CYCLOHEXAN
1651, 4hyuA, 0.7942, 2.57, 0.341, 322, 264, CRYSTAL STRUCTURE OF JNK1 IN COMPLEX WITH JIP1 PEPTIDE AND 4-{4-[4-(3- METHANESULFONYL-PROPOXY)-INDAZOL-1-YL]-PYRIMIDIN-2-YLAMINO}- CYCLOHEXAN
1652, 3ha8A, 0.7941, 3.10, 0.337, 342, 270, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/COMPOUND 14B
1653, 4ic8B, 0.7940, 3.03, 0.338, 336, 272, CRYSTAL STRUCTURE OF THE APO ERK5 KINASE DOMAIN
1654, 3v6sB, 0.7940, 2.58, 0.358, 340, 265, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
1655, 5o90A, 0.7939, 2.50, 0.384, 330, 263, CRYSTAL STRUCTURE OF A P38ALPHA T185G MUTANT IN COMPLEX WITH TAB1 PEPTIDE.
1656, 3mblA, 0.7939, 2.35, 0.270, 290, 259, CRYSTAL STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK 1) IN COMPLEX WITH LIGAND AND MGADP
1657, 3pp1A, 0.7937, 2.34, 0.270, 291, 259, CRYSTAL STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK 1) IN COMPLEX WITH LIGAND AND MGATP
1658, 1wbpA, 0.7937, 3.08, 0.257, 350, 272, SRPK1 BOUND TO 9MER DOCKING MOTIF PEPTIDE
1659, 3e8nA, 0.7936, 2.30, 0.271, 291, 258, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) COMPLEXED WITH A POTENT INHIBITOR RDEA119 AND MGATP
1660, 2qd9A, 0.7935, 2.49, 0.378, 330, 262, P38 ALPHA MAP KINASE INHIBITOR BASED ON HETEROBICYCLIC SCAFFOLDS
1661, 3objA, 0.7934, 2.66, 0.360, 332, 264, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MUTANTS IN RESPONSE TO INHIBITOR BINDING
1662, 2wmbC, 0.7933, 2.33, 0.980, 266, 254, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
1663, 1h26C, 0.7933, 2.38, 0.980, 267, 255, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53
1664, 4anbA, 0.7931, 2.40, 0.270, 282, 259, CRYSTAL STRUCTURES OF HUMAN MEK1 WITH CARBOXAMIDE-BASED ALLOSTERIC INHIBITOR XL518 (GDC-0973) OR RELATED ANALOGS.
1665, 3da6A, 0.7930, 2.79, 0.366, 328, 268, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH N-(3-METHYL- 4-(3-(2-(METHYLAMINO)PYRIMIDIN-4-YL)PYRIDIN-2-YLOXY) NAPHTHALEN-1-YL)-1H-BENZO[D]IMIDAZOL-2-AMINE
1666, 6eq9B, 0.7929, 2.65, 0.353, 332, 266, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH AMP-PCP 
1667, 4hysA, 0.7929, 2.68, 0.343, 321, 265, CRYSTAL STRUCTURE OF JNK1 IN COMPLEX WITH JIP1 PEPTIDE AND 4-(4- INDAZOL-1-YL-PYRIMIDIN-2-YLAMINO)-CYCLOHEXAN
1668, 4arkA, 0.7929, 2.40, 0.270, 291, 259, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN MAP KINASE KINASE 1 (MEK1) IN COMPLEX WITH  A SMALL MOLECULE INHIBITOR AND ADP
1669, 4cfmC, 0.7927, 2.36, 0.988, 266, 254, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
1670, 3sa0A, 0.7927, 3.02, 0.373, 354, 271, COMPLEX OF ERK2 WITH NORATHYRIOL
1671, 2ok1A, 0.7926, 2.77, 0.357, 333, 266, CRYSTAL STRUCTURE OF JNK3 BOUND TO N-BENZYL-4-(4-(3- CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
1672, 3eqgA, 0.7925, 2.40, 0.270, 314, 259, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A TERNARY COMPLEX WITH PD ADP AND MG2P
1673, 3tg1A, 0.7924, 2.68, 0.370, 334, 265, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH A MAPK DOCKING PARTNER
1674, 3eqhA, 0.7920, 2.40, 0.270, 314, 259, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A TERNARY COMPLEX WITH U0126 ADP AND MG2P
1675, 4u7zA, 0.7919, 2.32, 0.271, 291, 258, MITOGEN-ACTIVATED PROTEIN KINASE KINASE (MEK1) BOUND TO G805
1676, 3lfbA, 0.7919, 2.66, 0.354, 333, 263, HUMAN P38 MAP KINASE IN COMPLEX WITH RL98
1677, 4wuaA, 0.7918, 3.22, 0.269, 344, 275, CRYSTAL STRUCTURE OF HUMAN SRPK1 COMPLEXED TO AN INHIBITOR SRPIN340
1678, 3k3iA, 0.7917, 2.65, 0.371, 332, 264, P38ALPHA BOUND TO NOVEL DGF-OUT COMPOUND PF-00215955
1679, 6cnhA, 0.7916, 2.56, 0.299, 321, 264, HUMAN PRPF4B IN COMPLEX WITH REBASTINIB
1680, 3npcB, 0.7916, 3.28, 0.331, 356, 275, CRYSTAL STRUCTURE OF JNK2 COMPLEXED WITH BIRB796
1681, 3hvcA, 0.7915, 2.36, 0.371, 327, 259, CRYSTAL STRUCTURE OF HUMAN P38ALPHA MAP KINASE
1682, 5w5qA, 0.7913, 2.43, 0.262, 291, 260, MAP4K4 IN COMPLEX WITH INHIBITOR COMPOUND 12 (N3-METHYL-10-(3-METHYL- 3-(5-METHYLOXAZOL-2-YL)BUT-1-YN-1-YL)-6;7-DIHYDRO-5H-5;7- METHANOBENZO[C]IMIDAZO[1;2-A]AZEPINE-2;3-DICARBOXAMIDE) 
1683, 2o2uA, 0.7913, 2.65, 0.366, 319, 265, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH N-(3-CYANO-4567- TETRAHYDRO-1-BENZOTHIEN-2-YL)-2-FLUOROBENZAMIDE
1684, 3dogC, 0.7911, 2.36, 0.945, 267, 255, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR N-&-N1
1685, 6emhA, 0.7910, 2.82, 0.352, 344, 267, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH A PYRIDINYLIMIDAZOLE INHIBITOR 
1686, 3mh2A, 0.7910, 2.51, 0.368, 330, 261, MUTAGENESIS OF P38 MAP KINASE ESTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
1687, 2puuA, 0.7910, 2.55, 0.359, 330, 262, CRYSTAL STRUCTURE OF P38 COMPLEX WITH 1-(5-TERT-BUTYL-2-P- TOLYL-2H-PYRAZOL-3-YL)-3-[4-(6-MORPHOLIN-4-YLMETHYL- PYRIDIN-3-YL)NAPHTHALEN-1-YL]UREA
1688, 4dliA, 0.7909, 2.73, 0.371, 334, 264, HUMAN P38 MAP KINASE IN COMPLEX WITH RL87
1689, 2iw8C, 0.7909, 2.26, 0.929, 265, 253, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H-L83V- H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR
1690, 4zxtA, 0.7907, 3.06, 0.365, 348, 271, COMPLEX OF ERK2 WITH CATECHOL
1691, 4xoyA, 0.7906, 2.77, 0.381, 326, 265, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
1692, 3fc1X, 0.7906, 2.74, 0.364, 330, 264, CRYSTAL STRUCTURE OF P38 KINASE BOUND TO PYRIMIDO-PYRIDAZINONE INHIBITOR
1693, 3eqfA, 0.7905, 2.52, 0.269, 314, 260, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH K252A AND MG2P
1694, 4u40A, 0.7903, 2.45, 0.265, 295, 260, MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4) BOUND TO AMPPNP
1695, 4a9yA, 0.7902, 2.79, 0.374, 334, 265, P38ALPHA MAP KINASE BOUND TO CMPD 8
1696, 3oc1A, 0.7902, 2.57, 0.366, 330, 262, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
1697, 3mh3A, 0.7902, 2.73, 0.364, 334, 264, MUTAGENESIS OF P38 MAP KINASE ESTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
1698, 2bakA, 0.7902, 2.79, 0.374, 334, 265, P38ALPHA MAP KINASE BOUND TO MPAQ
1699, 6f5eB, 0.7901, 2.90, 0.336, 346, 268, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_D12_10_47 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
1700, 6emhB, 0.7901, 2.92, 0.351, 344, 268, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH A PYRIDINYLIMIDAZOLE INHIBITOR 
1701, 5o8uA, 0.7901, 2.68, 0.365, 331, 263, COVALENT INHIBITOR 4B BOUND TO THE LIPID POCKET OF P38ALPHA MUTANT S252C
1702, 5lmkC, 0.7901, 2.34, 0.984, 265, 253, STRUCTURE OF PHOPSHO-CDK2-CYCLIN A IN COMPLEX WITH AN ATP-COMPETITIVE INHIBITOR
1703, 5lenB, 0.7901, 2.90, 0.336, 346, 268, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_D12_10_47 IN COMPLEX WITH JNK1A1 AND JIP1 PEPTIDE
1704, 3uibA, 0.7898, 2.36, 0.322, 309, 258, MAP KINASE LMAMPK10 FROM LEISHMANIA MAJOR IN COMPLEX WITH SB203580
1705, 5xv7A, 0.7897, 3.20, 0.259, 350, 274, SRPK1 IN COMPLEX WITH ALECTINIB
1706, 5mtyA, 0.7897, 2.49, 0.363, 328, 259, DIBENZOSUBERONE INHIBITOR 8E IN COMPLEX WITH P38 MAPK
1707, 3e7oB, 0.7895, 2.51, 0.333, 326, 261, CRYSTAL STRUCTURE OF JNK2
1708, 4u81A, 0.7894, 2.47, 0.271, 289, 258, MEK1 KINASE BOUND TO SMALL MOLECULE INHIBITOR G659
1709, 1ianA, 0.7894, 2.44, 0.377, 328, 260, HUMAN P38 MAP KINASE INHIBITOR COMPLEX
1710, 5myvA, 0.7891, 3.34, 0.268, 352, 276, CRYSTAL STRUCTURE OF SRPK2 IN COMPLEX WITH COMPOUND 1
1711, 3v04A, 0.7891, 2.35, 0.268, 289, 257, DISCOVERY OF NOVEL ALLOSTERIC MEK INHIBITORS POSSESSING CLASSICAL AND NON-CLASSICAL BIDENTATE SER212 INTERACTIONS.
1712, 2p55A, 0.7890, 2.46, 0.271, 289, 258, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
1713, 3oz6A, 0.7887, 3.14, 0.368, 343, 269, CRYSTAL STRUCTURE OF MAPK FROM CRYPTOSPORIDIUM PARVUM CGD2_1960
1714, 3dv3A, 0.7886, 2.28, 0.270, 288, 256, MEK1 WITH PF-04622664 BOUND
1715, 2excX, 0.7885, 2.64, 0.364, 335, 264, INHIBITOR COMPLEX OF JNK3
1716, 3hv6A, 0.7884, 2.62, 0.363, 331, 262, HUMAN P38 MAP KINASE IN COMPLEX WITH RL39
1717, 1oiuC, 0.7884, 2.35, 0.976, 265, 253, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
1718, 3eqdA, 0.7883, 2.52, 0.269, 315, 260, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH ATP-GS AND MG2P
1719, 5tcoA, 0.7882, 2.52, 0.363, 327, 259, HUMAN P38 MAP KINASE IN COMPLEX WITH DIBENZOSUBERONE COMPOUND 1
1720, 3eqbA, 0.7882, 2.27, 0.273, 289, 256, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
1721, 4u79A, 0.7880, 2.84, 0.371, 337, 267, CRYSTAL STRUCTURE OF HUMAN JNK3 IN COMPLEX WITH A BENZENESULFONAMIDE INHIBITOR.
1722, 3eqiA, 0.7878, 2.54, 0.269, 315, 260, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH ADP AND MG2P
1723, 5bx0A, 0.7876, 2.53, 0.269, 315, 260, AN AUTOMATED MICROSCALE THERMOPHORESIS SCREENING APPROACH FOR FRAGMENT-BASED LEAD DISCOVERY
1724, 1s9jA, 0.7876, 2.49, 0.271, 289, 258, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
1725, 4an3A, 0.7875, 2.36, 0.268, 280, 257, CRYSTAL STRUCTURES OF HUMAN MEK1 WITH CARBOXAMIDE-BASED ALLOSTERIC INHIBITOR XL518 (GDC-0973) OR RELATED ANALOGS.
1726, 3v01A, 0.7875, 2.29, 0.273, 289, 256, DISCOVERY OF NOVEL ALLOSTERIC MEK INHIBITORS POSSESSING CLASSICAL AND NON-CLASSICAL BIDENTATE SER212 INTERACTIONS.
1727, 5my8A, 0.7874, 3.27, 0.269, 355, 275, CRYSTAL STRUCTURE OF SRPK1 IN COMPLEX WITH SPHINX31
1728, 3pg3A, 0.7873, 2.87, 0.361, 337, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH RL182
1729, 3hv7A, 0.7873, 2.63, 0.366, 330, 262, HUMAN P38 MAP KINASE IN COMPLEX WITH RL38
1730, 4n4sB, 0.7872, 2.94, 0.331, 337, 269, A DOUBLE MUTANT RAT ERK2 IN COMPLEX WITH A PYRAZOLO[34-D]PYRIMIDINE INHIBITOR
1731, 3g9lX, 0.7872, 2.81, 0.357, 336, 266, JNK3 BOUND TO (Z)-1-((6-FLUORO-4H-BENZO[D][13]DIOXIN-8-YL)METHYL)-3- (HYDROXYIMINO)-4-STYRYLINDOLIN-2-ONE
1732, 3my5C, 0.7871, 2.43, 0.980, 266, 254, CDK2/CYCLINA IN COMPLEX WITH DRB
1733, 3ddqC, 0.7869, 2.41, 0.976, 266, 254, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR ROSCOVITINE
1734, 3eqcA, 0.7868, 2.37, 0.268, 312, 257, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A TERNARY COMPLEX WITH COMPOUND 1 ATP-GS AND MG2P
1735, 5n68A, 0.7867, 2.53, 0.377, 328, 260, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9M
1736, 4an9A, 0.7866, 2.41, 0.271, 281, 258, CRYSTAL STRUCTURES OF HUMAN MEK1 WITH CARBOXAMIDE-BASED ALLOSTERIC INHIBITOR XL518 (GDC-0973) OR RELATED ANALOGS.
1737, 3vvhC, 0.7865, 2.58, 0.269, 283, 260, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH AN INHIBITOR AND MGATP
1738, 3zlsA, 0.7863, 2.48, 0.266, 315, 259, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 6
1739, 2w9fB, 0.7862, 2.10, 0.474, 261, 249, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
1740, 4u80A, 0.7860, 2.53, 0.267, 286, 258, MEK 1 KINASE BOUND TO G799
1741, 1s9iA, 0.7860, 2.43, 0.280, 303, 257, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (MEK2)IN A COMPLEX WITH LIGAND AND MGATP
1742, 3oy1A, 0.7858, 2.60, 0.366, 329, 262, HIGHLY SELECTIVE C-JUN N-TERMINAL KINASE (JNK) 2 AND 3 INHIBITORS WITH IN VITRO CNS-LIKE PHARMACOKINETIC PROPERTIES
1743, 3iw6A, 0.7858, 2.95, 0.371, 337, 267, HUMAN P38 MAP KINASE IN COMPLEX WITH A BENZYLPIPERAZIN- PYRROL
1744, 5n65A, 0.7856, 2.85, 0.370, 333, 265, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9H
1745, 5ekoA, 0.7855, 3.05, 0.353, 341, 269, CRYSTAL STRUCTURE OF MAPK13 COMPLEX WITH INHIBITOR
1746, 3zsiA, 0.7854, 2.66, 0.368, 326, 261, X-RAY STRUCTURE OF P38ALPHA BOUND TO VX-745
1747, 3vvhA, 0.7854, 2.40, 0.270, 287, 256, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH AN INHIBITOR AND MGATP
1748, 3vvhB, 0.7852, 2.61, 0.269, 290, 260, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH AN INHIBITOR AND MGATP
1749, 1ukhA, 0.7852, 2.56, 0.341, 321, 261, STRUCTURAL BASIS FOR THE SELECTIVE INHIBITION OF JNK1 BY THE SCAFFOLDING PROTEIN JIP1 AND SP600125
1750, 1jowB, 0.7850, 2.54, 0.480, 277, 256, CRYSTAL STRUCTURE OF A COMPLEX OF HUMAN CDK6 AND A VIRAL CYCLIN
1751, 3rtpA, 0.7848, 2.65, 0.363, 331, 262, DESIGN AND SYNTHESIS OF BRAIN PENETRANT SELECTIVE JNK INHIBITORS WITH IMPROVED PHARMACOKINETIC PROPERTIES FOR THE PREVENTION OF NEURODEGENERATION
1752, 5o8vA, 0.7847, 2.46, 0.372, 328, 258, COVALENT INHIBITOR 4A BOUND TO THE LIPID POCKET OF P38ALPHA MUTANT S251C
1753, 3ornA, 0.7847, 2.60, 0.265, 280, 260, MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH CH4987655 AND MGAMP-PNP
1754, 3iw7A, 0.7847, 2.92, 0.368, 335, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH AN IMIDAZO-PYRIDINE
1755, 4yr8F, 0.7845, 2.31, 0.352, 300, 253, CRYSTAL STRUCTURE OF JNK IN COMPLEX WITH A REGULATOR PROTEIN
1756, 3rp9A, 0.7843, 2.84, 0.367, 350, 264, CRYSTAL STRUCTURE OF THE APO MAPK FROM TOXOPLASMA GONDII 25.M01780 OR TGME49_007820
1757, 3k3jA, 0.7836, 2.65, 0.372, 329, 261, P38ALPHA BOUND TO NOVEL DFG-OUT COMPOUND PF-00416121
1758, 4mneE, 0.7835, 2.51, 0.266, 286, 259, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
1759, 4h39A, 0.7834, 3.07, 0.358, 340, 268, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH JIP1 PEPTIDE
1760, 2baqA, 0.7832, 2.76, 0.378, 329, 262, P38ALPHA BOUND TO RO3201195
1761, 3os3A, 0.7831, 2.47, 0.272, 272, 257, MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH CH4858061 AND MGATP
1762, 5wp1A, 0.7828, 3.11, 0.359, 340, 270, COMPLEX OF ERK2 WITH 5;7-DIHYDROXYCHROMONE 
1763, 4eymA, 0.7828, 3.02, 0.352, 340, 267, MAPK13 COMPLEX WITH INHIBITOR
1764, 3zshA, 0.7828, 2.86, 0.370, 331, 265, X-RAY STRUCTURE OF P38ALPHA BOUND TO SCIO-469
1765, 3hubA, 0.7826, 2.87, 0.370, 335, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH SCIOS-469
1766, 4mneH, 0.7823, 2.45, 0.267, 275, 258, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
1767, 4cfvC, 0.7823, 2.40, 0.980, 264, 252, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
1768, 3zlxA, 0.7822, 2.44, 0.268, 312, 257, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 18
1769, 3zlwA, 0.7821, 2.56, 0.264, 312, 258, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 3
1770, 5n63A, 0.7819, 2.40, 0.371, 325, 256, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9C
1771, 4eh5A, 0.7819, 2.49, 0.376, 329, 258, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F4 AND RL87
1772, 3hucA, 0.7819, 3.07, 0.367, 337, 267, HUMAN P38 MAP KINASE IN COMPLEX WITH RL40
1773, 2weiA, 0.7818, 2.38, 0.287, 278, 254, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE IN COMPLEX WITH 3- MB-PP1
1774, 1kv2A, 0.7816, 2.46, 0.377, 325, 257, HUMAN P38 MAP KINASE IN COMPLEX WITH BIRB 796
1775, 5d7aB, 0.7814, 2.28, 0.256, 286, 254, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
1776, 5n67A, 0.7812, 2.53, 0.376, 327, 258, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9L
1777, 5myvD, 0.7812, 3.46, 0.268, 351, 276, CRYSTAL STRUCTURE OF SRPK2 IN COMPLEX WITH COMPOUND 1
1778, 2b1pA, 0.7810, 2.72, 0.365, 331, 263, INHIBITOR COMPLEX OF JNK3
1779, 4mneD, 0.7809, 2.48, 0.271, 285, 258, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
1780, 4u40B, 0.7805, 2.83, 0.248, 299, 262, MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4) BOUND TO AMPPNP
1781, 4mneA, 0.7805, 2.54, 0.266, 286, 259, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
1782, 3lfeA, 0.7805, 2.86, 0.367, 334, 264, HUMAN P38 MAP KINASE IN COMPLEX WITH RL116
1783, 2y4iC, 0.7803, 2.41, 0.270, 313, 256, KSR2-MEK1 HETERODIMER
1784, 3lfaA, 0.7801, 2.83, 0.365, 333, 263, HUMAN P38 MAP KINASE IN COMPLEX WITH DASATINIB
1785, 2wmaC, 0.7801, 2.46, 0.976, 265, 253, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
1786, 1s9iB, 0.7799, 2.46, 0.278, 291, 255, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (MEK2)IN A COMPLEX WITH LIGAND AND MGATP
1787, 2yiwA, 0.7798, 2.50, 0.374, 325, 257, TRIAZOLOPYRIDINE INHIBITORS OF P38 KINASE
1788, 3l8sA, 0.7796, 2.91, 0.367, 334, 264, HUMAN P38 MAP KINASE IN COMPLEX WITH CP-547632
1789, 3slsA, 0.7795, 2.32, 0.260, 292, 254, CRYSTAL STRUCTURE OF HUMAN MEK-1 KINASE IN COMPLEX WITH UCB1353770 AND AMPPNP
1790, 3zlyA, 0.7794, 2.57, 0.268, 310, 257, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 8
1791, 5cwzB, 0.7793, 2.28, 0.241, 284, 253, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
1792, 5d7aC, 0.7789, 2.32, 0.260, 286, 254, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
1793, 5d7aA, 0.7789, 2.37, 0.259, 289, 255, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
1794, 2fslX, 0.7789, 2.79, 0.372, 332, 261, MITOGEN ACTIVATED PROTEIN KINASE P38ALPHA (D176A+F327S) ACTIVATING MUTANT FORM-A
1795, 6emhC, 0.7788, 2.85, 0.351, 334, 265, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH A PYRIDINYLIMIDAZOLE INHIBITOR 
1796, 2ewaA, 0.7788, 2.65, 0.373, 330, 260, DUAL BINDING MODE OF PYRIDINYLIMIDAZOLE TO MAP KINASE P38
1797, 4e6cA, 0.7787, 2.83, 0.378, 330, 262, P38A-PERIFOSINE COMPLEX
1798, 6emhD, 0.7786, 2.85, 0.343, 331, 265, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH A PYRIDINYLIMIDAZOLE INHIBITOR 
1799, 4e5aX, 0.7786, 2.69, 0.377, 332, 260, THE W197A MUTANT OF P38A MAP KINASE
1800, 5n64A, 0.7783, 2.64, 0.375, 329, 259, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9G
1801, 4u45A, 0.7783, 2.51, 0.268, 289, 257, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 25)
1802, 4u44A, 0.7783, 2.44, 0.270, 286, 256, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 16)
1803, 3iw5A, 0.7782, 3.08, 0.367, 336, 267, HUMAN P38 MAP KINASE IN COMPLEX WITH AN INDOLE DERIVATIVE
1804, 5cwzA, 0.7778, 2.29, 0.245, 284, 253, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
1805, 4zk5A, 0.7778, 2.49, 0.261, 286, 257, MAP4K4 IN COMPLEX WITH INHIBITOR GNE-495
1806, 4eyjA, 0.7776, 3.02, 0.371, 338, 267, MAPK13 COMPLEX WITH INHIBITOR
1807, 3zm4A, 0.7776, 2.56, 0.270, 309, 256, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 1
1808, 4aa0A, 0.7775, 2.78, 0.379, 328, 261, P38ALPHA MAP KINASE BOUND TO CMPD 2
1809, 5hzeA, 0.7773, 2.64, 0.260, 305, 258, MEK1 ADOPTS DFG-OUT CONFORMATION WHEN BOUND TO AN ANALOG OF E6201.
1810, 3slsB, 0.7773, 2.45, 0.263, 294, 255, CRYSTAL STRUCTURE OF HUMAN MEK-1 KINASE IN COMPLEX WITH UCB1353770 AND AMPPNP
1811, 6anlA, 0.7771, 3.16, 0.367, 338, 267, STRUCTURE-BASED DESIGN SYNTHESIS AND BIOLOGICAL EVALUATION OF IMIDAZO[12-B]PYRIDAZINE-BASED P38 MAP KINASE INHIBITORS
1812, 4mx9A, 0.7770, 2.58, 0.289, 459, 256, CDPK1 FROM NEOSPORA CANINUM IN COMPLEX WITH INHIBITOR UW1294
1813, 4u43A, 0.7769, 2.38, 0.239, 287, 255, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 6)
1814, 4obpA, 0.7769, 2.51, 0.261, 285, 257, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 29) 6-(2-FLUOROPYRIDIN-4- YL)PYRIDO[32-D]PYRIMIDIN-4-AMINE
1815, 4fzaB, 0.7769, 2.85, 0.263, 281, 259, CRYSTAL STRUCTURE OF MST4-MO25 COMPLEX
1816, 3lfcA, 0.7769, 2.88, 0.365, 334, 263, HUMAN P38 MAP KINASE IN COMPLEX WITH RL99
1817, 4onaA, 0.7768, 2.59, 0.289, 465, 256, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1517
1818, 4m97A, 0.7768, 2.58, 0.285, 465, 256, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM NEOSPORA CANINUM
1819, 3fi2A, 0.7768, 2.64, 0.356, 326, 261, CRYSTAL STRUCTURE OF JNK3 WITH AMINO-PYRAZOLE INHIBITOR SR- 3451
1820, 5kkrC, 0.7767, 2.49, 0.270, 309, 256, KSR2:MEK1 COMPLEX BOUND TO THE SMALL MOLECULE APS-2-79
1821, 6bfaA, 0.7765, 2.58, 0.285, 464, 256, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1553
1822, 3ma6B, 0.7765, 2.37, 0.312, 266, 253, CRYSTAL STRUCTURE OF KINASE DOMAIN OF TGCDPK1 IN PRESENCE OF 3BRB-PP1
1823, 3wigA, 0.7764, 2.60, 0.265, 278, 257, HUMAN MEK1 KINASE IN COMPLEX WITH CH5126766 AND MGAMP-PNP
1824, 4u44B, 0.7763, 2.96, 0.244, 296, 262, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 16)
1825, 4geoA, 0.7762, 2.64, 0.362, 326, 257, P38A MAP KINASE DEF-POCKET PENTA MUTANT (M194A L195A H228A I229A Y258A)
1826, 4m84A, 0.7761, 2.59, 0.285, 464, 256, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1455
1827, 4mxaA, 0.7759, 2.59, 0.289, 459, 256, CDPK1 FROM NEOSPORA CANINUM IN COMPLEX WITH INHIBITOR RM-1-132
1828, 4wg5A, 0.7758, 2.59, 0.285, 464, 256, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1647
1829, 3is5F, 0.7758, 2.15, 0.301, 266, 249, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
1830, 2i6lB, 0.7758, 2.87, 0.312, 269, 260, CRYSTAL STRUCTURE OF HUMAN MITOGEN ACTIVATED PROTEIN KINASE 6 (MAPK6)
1831, 3ku2A, 0.7756, 2.66, 0.296, 457, 257, CRYSTAL STRUCTURE OF INACTIVATED FORM OF CDPK1 FROM TOXOPLASMA GONDII TGME49.101440
1832, 5w91A, 0.7752, 2.54, 0.298, 451, 255, TOXOPLASMA GONDII CDPK1 IN COMPLEX WITH INHIBITOR LZH118
1833, 3fi3A, 0.7750, 2.60, 0.351, 328, 259, CRYSTAL STRUCTURE OF JNK3 WITH INDAZOLE INHIBITOR SR-3737
1834, 3v5tA, 0.7748, 2.54, 0.298, 460, 255, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1299
1835, 3iw8A, 0.7748, 2.98, 0.364, 334, 264, STRUCTURE OF INACTIVE HUMAN P38 MAP KINASE IN COMPLEX WITH A THIAZOLE-UREA
1836, 2bajA, 0.7748, 3.12, 0.370, 337, 265, P38ALPHA BOUND TO PYRAZOLOUREA
1837, 5j95A, 0.7747, 2.37, 0.268, 284, 254, MAP4K4 IN COMPLEX WITH INHIBITOR
1838, 4wg3A, 0.7746, 2.54, 0.298, 460, 255, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1610
1839, 4ihpA, 0.7746, 2.54, 0.290, 454, 255, CRYSTAL STRUCTURE OF TGCDPK1 WITH INHIBITOR BOUND
1840, 4yjnA, 0.7745, 2.53, 0.290, 460, 255, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1639
1841, 5w80A, 0.7744, 2.55, 0.298, 453, 255, TOXOPLASMA GONDII CDPK1 IN COMPLEX WITH INHIBITOR GXJ-237
1842, 5w5qB, 0.7744, 2.97, 0.252, 297, 262, MAP4K4 IN COMPLEX WITH INHIBITOR COMPOUND 12 (N3-METHYL-10-(3-METHYL- 3-(5-METHYLOXAZOL-2-YL)BUT-1-YN-1-YL)-6;7-DIHYDRO-5H-5;7- METHANOBENZO[C]IMIDAZO[1;2-A]AZEPINE-2;3-DICARBOXAMIDE) 
1843, 5ajqA, 0.7744, 2.74, 0.317, 280, 259, HUMAN LOK (STK10) IN COMPLEX WITH BOSUTINIB
1844, 3gcsA, 0.7744, 2.87, 0.370, 331, 262, HUMAN P38 MAP KINASE IN COMPLEX WITH SORAFENIB
1845, 5jn2A, 0.7743, 2.56, 0.298, 450, 255, CRYSTAL STRUCTURE OF TGCDPK1 BOUND TO NVPACU106
1846, 4jbvA, 0.7743, 2.54, 0.298, 458, 255, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1268
1847, 4wg4A, 0.7742, 2.54, 0.298, 454, 255, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1613
1848, 5w8rA, 0.7741, 2.56, 0.286, 456, 255, TOXOPLASMA GONDII CDPK1 IN COMPLEX WITH INHIBITOR 3CIB-PPI
1849, 3i79A, 0.7741, 2.64, 0.285, 455, 256, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1)
1850, 5w9eA, 0.7740, 2.55, 0.298, 451, 255, TOXOPLASMA GONDII CDPK1 IN COMPLEX WITH INHIBITOR GXJ-186
1851, 5ng3A, 0.7740, 3.08, 0.222, 283, 261, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
1852, 4ifgA, 0.7740, 2.58, 0.298, 452, 255, CRYSTAL STRUCTURE OF TGCDPK1 WITH INHIBITOR BOUND
1853, 5eknA, 0.7739, 2.99, 0.348, 336, 264, CRYSTAL STRUCTURE OF MAPK13 COMPLEX WITH INHIBITOR
1854, 3v5pA, 0.7739, 2.54, 0.298, 450, 255, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1288
1855, 4zp5A, 0.7737, 2.39, 0.264, 284, 254, MAP4K4 IN COMPLEX WITH INHIBITOR
1856, 4fzfB, 0.7737, 2.73, 0.266, 279, 256, CRYSTAL STRUCTURE OF MST4-MO25 COMPLEX WITH DKI
1857, 3n51A, 0.7737, 2.61, 0.285, 448, 256, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH BUMPED KINASE INHIBITOR RM-1-95
1858, 3upzA, 0.7736, 2.56, 0.298, 458, 255, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH BUMPLESS BKI ANALOG UW1243
1859, 3sxfA, 0.7736, 2.67, 0.284, 452, 257, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH BUMPED KINASE INHIBITOR RM-1-89
1860, 2yisA, 0.7736, 2.59, 0.374, 325, 257, TRIAZOLOPYRIDINE INHIBITORS OF P38 KINASE.
1861, 4tzrA, 0.7735, 2.55, 0.298, 461, 255, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1561
1862, 5jmsA, 0.7734, 2.57, 0.298, 447, 255, CRYSTAL STRUCTURE OF TGCDPK1 BOUND TO CGP060476
1863, 3upxA, 0.7734, 2.57, 0.298, 445, 255, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1300
1864, 3t3vA, 0.7733, 2.49, 0.287, 453, 254, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH BUMPED KINASE INHIBITOR RM-1-87
1865, 5w9rA, 0.7732, 2.63, 0.309, 445, 256, TOXOPLASMA GONDII CDPK1 IN COMPLEX WITH INHIBITOR LJQ138
1866, 5di1A, 0.7732, 2.40, 0.264, 285, 254, MAP4K4 IN COMPLEX WITH AN INHIBITOR
1867, 3sx9A, 0.7732, 2.55, 0.298, 457, 255, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH BUMPED KINASE INHIBITOR RM-1-132
1868, 3t3uA, 0.7730, 2.62, 0.285, 452, 256, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH BUMPED KINASE INHIBITOR RM-1-130
1869, 3i7bA, 0.7727, 2.74, 0.295, 459, 258, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH BUMPED KINASE INHIBITOR NM-PP1
1870, 5ax9C, 0.7726, 2.36, 0.257, 282, 253, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
1871, 3v51A, 0.7726, 2.57, 0.290, 459, 255, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR RM-1-176
1872, 5wjjA, 0.7725, 2.94, 0.369, 338, 263, STRUCTURE-BASED DESIGN SYNTHESIS AND BIOLOGICAL EVALUATION OF IMIDAZO[12-B]PYRIDAZINE-BASED P38 MAP KINASE INHIBITORS
1873, 4l46A, 0.7723, 2.53, 0.290, 317, 255, CRYSTAL STRUCTURES OF HUMAN P70S6K1-WT
1874, 4ih8A, 0.7723, 2.58, 0.294, 433, 255, CRYSTAL STRUCTURE OF TGCDPK1 WITH INHIBITOR BOUND
1875, 4dc2A, 0.7722, 2.63, 0.295, 328, 254, STRUCTURE OF PKC IN COMPLEX WITH A SUBSTRATE PEPTIDE FROM PAR-3
1876, 4l3lA, 0.7721, 2.53, 0.294, 291, 255, CRYSTAL STRUCTURES OF HUMAN P70S6K1 KINASE DOMAIN (ZINC ANOMALOUS)
1877, 3zs5A, 0.7721, 3.17, 0.361, 340, 266, STRUCTURAL BASIS FOR KINASE SELECTIVITY OF THREE CLINICAL P38ALPHA INHIBITORS
1878, 3zsgA, 0.7716, 3.16, 0.361, 337, 266, X-RAY STRUCTURE OF P38ALPHA BOUND TO TAK-715
1879, 2x7fB, 0.7713, 2.44, 0.268, 288, 254, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
1880, 3odyX, 0.7712, 2.63, 0.382, 321, 254, CRYSTAL STRUCTURE OF P38ALPHA Y323Q ACTIVE MUTANT
1881, 4l44A, 0.7711, 2.59, 0.298, 321, 255, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389A (FORM II)
1882, 3zh8A, 0.7711, 2.47, 0.294, 318, 252, A NOVEL SMALL MOLECULE APKC INHIBITOR
1883, 4l3jA, 0.7709, 2.55, 0.298, 291, 255, CRYSTAL STRUCTURES OF HUMAN P70S6K1 KINASE DOMAIN
1884, 4u42A, 0.7708, 2.33, 0.254, 282, 252, MAP4K4 T181E MUTANT BOUND TO INHIBITOR COMPOUND 1
1885, 4zk5B, 0.7706, 2.90, 0.247, 294, 259, MAP4K4 IN COMPLEX WITH INHIBITOR GNE-495
1886, 4fzdB, 0.7705, 2.50, 0.261, 275, 253, CRYSTAL STRUCTURE OF MST4-MO25 COMPLEX WITH WSF MOTIF
1887, 4uakA, 0.7703, 3.05, 0.253, 404, 261, MRCK BETA IN COMPLEX WITH ADP
1888, 4ic8A, 0.7703, 2.99, 0.332, 325, 262, CRYSTAL STRUCTURE OF THE APO ERK5 KINASE DOMAIN
1889, 3d0eB, 0.7703, 2.60, 0.289, 322, 253, CRYSTAL STRUCTURE OF HUMAN AKT2 IN COMPLEX WITH GSK690693
1890, 3d0eA, 0.7703, 2.60, 0.289, 322, 253, CRYSTAL STRUCTURE OF HUMAN AKT2 IN COMPLEX WITH GSK690693
1891, 5t6aA, 0.7701, 2.62, 0.298, 431, 255, CRYSTAL STRUCTURE OF TGCDPK1 FROM TOXOPLASMA GONDII COMPLEXED WITH 5GA
1892, 4xbuA, 0.7701, 2.81, 0.264, 292, 254, IN VITRO CRYSTAL STRUCTURE OF PAK4 IN COMPLEX WITH INKA PEPTIDE
1893, 3zh8B, 0.7701, 2.49, 0.294, 317, 252, A NOVEL SMALL MOLECULE APKC INHIBITOR
1894, 4e8aA, 0.7700, 2.83, 0.372, 327, 258, THE CRYSTAL STRUCTURE OF P38A MAP KINASE IN COMPLEX WITH PIA24
1895, 4rvtB, 0.7699, 3.13, 0.236, 297, 263, MAP4K4 IN COMPLEX WITH A PYRIDIN-2(1H)-ONE DERIVATIVE
1896, 1o6lA, 0.7699, 2.58, 0.289, 316, 253, CRYSTAL STRUCTURE OF AN ACTIVATED AKT/PROTEIN KINASE B (PKB-PIF CHIMERA) TERNARY COMPLEX WITH AMP-PNP AND GSK3 PEPTIDE
1897, 1o6kA, 0.7699, 2.57, 0.289, 317, 253, STRUCTURE OF ACTIVATED FORM OF PKB KINASE DOMAIN S474D WITH GSK3 PEPTIDE AND AMP-PNP
1898, 5ax9A, 0.7697, 2.34, 0.250, 282, 252, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
1899, 2f7xE, 0.7697, 2.70, 0.276, 336, 254, PROTEIN KINASE A BOUND TO (S)-2-(1H-INDOL-3-YL)-1-[5-((E)-2- PYRIDIN-4-YL-VINYL)-PYRIDIN-3-YLOXYMETHYL]-ETHYLAMINE
1900, 5ng3D, 0.7696, 3.01, 0.221, 278, 258, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
1901, 3wf7A, 0.7696, 2.77, 0.293, 288, 256, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PURINE DERIVATIVE 1-(9H-PURIN-6-YL)-N-[3-(TRIFLUOROMETHYL)PHENYL]PIPERIDINE- 4-CARBOXAMIDE
1902, 2oh0E, 0.7696, 2.57, 0.277, 336, 253, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH PYRIDINE-PYRAZOLOPYRIDINE BASED INHIBITORS
1903, 5t6iA, 0.7694, 2.60, 0.295, 427, 254, CRYSTAL STRUCTURE OF TGCDPK1 FROM TOXOPLASMA GONDII COMPLEXED WITH 5GB
1904, 4ualA, 0.7694, 2.86, 0.255, 403, 259, MRCK BETA IN COMPLEX WITH BDP00005290
1905, 1rejA, 0.7694, 2.63, 0.277, 333, 253, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 1
1906, 2uzvA, 0.7693, 2.73, 0.276, 336, 254, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
1907, 5otfA, 0.7692, 2.93, 0.262, 411, 260, MRCK BETA IN COMPLEX WITH BDP-00009066
1908, 3zh8C, 0.7692, 2.45, 0.299, 312, 251, A NOVEL SMALL MOLECULE APKC INHIBITOR
1909, 3we4A, 0.7692, 2.58, 0.294, 286, 255, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PYRIMIDINE DERIVATIVE PF-4708671 2-{[4-(5-ETHYLPYRIMIDIN-4-YL)PIPERAZIN-1- YL]METHYL}-5-(TRIFLUOROMETHYL)-1H-BENZIMIDAZOLE
1910, 2f7eE, 0.7692, 2.58, 0.277, 336, 253, PKA COMPLEXED WITH (S)-2-(1H-INDOL-3-YL)-1-(5-ISOQUINOLIN-6- YL-PYRIDIN-3-YLOXYMETHYL-ETYLAMINE
1911, 2ojfE, 0.7691, 2.71, 0.276, 336, 254, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH PYRIDINE-PYRAZOLOPYRIDINE BASED INHIBITORS
1912, 1re8A, 0.7690, 2.62, 0.277, 337, 253, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 2
1913, 5oteA, 0.7689, 3.03, 0.253, 407, 261, MRCK BETA IN COMPLEX WITH BDP-00008900
1914, 4o0vA, 0.7689, 2.94, 0.263, 290, 255, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
1915, 4nw5A, 0.7689, 2.53, 0.290, 302, 252, RSK2 N-TERMINAL KINASE IN COMPLEX WITH 2-AMINO-7-SUBSTITUTED BENZOXAZOLE COMPOUND 8
1916, 3amaA, 0.7689, 2.65, 0.285, 342, 253, PROTEIN KINASE A SIXFOLD MUTANT MODEL OF AURORA B WITH INHIBITOR JNJ- 7706621
1917, 3dfaA, 0.7688, 2.41, 0.303, 265, 251, CRYSTAL STRUCTURE OF KINASE DOMAIN OF CALCIUM-DEPENDENT PROTEIN KINASE CGD3_920 FROM CRYPTOSPORIDIUM PARVUM
1918, 2uzuE, 0.7687, 2.58, 0.273, 336, 253, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
1919, 2gfcA, 0.7687, 2.62, 0.277, 335, 253, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
1920, 4njdA, 0.7686, 2.96, 0.267, 290, 255, STRUCTURE OF P21-ACTIVATED KINASE 4 WITH A NOVEL INHIBITOR KY-04031
1921, 4aw2A, 0.7686, 3.06, 0.257, 398, 261, CRYSTAL STRUCTURE OF CDC42 BINDING PROTEIN KINASE ALPHA (MRCK ALPHA)
1922, 3e88B, 0.7686, 2.62, 0.289, 319, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1923, 3e88A, 0.7686, 2.62, 0.289, 319, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1924, 2uw7A, 0.7686, 2.78, 0.272, 335, 254, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  4-(4-CHLORO- PHENYL)-4-(4-(1H-PYRAZOL-4-YL)-PHENYL)-PIPERIDINE
1925, 1jbpE, 0.7686, 2.62, 0.277, 339, 253, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE COMPLEXED WITH A SUBSTRATE PEPTIDE ADP AND DETERGENT
1926, 4e5bA, 0.7685, 2.76, 0.374, 324, 257, STRUCTURE OF P38A MAP KINASE WITHOUT BOG
1927, 2gnjA, 0.7685, 2.64, 0.289, 335, 253, PKA THREE FOLD MUTANT MODEL OF RHO-KINASE WITH Y-27632
1928, 1rekA, 0.7685, 2.77, 0.276, 336, 254, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 8
1929, 4nw6A, 0.7683, 2.59, 0.289, 302, 253, RSK2 N-TERMINAL KINASE IN COMPLEX WITH 2-AMINO-7-SUBSTITUTED BENZOXAZOLE COMPOUND 27
1930, 2q0nA, 0.7683, 2.76, 0.260, 293, 254, STRUCTURE OF HUMAN P21 ACTIVATING KINASE 4 (PAK4) IN COMPLEX WITH A CONSENSUS PEPTIDE
1931, 2jdrA, 0.7683, 2.63, 0.289, 316, 253, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH THE INHIBITOR A- 443654
1932, 5d7vB, 0.7682, 2.67, 0.256, 264, 254, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
1933, 4uj2A, 0.7682, 2.78, 0.280, 335, 254, PROTEIN KINASE A IN COMPLEX WITH AN INHIBITOR
1934, 2uvxA, 0.7682, 2.64, 0.273, 335, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 7-AZAINDOLE
1935, 1q24A, 0.7682, 2.66, 0.273, 335, 253, PKA DOUBLE MUTANT MODEL OF PKB IN COMPLEX WITH MGATP
1936, 1q61A, 0.7681, 2.79, 0.276, 335, 254, PKA TRIPLE MUTANT MODEL OF PKB
1937, 3aglB, 0.7680, 2.64, 0.281, 335, 253, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1039
1938, 2gniA, 0.7680, 2.63, 0.292, 338, 253, PKA FIVEFOLD MUTANT MODEL OF RHO-KINASE WITH INHIBITOR FASUDIL (HA1077)
1939, 2gcdB, 0.7680, 2.75, 0.285, 308, 256, TAO2 KINASE DOMAIN-STAUROSPORINE STRUCTURE
1940, 3gcpA, 0.7679, 3.15, 0.366, 337, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH SB203580
1941, 2npqA, 0.7679, 2.79, 0.368, 326, 258, A NOVEL LIPID BINDING SITE IN THE P38 ALPHA MAP KINASE
1942, 1q62A, 0.7679, 2.66, 0.273, 336, 253, PKA DOUBLE MUTANT MODEL OF PKB
1943, 5bx6A, 0.7678, 2.65, 0.281, 343, 253, PKA IN COMPLEX WITH A HALOGENATED PHTHALAZINONE FRAGMENT COMPOUND.
1944, 3tv7D, 0.7678, 2.83, 0.279, 397, 258, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1342
1945, 2gnfA, 0.7678, 2.64, 0.292, 339, 253, PROTEIN KINASE A FIVEFOLD MUTANT MODEL OF RHO-KINASE WITH Y- 27632
1946, 4e6aA, 0.7677, 2.77, 0.370, 324, 257, P38A-PIA23 COMPLEX
1947, 2fsmX, 0.7677, 2.77, 0.370, 326, 257, MITOGEN ACTIVATED PROTEIN KINASE P38ALPHA (D176A+F327S) ACTIVATING MUTANT FORM-B
1948, 5t6kA, 0.7676, 2.49, 0.294, 432, 252, CRYSTAL STRUCTURE OF TGCDPK1 FROM TOXOPLASMA GONDII COMPLEXED WITH GW780159X
1949, 4yxrA, 0.7676, 2.66, 0.277, 334, 253, CRYSTAL STRUCTURE OF PKA IN COMPLEX WITH INHIBITOR.
1950, 4ujaA, 0.7676, 2.66, 0.281, 336, 253, PROTEIN KINASE A IN COMPLEX WITH AN INHIBITOR
1951, 4hptE, 0.7676, 2.65, 0.277, 335, 253, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE DISPLAYING COMPLETE PHOSPHORYL TRANSFER OF AMP-PNP ONTO A SUBSTRATE PEPTIDE
1952, 3twjA, 0.7676, 2.89, 0.267, 396, 258, RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1447
1953, 1ydrE, 0.7676, 2.64, 0.277, 334, 253, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H7 PROTEIN KINASE INHIBITOR 1-(5- ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE
1954, 5m0cA, 0.7675, 2.65, 0.281, 336, 253, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH THE FASUDIL-FRAGMENT ISOQUINOLINE-5-SULFONAMIDE 
1955, 4wnkA, 0.7675, 2.93, 0.277, 499, 256, CRYSTAL STRUCTURE OF BOVINE G PROTEIN COUPLED-RECEPTOR KINASE 5 IN COMPLEX WITH CCG215022
1956, 4rvtA, 0.7675, 2.38, 0.274, 281, 252, MAP4K4 IN COMPLEX WITH A PYRIDIN-2(1H)-ONE DERIVATIVE
1957, 3coiA, 0.7675, 3.32, 0.384, 344, 271, CRYSTAL STRUCTURE OF P38DELTA KINASE
1958, 2jdtA, 0.7675, 2.65, 0.273, 334, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH ISOQUINOLINE-5- SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL) AMIDE
1959, 2gnhA, 0.7675, 2.65, 0.292, 338, 253, PKA FIVE FOLD MUTANT MODEL OF RHO-KINASE WITH H1152P
1960, 1fmoE, 0.7675, 2.63, 0.273, 336, 253, CRYSTAL STRUCTURE OF A POLYHISTIDINE-TAGGED RECOMBINANT CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH THE PEPTIDE INHIBITOR PKI(5-24) AND ADENOSINE
1961, 1apmE, 0.7675, 2.64, 0.277, 338, 253, 2.0 ANGSTROM REFINED CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A PEPTIDE INHIBITOR AND DETERGENT
1962, 5dvrA, 0.7674, 2.52, 0.294, 386, 252, CRYSTAL STRUCTURE OF TGCDPK1 FROM TOXOPLASMA GONDII COMPLEXED WITH GW780159X
1963, 4ujbA, 0.7674, 2.66, 0.281, 344, 253, PROTEIN KINASE A IN COMPLEX WITH AN INHIBITOR
1964, 4uj9A, 0.7674, 2.66, 0.281, 339, 253, PROTEIN KINASE A IN COMPLEX WITH AN INHIBITOR
1965, 3qamE, 0.7674, 2.65, 0.273, 348, 253, CRYSTAL STRUCTURE OF GLU208ALA MUTANT OF CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
1966, 2gnlA, 0.7674, 2.82, 0.287, 338, 254, PKA THREEFOLD MUTANT MODEL OF RHO-KINASE WITH INHIBITOR H- 1152P
1967, 1jluE, 0.7674, 2.65, 0.277, 337, 253, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A PHOSPHORYLATED SUBSTRATE PEPTIDE AND DETERGENT
1968, 1bkxA, 0.7674, 2.60, 0.269, 337, 253, A BINARY COMPLEX OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE AND ADENOSINE FURTHER DEFINES CONFORMATIONAL FLEXIBILITY
1969, 5ml5A, 0.7673, 2.92, 0.369, 326, 260, HUMAN P38ALPHA MAPK IN COMPLEX WITH IMIDAZOLYL PYRIDINE INHIBITOR 11B
1970, 5li1A, 0.7673, 2.52, 0.303, 331, 251, STRUCTURE OF A PAR3-INHIBITORY PEPTIDE BOUND TO PKCIOTA CORE KINASE DOMAIN
1971, 4o0xA, 0.7673, 2.86, 0.264, 290, 254, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
1972, 3oogA, 0.7673, 2.64, 0.281, 333, 253, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH A SMALL FRAGMENT
1973, 2jdvA, 0.7673, 2.80, 0.272, 334, 254, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH A-443654
1974, 2f7zE, 0.7673, 2.62, 0.277, 336, 253, PROTEIN KINASE A BOUND TO (R)-1-(1H-INDOL-3-YLMETHYL)-2-(2- PYRIDIN-4-YL-[17]NAPHTYRIDIN-5-YLOXY)-EHYLAMINE
1975, 2c1aA, 0.7672, 2.65, 0.277, 335, 253, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL)AMIDE
1976, 5n3lA, 0.7671, 2.61, 0.278, 337, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-[(1R)-2-AMINO-1-HYDROXYETHYL]BENZENE-1 2-DIOL
1977, 5bx7A, 0.7671, 2.66, 0.281, 343, 253, PKA IN COMPLEX WITH A BENZOTHIOPHENE FRAGMENT COMPOUND.
1978, 4ij9A, 0.7671, 2.65, 0.273, 335, 253, BOVINE PKA C-ALPHA IN COMPLEX WITH 2-[[5-(4-PYRIDYL)-1H-124-TRIAZOL- 3-YL]SULFANYL]-1-(2-THIOPHENYL)ETHANONE
1979, 3tv7B, 0.7671, 2.86, 0.266, 397, 259, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1342
1980, 5j95B, 0.7670, 3.09, 0.257, 300, 261, MAP4K4 IN COMPLEX WITH INHIBITOR
1981, 5di1B, 0.7670, 3.08, 0.257, 300, 261, MAP4K4 IN COMPLEX WITH AN INHIBITOR
1982, 4ekkA, 0.7670, 2.56, 0.290, 318, 252, AKT1 WITH AMP-PNP
1983, 2erzE, 0.7670, 2.66, 0.277, 334, 253, CRYSTAL STRUCTURE OF C-AMP DEPENDENT KINASE (PKA) BOUND TO HYDROXYFASUDIL
1984, 4uj1A, 0.7669, 2.66, 0.281, 335, 253, PROTEIN KINASE A IN COMPLEX WITH AN INHIBITOR
1985, 4ie9A, 0.7669, 2.67, 0.277, 335, 253, BOVINE PKA C-ALPHA IN COMPLEX WITH 3-PYRIDYLMETHYL-5-METHYL-1H- PYRAZOLE-3-CARBOXYLATE
1986, 3e8dB, 0.7669, 2.66, 0.289, 317, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1987, 1ydsE, 0.7669, 2.65, 0.277, 334, 253, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H8 PROTEIN KINASE INHIBITOR [N-(2-METHYLAMINO)ETHYL]-5- ISOQUINOLINESULFONAMIDE
1988, 3e8dA, 0.7668, 2.66, 0.289, 315, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1989, 2vo7A, 0.7668, 2.66, 0.277, 335, 253, STRUCTURE OF PKA COMPLEXED WITH 4-(4-CHLOROBENZYL)-1-(7H- PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN-4-YLAMINE
1990, 2c1bA, 0.7668, 2.67, 0.277, 335, 253, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH ( 4R2S)-5 -(4-(4-CHLOROBENZYLOXY)PYRROLIDIN-2- YLMETHANESULFONYL)ISOQUINOLINE
1991, 6c0tA, 0.7667, 2.83, 0.234, 334, 256, CRYSTAL STRUCTURE OF CGMP-DEPENDENT PROTEIN KINASE IALPHA (PKG IALPHA) CATALYTIC DOMAIN BOUND WITH N46 
1992, 3thbA, 0.7667, 2.58, 0.258, 287, 252, STRUCTURE OF PLK1 KINASE DOMAIN IN COMPLEX WITH A BENZOLACTAM-DERIVED INHIBITOR
1993, 3pooA, 0.7667, 2.68, 0.281, 331, 253, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
1994, 3dneA, 0.7667, 2.67, 0.277, 336, 253, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
1995, 2gngA, 0.7667, 2.64, 0.289, 338, 253, PROTEIN KINASE A FIVEFOLD MUTANT MODEL OF RHO-KINASE
1996, 4yxsA, 0.7666, 2.67, 0.277, 335, 253, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
1997, 4axaA, 0.7666, 2.67, 0.273, 335, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH (1S)-2-AMINO-1-( 4-CHLOROPHENYL)-1-(4-(1H-PYRAZOL-4-YL)PHENYL)ETHAN-1-OL
1998, 3vqhA, 0.7665, 2.67, 0.281, 344, 253, BROMINE SAD PARTIALLY RESOLVES MULTIPLE BINDING MODES FOR PKA INHIBITOR H-89
1999, 3ambA, 0.7665, 2.67, 0.285, 340, 253, PROTEIN KINASE A SIXFOLD MUTANT MODEL OF AURORA B WITH INHIBITOR VX- 680
2000, 1atpE, 0.7665, 2.66, 0.277, 334, 253, 2.2 ANGSTROM REFINED CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH MNATP AND A PEPTIDE INHIBITOR
2001, 4zp5B, 0.7664, 3.09, 0.257, 300, 261, MAP4K4 IN COMPLEX WITH INHIBITOR
2002, 3lfdA, 0.7664, 3.02, 0.356, 331, 261, HUMAN P38 MAP KINASE IN COMPLEX WITH RL113
2003, 3e8eA, 0.7664, 2.67, 0.277, 341, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2004, 2fstX, 0.7664, 2.73, 0.375, 324, 256, MITOGEN ACTIVATED PROTEIN KINASE P38ALPHA (D176A+F327L) ACTIVATING MUTANT
2005, 5n3pA, 0.7663, 2.63, 0.282, 336, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 1H-INDOL-5-OL
2006, 5i0bA, 0.7663, 2.82, 0.264, 288, 254, STRUCTURE OF PAK4
2007, 5d7vC, 0.7663, 2.70, 0.256, 264, 254, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
2008, 4z84A, 0.7663, 2.82, 0.276, 335, 254, PKAB3 IN COMPLEX WITH PYRROLIDINE INHIBITOR 34A
2009, 3owpA, 0.7663, 2.68, 0.281, 334, 253, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
2010, 3nynB, 0.7663, 2.82, 0.272, 553, 254, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 6 IN COMPLEX WITH SANGIVAMYCIN
2011, 3e8cF, 0.7663, 2.66, 0.277, 341, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2012, 3e8cC, 0.7663, 2.66, 0.277, 341, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2013, 3e8cA, 0.7663, 2.66, 0.277, 341, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2014, 2x39A, 0.7663, 2.64, 0.289, 316, 253, STRUCTURE OF 4-AMINO-N-(4-CHLOROBENZYL)-1-(7H-PYRROLO(23-D) PYRIMIDIN-4-YL)PIPERIDINE-4-CARBOXAMIDE BOUND TO PKB
2015, 2rfeA, 0.7663, 2.70, 0.224, 286, 254, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE EGFR KINASE DOMAIN AND A MIG6 PEPTIDE
2016, 5d7vD, 0.7662, 2.70, 0.256, 264, 254, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
2017, 3fjqE, 0.7662, 2.67, 0.277, 334, 253, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA IN COMPLEX WITH PEPTIDE INHIBITOR PKI ALPHA (6-25)
2018, 3e8cD, 0.7662, 2.66, 0.277, 344, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2019, 3oxtA, 0.7661, 2.86, 0.280, 335, 254, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
2020, 3idbA, 0.7661, 2.68, 0.277, 341, 253, CRYSTAL STRUCTURE OF (108-268)RIIB:C HOLOENZYME OF CAMP- DEPENDENT PROTEIN KINASE
2021, 3e8cE, 0.7661, 2.66, 0.277, 336, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2022, 3e8cB, 0.7661, 2.66, 0.277, 344, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2023, 5n3qA, 0.7660, 2.63, 0.282, 336, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 3-AMINOBENZAMIDE
2024, 3v8sB, 0.7660, 2.85, 0.271, 397, 258, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH INDAZOLE DERIVATIVE (COMPOUND 18)
2025, 3e8eP, 0.7660, 2.66, 0.273, 341, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2026, 3e8eB, 0.7660, 2.66, 0.273, 337, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2027, 2uw4A, 0.7660, 2.62, 0.274, 334, 252, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 2-(4-(5-METHYL- 1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
2028, 2uw3A, 0.7660, 2.77, 0.273, 334, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 5-METHYL-4- PHENYL-1H-PYRAZOLE
2029, 3nynA, 0.7659, 2.84, 0.272, 553, 254, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 6 IN COMPLEX WITH SANGIVAMYCIN
2030, 2uw8A, 0.7659, 2.64, 0.274, 334, 252, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 2-(4-CHLORO- PHENYL)-2-PHENYL-ETHYLAMINE
2031, 5n3tA, 0.7658, 2.63, 0.282, 337, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 5-CHLOROTHIOPHENE-2-SULFONAMIDE
2032, 5m0lA, 0.7658, 2.67, 0.281, 338, 253, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH THE METHYLATED FASUDIL-DERIVED FRAGMENT N-METHYLISOQUINOLINE-5- SULFONAMIDE (LIGAND 02) 
2033, 3ovvA, 0.7658, 2.69, 0.281, 335, 253, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
2034, 3cquA, 0.7658, 2.53, 0.283, 318, 251, CRYSTAL STRUCTURE OF AKT-1 COMPLEXED WITH SUBSTRATE PEPTIDE AND INHIBITOR
2035, 3agmA, 0.7658, 2.81, 0.280, 337, 254, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-670
2036, 2uztA, 0.7658, 2.76, 0.276, 336, 254, PKA STRUCTURES OF AKT INDAZOLE-PYRIDINE INHIBITORS
2037, 5n3oA, 0.7657, 2.78, 0.281, 335, 253, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 3-(13-OXAZOL-5-YL)ANILINE
2038, 5n3nA, 0.7657, 2.63, 0.282, 337, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE [(2R)-24-DIHYDROXY-4-OXOBUTYL]- TRIMETHYLAZANIUM
2039, 5n3jA, 0.7657, 2.63, 0.278, 337, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-NITROBENZOIC ACID
2040, 3tkuA, 0.7657, 3.05, 0.254, 395, 260, MRCK BETA IN COMPLEX WITH FASUDIL
2041, 3nx8A, 0.7657, 2.65, 0.281, 333, 253, HUMAN CAMP DEPENDENT PROTEIN KINASE IN COMPLEX WITH PHENOL
2042, 1svgA, 0.7657, 2.82, 0.276, 338, 254, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 4
2043, 5n1hA, 0.7656, 2.62, 0.278, 337, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE METHYL 4-(AMINOMETHYL)BENZOATE
2044, 5n1gA, 0.7656, 2.62, 0.278, 337, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-(2-AMINO-13-THIAZOL-4-YL)-1- OXASPIRO[4.5]DECAN-2-ONE
2045, 4c38A, 0.7656, 2.64, 0.286, 334, 252, PKA-S6K1 CHIMERA WITH COMPOUND 21E (CCT239066) BOUND
2046, 3zo4A, 0.7656, 2.82, 0.276, 335, 254, THE SYNTHESIS AND EVALUATION OF DIAZASPIROCYCLIC PROTEIN KINASE INHIBITORS
2047, 3tkuB, 0.7656, 3.05, 0.254, 395, 260, MRCK BETA IN COMPLEX WITH FASUDIL
2048, 3e8eI, 0.7656, 2.66, 0.273, 345, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2049, 5uzkA, 0.7655, 2.68, 0.281, 335, 253, CRYSTAL STRUCTURE OF PKA BOUND TO AN PYRROLO PYRIDINE INHIBITOR
2050, 2uzwE, 0.7655, 2.76, 0.276, 336, 254, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
2051, 1xh9A, 0.7655, 2.84, 0.280, 336, 254, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
2052, 3v8sD, 0.7654, 2.87, 0.271, 397, 258, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH INDAZOLE DERIVATIVE (COMPOUND 18)
2053, 3fhiA, 0.7654, 2.70, 0.277, 336, 253, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN THE CATALYTIC AND REGULATORY (RI{ALPHA}) SUBUNITS OF PKA
2054, 2gu8A, 0.7654, 2.69, 0.277, 335, 253, DISCOVERY OF 2-PYRIMIDYL-5-AMIDOTHIOPHENES AS NOVEL AND POTENT INHIBITORS FOR AKT: SYNTHESIS AND SAR STUDIES
2055, 1q8uA, 0.7654, 2.67, 0.277, 341, 253, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH RHO-KINASE INHIBITOR H-1152P
2056, 1q8tA, 0.7654, 2.67, 0.277, 338, 253, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH RHO-KINASE INHIBITOR Y-27632
2057, 5ta6A, 0.7653, 2.71, 0.257, 294, 253, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A NOVEL 56- DIHYDROIMIDAZOLO[15-F]PTERIDINE INHIBITOR.
2058, 4ekkB, 0.7653, 2.69, 0.281, 318, 253, AKT1 WITH AMP-PNP
2059, 3x2vA, 0.7653, 2.63, 0.274, 331, 252, MICHAELIS-LIKE COMPLEX OF CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
2060, 3x2uA, 0.7653, 2.64, 0.278, 336, 252, MICHAELIS-LIKE INITIAL COMPLEX OF CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT.
2061, 3e87B, 0.7653, 2.67, 0.289, 321, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2062, 3e87A, 0.7653, 2.67, 0.289, 321, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2063, 2vo0A, 0.7653, 2.83, 0.272, 340, 254, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  C-(4-(4- CHLOROPHENYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YL)METHYLAMINE
2064, 1cdkB, 0.7653, 2.68, 0.277, 342, 253, CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT (E.C.2.7.1.37) (PROTEIN KINASE A) COMPLEXED WITH PROTEIN KINASE INHIBITOR PEPTIDE FRAGMENT 5-24 (PKI(5-24) ISOELECTRIC VARIANT CA) AND MN2+ ADENYLYL IMIDODIPHOSPHATE (MNAMP-PNP) AT PH 5.6 AND 7C AND 4C
2065, 5n3gA, 0.7652, 2.63, 0.282, 337, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE (R)-14-OXAZEPAN-6-OL
2066, 4u45B, 0.7652, 3.08, 0.246, 295, 260, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 25)
2067, 3w2sA, 0.7652, 2.56, 0.206, 307, 252, EGFR KINASE DOMAIN WITH COMPOUND4
2068, 2fsoX, 0.7652, 2.73, 0.371, 325, 256, MITOGEN ACTIVATED PROTEIN KINASE P38ALPHA (D176A) ACTIVATING MUTANT
2069, 1xh6A, 0.7652, 2.70, 0.277, 331, 253, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
2070, 1xh5A, 0.7652, 2.82, 0.276, 335, 254, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
2071, 3twjC, 0.7651, 2.90, 0.271, 396, 258, RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1447
2072, 3dndA, 0.7651, 2.67, 0.277, 334, 253, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
2073, 2uvyA, 0.7651, 2.78, 0.273, 333, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH METHYL-(4-(9H- PURIN-6-YL)-BENZYL)-AMINE
2074, 1vebA, 0.7651, 2.81, 0.276, 338, 254, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 5
2075, 5n23A, 0.7650, 2.66, 0.286, 333, 252, PROTEIN KINASE A MUTANTS AS SURROGATE MODEL FOR AURORA B WITH AT9283 INHIBITOR
2076, 5n1fA, 0.7650, 2.63, 0.278, 337, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE N-QUINOLIN-5-YLPYRIDINE-3-CARBOXAMIDE
2077, 4o22A, 0.7650, 2.77, 0.277, 336, 253, BINARY COMPLEX OF METAL-FREE PKAC WITH SP20.
2078, 3zo3A, 0.7650, 2.64, 0.278, 337, 252, THE SYNTHESIS AND EVALUATION OF DIAZASPIROCYCLIC PROTEIN KINASE INHIBITORS
2079, 3qfvB, 0.7650, 3.16, 0.253, 396, 261, MRCK BETA IN COMPLEX WITH TPCA-1
2080, 2vo6A, 0.7650, 2.80, 0.273, 335, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  4-(4- CHLOROBENZYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YLAMINE
2081, 1sveA, 0.7650, 2.68, 0.277, 341, 253, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 1
2082, 5n3sA, 0.7649, 2.65, 0.282, 337, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-HYDROXYBENZAMIDE
2083, 4u41A, 0.7649, 2.33, 0.260, 275, 250, MAP4K4 BOUND TO INHIBITOR COMPOUND 1
2084, 2vnyA, 0.7649, 2.80, 0.273, 334, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH (1-(9H-PURIN-6- YL)PIPERIDIN-4-YL)AMINE
2085, 1ydtE, 0.7649, 2.68, 0.277, 334, 253, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H89 PROTEIN KINASE INHIBITOR N-[2- (4-BROMOCINNAMYLAMINO)ETHYL]-5-ISOQUINOLINE
2086, 5n3hA, 0.7648, 2.65, 0.282, 337, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE PYRIDINE-3-CARBOXAMIDE
2087, 3mvjA, 0.7648, 2.69, 0.281, 334, 253, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
2088, 2x7fC, 0.7648, 2.44, 0.270, 285, 252, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
2089, 2vnwA, 0.7648, 2.79, 0.273, 334, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH (1-(9H-PURIN-6- YL)PIPERIDIN-4-YL)METHANAMINE
2090, 4o0yA, 0.7647, 2.99, 0.263, 290, 255, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
2091, 4l67A, 0.7647, 2.90, 0.260, 289, 254, CRYSTAL STRUCTURE OF CATALYTIC DOMAIN OF PAK4
2092, 4a4oA, 0.7647, 2.52, 0.259, 290, 251, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A 2- (2-AMINO-PYRIMIDIN-4-YL)-1567-TETRAHYDRO-PYRROLOPYRIDIN- 4-ONE INHIBITOR
2093, 2uw5A, 0.7647, 2.79, 0.273, 333, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  (R)-2-(4- CHLORO-PHENYL)-2-(4-1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
2094, 2i0eB, 0.7647, 2.57, 0.249, 300, 253, STRUCTURE OF CATALYTIC DOMAIN OF HUMAN PROTEIN KINASE C BETA II COMPLEXED WITH A BISINDOLYLMALEIMIDE INHIBITOR
2095, 4wb7B, 0.7646, 2.66, 0.282, 402, 252, CRYSTAL STRUCTURE OF A CHIMERIC FUSION OF HUMAN DNAJ (HSP40) AND CAMP- DEPENDENT PROTEIN KINASE A (CATALYTIC ALPHA SUBUNIT)
2096, 3qfvA, 0.7646, 3.06, 0.254, 395, 260, MRCK BETA IN COMPLEX WITH TPCA-1
2097, 2jdsA, 0.7646, 2.65, 0.278, 334, 252, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A- 443654
2098, 5n3mA, 0.7645, 2.64, 0.278, 337, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE D-ARGININE
2099, 4dh5A, 0.7645, 2.79, 0.277, 333, 253, ROOM TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A CATALYTIC SUBUNIT WITH HIGH MG2+ ADP PHOSPHATE AND IP20
2100, 4c37A, 0.7645, 2.80, 0.285, 335, 253, PKA-S6K1 CHIMERA WITH COMPOUND 21A (CCT196539) BOUND
2101, 3mvhA, 0.7645, 2.75, 0.281, 311, 253, CRYSTAL STRUCTURE OF AKT-1-INHIBITOR COMPLEXES
2102, 3e8eL, 0.7645, 2.67, 0.273, 336, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2103, 3e8eE, 0.7645, 2.67, 0.273, 341, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2104, 2vo3A, 0.7645, 2.79, 0.273, 334, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  C-(4-(4- CHLOROPHENYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YL)METHYLAMINE
2105, 5n3kA, 0.7644, 2.65, 0.282, 337, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE O-GUANIDINO-L-HOMOSERINE
2106, 5h2uB, 0.7644, 2.68, 0.257, 263, 253, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
2107, 4wb7A, 0.7644, 2.66, 0.282, 402, 252, CRYSTAL STRUCTURE OF A CHIMERIC FUSION OF HUMAN DNAJ (HSP40) AND CAMP- DEPENDENT PROTEIN KINASE A (CATALYTIC ALPHA SUBUNIT)
2108, 4c36A, 0.7644, 2.65, 0.286, 335, 252, PKA-S6K1 CHIMERA WITH COMPOUND 15E (CCT147581) BOUND
2109, 4a4lA, 0.7644, 2.53, 0.259, 290, 251, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A 5-(2-AMINO-PYRIMIDIN-4-YL)-1H-PYRROLE INHIBITOR
2110, 3kb7A, 0.7644, 2.62, 0.258, 289, 252, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
2111, 2cpkE, 0.7644, 2.65, 0.278, 333, 252, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CYCLIC ADENOSINE MONOPHOSPHATE-DEPENDENT PROTEIN KINASE
2112, 2yacA, 0.7643, 2.53, 0.259, 290, 251, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH NMS-P937
2113, 2uvzA, 0.7643, 2.66, 0.274, 334, 252, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH C-PHENYL-C-(4-( 9H-PURIN-6-YL)-PHENYL)-METHYLAMINE
2114, 1rdqE, 0.7643, 2.70, 0.273, 340, 253, HYDROLYSIS OF ATP IN THE CRYSTAL OF Y204A MUTANT OF CAMP-DEPENDENT PROTEIN KINASE
2115, 5n3iA, 0.7642, 2.64, 0.278, 337, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE METHYL (2S)-2-AMINO-3-PHENYLPROPANOATE
2116, 4oboB, 0.7642, 3.13, 0.249, 297, 261, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 22) 6-(3-CHLOROPHENYL) QUINAZOLIN-4-AMINE
2117, 4c33A, 0.7642, 2.65, 0.286, 335, 252, PKA-S6K1 CHIMERA APO
2118, 3kkvA, 0.7642, 2.65, 0.278, 335, 252, STRUCTURE OF PKA WITH A PROTEIN KINASE B-SELECTIVE INHIBITOR.
2119, 4wb5A, 0.7641, 2.67, 0.282, 335, 252, CRYSTAL STRUCTURE OF HUMAN CAMP-DEPENDENT PROTEIN KINASE A (CATALYTIC ALPHA SUBUNIT)
2120, 4u41B, 0.7641, 3.03, 0.246, 297, 260, MAP4K4 BOUND TO INHIBITOR COMPOUND 1
2121, 4dh8A, 0.7641, 2.66, 0.278, 333, 252, ROOM TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A CATALYTIC SUBUNIT WITH HIGH MG2+ AMP-PNP AND IP20
2122, 3zo2A, 0.7641, 2.80, 0.277, 340, 253, THE SYNTHESIS AND EVALUATION OF DIAZASPIROCYCLIC PROTEIN KINASE INHIBITORS
2123, 2uw9A, 0.7641, 2.72, 0.281, 316, 253, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH 4-(4-CHLORO- PHENYL)-4-(4-(1H-PYRAZOL-4-YL)-PHENYL)-PIPERIDINE
2124, 1svhA, 0.7641, 2.84, 0.276, 335, 254, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 8
2125, 1l3rE, 0.7641, 2.66, 0.278, 338, 252, CRYSTAL STRUCTURE OF A TRANSITION STATE MIMIC OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
2126, 5n3rA, 0.7640, 2.63, 0.278, 336, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 2-(CARBAMOYLAMINO)-4- METHYLSULFANYLBUTANOIC ACID
2127, 4u3yB, 0.7640, 3.19, 0.252, 300, 262, APO MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4)
2128, 4obqB, 0.7640, 2.88, 0.245, 293, 257, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 31) N-[3-(4- AMINOQUINAZOLIN-6-YL)-5-FLUOROPHENYL]-2-(PYRROLIDIN-1-YL)ACETAMIDE
2129, 4o21A, 0.7640, 2.65, 0.278, 333, 252, PRODUCT COMPLEX OF METAL-FREE PKAC ATP-GAMMA-S AND SP20.
2130, 3qalE, 0.7640, 2.70, 0.273, 339, 253, CRYSTAL STRUCTURE OF ARG280ALA MUTANT OF CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
2131, 3p0mA, 0.7640, 2.69, 0.281, 335, 253, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
2132, 2uw6A, 0.7640, 2.80, 0.273, 334, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  (S)-2-(4- CHLORO-PHENYL)-2-(4-1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
2133, 2uw0A, 0.7640, 2.80, 0.273, 334, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  6-(4-(4-(4- CHLORO-PHENYL)-PIPERIDIN-4-YL)-PHENYL)-9H-PURINE
2134, 5j5xA, 0.7639, 2.70, 0.281, 340, 253, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1416
2135, 4l43A, 0.7639, 2.42, 0.295, 316, 251, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389A (FORM I)
2136, 4iafA, 0.7639, 2.65, 0.278, 333, 252, ROOM TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH MG2+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
2137, 3x2wA, 0.7639, 2.79, 0.277, 336, 253, MICHAELIS COMPLEX OF CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
2138, 3mv5A, 0.7639, 2.69, 0.289, 315, 253, CRYSTAL STRUCTURE OF AKT-1-INHIBITOR COMPLEXES
2139, 4j52A, 0.7638, 2.63, 0.258, 293, 252, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A PYRIMIDODIAZEPINONE INHIBITOR
2140, 4ib3A, 0.7638, 2.65, 0.278, 336, 252, STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH ADP PHOSPHORYLATED PEPTIDE PSP20 AND NO METAL
2141, 3ow3A, 0.7638, 2.71, 0.277, 334, 253, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
2142, 1u5qB, 0.7638, 2.81, 0.285, 308, 256, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
2143, 4z83E, 0.7637, 2.85, 0.276, 335, 254, PKAB3 IN COMPLEX WITH PYRROLIDINE INHIBITOR 47A
2144, 2r5tA, 0.7637, 2.58, 0.274, 284, 252, CRYSTAL STRUCTURE OF INACTIVE SERUM AND GLUCOCORTICOID- REGULATED KINASE 1 IN COMPLEX WITH AMP-PNP
2145, 2owbA, 0.7637, 2.62, 0.258, 294, 252, STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN POLO-LIKE KINASE 1
2146, 4l42A, 0.7636, 2.48, 0.298, 299, 252, CRYSTAL STRUCTURES OF HUMAN P70S6K1-PIF
2147, 2rkuA, 0.7635, 2.74, 0.257, 294, 253, STRUCTURE OF PLK1 IN COMPLEX WITH BI2536
2148, 1cdkA, 0.7635, 2.70, 0.277, 342, 253, CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT (E.C.2.7.1.37) (PROTEIN KINASE A) COMPLEXED WITH PROTEIN KINASE INHIBITOR PEPTIDE FRAGMENT 5-24 (PKI(5-24) ISOELECTRIC VARIANT CA) AND MN2+ ADENYLYL IMIDODIPHOSPHATE (MNAMP-PNP) AT PH 5.6 AND 7C AND 4C
2149, 5h2uD, 0.7634, 2.69, 0.257, 263, 253, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
2150, 4xw6A, 0.7634, 2.67, 0.278, 334, 252, X-RAY STRUCTURE OF PKAC WITH ADP FREE PHOSPHATE ION CP20 MAGNESIUM IONS
2151, 3nyoB, 0.7634, 2.85, 0.272, 553, 254, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 6 IN COMPLEX WITH AMP
2152, 2f2uB, 0.7634, 2.93, 0.266, 383, 259, CRYSTAL STRUCTURE OF THE RHO-KINASE KINASE DOMAIN
2153, 1smhA, 0.7634, 2.84, 0.276, 348, 254, PROTEIN KINASE A VARIANT COMPLEX WITH COMPLETELY ORDERED N- TERMINAL HELIX
2154, 4wb6B, 0.7633, 2.74, 0.285, 340, 253, CRYSTAL STRUCTURE OF A L205R MUTANT OF HUMAN CAMP-DEPENDENT PROTEIN KINASE A (CATALYTIC ALPHA SUBUNIT)
2155, 4iacA, 0.7633, 2.63, 0.274, 333, 252, X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH MG2+ CONCENTRATION AMP-PCP AND PSEUDO-SUBSTRATE PEPTIDE SP20
2156, 3zo1A, 0.7633, 2.81, 0.277, 339, 253, THE SYNTHESIS AND EVALUATION OF DIAZASPIROCYCLIC PROTEIN KINASE INHIBITORS
2157, 4oboA, 0.7632, 2.36, 0.260, 275, 250, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 22) 6-(3-CHLOROPHENYL) QUINAZOLIN-4-AMINE
2158, 5xvfA, 0.7631, 2.88, 0.260, 289, 254, CRYSTAL STRUCTURE OF PAK4 IN COMPLEX WITH INHIBITOR CZH062
2159, 5xvaA, 0.7631, 2.97, 0.264, 292, 254, CRYSTAL STRUCTURE OF PAK4 IN COMPLEX WITH INHIBITOR CZH216
2160, 5wnoA, 0.7631, 2.65, 0.209, 302, 253, CRYSTAL STRUCTURE OF C. ELEGANS LET-23 KINASE DOMAIN COMPLEXED WITH AMP-PNP
2161, 4wb8A, 0.7631, 2.69, 0.282, 334, 252, CRYSTAL STRUCTURE OF HUMAN CAMP-DEPENDENT PROTEIN KINASE A (CATALYTIC ALPHA SUBUNIT) EXON 1 DELETION
2162, 5x2aB, 0.7630, 2.99, 0.206, 322, 257, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R IN COMPLEX WITH SKLB(3)
2163, 3ocbA, 0.7630, 2.63, 0.283, 315, 251, AKT1 KINASE DOMAIN WITH PYRROLOPYRIMIDINE INHIBITOR
2164, 3fc2A, 0.7630, 2.54, 0.259, 293, 251, PLK1 IN COMPLEX WITH BI6727
2165, 2qurA, 0.7630, 2.71, 0.277, 338, 253, CRYSTAL STRUCTURE OF F327A/K285P MUTANT OF CAMP-DEPENDENT PROTEIN KINASE
2166, 4wboC, 0.7629, 2.83, 0.271, 481, 255, BOVINE G PROTEIN COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH AMLEXANOX
2167, 4j53A, 0.7629, 2.63, 0.258, 293, 252, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH TAK-960
2168, 4iakA, 0.7628, 2.67, 0.278, 334, 252, LOW TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH SR2+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
2169, 5h2uC, 0.7627, 2.70, 0.257, 264, 253, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
2170, 4xw5A, 0.7627, 2.82, 0.277, 334, 253, X-RAY STRUCTURE OF PKAC WITH ATP CP20 CALCIUM IONS
2171, 4x6rA, 0.7627, 2.67, 0.278, 347, 252, AN ISOFORM-SPECIFIC MYRISTYLATION SWITCH TARGETS RIIB PKA HOLOENZYMES TO MEMBRANES
2172, 4wihA, 0.7627, 2.73, 0.277, 350, 253, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS
2173, 1u5rB, 0.7627, 2.75, 0.282, 308, 255, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
2174, 1bi8C, 0.7627, 2.69, 0.456, 264, 252, MECHANISM OF G1 CYCLIN DEPENDENT KINASE INHIBITION FROM THE STRUCTURES CDK6-P19INK4D INHIBITOR COMPLEX
2175, 1bi8A, 0.7627, 2.69, 0.456, 264, 252, MECHANISM OF G1 CYCLIN DEPENDENT KINASE INHIBITION FROM THE STRUCTURES CDK6-P19INK4D INHIBITOR COMPLEX
2176, 3nyoA, 0.7625, 2.87, 0.272, 553, 254, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 6 IN COMPLEX WITH AMP
2177, 4iayA, 0.7624, 2.83, 0.277, 333, 253, ROOM TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH SR2+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
2178, 4fl2A, 0.7624, 2.61, 0.206, 555, 253, STRUCTURAL AND BIOPHYSICAL CHARACTERIZATION OF THE SYK ACTIVATION SWITCH
2179, 4dh3A, 0.7624, 2.68, 0.278, 333, 252, LOW TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A CATALYTIC SUBUNIT WITH HIGH MG2+ ATP AND IP20
2180, 3mvjE, 0.7624, 2.68, 0.273, 334, 253, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
2181, 1xh8A, 0.7624, 2.65, 0.278, 337, 252, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
2182, 5vhbA, 0.7623, 2.70, 0.278, 325, 252, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH THE PKI PEPTIDE AND AMINOBENZOTHIAZOLE BASED INHIBITOR
2183, 4l45A, 0.7623, 2.43, 0.299, 317, 251, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389E
2184, 4dg2E, 0.7623, 2.67, 0.278, 347, 252, CRYSTAL STRUCTURE OF MYRISTOYLATED WT CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE IN COMPLEX WITH SP20
2185, 3aglA, 0.7623, 2.68, 0.273, 338, 253, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1039
2186, 2qcsA, 0.7623, 2.69, 0.278, 335, 252, A COMPLEX STRUCTURE BETWEEN THE CATALYTIC AND REGULATORY SUBUNIT OF PROTEIN KINASE A THAT REPRESENTS THE INHIBITED STATE
2187, 1bx6A, 0.7623, 2.70, 0.273, 337, 253, CRYSTAL STRUCTURE OF THE POTENT NATURAL PRODUCT INHIBITOR BALANOL IN COMPLEX WITH THE CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
2188, 5izfA, 0.7622, 2.86, 0.280, 336, 254, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1408
2189, 4zjiD, 0.7622, 2.68, 0.307, 280, 254, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
2190, 4dh7A, 0.7622, 2.69, 0.278, 333, 252, LOW TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A CATALYTIC SUBUNIT WITH HIGH MG2+ AMP-PNP AND IP20 
2191, 3ggfA, 0.7622, 2.51, 0.274, 275, 252, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE MST4 IN COMPLEX WITH AN QUINAZOLIN
2192, 5n7pA, 0.7621, 2.76, 0.277, 350, 253, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 3-AMINO-5-(PYRROLIDIN-1-YL)-1H-PYRAZOLE- 4-CARBONITRILE
2193, 4iadA, 0.7621, 2.69, 0.278, 334, 252, LOW TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH MG2+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
2194, 4dfxE, 0.7621, 2.68, 0.278, 347, 252, CRYSTAL STRUCTURE OF MYRISTOYLATED K7C CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE IN COMPLEX WITH SP20 AND AMP-PNP
2195, 3l9lA, 0.7621, 2.77, 0.277, 338, 253, CRYSTAL STRUCTURE OF PKA WITH COMPOUND 36
2196, 2gcdA, 0.7621, 2.72, 0.286, 308, 255, TAO2 KINASE DOMAIN-STAUROSPORINE STRUCTURE
2197, 1xhaA, 0.7621, 2.85, 0.276, 348, 254, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
2198, 6fd3A, 0.7620, 2.94, 0.299, 296, 254, THIOPHOSPHORYLATED PAK3 KINASE DOMAIN
2199, 4xw4A, 0.7620, 2.81, 0.277, 334, 253, X-RAY STRUCTURE OF PKAC WITH AMPPNP SP20 CALCIUM IONS
2200, 4pniA, 0.7620, 2.88, 0.266, 492, 256, BOVINE G PROTEIN-COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH GSK2163632A
2201, 2vd5A, 0.7620, 2.98, 0.272, 390, 257, STRUCTURE OF HUMAN MYOTONIC DYSTROPHY PROTEIN KINASE IN COMPLEX WITH THE BISINDOYLMALEIDE INHIBITOR BIM VIII
2202, 1xh7A, 0.7620, 2.83, 0.277, 337, 253, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
2203, 5ng3B, 0.7619, 2.95, 0.224, 275, 255, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
2204, 4nusA, 0.7619, 2.91, 0.294, 301, 255, RSK2 N-TERMINAL KINASE IN COMPLEX WITH LJH685
2205, 3ncgA, 0.7619, 2.49, 0.311, 426, 251, ACTIVATED CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM CRYPTOSPORIDIUM PARVUM (CPCDPK1) IN COMPLEX WITH BUMPED KINASE INHIBITOR NM-PP1
2206, 1stcE, 0.7619, 2.82, 0.276, 334, 254, CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH STAUROSPORINE
2207, 1bi7A, 0.7619, 2.71, 0.446, 269, 251, MECHANISM OF G1 CYCLIN DEPENDENT KINASE INHIBITION FROM THE STRUCTURE OF THE CDK6-P16INK4A TUMOR SUPPRESSOR COMPLEX
2208, 4ib1A, 0.7618, 2.69, 0.278, 335, 252, STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH K+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
2209, 4b6lA, 0.7618, 2.85, 0.283, 281, 254, DISCOVERY OF ORAL POLO-LIKE KINASE (PLK) INHIBITORS WITH ENHANCED SELECTIVITY PROFILE USING RESIDUE TARGETED DRUG DESIGN
2210, 2etkB, 0.7618, 2.97, 0.267, 398, 258, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO HYDROXYFASUDIL
2211, 2cdzA, 0.7618, 2.80, 0.266, 289, 252, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH CGP74514A
2212, 5d7vA, 0.7617, 2.73, 0.256, 268, 254, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
2213, 4dfzE, 0.7617, 2.67, 0.278, 347, 252, CRYSTAL STRUCTURE OF MYRISTOYLATED K7C CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE IN COMPLEX WITH SP20
2214, 3tnpF, 0.7617, 2.67, 0.274, 334, 252, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
2215, 3tnpC, 0.7617, 2.67, 0.274, 334, 252, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
2216, 3ocbB, 0.7617, 2.63, 0.283, 319, 251, AKT1 KINASE DOMAIN WITH PYRROLOPYRIMIDINE INHIBITOR
2217, 3dy7A, 0.7617, 2.29, 0.275, 260, 247, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
2218, 2jedA, 0.7617, 2.78, 0.280, 324, 254, THE CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE PROTEIN KINASE C THETA IN COMPLEX WITH NVP-XAA228 AT 2.32A RESOLUTION.
2219, 5ta8A, 0.7616, 2.70, 0.258, 294, 252, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A NOVEL 56- DIHYDROIMIDAZOLO[15-F]PTERIDINE INHIBITOR
2220, 5n7uA, 0.7616, 2.76, 0.277, 350, 253, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-BROMO-35-DIMETHYL-1H-PYRAZOLE
2221, 4o27B, 0.7616, 2.65, 0.274, 281, 252, CRYSTAL STRUCTURE OF MST3-MO25 COMPLEX WITH WIF MOTIF
2222, 4dh1A, 0.7616, 2.84, 0.277, 333, 253, LOW TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A CATALYTIC SUBUNIT WITH LOW MG2+ ATP AND IP20
2223, 5lihA, 0.7615, 2.54, 0.297, 324, 249, STRUCTURE OF A PEPTIDE-SUBSTRATE BOUND TO PKCIOTA CORE KINASE DOMAIN
2224, 5kktB, 0.7615, 2.97, 0.267, 394, 258, ROCK 1 BOUND TO AZAINDOLE THIOZOLE PIPERAZINE INHIBITOR
2225, 4wboA, 0.7615, 2.82, 0.267, 497, 255, BOVINE G PROTEIN COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH AMLEXANOX
2226, 4hpuE, 0.7615, 2.70, 0.278, 336, 252, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE DISPLAYING PARTIAL PHOSPHORYL TRANSFER OF AMP-PNP ONTO A SUBSTRATE PEPTIDE
2227, 6c0uA, 0.7614, 2.66, 0.273, 338, 253, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE CALPHA SUBUNIT BOUND WITH N46 
2228, 4ib0A, 0.7614, 2.69, 0.278, 334, 252, X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH NA+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
2229, 3iw4B, 0.7614, 2.66, 0.261, 325, 253, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
2230, 5jr7A, 0.7613, 2.66, 0.278, 335, 252, CRYSTAL STRUCTURE OF AN ACRDYS HETERODIMER [RIA(92-365):C] OF PKA
2231, 4wboD, 0.7613, 2.84, 0.267, 491, 255, BOVINE G PROTEIN COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH AMLEXANOX
2232, 4dg0E, 0.7612, 2.70, 0.278, 338, 252, CRYSTAL STRUCTURE OF MYRISTOYLATED WT CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE IN COMPLEX WITH SP20 AND AMP-PNP
2233, 3dxnA, 0.7612, 2.49, 0.324, 258, 247, CRYSTAL STRUCTURE OF THE CALCIUM-DEPENDENT KINASE FROM TOXOPLASMA GONDII 541.M00134 KINASE DOMAIN.
2234, 5n1eA, 0.7611, 2.77, 0.277, 347, 253, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE N-(13-BENZODIOXOL-5-YL)-2-PIPERIDIN-1- YLACETAMIDE
2235, 4x6qC, 0.7611, 2.67, 0.274, 334, 252, AN ISOFORM-SPECIFIC MYRISTYLATION SWITCH TARGETS RIIB PKA HOLOENZYMES TO MEMBRANES
2236, 4jdiA, 0.7611, 2.91, 0.260, 289, 254, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 IN COMPLEX WITH PAKTIDE S PEPTIDE SUBSTRATE
2237, 4iazA, 0.7611, 2.85, 0.277, 334, 253, STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH BA2+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
2238, 1xh4A, 0.7611, 2.84, 0.277, 334, 253, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
2239, 4wb6A, 0.7610, 2.72, 0.286, 336, 252, CRYSTAL STRUCTURE OF A L205R MUTANT OF HUMAN CAMP-DEPENDENT PROTEIN KINASE A (CATALYTIC ALPHA SUBUNIT)
2240, 4iaiA, 0.7610, 2.70, 0.278, 333, 252, X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH CA2+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
2241, 2x7fA, 0.7610, 2.35, 0.269, 276, 249, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
2242, 5mhiA, 0.7609, 2.78, 0.277, 348, 253, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE (5-CHLORO-2-METHOXYPHENYL)METHANAMINE
2243, 4usdA, 0.7609, 2.26, 0.324, 268, 247, HUMAN STK10 (LOK) WITH SB-633825
2244, 4dg3E, 0.7609, 2.71, 0.278, 335, 252, CRYSTAL STRUCTURE OF R336A MUTANT OF CAMP-DEPENDENT PROTEIN KINASE WITH UNPHOSPHORYLATED TURN MOTIF.
2245, 3pvbA, 0.7609, 2.71, 0.278, 341, 252, CRYSTAL STRUCTURE OF (73-244)RIA:C HOLOENZYME OF CAMP-DEPENDENT PROTEIN KINASE
2246, 3iw4A, 0.7609, 2.67, 0.261, 330, 253, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
2247, 3w32A, 0.7608, 3.20, 0.195, 317, 261, EGFR KINASE DOMAIN COMPLEXED WITH COMPOUND 20A
2248, 3i7cA, 0.7608, 2.59, 0.287, 449, 251, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH BUMPED KINASE INHIBITOR NA-PP2
2249, 2g1tA, 0.7608, 2.68, 0.239, 271, 251, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
2250, 4yhfB, 0.7607, 2.77, 0.199, 269, 251, BRUTON S TYROSINE KINASE IN COMPLEX WITH A T-BUTYL CYANOACRYLAMIDE INHIBITOR
2251, 6c9dA, 0.7606, 2.73, 0.313, 425, 252, CRYSTAL STRUCTURE OF KA1-AUTOINHIBITED MARK1 KINASE 
2252, 5xvgA, 0.7606, 2.99, 0.264, 292, 254, CRYSTAL STRUCTURE OF PAK4 IN COMPLEX WITH INHIBITOR CZH226
2253, 5u7qB, 0.7606, 2.81, 0.270, 385, 256, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
2254, 3l9lB, 0.7606, 2.80, 0.277, 337, 253, CRYSTAL STRUCTURE OF PKA WITH COMPOUND 36
2255, 3idcA, 0.7606, 2.73, 0.277, 341, 253, CRYSTAL STRUCTURE OF (102-265)RIIB:C HOLOENZYME OF CAMP- DEPENDENT PROTEIN KINASE
2256, 5lcqA, 0.7605, 2.67, 0.282, 350, 252, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH LONG-CHAIN FASUDIL-DERIVATIVE (LIGAND 05)
2257, 3qklA, 0.7605, 2.81, 0.289, 317, 253, SPIROCHROMANE AKT INHIBITORS
2258, 3l9mA, 0.7605, 2.79, 0.277, 338, 253, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 18
2259, 3iw4C, 0.7605, 2.66, 0.261, 332, 253, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
2260, 2hy81, 0.7605, 2.88, 0.298, 293, 255, PAK1 COMPLEX WITH ST2001
2261, 5n1lA, 0.7604, 2.72, 0.278, 347, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 25-DIMETHYL-N-PYRIDIN-4-YLFURAN-3- CARBOXAMIDE
2262, 5n33A, 0.7602, 2.71, 0.274, 347, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 3-AMINO-5-(TRIFLUOROMETHYL)-1H-PYRIDIN-2- ONE
2263, 3a8xA, 0.7602, 2.61, 0.290, 334, 252, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
2264, 4j7bA, 0.7601, 2.54, 0.264, 284, 250, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1
2265, 2g1tB, 0.7601, 2.75, 0.239, 273, 251, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
2266, 6gt1B, 0.7600, 2.47, 0.333, 269, 246, NEK7 BOUND TO PURINE INHIBITOR 
2267, 5m57A, 0.7600, 2.07, 0.296, 261, 243, NEK2 BOUND TO ARYLAMINOPURINE 6
2268, 5m0bA, 0.7600, 2.68, 0.282, 350, 252, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH A SHORT-CHAINED N-(2-AMINOETHYL)ISOQUINOLINE-5-SULFONAMIDE) FASUDIL-DERIVATIVE (LIGAND 03) 
2269, 5h2uA, 0.7600, 2.72, 0.257, 265, 253, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
2270, 3is5B, 0.7600, 2.15, 0.299, 260, 244, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
2271, 2jdoA, 0.7600, 2.59, 0.283, 314, 251, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH ISOQUINOLINE-5- SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL) AMIDE
2272, 2j0iA, 0.7600, 2.88, 0.265, 289, 253, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4
2273, 5m75A, 0.7599, 2.80, 0.269, 350, 253, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH A (S)-METHYL SUBSTITUED FASUDIL-DERIVATIVE 
2274, 4ygaC, 0.7599, 2.73, 0.300, 449, 253, CDPK1 FROM TOXOPLASMA GONDII BOUND TO INHIBITORY VHH-1B7
2275, 4xbrA, 0.7597, 2.90, 0.260, 315, 254, IN CELLULO CRYSTAL STRUCTURE OF PAK4 IN COMPLEX WITH INKA
2276, 5jr7C, 0.7596, 2.68, 0.278, 335, 252, CRYSTAL STRUCTURE OF AN ACRDYS HETERODIMER [RIA(92-365):C] OF PKA
2277, 3bwjA, 0.7596, 2.74, 0.278, 338, 252, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR LEAD COMPOUND ARC-1034
2278, 4u43B, 0.7595, 3.09, 0.239, 302, 259, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 6)
2279, 4otdA, 0.7595, 2.69, 0.294, 334, 252, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN
2280, 4o0tA, 0.7595, 2.96, 0.298, 292, 255, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
2281, 3ma6A, 0.7595, 2.62, 0.300, 267, 253, CRYSTAL STRUCTURE OF KINASE DOMAIN OF TGCDPK1 IN PRESENCE OF 3BRB-PP1
2282, 5zj6B, 0.7594, 3.03, 0.247, 270, 255, CRYSTAL STRUCTURE OF HCK KINASE COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[TRANS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4- PHENOXYPHENYL)-7H-PYRROLO[2;3-D]PYRIMIDIN-4-AMINE 
2283, 3ow4A, 0.7594, 2.69, 0.283, 317, 251, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
2284, 3cqwA, 0.7594, 2.73, 0.290, 318, 252, CRYSTAL STRUCTURE OF AKT-1 COMPLEXED WITH SUBSTRATE PEPTIDE AND INHIBITOR
2285, 4y5qA, 0.7593, 2.57, 0.306, 449, 252, ACTIVATED CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM CRYPTOSPORIDIUM PARVUM (CPCDPK1) IN COMPLEX WITH AMP
2286, 4ks7A, 0.7593, 3.00, 0.283, 286, 254, PAK6 KINASE DOMAIN IN COMPLEX WITH PF-3758309
2287, 3mwuA, 0.7593, 2.60, 0.306, 447, 252, ACTIVATED CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM CRYPTOSPORIDIUM PARVUM (CPCDPK1) IN COMPLEX WITH BUMPED KINASE INHIBITOR RM-1-95
2288, 5n37A, 0.7592, 2.92, 0.281, 347, 253, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE N-(13-BENZODIOXOL-5-YLMETHYL) CYCLOPENTANAMINE
2289, 3l9mB, 0.7592, 2.69, 0.282, 336, 252, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 18
2290, 5zj6A, 0.7591, 3.03, 0.247, 271, 255, CRYSTAL STRUCTURE OF HCK KINASE COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[TRANS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4- PHENOXYPHENYL)-7H-PYRROLO[2;3-D]PYRIMIDIN-4-AMINE 
2291, 5vedA, 0.7591, 2.92, 0.268, 289, 254, PAK4 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
2292, 5uplA, 0.7591, 2.88, 0.260, 290, 254, CDC42 BINDS PAK4 VIA AN EXTENDED GTPASE-EFFECTOR INTEFACE - 2 PEPTIDE: PAK4FL CDC42 - UNREFINED
2293, 5upkB, 0.7591, 2.93, 0.260, 288, 254, CDC42 BINDS PAK4 VIA AN EXTENDED GTPASE-EFFECTOR INTERFACE - 3 PEPTIDE: PAK4CAT PAK4-N45 CDC42
2294, 5n1nA, 0.7591, 2.75, 0.278, 348, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 2-CHLORO-9-PROPAN-2-YLPURINE
2295, 4y95C, 0.7591, 2.84, 0.190, 266, 253, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
2296, 4y95B, 0.7591, 2.84, 0.190, 266, 253, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
2297, 4wboB, 0.7591, 2.88, 0.267, 495, 255, BOVINE G PROTEIN COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH AMLEXANOX
2298, 1u5qA, 0.7591, 2.75, 0.286, 308, 255, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
2299, 2g1tC, 0.7590, 2.77, 0.239, 276, 251, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
2300, 6c9dB, 0.7589, 2.76, 0.317, 422, 252, CRYSTAL STRUCTURE OF KA1-AUTOINHIBITED MARK1 KINASE 
2301, 5m51A, 0.7589, 2.12, 0.292, 260, 243, NEK2 BOUND TO ARYLAMINOPURINE COMPOUND 8
2302, 3tnqB, 0.7589, 2.90, 0.277, 331, 253, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
2303, 2i0eA, 0.7589, 2.60, 0.254, 326, 252, STRUCTURE OF CATALYTIC DOMAIN OF HUMAN PROTEIN KINASE C BETA II COMPLEXED WITH A BISINDOLYLMALEIMIDE INHIBITOR
2304, 5x2fD, 0.7588, 2.93, 0.204, 309, 255, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R IN COMPLEX WITH SKLB(6)
2305, 5n3aA, 0.7588, 2.77, 0.278, 349, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-METHYL-5-(1-METHYLIMIDAZOL-2-YL)-13- THIAZOL-2-AMINE
2306, 5n1mA, 0.7588, 2.75, 0.278, 347, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE (5-CHLORO-2-METHOXYPHENYL)METHANAMINE
2307, 5kksB, 0.7588, 3.00, 0.271, 395, 258, ROCK 1 BOUND TO AZAINDOLE THIOZOLE INHIBITOR
2308, 5bmsA, 0.7588, 2.95, 0.260, 290, 254, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 4 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
2309, 4fieB, 0.7588, 2.90, 0.260, 300, 254, FULL-LENGTH HUMAN PAK4
2310, 4fieA, 0.7588, 2.90, 0.260, 300, 254, FULL-LENGTH HUMAN PAK4
2311, 2rfdA, 0.7588, 2.78, 0.214, 288, 252, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE EGFR KINASE DOMAIN AND A MIG6 PEPTIDE
2312, 5n3cA, 0.7587, 2.77, 0.282, 348, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE THIOPHENE-3-CARBOXIMIDAMIDE
2313, 4obpB, 0.7587, 2.94, 0.246, 290, 256, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 29) 6-(2-FLUOROPYRIDIN-4- YL)PYRIDO[32-D]PYRIMIDIN-4-AMINE
2314, 4crsA, 0.7587, 2.55, 0.292, 331, 250, HUMAN PROTEIN KINASE N2 (PKN2 PRKCL2) IN COMPLEX WITH ATPGAMMAS
2315, 4gv1A, 0.7586, 2.74, 0.298, 329, 252, PKB ALPHA IN COMPLEX WITH AZD5363
2316, 3nyvA, 0.7586, 2.54, 0.300, 445, 250, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH NON-SPECIFIC INHIBITOR WHI-P180
2317, 3hdmA, 0.7586, 2.64, 0.274, 285, 252, CRYSTAL STRUCTURE OF SERUM AND GLUCOCORTICOID-REGULATED KINASE 1 IN COMPLEX WITH COMPOUND 1
2318, 5n39A, 0.7585, 2.75, 0.278, 347, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 2-(23-DIHYDROBENZO[B][14]DIOXIN-6-YL) PYRROLIDINE
2319, 5n36A, 0.7585, 2.75, 0.278, 347, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 3H-ISOINDOL-2-IUM-1-AMINE
2320, 4m69A, 0.7585, 2.73, 0.270, 284, 252, CRYSTAL STRUCTURE OF THE MOUSE RIP3-MLKL COMPLEX
2321, 5m6vA, 0.7584, 2.83, 0.269, 350, 253, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH A DOUBLE METHYLATED FASUDIL-DERIVATIVE 
2322, 3hdnA, 0.7584, 2.58, 0.276, 280, 250, CRYSTAL STRUCTURE OF SERUM AND GLUCOCORTICOID-REGULATED KINASE 1 IN COMPLEX WITH COMPOUND 2
2323, 5ax9B, 0.7583, 2.44, 0.261, 274, 249, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
2324, 4zy5B, 0.7583, 2.84, 0.302, 287, 258, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 17
2325, 4ygaE, 0.7583, 2.72, 0.300, 442, 253, CDPK1 FROM TOXOPLASMA GONDII BOUND TO INHIBITORY VHH-1B7
2326, 4dinA, 0.7583, 2.74, 0.269, 340, 253, NOVEL LOCALIZATION AND QUATERNARY STRUCTURE OF THE PKA RI BETA HOLOENZYME
2327, 3c4xB, 0.7583, 3.06, 0.266, 475, 256, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ATP AND MAGNESIUM CHLORIDE AT 2.9A
2328, 5p9fA, 0.7582, 2.86, 0.198, 266, 253, BTK IN COMPLEX WITH GDC-0834
2329, 5n3eA, 0.7582, 2.77, 0.278, 348, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 6-DIMETHYLAMINOPYRIDINE-3-CARBOXYLIC ACID
2330, 5d9kA, 0.7582, 2.45, 0.292, 280, 250, RSK2 N-TERMINAL KINASE IN COMPLEX WITH BI-D1870
2331, 4ygaA, 0.7582, 2.66, 0.302, 448, 252, CDPK1 FROM TOXOPLASMA GONDII BOUND TO INHIBITORY VHH-1B7
2332, 3tv4B, 0.7582, 2.64, 0.207, 276, 251, HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH AN BROMOPYRIDINE BENZAMIDE INHIBITOR
2333, 2ou7A, 0.7582, 2.78, 0.257, 292, 253, STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN POLO-LIKE KINASE 1
2334, 5n32A, 0.7581, 2.75, 0.278, 345, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-CHLOROBENZYL CARBAMIMIDOTHIOATE
2335, 4fiiA, 0.7581, 2.96, 0.260, 291, 254, CATALYTIC DOMAIN OF HUMAN PAK4 WITH RPKPLVDP PEPTIDE
2336, 4fihA, 0.7581, 2.97, 0.260, 291, 254, CATALYTIC DOMAIN OF HUMAN PAK4 WITH QKFTGLPRQW PEPTIDE
2337, 5n3bA, 0.7580, 2.77, 0.282, 342, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 2-(PYRIDIN-3-YL)ETHANAMINE
2338, 4wotD, 0.7580, 2.80, 0.267, 389, 255, ROCK2 IN COMPLEX WITH 1426382-07-1
2339, 3tv6B, 0.7580, 2.66, 0.207, 276, 251, HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH A METHOXYPYRAZOLOPYRIDINYL BENZAMIDE INHIBITOR
2340, 4y95D, 0.7579, 2.85, 0.194, 265, 253, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
2341, 4y95A, 0.7579, 2.85, 0.194, 266, 253, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
2342, 4utdA, 0.7579, 2.69, 0.304, 266, 250, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO AMPPCP IN AN ACTIVE CONFORMATION
2343, 2etrB, 0.7579, 2.97, 0.264, 398, 258, CRYSTAL STRUCTURE OF ROCK I BOUND TO Y-27632
2344, 2esmB, 0.7579, 2.92, 0.268, 398, 257, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO FASUDIL
2345, 5x2fB, 0.7578, 2.99, 0.195, 312, 256, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R IN COMPLEX WITH SKLB(6)
2346, 4u3zB, 0.7578, 3.07, 0.241, 294, 257, APO MAP4K4 T181E PHOSPHOMIMETIC MUTANT
2347, 4fijA, 0.7578, 2.95, 0.260, 291, 254, CATALYTIC DOMAIN OF HUMAN PAK4
2348, 3pfqA, 0.7578, 2.76, 0.249, 520, 253, CRYSTAL STRUCTURE AND ALLOSTERIC ACTIVATION OF PROTEIN KINASE C BETA II
2349, 5n3dA, 0.7577, 2.78, 0.278, 346, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-(TRIFLUOROMETHYL)BENZENECARBOXIMIDAMIDE
2350, 5j87D, 0.7577, 2.76, 0.199, 263, 251, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
2351, 4eklA, 0.7577, 2.73, 0.283, 329, 251, AKT1 WITH GDC0068
2352, 5vibA, 0.7576, 2.85, 0.277, 308, 253, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH THE PKI PEPTIDE AND AMINOBENZOTHIAZOLE BASED INHIBITORS
2353, 4hzsD, 0.7576, 2.62, 0.262, 319, 248, CRYSTAL STRUCTURE OF ACK1 KINASE DOMAIN WITH C-TERMINAL SH3 DOMAIN
2354, 4hzsC, 0.7576, 2.62, 0.262, 319, 248, CRYSTAL STRUCTURE OF ACK1 KINASE DOMAIN WITH C-TERMINAL SH3 DOMAIN
2355, 4hzsB, 0.7576, 2.62, 0.262, 319, 248, CRYSTAL STRUCTURE OF ACK1 KINASE DOMAIN WITH C-TERMINAL SH3 DOMAIN
2356, 4hzsA, 0.7576, 2.61, 0.262, 319, 248, CRYSTAL STRUCTURE OF ACK1 KINASE DOMAIN WITH C-TERMINAL SH3 DOMAIN
2357, 4appA, 0.7576, 2.98, 0.260, 291, 254, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH (S)-N-(5-(3-BENZYL-1-METHYLPIPERAZINE-4- CARBONYL)-66-DIMETHYL-1456-TETRAHYDROPYRROLO(34-C) PYRAZOL-3-YL)-3-PHENOXYBENZAMIDE
2358, 2g1tD, 0.7576, 2.88, 0.226, 277, 252, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
2359, 5n1kA, 0.7575, 2.79, 0.278, 341, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 2-AMINO-1-(4-FLUOROPHENYL)ETHANOL
2360, 4zjiC, 0.7575, 2.67, 0.306, 281, 252, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
2361, 5n1dA, 0.7574, 2.65, 0.275, 348, 251, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE N-METHYL-1-(5-PYRIDIN-3-YLOXYFURAN-2-YL) METHANAMINE
2362, 5lcuA, 0.7574, 2.80, 0.269, 350, 253, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH A S-METHYL-PIPERAZINE SUBSTITUTED FASUDIL-DERIVATIVE (LIGAND 01)
2363, 5lcpA, 0.7574, 2.79, 0.269, 350, 253, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH FASUDIL (M77)
2364, 4tthB, 0.7574, 2.42, 0.514, 256, 245, CRYSTAL STRUCTURE OF A CDK6/VCYCLIN COMPLEX WITH INHIBITOR BOUND
2365, 4otfA, 0.7574, 2.80, 0.198, 262, 252, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH GDC0834
2366, 5vefA, 0.7572, 2.98, 0.260, 289, 254, PAK4 KINASE DOMAIN IN COMPLEX WITH FASUDIL
2367, 4ygaG, 0.7572, 2.70, 0.302, 447, 252, CDPK1 FROM TOXOPLASMA GONDII BOUND TO INHIBITORY VHH-1B7
2368, 4rx5A, 0.7572, 2.69, 0.199, 265, 251, BRUTON S TYROSINE KINASE (BTK) WITH PYRIDAZINONE COMPOUND 23
2369, 4ra5B, 0.7572, 2.88, 0.281, 310, 253, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH LIGAND COMPOUND 11A (6- [(13-DIMETHYL-AZETIDIN-3-YL)-METHYL-AMINO]-4(R)-METHYL-7-PHENYL-2 10-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
2370, 3ocsA, 0.7572, 2.79, 0.198, 264, 252, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE IN COMPLEX WITH INHIBITOR CGI1746
2371, 5u7rC, 0.7571, 2.86, 0.270, 387, 256, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
2372, 5dzcA, 0.7571, 2.84, 0.276, 816, 254, CRYSTAL STRUCTURE OF PVX_084705 IN COMPLEX WITH AMP-PNP
2373, 4wbbB, 0.7571, 2.92, 0.277, 334, 253, SINGLE TURNOVER AUTOPHOSPHORYLATION CYCLE OF THE PKA RIIB HOLOENZYME
2374, 4hctA, 0.7571, 2.70, 0.227, 265, 251, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 52
2375, 3c4wB, 0.7571, 2.96, 0.267, 518, 255, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ATP AND MAGNESIUM CHLORIDE AT 2.7A
2376, 3ag9B, 0.7571, 2.92, 0.280, 317, 254, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1012
2377, 2xh5A, 0.7571, 2.85, 0.281, 316, 253, STRUCTURE OF 4-(4-TERT-BUTYLBENZYL)-1-(7H-PYRROLO(23-D) PYRIMIDIN-4-YL)PIPERIDIN-4-AMINE BOUND TO PKB
2378, 1u5rA, 0.7571, 2.80, 0.286, 308, 255, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
2379, 5veeA, 0.7570, 2.94, 0.268, 289, 254, PAK4 KINASE DOMAIN IN COMPLEX WITH FRAX486
2380, 5f9eB, 0.7570, 2.95, 0.287, 293, 254, STRUCTURE OF PROTEIN KINASE C THETA WITH COMPOUND 10: 22-DIMETHYL-7- (2-OXIDANYLIDENE-3~{H}-IMIDAZO[45-B]PYRIDIN-1-YL)-1-(PHENYLMETHYL)- 3~{H}-QUINAZOLIN-4-ONE
2381, 4jdjA, 0.7570, 2.92, 0.261, 288, 253, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 F461V MUTANT IN COMPLEX WITH PAKTIDE T PEPTIDE SUBSTRATE
2382, 3qkmA, 0.7570, 2.87, 0.289, 329, 253, SPIROCYCLIC SULFONAMIDES AS AKT INHIBITORS
2383, 5vfiA, 0.7569, 2.88, 0.198, 271, 253, BRUTON S TYROSINE KINASE (BTK) WITH GDC-0853
2384, 2v5qA, 0.7569, 2.84, 0.257, 285, 253, CRYSTAL STRUCTURE OF WILD-TYPE PLK-1 KINASE DOMAIN IN COMPLEX WITH A SELECTIVE DARPIN
2385, 2jedB, 0.7569, 2.86, 0.280, 320, 254, THE CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE PROTEIN KINASE C THETA IN COMPLEX WITH NVP-XAA228 AT 2.32A RESOLUTION.
2386, 5n1oA, 0.7568, 2.79, 0.274, 335, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 2-CHLORO-4-(CHLOROMETHYL)-5- HYDROXYPHENYL)ETHAN-1-ONE
2387, 5m6yA, 0.7568, 2.83, 0.269, 350, 253, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH A METHYLISOQUINOLINE FASUDIL-DERIVATIVE 
2388, 5lihB, 0.7568, 2.46, 0.301, 318, 246, STRUCTURE OF A PEPTIDE-SUBSTRATE BOUND TO PKCIOTA CORE KINASE DOMAIN
2389, 2v5qB, 0.7568, 2.80, 0.257, 285, 253, CRYSTAL STRUCTURE OF WILD-TYPE PLK-1 KINASE DOMAIN IN COMPLEX WITH A SELECTIVE DARPIN
2390, 5izjA, 0.7567, 2.80, 0.277, 328, 253, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1411
2391, 4yvcB, 0.7567, 3.07, 0.266, 392, 259, ROCK 1 BOUND TO THIAZOLE INHIBITOR
2392, 4figA, 0.7567, 2.92, 0.256, 292, 254, CATALYTIC DOMAIN OF HUMAN PAK4
2393, 5f9eA, 0.7566, 2.99, 0.287, 334, 254, STRUCTURE OF PROTEIN KINASE C THETA WITH COMPOUND 10: 22-DIMETHYL-7- (2-OXIDANYLIDENE-3~{H}-IMIDAZO[45-B]PYRIDIN-1-YL)-1-(PHENYLMETHYL)- 3~{H}-QUINAZOLIN-4-ONE
2394, 4fifA, 0.7566, 2.93, 0.260, 293, 254, CATALYTIC DOMAIN OF HUMAN PAK4 WITH RPKPLVDP PEPTIDE
2395, 3v8sC, 0.7566, 3.14, 0.264, 395, 258, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH INDAZOLE DERIVATIVE (COMPOUND 18)
2396, 3dkcA, 0.7566, 2.92, 0.224, 312, 254, STRUCTURE OF MET RECEPTOR TYROSINE KINASE IN COMPLEX WITH ATP
2397, 5bpyA, 0.7565, 2.75, 0.199, 263, 251, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-824171 AKA 6-[(3R)-3-(4-TERT-BU TYLBENZAMIDO) PIPERIDIN-1-YL]-2-{[4-(MORPHOLINE-4-CARBONYL) PHENYL]AMINO}PYRIDINE- 3-CARBOXAMIDE
2398, 4usdB, 0.7565, 2.30, 0.329, 267, 246, HUMAN STK10 (LOK) WITH SB-633825
2399, 3v8sA, 0.7565, 3.14, 0.267, 395, 258, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH INDAZOLE DERIVATIVE (COMPOUND 18)
2400, 3skcB, 0.7565, 2.66, 0.207, 276, 251, HUMAN B-RAF KINASE IN COMPLEX WITH AN AMIDE LINKED PYRAZOLOPYRIDINE INHIBITOR
2401, 3pozA, 0.7565, 2.79, 0.210, 293, 252, EGFR KINASE DOMAIN COMPLEXED WITH TAK-285
2402, 3ow4B, 0.7565, 2.75, 0.283, 317, 251, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
2403, 4jdkA, 0.7564, 2.92, 0.261, 288, 253, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 F461V MUTANT IN COMPLEX WITH PAKTIDE S PEPTIDE SUBSTRATE
2404, 3w33A, 0.7564, 2.62, 0.212, 297, 250, EGFR KINASE DOMAIN COMPLEXED WITH COMPOUND 19B
2405, 3qkkA, 0.7564, 2.70, 0.287, 326, 251, SPIROCHROMANE AKT INHIBITORS
2406, 3d9vB, 0.7564, 2.93, 0.261, 398, 257, CRYSTAL STRUCTURE OF ROCK I BOUND TO H-1152P A DI- METHYLATED VARIANT OF FASUDIL
2407, 3d5uA, 0.7564, 2.81, 0.277, 288, 253, CRYSTAL STRUCTURE OF A WILDTYPE POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN.
2408, 4zy4B, 0.7563, 2.88, 0.302, 292, 258, CRYSTAL STRUCTURE OF P21 ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 4
2409, 4u3zA, 0.7563, 2.94, 0.220, 282, 255, APO MAP4K4 T181E PHOSPHOMIMETIC MUTANT
2410, 4fifB, 0.7563, 2.94, 0.256, 292, 254, CATALYTIC DOMAIN OF HUMAN PAK4 WITH RPKPLVDP PEPTIDE
2411, 4yomB, 0.7562, 2.76, 0.273, 322, 253, STRUCTURE OF SAD KINASE
2412, 4q9zB, 0.7562, 2.98, 0.287, 308, 254, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH COMPOUND35 ((1R)-9- (AZETIDIN-3-YLAMINO)-18-DIMETHYL-35-DIHYDRO[124]TRIAZINO[34- C][14]BENZOXAZIN-2(1H)-ONE)
2413, 4j7bD, 0.7562, 2.56, 0.265, 281, 249, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1
2414, 4figB, 0.7562, 2.92, 0.260, 292, 254, CATALYTIC DOMAIN OF HUMAN PAK4
2415, 4aotA, 0.7562, 2.54, 0.327, 278, 248, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 (LOK) BOUND TO GW830263A
2416, 4lg4B, 0.7561, 2.74, 0.276, 284, 254, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
2417, 3is5A, 0.7561, 2.16, 0.292, 260, 243, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
2418, 3gubA, 0.7561, 2.58, 0.275, 278, 247, CRYSTAL STRUCTURE OF DAPKL93G COMPLEXED WITH N6-(2- PHENYLETHYL)ADENOSINE
2419, 1vzoA, 0.7561, 2.78, 0.267, 319, 251, THE STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF MSK1 REVEALS A NOVEL AUTOINHIBITORY CONFORMATION FOR A DUAL KINASE PROTEIN
2420, 5vgoA, 0.7560, 2.70, 0.199, 265, 251, BRUTON S TYROSINE KINASE (BTK) WITH COMPOUND G-744
2421, 5u7qD, 0.7560, 2.87, 0.258, 383, 256, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
2422, 5m71A, 0.7560, 2.82, 0.269, 350, 253, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH AN (R)-METHYL SUBSTITUED FASUDIL-DERIVATIVE. 
2423, 5lctA, 0.7560, 2.69, 0.271, 350, 251, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH A R-METHYL-PIPERAZINE SUBSTITUTED FASUDIL-DERIVATIVE (LIGAND 02)
2424, 5dh3B, 0.7560, 2.88, 0.294, 283, 255, CRYSTAL STRUCTURE OF MST2 IN COMPLEX WITH XMU-MP-1
2425, 5da3A, 0.7560, 2.84, 0.256, 263, 254, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN WITH INHIBITOR
2426, 4yveB, 0.7560, 2.96, 0.272, 393, 257, ROCK 1 BOUND TO METHOXYPHENYL THIAZOLE INHIBITOR
2427, 4jdhA, 0.7560, 2.99, 0.260, 289, 254, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 IN COMPLEX WITH PAKTIDE T PEPTIDE SUBSTRATE
2428, 4fr4F, 0.7560, 2.97, 0.245, 346, 257, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE 32A (YANK1)
2429, 4eheB, 0.7560, 2.68, 0.207, 276, 251, B-RAF KINASE DOMAIN IN COMPLEX WITH AN AMINOTHIENOPYRIMIDINE-BASED INHIBITOR
2430, 3krwA, 0.7560, 3.02, 0.267, 618, 255, HUMAN GRK2 IN COMPLEX WITH GBETGAMMA SUBUNITS AND BALANOL (SOAK)
2431, 1xkkA, 0.7560, 2.80, 0.214, 289, 252, EGFR KINASE DOMAIN COMPLEXED WITH A QUINAZOLINE INHIBITOR- GW572016
2432, 3orxC, 0.7559, 2.68, 0.271, 283, 251, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2433, 3orxB, 0.7559, 2.68, 0.275, 280, 251, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2434, 3orxA, 0.7559, 2.68, 0.271, 283, 251, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2435, 3krxA, 0.7559, 3.03, 0.267, 618, 255, HUMAN GRK2 IN COMPLEX WITH GBETGAMMA SUBUNITS AND BALANOL (CO-CRYSTAL)
2436, 4zjiA, 0.7558, 2.81, 0.285, 278, 253, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
2437, 4ra5A, 0.7558, 2.94, 0.280, 332, 254, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH LIGAND COMPOUND 11A (6- [(13-DIMETHYL-AZETIDIN-3-YL)-METHYL-AMINO]-4(R)-METHYL-7-PHENYL-2 10-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
2438, 4aw1A, 0.7558, 2.78, 0.287, 283, 251, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PS210 BOUND TO THE PIF-POCKET
2439, 3orxD, 0.7558, 2.69, 0.271, 282, 251, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2440, 5kupA, 0.7557, 2.70, 0.199, 265, 251, BRUTON S TYROSINE KINASE (BTK) WITH PYRIDAZINONE COMPOUND 9
2441, 5d9kB, 0.7557, 2.55, 0.292, 280, 250, RSK2 N-TERMINAL KINASE IN COMPLEX WITH BI-D1870
2442, 5ezrA, 0.7556, 2.83, 0.276, 803, 254, CRYSTAL STRUCTURE OF PVX_084705 BOUND TO COMPOUND
2443, 5bmlB, 0.7556, 3.04, 0.267, 395, 258, ROCK 1 BOUND TO A PYRIDINE THIAZOLE INHIBITOR
2444, 4otgA, 0.7556, 2.72, 0.290, 322, 252, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN IN COMPLEX WITH LESTAURTINIB
2445, 5w7tB, 0.7555, 2.61, 0.262, 276, 248, STRUCTURE OF PHOSPHORYLATED WNK1 
2446, 5lcrA, 0.7555, 2.83, 0.269, 350, 253, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH OPEN-CHAIN FASUDIL-DERIVATIVE (LIGAND 04)
2447, 4otrA, 0.7555, 2.86, 0.194, 263, 252, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6-CYCLOPROPYL-2- [3-[5-[[5-(4-ETHYLPIPERAZIN-1-YL)-2-PYRIDYL]AMINO]-1-METHYL-6-OXO-3- PYRIDYL]-2-(HYDROXYMETHYL)PHENYL]-8-FLUORO-ISOQUINOLIN-1-ONE
2448, 4c35A, 0.7555, 2.73, 0.283, 337, 251, PKA-S6K1 CHIMERA WITH COMPOUND 1 (NU1085) BOUND
2449, 5dbxB, 0.7554, 2.45, 0.278, 282, 245, CRYSTAL STRUCTURE OF MURINE SPAK(T243D) IN COMPLEX WITH AMPPNP
2450, 4zjjA, 0.7554, 2.87, 0.283, 280, 254, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
2451, 4ks8A, 0.7554, 2.89, 0.287, 286, 251, PAK6 KINASE DOMAIN IN COMPLEX WITH SUNITINIB
2452, 2vd5B, 0.7554, 2.95, 0.275, 380, 255, STRUCTURE OF HUMAN MYOTONIC DYSTROPHY PROTEIN KINASE IN COMPLEX WITH THE BISINDOYLMALEIDE INHIBITOR BIM VIII
2453, 4otqA, 0.7553, 2.85, 0.194, 263, 252, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 1-[5-[3-(7-TERT- BUTYL-4-OXO-QUINAZOLIN-3-YL)-2-METHYL-PHENYL]-1-METHYL-2-OXO-3- PYRIDYL]-3-METHYL-UREA
2454, 4fr4D, 0.7553, 2.98, 0.245, 346, 257, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE 32A (YANK1)
2455, 3wf8A, 0.7553, 2.94, 0.306, 287, 255, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A QUINOLINE DERIVATIVE 2-OXO-2-[(4-SULFAMOYLPHENYL)AMINO]ETHYL 78910- TETRAHYDRO-6H-CYCLOHEPTA[B]QUINOLINE-11-CARBOXYLATE
2456, 4mbjB, 0.7552, 2.71, 0.207, 276, 251, HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH AN IMIDAZOPYRIDINE-BASED INHIBITOR
2457, 4e4xB, 0.7552, 2.72, 0.207, 274, 251, CRYSTAL STRUCTURE OF B-RAF KINASE DOMAIN IN COMPLEX WITH A DIHYDROPYRIDO[23-D]PYRIMIDINONE-BASED INHIBITOR
2458, 5j87B, 0.7551, 2.76, 0.203, 274, 251, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
2459, 4yhfA, 0.7551, 2.74, 0.200, 268, 250, BRUTON S TYROSINE KINASE IN COMPLEX WITH A T-BUTYL CYANOACRYLAMIDE INHIBITOR
2460, 4hjoA, 0.7551, 2.79, 0.210, 278, 252, CRYSTAL STRUCTURE OF THE INACTIVE EGFR TYROSINE KINASE DOMAIN WITH ERLOTINIB
2461, 4hcuA, 0.7551, 2.71, 0.227, 263, 251, CRYSTAL STRUCTURE OF ITK IN COMPLEXT WITH COMPOUND 40
2462, 5h0gA, 0.7550, 3.02, 0.244, 446, 254, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-N4-DIMETHYLPENTANAMIDE
2463, 4pp7B, 0.7550, 2.71, 0.203, 274, 251, HIGHLY POTENT AND SELECTIVE 3-N-METHYLQUINAZOLINE-4(3H)-ONE BASED INHIBITORS OF B-RAFV600E KINASE
2464, 3c51A, 0.7550, 2.96, 0.267, 487, 255, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ADP AND MAGNESIUM CHLORIDE AT 3.55A
2465, 5p9gA, 0.7549, 2.87, 0.198, 265, 252, STRUCTURE OF BTK WITH RN486
2466, 4ypdA, 0.7549, 2.58, 0.271, 281, 247, CRYSTAL STRUCTURE OF DAPK1 CATALYTIC DOMAIN IN COMPLEX WITH THE HINGE BINDING FRAGMENT 4-METHYLPYRIDAZINE
2467, 4q9zA, 0.7549, 2.85, 0.281, 331, 253, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH COMPOUND35 ((1R)-9- (AZETIDIN-3-YLAMINO)-18-DIMETHYL-35-DIHYDRO[124]TRIAZINO[34- C][14]BENZOXAZIN-2(1H)-ONE)
2468, 5p9mA, 0.7548, 2.81, 0.193, 271, 254, BTK1 BINDS COVALENTLY TO HY-15771 ONO-4059
2469, 5h0eA, 0.7548, 3.02, 0.244, 446, 254, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-4-METHYLPENTANAMIDE
2470, 4yo4A, 0.7548, 2.66, 0.270, 280, 248, CRYSTAL STRUCTURE OF DAPK1 CATALYTIC DOMAIN IN COMPLEX WITH THE HINGE BINDING FRAGMENT PHTHALAZINE
2471, 4jboA, 0.7548, 2.63, 0.293, 266, 249, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
2472, 3wf9A, 0.7548, 2.89, 0.307, 287, 254, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A QUINOLINE DERIVATIVE 1-OXO-1-[(4-SULFAMOYLPHENYL)AMINO]PROPAN-2-YL-2-METHYL-1 234-TETRAHYDROACRIDINE-9-CARBOXYLATE
2473, 3gu6A, 0.7548, 2.66, 0.274, 280, 248, CRYSTAL STRUCTURE OF DAPKQ23V-ADP
2474, 5ajqB, 0.7547, 2.41, 0.320, 267, 247, HUMAN LOK (STK10) IN COMPLEX WITH BOSUTINIB
2475, 3wf6A, 0.7547, 2.72, 0.309, 277, 249, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE DERIVATIVE 4-[4-(1H-INDOL-3-YL)-36- DIHYDROPYRIDIN-1(2H)-YL]-1H-PYRAZOLO[34-D]PYRIMIDINE
2476, 3dfcB, 0.7547, 2.65, 0.270, 280, 248, CRYSTAL STRUCTURE OF A GLYCINE-RICH LOOP MUTANT OF THE DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN WITH AMPPNP
2477, 2rgpA, 0.7547, 2.83, 0.215, 284, 251, STRUCTURE OF EGFR IN COMPLEX WITH HYDRAZONE A POTENT DUAL INHIBITOR
2478, 5wneA, 0.7546, 3.18, 0.260, 384, 258, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
2479, 3c50A, 0.7546, 2.99, 0.267, 499, 255, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ADP AND MAGNESIUM CHLORIDE AT 2.6A
2480, 6gt1A, 0.7545, 2.46, 0.322, 267, 245, NEK7 BOUND TO PURINE INHIBITOR 
2481, 4zjiB, 0.7545, 2.84, 0.285, 276, 253, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
2482, 3gu7A, 0.7545, 2.67, 0.270, 280, 248, CRYSTAL STRUCTURE OF DAPKQ23V-ADP-MG2+
2483, 3c50B, 0.7545, 3.10, 0.266, 496, 256, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ADP AND MAGNESIUM CHLORIDE AT 2.6A
2484, 5h09A, 0.7544, 3.02, 0.244, 446, 254, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-ETHYL2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-4-METHYLPENTANOATE
2485, 4u8zA, 0.7544, 2.81, 0.274, 289, 252, CRYSTAL STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF- 06447475)
2486, 3h9oA, 0.7544, 2.57, 0.273, 275, 249, PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK-1) IN COMPLEX WITH COMPOUND 9
2487, 3gu8A, 0.7544, 2.67, 0.270, 278, 248, CRYSTAL STRUCTURE OF DAPKL93G WITH N6-CYCLOPENTYLADENOSINE
2488, 4qoxA, 0.7543, 2.72, 0.306, 462, 252, CRYSTAL STRUCTURE OF CDPK4 FROM PLASMODIUM FALCIPARUM PF3D7_0717500
2489, 3rwqA, 0.7543, 2.72, 0.275, 283, 251, DISCOVERY OF A NOVEL POTENT AND SELECTIVE INHIBITOR OF 3- PHOSPHOINOSITIDE DEPENDENT KINASE (PDK1)
2490, 3gu4A, 0.7543, 2.67, 0.270, 280, 248, CRYSTAL STRUCTURE OF DAPKQ23V-AMPPNP
2491, 5wngD, 0.7542, 3.10, 0.266, 396, 256, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
2492, 4apcB, 0.7542, 2.92, 0.246, 296, 252, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1)
2493, 3q53A, 0.7542, 2.91, 0.298, 291, 255, STRUCTURE OF PHOSPHORYLATED PAK1 KINASE DOMAIN IN COMPLEX WITH ATP
2494, 3ndmB, 0.7542, 3.17, 0.265, 396, 257, CRYSTAL STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT ISOQUINOLONE DERIVATIVE
2495, 5h0hA, 0.7541, 3.02, 0.244, 446, 254, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-NN4-TRIMETHYLPENTANAMIDE
2496, 3rwpA, 0.7541, 2.59, 0.269, 277, 249, DISCOVERY OF A NOVEL POTENT AND SELECTIVE INHIBITOR OF 3- PHOSPHOINOSITIDE DEPENDENT KINASE (PDK1)
2497, 3l9nA, 0.7541, 2.88, 0.277, 332, 253, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 27
2498, 3dgkA, 0.7541, 2.66, 0.274, 278, 248, CRYSTAL STRUCTURE OF A GLYCINE-RICH LOOP MUTANT OF THE DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN
2499, 5h0bA, 0.7540, 3.03, 0.244, 446, 254, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-4-METHYLPENTANOIC ACID
2500, 5fd2A, 0.7540, 2.44, 0.207, 264, 246, B-RAF WILD-TYPE KINASE DOMAIN IN COMPLEX WITH A PURINYLPYRIDINYLAMINO- BASED INHIBITOR
2501, 4l6qB, 0.7540, 3.00, 0.267, 388, 255, ROCK2 IN COMPLEX WITH BENZOXABOROLE
2502, 4l6qA, 0.7540, 2.99, 0.267, 388, 255, ROCK2 IN COMPLEX WITH BENZOXABOROLE
2503, 4fr4A, 0.7540, 2.99, 0.241, 350, 257, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE 32A (YANK1)
2504, 4c34A, 0.7540, 2.76, 0.283, 336, 251, PKA-S6K1 CHIMERA WITH STAUROSPORINE BOUND
2505, 5ng3C, 0.7539, 2.94, 0.226, 272, 252, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
2506, 5dt3A, 0.7539, 2.70, 0.297, 263, 249, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P6122
2507, 4rfyA, 0.7539, 2.80, 0.195, 263, 251, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6- (DIMETHYLAMINO)-2-[2-(HYDROXYMETHYL)-3-[1-METHYL-5-[[5-(MORPHOLINE-4- CARBONYL)-2-PYRIDYL]AMINO]-6-OXO-3-PYRIDYL]PHENYL]-34- DIHYDROISOQUINOLIN-1-ONE
2508, 3ndmD, 0.7539, 3.18, 0.265, 396, 257, CRYSTAL STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT ISOQUINOLONE DERIVATIVE
2509, 3iopA, 0.7539, 2.58, 0.273, 275, 249, PDK-1 IN COMPLEX WITH THE INHIBITOR COMPOUND-8I
2510, 5orzA, 0.7538, 2.66, 0.302, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2511, 5nw8A, 0.7538, 2.64, 0.276, 337, 250, CRYSTAL STRUCTURE OF THE PROTEIN-KINASE A CATALYTIC SUBUNIT FROM CRITECULUS GRISEUS IN COMPLEX WITH COMPOUNDS RKP032 AND FASUDIL 
2512, 4ow8A, 0.7538, 2.63, 0.269, 276, 249, CRYSTAL STRUCTURE OF KINASE DOMAIN OF PKNA FROM MTB
2513, 4idtB, 0.7538, 2.73, 0.256, 335, 250, CRYSTAL STRUCTURE OF NIK WITH 11-BROMO-5678-TETRAHYDROPYRIMIDO[4  5 :34]CYCLOHEPTA[12-B]INDOL-2-AMINE (T28)
2514, 3gu5A, 0.7537, 2.69, 0.274, 280, 248, CRYSTAL STRUCTURE OF DAPKQ23V-AMPPNP-MG2+
2515, 2pe0A, 0.7537, 2.56, 0.273, 275, 249, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) 5-HYDROXY-3-[1-(1H-PYRROL-2-YL)-ETH-(Z)-YLIDENE]-13-DIHYDRO- INDOL-2-ONE COMPLEX
2516, 1uu7A, 0.7537, 2.72, 0.275, 280, 251, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-2
2517, 4zseA, 0.7536, 2.76, 0.208, 297, 250, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
2518, 4u3yA, 0.7536, 3.15, 0.231, 295, 260, APO MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4)
2519, 4ixpA, 0.7536, 2.54, 0.309, 334, 249, CRYSTAL STRUCTURE OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE (MELK)
2520, 3tv7C, 0.7536, 3.18, 0.264, 394, 258, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1342
2521, 5os5A, 0.7535, 2.66, 0.302, 267, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2522, 5os4A, 0.7535, 2.67, 0.302, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2523, 3sc1A, 0.7535, 2.75, 0.287, 278, 251, NOVEL ISOQUINOLONE PDK1 INHIBITORS DISCOVERED THROUGH FRAGMENT-BASED LEAD DISCOVERY
2524, 3bhyA, 0.7535, 2.48, 0.256, 268, 246, CRYSTAL STRUCTURE OF HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3) IN COMPLEX WITH A BETA-CARBOLINE LIGAND
2525, 1jkkA, 0.7535, 2.69, 0.278, 277, 248, 2.4A X-RAY STRUCTURE OF TERNARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE AND MG.
2526, 5orpA, 0.7534, 2.67, 0.302, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2527, 4idtA, 0.7534, 2.74, 0.260, 334, 250, CRYSTAL STRUCTURE OF NIK WITH 11-BROMO-5678-TETRAHYDROPYRIMIDO[4  5 :34]CYCLOHEPTA[12-B]INDOL-2-AMINE (T28)
2528, 2v55A, 0.7534, 3.12, 0.261, 393, 257, MECHANISM OF MULTI-SITE PHOSPHORYLATION FROM A ROCK-I:RHOE COMPLEX STRUCTURE
2529, 5o0eA, 0.7533, 2.63, 0.276, 349, 250, CRYSTAL STRUCTURE OF THE PROTEIN-KINASE A CATALYTIC SUBUNIT FROM CRITECULUS GRISEUS IN COMPLEX WITH COMPOUNDS RKP120 AND FASUDIL 
2530, 5hg5A, 0.7533, 3.02, 0.213, 302, 254, EGFR (L858R T790M V948R) IN COMPLEX WITH N-{3-[(2-{[4-(4- METHYLPIPERAZIN-1-YL)PHENYL]AMINO}-7H-PYRROLO[23-D]PYRIMIDIN-4-YL) OXY]PHENYL}PROP-2-ENAMIDE
2531, 4y93A, 0.7533, 2.90, 0.194, 429, 252, CRYSTAL STRUCTURE OF THE PH-TH-KINASE CONSTRUCT OF BRUTON S TYROSINE KINASE (BTK)
2532, 4rg0A, 0.7533, 2.89, 0.194, 263, 252, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 2-[8-FLUORO-2- [2-(HYDROXYMETHYL)-3-[1-METHYL-5-[[5-(4-METHYLPIPERAZIN-1-YL)-2- PYRIDYL]AMINO]-6-OXO-3-PYRIDYL]PHENYL]-1-OXO-34-DIHYDROISOQUINOLIN- 6-YL]-2-METHYL-PROPANENITRILE
2533, 4l9iB, 0.7533, 3.11, 0.266, 493, 256, BOVINE G PROTEIN COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH PAROXETINE
2534, 3tv7A, 0.7533, 3.07, 0.276, 394, 257, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1342
2535, 1okzA, 0.7533, 2.73, 0.291, 276, 251, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH UCN-01
2536, 5orxA, 0.7532, 2.66, 0.302, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2537, 5orvA, 0.7532, 2.68, 0.302, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2538, 4w8eA, 0.7532, 2.86, 0.278, 290, 252, STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF-06645342)
2539, 3igoA, 0.7532, 2.53, 0.313, 446, 249, CRYSTAL STRUCTURE OF CRYPTOSPORIDIUM PARVUM CDPK1 CGD3_920
2540, 3c4wA, 0.7532, 3.00, 0.267, 494, 255, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ATP AND MAGNESIUM CHLORIDE AT 2.7A
2541, 3a8xB, 0.7532, 2.71, 0.302, 329, 252, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
2542, 2xchA, 0.7532, 2.74, 0.275, 278, 251, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
2543, 2pe2A, 0.7532, 2.65, 0.284, 275, 250, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) 3-{5-[2-OXO-5-UREIDO-12-DIHYDRO-INDOL-(3Z)-YLIDENEMETHYL]-1H- PYRROL-3-YL}-N-(2-PIPERIDIN-1-YL-ETHYL)-BENZAMIDE COMPLEX
2544, 5osdA, 0.7531, 2.67, 0.302, 266, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2545, 5orrA, 0.7531, 2.67, 0.302, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2546, 4wotA, 0.7531, 2.99, 0.266, 389, 256, ROCK2 IN COMPLEX WITH 1426382-07-1
2547, 4ot6A, 0.7531, 2.78, 0.195, 265, 251, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 4- METHANESULFONYL-N-(3-{8-[4-(MORPHOLINE-4-CARBONYL)-PHENYLAMINO]- IMIDAZO[12-A]PYRAZIN-6-YL}-PHENYL)-BENZAMIDE
2548, 5p9hA, 0.7530, 2.83, 0.199, 264, 251, BTK1 COCRYSTALLIZED WITH RN983
2549, 5os1A, 0.7530, 2.67, 0.302, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2550, 5orwA, 0.7530, 2.67, 0.302, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2551, 5ho7A, 0.7530, 2.59, 0.265, 280, 249, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
2552, 5hkmA, 0.7530, 2.57, 0.281, 272, 249, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
2553, 3nuuA, 0.7530, 2.54, 0.282, 276, 248, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT11
2554, 3is5C, 0.7530, 2.23, 0.300, 259, 243, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
2555, 3c4xA, 0.7530, 3.16, 0.266, 496, 256, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ATP AND MAGNESIUM CHLORIDE AT 2.9A
2556, 2w4jA, 0.7530, 2.67, 0.270, 276, 248, X-RAY STRUCTURE OF A DAP-KINASE 2-277
2557, 2acxA, 0.7530, 3.02, 0.281, 495, 256, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 6 BOUND TO AMPPNP
2558, 5osfA, 0.7529, 2.68, 0.302, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2559, 5oseA, 0.7529, 2.68, 0.302, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2560, 5os0A, 0.7529, 2.68, 0.302, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2561, 5oryA, 0.7529, 2.67, 0.302, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2562, 5ok3A, 0.7529, 2.63, 0.276, 349, 250, CRYSTAL STRUCTURE OF THE PROTEIN-KINASE A CATALYTIC SUBUNIT FROM CRITECULUS GRISEUS IN COMPLEX WITH COMPOUNDS RKP241 AND FASUDIL 
2563, 5cnnB, 0.7529, 2.71, 0.216, 304, 250, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN MUTANT I682Q
2564, 4wotC, 0.7529, 3.10, 0.266, 392, 256, ROCK2 IN COMPLEX WITH 1426382-07-1
2565, 3ggfB, 0.7529, 2.55, 0.275, 270, 251, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE MST4 IN COMPLEX WITH AN QUINAZOLIN
2566, 2z7rA, 0.7529, 2.11, 0.320, 265, 241, CRYSTAL STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF HUMAN RSK1 BOUND TO STAUROSPORINE
2567, 1jklA, 0.7529, 2.72, 0.270, 280, 248, 1.6A X-RAY STRUCTURE OF BINARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE
2568, 5x2aD, 0.7528, 2.84, 0.214, 297, 252, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R IN COMPLEX WITH SKLB(3)
2569, 3ionA, 0.7528, 2.54, 0.278, 274, 248, PDK1 IN COMPLEX WITH COMPOUND 8H
2570, 1phkA, 0.7528, 2.70, 0.293, 277, 249, TWO STRUCTURES OF THE CATALYTIC DOMAIN OF PHOSPHORYLASE KINASE: AN ACTIVE PROTEIN KINASE COMPLEXED WITH NUCLEOTIDE SUBSTRATE-ANALOGUE AND PRODUCT
2571, 5ho8A, 0.7527, 2.54, 0.274, 278, 248, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
2572, 4wotB, 0.7527, 3.15, 0.261, 394, 257, ROCK2 IN COMPLEX WITH 1426382-07-1
2573, 2v55C, 0.7527, 3.09, 0.257, 396, 257, MECHANISM OF MULTI-SITE PHOSPHORYLATION FROM A ROCK-I:RHOE COMPLEX STRUCTURE
2574, 1okyA, 0.7527, 2.74, 0.271, 281, 251, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
2575, 1ig1A, 0.7527, 2.71, 0.278, 280, 248, 1.8A X-RAY STRUCTURE OF TERNARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE AND MN.
2576, 5n3fA, 0.7526, 2.75, 0.272, 318, 250, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE N-[3-(AMINOMETHYL)PHENYL]ACETAMIDE
2577, 4hcvA, 0.7526, 2.78, 0.227, 263, 251, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 53
2578, 5w7tA, 0.7525, 2.84, 0.256, 276, 250, STRUCTURE OF PHOSPHORYLATED WNK1 
2579, 4z3vA, 0.7525, 2.87, 0.198, 271, 252, FRAGMENT-BASED DISCOVERY OF A SMALL MOLECULE REVERSIBLE INHIBITOR OF BRUTON S TYROSINE KINASE
2580, 1z5mA, 0.7525, 2.60, 0.269, 275, 249, CRYSTAL STRUCTURE OF N1-[3-[[5-BROMO-2-[[3-[(1-PYRROLIDINYLCARBONYL) AMINO]PHENYL]AMINO]-4-PYRIMIDINYL]AMINO]PROPYL]-22- DIMETHYLPROPANEDIAMIDE COMPLEXED WITH HUMAN PDK1
2581, 1jksA, 0.7525, 2.72, 0.274, 280, 248, 1.5A X-RAY STRUCTURE OF APO FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
2582, 5os6A, 0.7524, 2.69, 0.302, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2583, 5os3A, 0.7524, 2.69, 0.302, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2584, 5oroA, 0.7524, 2.69, 0.302, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2585, 5j87A, 0.7524, 2.78, 0.199, 263, 251, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
2586, 4rewA, 0.7524, 2.61, 0.306, 411, 248, CRYSTAL STRUCTURE OF THE NON-PHOSPHORYLATED HUMAN ALPHA1 BETA2 GAMMA1 HOLO-AMPK COMPLEX
2587, 4pf4A, 0.7524, 2.68, 0.274, 278, 248, 1.1A X-RAY STRUCTURE OF THE APO CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE 1 AA 1-277
2588, 4fr4E, 0.7524, 3.02, 0.245, 342, 257, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE 32A (YANK1)
2589, 4eqmD, 0.7524, 2.24, 0.240, 268, 242, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
2590, 3a7fA, 0.7524, 2.85, 0.274, 283, 252, HUMAN MST3 KINASE
2591, 2srcA, 0.7524, 2.91, 0.250, 449, 252, CRYSTAL STRUCTURE OF HUMAN TYROSINE-PROTEIN KINASE C-SRC IN COMPLEX WITH AMP-PNP
2592, 2h9vA, 0.7524, 3.21, 0.257, 383, 257, STRUCTURAL BASIS FOR INDUCED-FIT BINDING OF RHO-KINASE TO THE INHIBITOR Y27632
2593, 5wneD, 0.7523, 3.13, 0.266, 396, 256, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
2594, 5lvpD, 0.7523, 2.82, 0.290, 276, 252, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH AN HM-PEPTIDE BOUND TO THE PIF-POCKET
2595, 4aotB, 0.7523, 2.68, 0.320, 279, 250, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 (LOK) BOUND TO GW830263A
2596, 3plsA, 0.7523, 2.95, 0.229, 298, 253, RON IN COMPLEX WITH LIGAND AMP-PNP
2597, 5vloB, 0.7522, 2.89, 0.311, 293, 251, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2598, 5ornA, 0.7522, 2.69, 0.302, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2599, 5kktA, 0.7522, 2.96, 0.260, 389, 254, ROCK 1 BOUND TO AZAINDOLE THIOZOLE PIPERAZINE INHIBITOR
2600, 5dnrA, 0.7522, 2.66, 0.302, 264, 248, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P41212
2601, 4eqmF, 0.7522, 2.23, 0.240, 268, 242, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
2602, 3d5wA, 0.7522, 2.81, 0.271, 284, 251, CRYSTAL STRUCTURE OF A PHOSPHORYLATED POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH ADP.
2603, 5cwzC, 0.7521, 2.24, 0.258, 271, 244, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
2604, 4b9dB, 0.7521, 2.93, 0.247, 295, 251, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1) WITH INHIBITOR.
2605, 2r7bA, 0.7521, 2.63, 0.277, 274, 249, CRYSTAL STRUCTURE OF THE PHOSPHOINOSITIDE-DEPENDENT KINASE- 1 (PDK-1)CATALYTIC DOMAIN BOUND TO A DIBENZONAPHTHYRIDINE INHIBITOR
2606, 5u8lA, 0.7520, 2.95, 0.213, 289, 253, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH A SULFONYL FLUORIDE PROBE XO44
2607, 5he0A, 0.7520, 3.11, 0.267, 621, 255, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG215022
2608, 4obqA, 0.7520, 2.35, 0.280, 275, 246, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 31) N-[3-(4- AMINOQUINAZOLIN-6-YL)-5-FLUOROPHENYL]-2-(PYRROLIDIN-1-YL)ACETAMIDE
2609, 3nunA, 0.7520, 2.54, 0.270, 278, 248, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH LEAD COMPOUND
2610, 5f0aA, 0.7519, 2.86, 0.276, 811, 254, CRYSTAL STRUCTURE OF PVX_084705 WITH BOUND 1-TERT-BUTYL-3-(3- CHLOROPHENOXY)-1H-PYRAZOLO[34-D]PYRIMIDIN-4-AMINE INHIBITOR
2611, 5dr2A, 0.7519, 2.72, 0.293, 264, 249, AURORA A KINASE IN COMPLEX WITH AA30 AND ATP IN SPACE GROUP P6122
2612, 5dn3A, 0.7519, 2.66, 0.302, 264, 248, AURORA A IN COMPLEX WITH ATP AND AA35.
2613, 3orzB, 0.7519, 2.82, 0.287, 278, 251, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
2614, 3nusA, 0.7519, 2.55, 0.282, 276, 248, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT8
2615, 2xikA, 0.7519, 2.79, 0.287, 288, 251, STRUCTURE OF HUMAN YSK1 (YEAST SPS1-STE20-RELATED KINASE 1)
2616, 5u7rD, 0.7518, 2.81, 0.270, 382, 252, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
2617, 5orsA, 0.7518, 2.69, 0.302, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2618, 4eqmE, 0.7518, 2.23, 0.240, 268, 242, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
2619, 3wf5A, 0.7518, 2.75, 0.313, 277, 249, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE DERIVATIVE 4-[4-(1H-BENZIMIDAZOL-2-YL)PIPERIDIN-1- YL]-1H-PYRAZOLO[34-D]PYRIMIDINE
2620, 3t8oA, 0.7518, 2.90, 0.256, 493, 254, RHODOPSIN KINASE (GRK1) L166K MUTANT AT 2.5A RESOLUTION
2621, 3qcqA, 0.7518, 2.54, 0.274, 276, 248, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-(3- AMINO-1H-INDAZOL-6-YL)-N4-ETHYL-24-PYRIMIDINEDIAMINE
2622, 3orzD, 0.7518, 2.82, 0.287, 278, 251, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
2623, 3o7lB, 0.7518, 2.73, 0.268, 326, 250, CRYSTAL STRUCTURE OF PHOSPHOLAMBAN (1-19):PKA C-SUBUNIT:AMP-PNP:MG2+ COMPLEX
2624, 5wnfD, 0.7517, 3.04, 0.267, 396, 255, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
2625, 5izjB, 0.7517, 2.94, 0.276, 325, 254, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1411
2626, 5hg8A, 0.7517, 3.02, 0.213, 300, 254, EGFR (L858R T790M V948R) IN COMPLEX WITH N-[3-({2-[(1-METHYL-1H- PYRAZOL-4-YL)AMINO]-7H-PYRROLO[23-D]PYRIMIDIN-4-YL}OXY)PHENYL]PROP- 2-ENAMIDE
2627, 4fr4C, 0.7517, 3.02, 0.241, 344, 257, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE 32A (YANK1)
2628, 1zrzA, 0.7517, 2.71, 0.292, 310, 250, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF ATYPICAL PROTEIN KINASE C-IOTA
2629, 5o2cA, 0.7516, 3.06, 0.229, 368, 253, CRYSTAL STRUCTURE OF WNK3 KINASE AND CCT1 DIDOMAIN IN A UNPHOSPHORYLATED STATE
2630, 4rfzA, 0.7516, 2.82, 0.195, 263, 251, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6- (DIMETHYLAMINO)-8-FLUORO-2-[2-(HYDROXYMETHYL)-3-[1-METHYL-5-[[5- (MORPHOLINE-4-CARBONYL)-2-PYRIDYL]AMINO]-6-OXO-3- PYRIDYL]PHENYL]ISOQUINOLIN-1-ONE
2631, 3eh9A, 0.7516, 2.68, 0.271, 278, 247, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE COMPLEXED WITH ADP
2632, 2biyA, 0.7516, 2.90, 0.285, 287, 253, STRUCTURE OF PDK1-S241A MUTANT KINASE DOMAIN
2633, 1uvrA, 0.7516, 2.78, 0.283, 284, 251, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-8
2634, 1uu3A, 0.7516, 2.68, 0.280, 276, 250, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH LY333531
2635, 6f3fA, 0.7515, 2.92, 0.250, 448, 252, AUTOINHIBITED SRC KINASE BOUND TO ADP
2636, 5dbxA, 0.7515, 2.55, 0.272, 284, 246, CRYSTAL STRUCTURE OF MURINE SPAK(T243D) IN COMPLEX WITH AMPPNP
2637, 5ar5A, 0.7515, 2.79, 0.202, 284, 253, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BENZIMIDAZOLE
2638, 4ot5A, 0.7515, 2.83, 0.195, 263, 251, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 4-TERT-BUTYL-N- (3-{8-[4-(4-METHYL-PIPERAZINE-1-CARBONYL)-PHENYLAMINO]-IMIDAZO[12- A]PYRAZIN-6-YL}-PHENYL)-BENZAMIDE
2639, 3mj2A, 0.7515, 2.68, 0.229, 259, 249, X-RAY CRYSTAL STRUCTURE OF ITK COMPLEXED WITH INHIBITOR BMS-509744
2640, 3f5uA, 0.7515, 2.66, 0.267, 279, 247, CRYSTAL STRUCTURE OF THE DEATH ASSOCIATED PROTEIN KINASE IN COMPLEX WITH AMPPNP AND MG2+
2641, 2xckA, 0.7515, 2.72, 0.260, 275, 250, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
2642, 5u7rA, 0.7514, 3.13, 0.270, 387, 256, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
2643, 5d9lA, 0.7514, 2.62, 0.300, 299, 250, RSK2 N-TERMINAL KINASE IN COMPLEX WITH BIS-PHENOL PYRAZOLE
2644, 1ql6A, 0.7514, 2.65, 0.294, 281, 248, THE CATALYTIC MECHANISM OF PHOSPHORYLASE KINASE PROBED BY MUTATIONAL STUDIES
2645, 5wngA, 0.7513, 3.04, 0.262, 395, 256, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
2646, 5p9jA, 0.7513, 2.89, 0.198, 263, 252, BTK1 COCRYSTALLIZED WITH IBRUTINIB
2647, 4nwmA, 0.7513, 2.87, 0.199, 261, 251, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-809959 AKA 4-TERT-BUTYL-N-[2-ME THYL-3-(6-{[4- (MORPHOLINE-4-CARBONYL)PHENYL]AMINO}-9H- PURIN-2-YL)PHENYL]BENZAMIDE
2648, 2pe1A, 0.7513, 2.63, 0.269, 275, 249, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) {2-OXO-3-[1-(1H-PYRROL-2-YL)-ETH-(Z)-YLIDENE]-23-DIHYDRO-1H- INDOL-5-YL}-UREA {BX-517} COMPLEX
2649, 1uu8A, 0.7513, 2.67, 0.280, 277, 250, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-1
2650, 1h1wA, 0.7513, 2.80, 0.283, 284, 251, HIGH RESOLUTION CRYSTAL STRUCTURE OF THE HUMAN PDK1 CATALYTIC DOMAIN
2651, 5yu9D, 0.7512, 2.76, 0.209, 300, 249, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH IBRUTINIB
2652, 5p9kA, 0.7512, 2.89, 0.198, 271, 252, CRYSTAL STRUCTURE OF BTK WITH CNX 774
2653, 5o21A, 0.7512, 2.65, 0.246, 272, 248, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED STATE WITH CHLORIDE BOUND IN THE ACTIVE SITE
2654, 5lvpC, 0.7512, 2.80, 0.279, 275, 251, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH AN HM-PEPTIDE BOUND TO THE PIF-POCKET
2655, 5ebzI, 0.7512, 3.29, 0.238, 655, 260, CRYSTAL STRUCTURE OF HUMAN IKK1
2656, 5av3A, 0.7512, 2.66, 0.275, 275, 247, CRYSTAL STRUCTURE OF DAPK1-KAEMPFEROL COMPLEX IN THE PRESENCE OF IODIDE IONS.
2657, 5ar2B, 0.7512, 2.96, 0.211, 285, 256, RIP2 KINASE CATALYTIC DOMAIN (1 - 310)
2658, 4qmyA, 0.7512, 3.01, 0.277, 287, 253, MST3 IN COMPLEX WITH STAUROSPORINE
2659, 3nuyA, 0.7512, 2.57, 0.278, 276, 248, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT17
2660, 3nczA, 0.7512, 3.16, 0.264, 399, 258, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT 2H-ISOQUINOLIN-1-ONE INHIBITOR
2661, 5x2cB, 0.7511, 2.79, 0.207, 303, 251, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R IN COMPLEX WITH SKLB(5)
2662, 5o21B, 0.7511, 2.74, 0.245, 273, 249, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED STATE WITH CHLORIDE BOUND IN THE ACTIVE SITE
2663, 5av0A, 0.7511, 2.66, 0.275, 275, 247, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH 73 4 - TRIHYDROXYISOFLAVONE.
2664, 4eqmA, 0.7511, 2.38, 0.250, 269, 244, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
2665, 3nrmA, 0.7511, 2.66, 0.306, 263, 248, IMIDAZO[12-A]PYRAZINE-BASED AURORA KINASE INHIBITORS
2666, 3ehaA, 0.7511, 2.68, 0.271, 279, 247, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE COMPLEXED WITH AMPPNP
2667, 6ccyA, 0.7510, 2.80, 0.283, 325, 251, CRYSTAL STRUCTURE OF AKT1 IN COMPLEX WITH A SELECTIVE INHIBITOR 
2668, 6babA, 0.7510, 2.82, 0.308, 290, 250, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2669, 5kksA, 0.7510, 3.03, 0.267, 395, 255, ROCK 1 BOUND TO AZAINDOLE THIOZOLE INHIBITOR
2670, 4eqmB, 0.7510, 2.39, 0.250, 269, 244, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
2671, 3orzC, 0.7510, 2.77, 0.288, 276, 250, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
2672, 3f5gA, 0.7510, 2.58, 0.272, 279, 246, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE IN COMPLEX WITH ADP AND MG2+
2673, 6aywB, 0.7509, 2.91, 0.299, 293, 251, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2674, 5hngA, 0.7509, 2.61, 0.265, 280, 249, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
2675, 4zjjB, 0.7509, 2.80, 0.286, 277, 252, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
2676, 4qmoA, 0.7509, 2.86, 0.274, 288, 252, MST3 IN COMPLEX WITH IMIDAZOLO-OXINDOLE PKR INHIBITOR C16
2677, 4jajA, 0.7509, 2.71, 0.302, 265, 248, CRYSTAL STRUCTURE OF AURORA KINASE A IN COMPLEX WITH BENZO[C][1 8]NAPHTHYRIDIN-6(5H)-ONE
2678, 3qcsA, 0.7509, 2.55, 0.274, 276, 248, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-[2- AMINO-6-(4-MORPHOLINYL)-4-PYRIMIDINYL]-1H-INDAZOL-3-AMINE
2679, 3orzA, 0.7509, 2.78, 0.288, 276, 250, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
2680, 2etkA, 0.7509, 3.09, 0.262, 400, 256, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO HYDROXYFASUDIL
2681, 5u7qC, 0.7508, 3.06, 0.267, 390, 255, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
2682, 5nttA, 0.7508, 2.96, 0.295, 276, 254, CRYSTAL STRUCTURE OF HUMAN MPS1 (TTK) C604Y MUTANT IN COMPLEX WITH NMS-P715
2683, 5lvnA, 0.7508, 2.86, 0.283, 283, 251, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ADENOSINE BOUND TO THE ATP- BINDING SITE
2684, 5ebzL, 0.7508, 3.22, 0.238, 655, 260, CRYSTAL STRUCTURE OF HUMAN IKK1
2685, 5dh3A, 0.7508, 2.98, 0.294, 287, 255, CRYSTAL STRUCTURE OF MST2 IN COMPLEX WITH XMU-MP-1
2686, 4zseB, 0.7508, 2.77, 0.208, 313, 250, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
2687, 4nzwB, 0.7508, 2.34, 0.278, 266, 245, CRYSTAL STRUCTURE OF STK25-MO25 COMPLEX
2688, 3qcxA, 0.7508, 2.57, 0.270, 276, 248, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-{2- AMINO-6-[(3R)-3-METHYL-4-MORPHOLINYL]-4-PYRIMIDINYL}-1H-INDAZOL-3- AMINE
2689, 3qc9C, 0.7508, 3.08, 0.255, 482, 255, CRYSTAL STRUCTURE OF CROSS-LINKED BOVINE GRK1 T8C/N480C DOUBLE MUTANT COMPLEXED WITH ADP AND MG
2690, 5jrsA, 0.7507, 2.63, 0.202, 258, 247, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH 4-[2-FLUORO-3-(4-OXO -34-DIHYDROQUINAZOLIN-3-YL) PHENYL]-7-(2-HYDROXYPROPAN-2-Y L)-9H-CARBAZOLE-1-CARBOXAMIDE
2691, 5j87C, 0.7507, 2.86, 0.199, 261, 251, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
2692, 4qmxA, 0.7507, 2.89, 0.275, 287, 251, MST3 IN COMPLEX WITH SARACATINIB
2693, 4nttB, 0.7507, 2.99, 0.272, 339, 254, STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE BOUND TO ADP AND ONE MAGNESIUM ION
2694, 4eqmC, 0.7507, 2.39, 0.250, 269, 244, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
2695, 3pwyA, 0.7507, 2.80, 0.291, 281, 251, CRYSTAL STRUCTURE OF AN EXTENDER (SPD28345)-MODIFIED HUMAN PDK1 COMPLEX 2
2696, 5x2fC, 0.7506, 2.66, 0.210, 302, 248, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R IN COMPLEX WITH SKLB(6)
2697, 5x2cA, 0.7506, 2.70, 0.209, 304, 249, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R IN COMPLEX WITH SKLB(5)
2698, 5h9bA, 0.7506, 2.67, 0.320, 269, 247, DROSOPHILA CAMKII-WT IN COMPLEX WITH A FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/AMPPN
2699, 4ra4A, 0.7506, 2.74, 0.263, 317, 251, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE C ALPHA IN COMPLEX WITH COMPOUND 28 ((R)-6-((3S4S)-13-DIMETHYL-PIPERIDIN-4-YL)-7-(2-FLUORO- PHENYL)-4-METHYL-210-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
2700, 2x4zA, 0.7506, 2.98, 0.265, 290, 253, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH PF-03758309
2701, 1q8wA, 0.7506, 2.79, 0.275, 334, 251, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH RHO-KINASE INHIBITOR FASUDIL (HA-1077)
2702, 5wnhD, 0.7505, 3.16, 0.266, 397, 256, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
2703, 5ortA, 0.7505, 2.71, 0.302, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2704, 5lxmA, 0.7505, 2.70, 0.296, 266, 247, CRYSTAL STRUCTURE OF AURORA-A BOUND TO A HYDROCARBON-STAPLED PROTEOMIMETIC OF TPX2
2705, 5av1A, 0.7505, 2.67, 0.271, 275, 247, CRYSTAL STRUCTURE OF DAPK1 IN THE PRESENCE OF BROMIDE IONS.
2706, 4qmsA, 0.7504, 2.94, 0.278, 283, 252, MST3 IN COMPLEX WITH DASATINIB
2707, 3rcjA, 0.7504, 2.82, 0.287, 281, 251, RAPID PREPARATION OF TRIAZOLYL SUBSTITUTED NH-HETEROCYCLIC KINASE INHIBITORS VIA ONE-POT SONOGASHIRA COUPLING TMS-DEPROTECTION CUAAC SEQUENCE
2708, 6es0B, 0.7503, 2.90, 0.231, 287, 255, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH THE ACTIVATION LOOP TARGETING INHIBITOR CS-R35
2709, 4w8dA, 0.7503, 2.75, 0.272, 289, 250, CRYSTAL STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF- 06454589).
2710, 4w7pC, 0.7503, 3.10, 0.259, 383, 255, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO YB-15-QD37
2711, 4w7pB, 0.7503, 3.20, 0.261, 387, 257, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO YB-15-QD37
2712, 3lm0A, 0.7503, 2.78, 0.224, 278, 250, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE 17B (STK17B)
2713, 2rfeB, 0.7503, 2.50, 0.224, 273, 246, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE EGFR KINASE DOMAIN AND A MIG6 PEPTIDE
2714, 5wnfA, 0.7502, 3.06, 0.262, 395, 256, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
2715, 5fg8A, 0.7502, 2.67, 0.320, 269, 247, DROSOPHILA CAMKII-WT IN COMPLEX WITH A FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/ADP
2716, 5ackA, 0.7502, 2.88, 0.283, 286, 251, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND 7 BOUND TO THE PIF-POCKET
2717, 3dbeA, 0.7502, 2.70, 0.273, 284, 249, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH COMPOUND 557
2718, 3belA, 0.7502, 2.68, 0.218, 280, 248, X-RAY STRUCTURE OF EGFR IN COMPLEX WITH OXIME INHIBITOR
2719, 2ozoA, 0.7502, 2.80, 0.228, 545, 250, AUTOINHIBITED INTACT HUMAN ZAP-70
2720, 2oi4X, 0.7502, 2.53, 0.263, 275, 247, CRYSTAL STRUCTURE OF HUMAN PIM1 IN COMPLEX WITH FLUORINATED RUTHENIUM PYRIDOCARBAZOLE
2721, 5av2A, 0.7501, 2.67, 0.271, 275, 247, CRYSTAL STRUCTURE OF DAPK1-KAEMPFEROL COMPLEX IN THE PRESENCE OF BROMIDE IONS.
2722, 5auyA, 0.7501, 2.66, 0.275, 275, 247, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH MORIN.
2723, 4qmmA, 0.7501, 2.89, 0.274, 288, 252, MST3 IN COMPLEX WITH AT-9283 4-[(2-{4-[(CYCLOPROPYLCARBAMOYL)AMINO]- 1H-PYRAZOL-3-YL}-1H-BENZIMIDAZOL-6-YL)METHYL]MORPHOLIN-4-IUM
2724, 2bujA, 0.7501, 2.69, 0.242, 291, 248, CRYSTAL STRUCTURE OF THE HUMAN SERINE-THREONINE KINASE 16 IN COMPLEX WITH STAUROSPORINE
2725, 1yrpB, 0.7501, 2.49, 0.269, 275, 245, CATALYTIC DOMAIN OF HUMAN ZIP KINASE PHOSPHORYLATED AT THR265
2726, 1yrpA, 0.7501, 2.49, 0.269, 275, 245, CATALYTIC DOMAIN OF HUMAN ZIP KINASE PHOSPHORYLATED AT THR265
2727, 1ol7A, 0.7501, 2.73, 0.306, 261, 248, STRUCTURE OF HUMAN AURORA-A 122-403 PHOSPHORYLATED ON THR287 THR288
2728, 5uuuA, 0.7500, 3.17, 0.270, 414, 256, DESIGN SYNTHESIS AND EVALUATION OF THE FIRST SELECTIVE AND POTENT G- PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2) INHIBITOR FOR THE POTENTIAL TREATMENT OF HEART FAILURE
2729, 4zlzA, 0.7500, 2.86, 0.199, 270, 251, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE IN COMPLEX WITH A SUBSTITUTED CINNOLINE
2730, 4nwmB, 0.7500, 2.79, 0.200, 261, 250, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-809959 AKA 4-TERT-BUTYL-N-[2-ME THYL-3-(6-{[4- (MORPHOLINE-4-CARBONYL)PHENYL]AMINO}-9H- PURIN-2-YL)PHENYL]BENZAMIDE
2731, 3uo5A, 0.7500, 2.85, 0.304, 267, 250, AURORA A IN COMPLEX WITH YL1-038-31
2732, 3kexA, 0.7500, 2.89, 0.194, 292, 253, CRYSTAL STRUCTURE OF THE CATALYTICALLY INACTIVE KINASE DOMAIN OF THE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3)
2733, 2o64A, 0.7500, 2.59, 0.263, 274, 247, CRYSTAL STRUCTURE OF PIM1 WITH QUERCETAGETIN
2734, 5u7rB, 0.7499, 3.06, 0.271, 387, 255, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
2735, 4o0sA, 0.7499, 2.77, 0.305, 265, 249, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
2736, 4d28C, 0.7499, 2.84, 0.317, 279, 252, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.11 AT5G35410
2737, 4cegA, 0.7498, 2.74, 0.302, 264, 248, CRYSTAL STRUCTURE OF AURORA A 122-403 C290A C393A BOUND TO ADP
2738, 2h8hA, 0.7498, 2.87, 0.239, 444, 251, SRC KINASE IN COMPLEX WITH A QUINAZOLINE INHIBITOR
2739, 1uu9A, 0.7498, 2.70, 0.280, 276, 250, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-3
2740, 5x2fA, 0.7497, 2.86, 0.204, 301, 250, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R IN COMPLEX WITH SKLB(6)
2741, 4i24B, 0.7497, 2.80, 0.212, 304, 250, STRUCTURE OF T790M EGFR KINASE DOMAIN CO-CRYSTALLIZED WITH DACOMITINIB
2742, 4fr4B, 0.7497, 3.05, 0.241, 350, 257, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE 32A (YANK1)
2743, 3ckxA, 0.7497, 2.86, 0.279, 276, 251, CRYSTAL STRUCTURE OF STERILE 20-LIKE KINASE 3 (MST3 STK24) IN COMPLEX WITH STAUROSPORINE
2744, 5n4vA, 0.7496, 2.49, 0.268, 273, 246, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUSPEPTIDE AND FRAGMENT LIKE MOLEKULE 2-CYCLOPROPYL-45- DIMETHYLTHIENO[54-D]PYRIMIDINE-6-CARBOXYLIC ACID
2745, 5hvuA, 0.7496, 3.03, 0.263, 394, 255, RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH A PYRIDINE THIAZOLE PIPERIDINE INHIBITOR
2746, 5ebzC, 0.7496, 3.30, 0.238, 655, 261, CRYSTAL STRUCTURE OF HUMAN IKK1
2747, 4deeA, 0.7496, 2.80, 0.301, 271, 249, AURORA A IN COMPLEX WITH ADP
2748, 1szmA, 0.7496, 2.83, 0.279, 317, 251, DUAL BINDING MODE OF BISINDOLYLMALEIMIDE 2 TO PROTEIN KINASE A (PKA)
2749, 1kswA, 0.7496, 2.97, 0.246, 449, 252, STRUCTURE OF HUMAN C-SRC TYROSINE KINASE (THR338GLY MUTANT) IN COMPLEX WITH N6-BENZYL ADP
2750, 5yu9C, 0.7495, 2.79, 0.217, 306, 249, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH IBRUTINIB
2751, 5he1A, 0.7495, 3.15, 0.271, 618, 255, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224062
2752, 4dawA, 0.7495, 2.87, 0.304, 293, 253, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH THE RUTHENIUM PHTHALIMIDE COMPLEX
2753, 3c4zA, 0.7495, 3.06, 0.267, 493, 255, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ADP AND MAGNESIUM CHLORIDE AT 1.84A
2754, 5ebzH, 0.7494, 3.28, 0.238, 655, 260, CRYSTAL STRUCTURE OF HUMAN IKK1
2755, 3orxG, 0.7494, 2.64, 0.277, 274, 249, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2756, 2xuuA, 0.7494, 2.83, 0.268, 301, 250, CRYSTAL STRUCTURE OF A DAP-KINASE 1 MUTANT
2757, 2esmA, 0.7494, 3.10, 0.262, 400, 256, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO FASUDIL
2758, 6gttA, 0.7493, 2.56, 0.321, 282, 249, HUMAN STK10 BOUND TO BIRB-796 
2759, 5lvlA, 0.7493, 2.88, 0.283, 285, 251, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH COMPOUND PS653 BOUND TO THE ATP-BINDING SITE
2760, 4mblA, 0.7493, 2.56, 0.263, 274, 247, DISCOVERY OF PYRAZOLO[15A]PYRIMIDINE-BASED PIM1 INHIBITORS
2761, 4jx7A, 0.7493, 2.57, 0.267, 274, 247, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH INHIBITOR 2-[(TRANS- 4-AMINOCYCLOHEXYL)AMINO]-4-{[3-(TRIFLUOROMETHYL) PHENYL]AMINO}PYRIDO[43-D]PYRIMIDIN-5(6H)-ONE
2762, 4jx3A, 0.7493, 2.55, 0.267, 274, 247, CRYSTAL STRUCTURE OF PIM1 KINASE
2763, 3cxwA, 0.7493, 2.57, 0.267, 272, 247, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A BETA CARBOLINE LIGAND I
2764, 6babD, 0.7492, 2.85, 0.312, 291, 250, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2765, 5v82A, 0.7492, 2.56, 0.267, 273, 247, PIM1 KINASE IN COMPLEX WITH CPD17 (1-(6-(44-DIFLUOROPIPERIDIN-3-YL) PYRIDIN-2-YL)-6-(6-METHYLPYRAZIN-2-YL)-1H-PYRAZOLO[43-C]PYRIDINE)
2766, 5u7qA, 0.7492, 3.10, 0.267, 388, 255, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
2767, 5objA, 0.7492, 2.76, 0.304, 260, 247, AURORA A KINASE IN COMPLEX WITH 2-(3-FLUOROPHENYL)QUINOLINE-4- CARBOXYLIC ACID AND ATP
2768, 5d41B, 0.7492, 2.81, 0.208, 302, 250, EGFR KINASE DOMAIN IN COMPLEX WITH MUTANT SELECTIVE ALLOSTERIC INHIBITOR
2769, 4xx9A, 0.7492, 2.88, 0.283, 288, 251, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RF4
2770, 4tnbA, 0.7492, 3.15, 0.281, 529, 256, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 5 IN COMPLEX WITH SANGIVAMYCIN
2771, 3vc4A, 0.7492, 2.62, 0.263, 274, 247, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2772, 3orxH, 0.7492, 2.65, 0.277, 274, 249, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2773, 3db6A, 0.7492, 2.80, 0.278, 287, 252, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH COMPOUND 902
2774, 2bzhB, 0.7492, 2.54, 0.263, 275, 247, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU1
2775, 6cz3A, 0.7491, 2.59, 0.261, 262, 249, STRUCTURE OF THE PTK6 KINASE DOMAIN BOUND TO A TYPE I INHIBITOR (3- FLUORO-4-{[6-METHYL-3-(1H-PYRAZOL-4-YL)IMIDAZO[1;2-A]PYRAZIN-8- YL]AMINO}PHENYL)(MORPHOLIN-4-YL)METHANONE 
2776, 6b16B, 0.7491, 2.73, 0.306, 281, 252, P21-ACTIVATED KINASE 1 IN COMPLEX WITH A 4-AZAINDOLE INHIBITOR
2777, 5p9iA, 0.7491, 2.91, 0.198, 271, 252, BTK1 SOAKED WITH IBRUTINIB-REV
2778, 5he2A, 0.7491, 3.14, 0.267, 628, 255, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224406
2779, 4yhjB, 0.7491, 3.10, 0.275, 490, 255, STRUCTURE AND FUNCTION OF THE HYPERTENSION VARIANT A486V OF G PROTEIN- COUPLED RECEPTOR KINASE 4 (GRK4)
2780, 4rqvA, 0.7491, 2.88, 0.283, 288, 251, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RS2
2781, 3orxE, 0.7491, 2.65, 0.277, 274, 249, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2782, 5uzjB, 0.7490, 2.93, 0.272, 386, 254, CRYSTAL STRUCTURE OF ROCK1 BOUND TO AN AMINOPYRIDINE INHIBITOR
2783, 5ntjA, 0.7490, 2.97, 0.277, 346, 253, CRYSTAL STRUCTURE OF THE PROTEIN-KINASE A CATALYTIC SUBUNIT FROM CRITECULUS GRISEUS IN COMPLEX WITH COMPOUND RKP032 
2784, 5ebzJ, 0.7490, 3.27, 0.235, 655, 260, CRYSTAL STRUCTURE OF HUMAN IKK1
2785, 5ebzE, 0.7490, 3.25, 0.238, 655, 260, CRYSTAL STRUCTURE OF HUMAN IKK1
2786, 5auxA, 0.7490, 2.64, 0.276, 275, 246, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH KAEMPFEROL.
2787, 4rqkA, 0.7490, 2.87, 0.283, 285, 251, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RS1
2788, 4k11A, 0.7490, 2.90, 0.243, 447, 251, THE STRUCTURE OF 1NA IN COMPLEX WITH SRC T338G
2789, 3r04A, 0.7490, 2.52, 0.264, 271, 246, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
2790, 3a8wB, 0.7490, 2.65, 0.288, 327, 250, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
2791, 2acxB, 0.7490, 2.99, 0.287, 492, 254, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 6 BOUND TO AMPPNP
2792, 5gtyH, 0.7489, 2.78, 0.217, 300, 249, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
2793, 5auvA, 0.7489, 2.72, 0.275, 275, 247, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH APIGENIN.
2794, 4wrsA, 0.7489, 2.52, 0.268, 273, 246, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH AN AZASPIRO PYRAZINYL-INDAZOLE INHIBITOR.
2795, 4qmpA, 0.7489, 2.90, 0.274, 289, 252, MST3 IN COMPLEX WITH CDK1/2 INHIBITOR III 5-AMINO-3-{[4- (AMINOSULFONYL)PHENYL]AMINO}-N-(26-DIFLUOROPHENYL)-1H-124- TRIAZOLE-1-CARBOTHIOAMIDE
2796, 4k0yA, 0.7489, 2.56, 0.267, 274, 247, STRUCTURE OF PIM-1 KINASE BOUND TO N-(4-FLUOROPHENYL)-7-HYDROXY-5- (PIPERIDIN-4-YL)PYRAZOLO[15-A]PYRIMIDINE-3-CARBOXAMIDE
2797, 3a8wA, 0.7489, 2.65, 0.296, 326, 250, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
2798, 2rfdB, 0.7489, 2.95, 0.202, 286, 253, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE EGFR KINASE DOMAIN AND A MIG6 PEPTIDE
2799, 2fumB, 0.7489, 2.36, 0.262, 262, 244, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
2800, 2etrA, 0.7489, 3.11, 0.262, 400, 256, CRYSTAL STRUCTURE OF ROCK I BOUND TO Y-27632
2801, 5os2A, 0.7488, 2.60, 0.306, 261, 245, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2802, 5o5mA, 0.7488, 2.78, 0.272, 336, 250, CRYSTAL STRUCTURE OF THE PROTEIN-KINASE A CATALYTIC SUBUNIT FROM CRITECULUS GRISEUS IN COMPLEX WITH COMPOUNDS RKP120 AND RKP117 
2803, 5m0uA, 0.7488, 2.71, 0.273, 346, 249, APOSTRUCTURE STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) FROM CHO CELLS WITH A PEPTIDIC INHIBITOR FRAGMENT 
2804, 5ebzK, 0.7488, 3.27, 0.238, 655, 260, CRYSTAL STRUCTURE OF HUMAN IKK1
2805, 4zseC, 0.7488, 2.69, 0.210, 301, 248, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
2806, 4apcA, 0.7488, 2.87, 0.257, 293, 249, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1)
2807, 3qd3A, 0.7488, 2.59, 0.270, 278, 248, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 11- DIMETHYLETHYL {(3R6S)-1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4- PYRIMIDINYL]-6-METHYL-3-PIPERIDINYL}CARBAMATE
2808, 3pp0B, 0.7488, 2.88, 0.213, 296, 253, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN HER2 (ERBB2).
2809, 2xj0A, 0.7488, 2.61, 0.267, 274, 247, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-4 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
2810, 5lvoA, 0.7487, 2.88, 0.283, 285, 251, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PSE10 BOUND TO THE PIF-POCKET
2811, 4yuqA, 0.7487, 2.70, 0.301, 462, 246, CDPK1 FROM EIMERIA TENELLA IN COMPLEX WITH INHIBITOR UW1354
2812, 3orxF, 0.7487, 2.65, 0.277, 274, 249, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2813, 3jpvA, 0.7487, 2.51, 0.268, 273, 246, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A PYRROLO[23- A]CARBAZOLE LIGAND
2814, 3hrfA, 0.7487, 2.91, 0.283, 284, 251, CRYSTAL STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH AN ALLOSTERIC ACTIVATOR BOUND TO THE PIF-POCKET
2815, 5uwdA, 0.7486, 2.55, 0.211, 271, 246, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN (L858R T790M V948R) IN COMPLEX WITH THE COVALENT INHIBITOR CO-1686
2816, 5ebzF, 0.7486, 3.29, 0.238, 655, 260, CRYSTAL STRUCTURE OF HUMAN IKK1
2817, 5ar8B, 0.7486, 2.65, 0.229, 274, 249, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIPHENYLSULFONAMIDE
2818, 4w7pD, 0.7486, 3.20, 0.256, 387, 258, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO YB-15-QD37
2819, 3uohB, 0.7486, 2.45, 0.311, 264, 244, AURORA A IN COMPLEX WITH RPM1722
2820, 3uohA, 0.7486, 2.45, 0.311, 264, 244, AURORA A IN COMPLEX WITH RPM1722
2821, 3r00A, 0.7486, 2.62, 0.263, 274, 247, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
2822, 1qcfA, 0.7485, 2.90, 0.243, 449, 251, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH A SRC FAMILY- SELECTIVE TYROSINE KINASE INHIBITOR
2823, 6bskA, 0.7484, 2.52, 0.268, 273, 246, HUMAN PIM1 KINASE IN COMPLEX WITH COMPOUND 12B
2824, 5x2aA, 0.7484, 2.72, 0.202, 297, 248, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R IN COMPLEX WITH SKLB(3)
2825, 5dgzA, 0.7484, 2.51, 0.264, 273, 246, DISCOVERY OF 35-SUBSTITUTED 6-AZAINDAZOLES AS POTENT PAN-PIM INHIBITORS
2826, 5deyB, 0.7484, 2.78, 0.306, 281, 252, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND G-5555
2827, 4zseD, 0.7484, 2.84, 0.220, 297, 250, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
2828, 4a06A, 0.7484, 2.88, 0.287, 282, 251, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC ACTIVATOR PS114 BOUND TO THE PIF-POCKET
2829, 3vbqA, 0.7484, 2.54, 0.264, 271, 246, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2830, 3d9vA, 0.7484, 3.13, 0.262, 400, 256, CRYSTAL STRUCTURE OF ROCK I BOUND TO H-1152P A DI- METHYLATED VARIANT OF FASUDIL
2831, 2gs7A, 0.7484, 2.70, 0.222, 281, 248, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
2832, 2f2uA, 0.7484, 3.19, 0.265, 386, 257, CRYSTAL STRUCTURE OF THE RHO-KINASE KINASE DOMAIN
2833, 5wnhA, 0.7483, 3.09, 0.262, 394, 256, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
2834, 5u9dA, 0.7483, 2.92, 0.198, 271, 252, DISCOVERY OF A POTENT BTK INHIBITOR WITH A NOVEL BINDING MODE USING PARALLEL SELECTIONS WITH A DNA-ENCODED CHEMICAL LIBRARY
2835, 5ipjA, 0.7483, 2.53, 0.268, 273, 246, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A QUINAZOLINONE-PYRROLOPYRROLONE INHIBITOR.
2836, 4qnaA, 0.7483, 2.93, 0.275, 284, 251, MST3 IN COMPLEX WITH 2-(46-DIAMINO-135-TRIAZIN-2-YL)PHENOL
2837, 4b4lA, 0.7483, 2.85, 0.268, 299, 250, CRYSTAL STRUCTURE OF AN ARD DAP-KINASE 1 MUTANT
2838, 3qcyA, 0.7483, 2.58, 0.283, 275, 247, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 4-[2- AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4-PYRIMIDINYL]-N-PHENYL-2- MORPHOLINECARBOXAMIDE
2839, 3pvwA, 0.7483, 3.09, 0.267, 613, 255, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND A SELECTIVE KINASE INHIBITOR (CMPD103A)
2840, 4w7pA, 0.7482, 3.22, 0.256, 388, 258, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO YB-15-QD37
2841, 4rerA, 0.7482, 2.62, 0.316, 458, 247, CRYSTAL STRUCTURE OF THE PHOSPHORYLATED HUMAN ALPHA1 BETA2 GAMMA1 HOLO-AMPK COMPLEX BOUND TO AMP AND CYCLODEXTRIN
2842, 4bn1A, 0.7482, 2.55, 0.298, 261, 245, CRYSTAL STRUCTURE OF V174M MUTANT OF AURORA-A KINASE
2843, 4alvA, 0.7482, 2.61, 0.263, 274, 247, BENZOFUROPYRIMIDINONE INHIBITORS OF PIM-1
2844, 3r01A, 0.7482, 2.62, 0.263, 274, 247, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
2845, 3c4eD, 0.7482, 2.54, 0.264, 273, 246, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
2846, 5v80A, 0.7481, 2.52, 0.268, 273, 246, PIM1 KINASE IN COMPLEX WITH CPD1 (1-METHYL-4-(3-(6-(PIPERAZIN-1-YL) PYRIDIN-2-YL)-1H-PYRAZOLO[3;4-C]PYRIDIN-5-YL)PIPERAZIN-2-ONE) 
2847, 5kgdA, 0.7481, 2.52, 0.268, 273, 246, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 2-PYRIDIN-3-YL-1~{H}- BENZIMIDAZOLE
2848, 5ebzB, 0.7481, 3.28, 0.238, 655, 260, CRYSTAL STRUCTURE OF HUMAN IKK1
2849, 5ebzA, 0.7481, 3.32, 0.245, 655, 261, CRYSTAL STRUCTURE OF HUMAN IKK1
2850, 4rrvA, 0.7481, 2.90, 0.283, 283, 251, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND PIFTIDE
2851, 4mbiA, 0.7481, 2.59, 0.263, 274, 247, DISCOVERY OF PYRAZOLO[15A]PYRIMIDINE-BASED PIM1 INHIBITORS
2852, 4deaA, 0.7481, 2.84, 0.304, 266, 250, AURORA A IN COMPLEX WITH YL1-038-18
2853, 4ct2A, 0.7481, 2.84, 0.292, 277, 250, HUMAN PDK1-PKCZETA KINASE CHIMERA
2854, 3vbtA, 0.7481, 2.54, 0.264, 267, 246, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2855, 3qf9A, 0.7481, 2.53, 0.268, 274, 246, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A FURAN- THIAZOLIDINEDIONE LIGAND
2856, 5n4uA, 0.7480, 2.52, 0.264, 272, 246, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUSPEPTIDE AND FRAGMENT LIKE MOLEKULE 5-(2-AMINO-13-THIAZOL-4- YL)-13-DIHYDROBENZIMIDAZOL-2-ONE
2857, 5j7bB, 0.7480, 2.79, 0.230, 281, 252, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE GSK583 COMPLEX
2858, 5dylA, 0.7480, 2.83, 0.271, 802, 251, CRYSTAL STRUCTURE OF PVX_084705
2859, 4wt6A, 0.7480, 2.53, 0.264, 273, 246, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A THIADIAZOLAMINE-INDOLE INHIBITOR.
2860, 3c0gA, 0.7480, 3.12, 0.290, 309, 252, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P1 FORM
2861, 1yxxA, 0.7480, 2.62, 0.263, 274, 247, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH (3E)-3-[(4- HYDROXYPHENYL)IMINO]-1H-INDOL-2(3H)-ONE
2862, 5vjaC, 0.7479, 2.64, 0.285, 265, 246, CRYSTAL STRUCTURE OF HUMAN ZIPPER-INTERACTING PROTEIN KINASE (ZIPK; ALIAS DAPK3) IN COMPLEX WITH A PYRAZOLO[3;4-D]PYRIMIDINONE LIGAND (HS38) 
2863, 5diaA, 0.7479, 2.54, 0.264, 273, 246, PIM1 IN COMPLEX WITH CPD36 ((1S3S)-N1-(6-(5-(PYRIDIN-3-YL)-1H- PYRAZOLO[34-C]PYRIDIN-3-YL)PYRIDIN-2-YL)CYCLOHEXANE-13-DIAMINE)
2864, 4gw8A, 0.7479, 2.53, 0.268, 273, 246, HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND LEUCETTINE L41
2865, 3vbvA, 0.7479, 2.55, 0.264, 268, 246, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2866, 1xqzA, 0.7479, 2.68, 0.270, 277, 248, CRYSTAL STRUCTURE OF HPIM-1 KINASE AT 2.1 A RESOLUTION
2867, 6cz2A, 0.7478, 2.60, 0.261, 261, 249, STRUCTURE OF THE PTK6 KINASE DOMAIN 
2868, 6aywA, 0.7478, 2.93, 0.299, 293, 251, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2869, 5o23B, 0.7478, 2.79, 0.240, 278, 250, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED APO STATE
2870, 5dhjA, 0.7478, 2.52, 0.268, 273, 246, PIM1 IN COMPLEX WITH CPD4 (3-METHYL-5-(PYRIDIN-3-YL)-1H-PYRAZOLO[34- C]PYRIDINE)
2871, 4ty1A, 0.7478, 2.53, 0.268, 273, 246, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH AN AMINOOXADIAZOLE-INDOLE INHIBITOR.
2872, 3lm5A, 0.7478, 2.67, 0.234, 274, 248, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE 17B (STK17B) IN COMPLEX WITH QUERCETIN
2873, 5telA, 0.7477, 2.62, 0.263, 273, 247, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
2874, 5auwA, 0.7477, 2.67, 0.276, 274, 246, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH QUERCETIN.
2875, 4yveA, 0.7477, 3.07, 0.263, 390, 255, ROCK 1 BOUND TO METHOXYPHENYL THIAZOLE INHIBITOR
2876, 4pnkA, 0.7477, 3.16, 0.271, 625, 255, G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH GSK180736A
2877, 3r02A, 0.7477, 2.54, 0.264, 271, 246, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
2878, 3hrcA, 0.7477, 2.90, 0.283, 279, 251, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ATP
2879, 2o3pA, 0.7477, 2.62, 0.263, 274, 247, CRYSTAL STRUCTURE OF PIM1 WITH QUERCETIN
2880, 2j2iB, 0.7477, 2.51, 0.268, 273, 246, CRYSTAL STRUCTURE OF THE HUMAB PIM1 IN COMPLEX WITH LY333531
2881, 2fumA, 0.7477, 2.37, 0.275, 263, 244, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
2882, 5uvcA, 0.7476, 3.11, 0.267, 457, 255, DESIGN SYNTHESIS AND EVALUATION OF THE FIRST SELECTIVE AND POTENT G- PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2) INHIBITOR FOR THE POTENTIAL TREATMENT OF HEART FAILURE
2883, 5n4zA, 0.7476, 2.53, 0.264, 272, 246, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUS PEPTIDE AND FRAGMENT LIKE MOLECULE (E)-4-(4-HYDROXYPHENYL)BUT-3-EN-2- ONE
2884, 4xh6A, 0.7476, 2.53, 0.268, 273, 246, CRYSTAL STRUCTURE OF PROTO-ONCOGENE KINASE PIM1 BOUND TO HISPIDULIN
2885, 4ct1A, 0.7476, 2.89, 0.287, 283, 251, HUMAN PDK1-PKCZETA KINASE CHIMERA IN COMPLEX WITH ALLOSTERIC COMPOUND PS315 BOUND TO THE PIF-POCKET
2886, 4aluA, 0.7476, 2.63, 0.263, 274, 247, BENZOFUROPYRIMIDINONE INHIBITORS OF PIM-1
2887, 3vbxA, 0.7476, 2.55, 0.264, 268, 246, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2888, 3uokA, 0.7476, 2.56, 0.302, 265, 245, AURORA A IN COMPLEX WITH YL5-81-1
2889, 3qc9D, 0.7476, 3.05, 0.268, 486, 254, CRYSTAL STRUCTURE OF CROSS-LINKED BOVINE GRK1 T8C/N480C DOUBLE MUTANT COMPLEXED WITH ADP AND MG
2890, 3qc9B, 0.7476, 3.05, 0.268, 481, 254, CRYSTAL STRUCTURE OF CROSS-LINKED BOVINE GRK1 T8C/N480C DOUBLE MUTANT COMPLEXED WITH ADP AND MG
2891, 3a7iA, 0.7476, 3.00, 0.278, 286, 252, HUMAN MST3 KINASE IN COMPLEX WITH ADENINE
2892, 3a62A, 0.7476, 2.25, 0.321, 263, 243, CRYSTAL STRUCTURE OF PHOSPHORYLATED P70S6K1
2893, 2bzjA, 0.7476, 2.52, 0.264, 273, 246, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU3
2894, 1yxvA, 0.7476, 2.64, 0.263, 274, 247, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH 34-DIHYDROXY-1- METHYLQUINOLIN-2(1H)-ONE
2895, 4wsyA, 0.7475, 2.54, 0.268, 273, 246, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A THIAZOLAMINE-INDAZOLE INHIBITOR.
2896, 4ll5A, 0.7475, 2.52, 0.268, 268, 246, CRYSTAL STRUCTURE OF PIM-1 IN COMPLEX WITH THE FLUORESCENT COMPOUND SKF86002
2897, 3vs3B, 0.7475, 2.54, 0.249, 431, 245, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[TRANS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)- 7H-PYRROLO[23-D]PYRIMIDIN-4-AMINE
2898, 3uolB, 0.7475, 2.43, 0.303, 263, 244, AURORA A IN COMPLEX WITH SO2-162
2899, 3uolA, 0.7475, 2.43, 0.303, 263, 244, AURORA A IN COMPLEX WITH SO2-162
2900, 3uokB, 0.7475, 2.56, 0.302, 265, 245, AURORA A IN COMPLEX WITH YL5-81-1
2901, 3qc9A, 0.7475, 3.05, 0.268, 486, 254, CRYSTAL STRUCTURE OF CROSS-LINKED BOVINE GRK1 T8C/N480C DOUBLE MUTANT COMPLEXED WITH ADP AND MG
2902, 1yxuC, 0.7475, 2.54, 0.264, 272, 246, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
2903, 1wvxA, 0.7475, 2.51, 0.265, 275, 245, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
2904, 5ndtA, 0.7474, 2.52, 0.268, 273, 246, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUS PEPTIDE AND FRAGMENT LIKE MOLECULE (E)-3-(2-(THIOPHEN-2-YL)VINYL)-3; 4-DIHYDROQUINOXALIN-2(1H)-ONE 
2905, 5n4rA, 0.7474, 2.53, 0.268, 273, 246, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUS PEPTIDE AND FRAGMENT LIKE MOLECULE 2-(AZEPAN-1-YL)-1-(1H-INDOL-3-YL) PROPAN-1-ONE
2906, 5lvpB, 0.7474, 2.80, 0.287, 276, 251, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH AN HM-PEPTIDE BOUND TO THE PIF-POCKET
2907, 5av4A, 0.7474, 2.67, 0.272, 274, 246, CRYSTAL STRUCTURE OF DAPK1-GENISTEIN COMPLEX IN THE PRESENCE OF BROMIDE IONS.
2908, 4alwA, 0.7474, 2.66, 0.263, 273, 247, BENZOFUROPYRIMIDINONE INHIBITORS OF PIM-1
2909, 3vbyA, 0.7474, 2.55, 0.264, 267, 246, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2910, 3tv6A, 0.7474, 2.71, 0.214, 268, 248, HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH A METHOXYPYRAZOLOPYRIDINYL BENZAMIDE INHIBITOR
2911, 3jxwA, 0.7474, 2.63, 0.263, 274, 247, DISCOVERY OF 3H-BENZO[45]THIENO[32-D]PYRIMIDIN-4-ONES AS POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS
2912, 3g51A, 0.7474, 2.32, 0.314, 280, 242, STRUCTURAL DIVERSITY OF THE ACTIVE CONFORMATION OF THE N- TERMINAL KINASE DOMAIN OF P90 RIBOSOMAL S6 KINASE 2
2913, 2rfeD, 0.7474, 2.61, 0.219, 278, 247, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE EGFR KINASE DOMAIN AND A MIG6 PEPTIDE
2914, 5kgeA, 0.7473, 2.54, 0.268, 273, 246, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 5-(34-DICHLOROPHENYL)- 1~{H}-PYRAZOL-3-AMINE
2915, 5eolA, 0.7473, 2.55, 0.268, 273, 246, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A MACROCYCLIC QUINOXALINE-PYRROLODIHYDROPIPERIDINONE INHIBITOR
2916, 5dykA, 0.7473, 2.90, 0.265, 809, 253, CRYSTAL STRUCTURE OF PF3D7_1436600
2917, 4mtaA, 0.7473, 2.55, 0.268, 273, 246, CRYSTAL STRUCTURE OF PIM-1 KINASE DOMAIN IN COMPLEX WITH 2-METHYL-5- PHENYLFURAN-3-CARBOXYLIC ACID
2918, 4m0yA, 0.7473, 2.83, 0.227, 263, 251, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 1 [4- (CARBAMOYLAMINO)-1-(NAPHTHALEN-1-YL)-1H-PYRAZOLE-3-CARBOXAMIDE]
2919, 4dtkA, 0.7473, 2.55, 0.268, 273, 246, NOVEL AND SELECTIVE PAN-PIM KINASE INHIBITOR
2920, 4at5A, 0.7473, 2.91, 0.231, 294, 255, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH GW2580
2921, 2bilB, 0.7473, 2.60, 0.267, 274, 247, THE HUMAN PROTEIN KINASE PIM1 IN COMPLEX WITH ITS CONSENSUS PEPTIDE PIMTIDE
2922, 5nclA, 0.7472, 3.02, 0.272, 418, 254, CRYSTAL STRUCTURE OF THE CBK1-MOB2 KINASE-COACTIVATOR COMPLEX WITH AN SSD1 PEPTIDE 
2923, 5ebzG, 0.7472, 3.29, 0.235, 655, 260, CRYSTAL STRUCTURE OF HUMAN IKK1
2924, 4m15A, 0.7472, 2.83, 0.227, 263, 251, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 9 [4- (CARBAMOYLAMINO)-1-[7-(PROPAN-2-YLOXY)NAPHTHALEN-1-YL]-1H-PYRAZOLE-3- CARBOXAMIDE] AND ADP
2925, 4as0A, 0.7472, 2.52, 0.268, 273, 246, CYCLOMETALATED PHTHALIMIDES AS PROTEIN KINASE INHIBITORS
2926, 1mq4A, 0.7472, 2.65, 0.305, 261, 246, CRYSTAL STRUCTURE OF AURORA-A PROTEIN KINASE
2927, 5n4xA, 0.7471, 2.54, 0.268, 272, 246, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUSPEPTIDE AND FRAGMENT LIKE MOLEKULE 45-DIBROMOTHIOPHENE-2- CARBOHYDRAZIDE
2928, 5kgiA, 0.7471, 2.54, 0.268, 273, 246, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR 2-[34-BIS(CHLORANYL) PHENOXY]ETHANAMINE
2929, 3jyaA, 0.7471, 2.65, 0.263, 274, 247, DISCOVERY OF 3H-BENZO[45]THIENO[32-D]PYRIMIDIN-4-ONES AS POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS
2930, 3c0gB, 0.7471, 3.13, 0.290, 320, 252, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P1 FORM
2931, 1yxuA, 0.7471, 2.54, 0.264, 273, 246, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
2932, 5xzvB, 0.7470, 2.25, 0.322, 371, 239, CRYSTAL STRUCTURE OF RAD53 1-466 IN COMPLEX WITH AMP-PNP
2933, 5vjaB, 0.7470, 2.77, 0.273, 266, 249, CRYSTAL STRUCTURE OF HUMAN ZIPPER-INTERACTING PROTEIN KINASE (ZIPK; ALIAS DAPK3) IN COMPLEX WITH A PYRAZOLO[3;4-D]PYRIMIDINONE LIGAND (HS38) 
2934, 5mrbA, 0.7470, 2.56, 0.306, 264, 248, CRYSTAL STRUCTURE OF HUMAN MPS1 (TTK) IN COMPLEX WITH CPD-5
2935, 4pp7A, 0.7470, 2.69, 0.214, 267, 248, HIGHLY POTENT AND SELECTIVE 3-N-METHYLQUINAZOLINE-4(3H)-ONE BASED INHIBITORS OF B-RAFV600E KINASE
2936, 4i6hA, 0.7470, 2.87, 0.250, 285, 252, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE ALPHA-SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
2937, 3t9tA, 0.7470, 2.88, 0.219, 263, 251, CRYSTAL STRUCTURE OF BTK MUTANT (F435TK596R) COMPLEXED WITH IMIDAZO[15-A]QUINOXALINE
2938, 1yxuB, 0.7470, 2.55, 0.264, 273, 246, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
2939, 5turA, 0.7469, 2.62, 0.267, 270, 247, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
2940, 5lvpA, 0.7469, 2.84, 0.283, 275, 251, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH AN HM-PEPTIDE BOUND TO THE PIF-POCKET
2941, 5lvmA, 0.7469, 2.91, 0.283, 283, 251, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ADENINE BOUND TO THE ATP- BINDING SITE
2942, 5kcxA, 0.7469, 2.57, 0.268, 272, 246, PIM-1 KINASE IN COMPLEX WITH A SELECTIVE N-SUBSTITUTED 7-AZAINDOLE INHIBITOR
2943, 5cnoA, 0.7469, 2.81, 0.221, 300, 249, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN MUTANT V924R
2944, 5bmlA, 0.7469, 3.04, 0.260, 393, 254, ROCK 1 BOUND TO A PYRIDINE THIAZOLE INHIBITOR
2945, 4zlyA, 0.7469, 2.89, 0.199, 270, 251, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE BOUND TO A CINNOLINE FRAGMENT
2946, 4n70A, 0.7469, 2.59, 0.268, 274, 246, PIM1 COMPLEXED WITH A PYRIDYLCARBOXAMIDE
2947, 4k18A, 0.7469, 2.58, 0.275, 277, 247, STRUCTURE OF PIM-1 KINASE BOUND TO 5-(4-CYANOBENZYL)-N-(4- FLUOROPHENYL)-7-HYDROXYPYRAZOLO[15-A]PYRIMIDINE-3-CARBOXAMIDE
2948, 4b9dA, 0.7469, 2.92, 0.257, 290, 249, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1) WITH INHIBITOR.
2949, 4aw0A, 0.7469, 2.88, 0.284, 283, 250, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PS182 BOUND TO THE PIF-POCKET
2950, 1jktB, 0.7469, 2.53, 0.260, 276, 246, TETRAGONAL CRYSTAL FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
2951, 5gtyG, 0.7468, 2.77, 0.214, 299, 248, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
2952, 5ar4B, 0.7468, 2.82, 0.226, 279, 252, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH SB-203580
2953, 4yvcA, 0.7468, 3.03, 0.256, 388, 254, ROCK 1 BOUND TO THIAZOLE INHIBITOR
2954, 4c57A, 0.7468, 3.05, 0.258, 310, 256, STRUCTURE OF GAK KINASE IN COMPLEX WITH A NANOBODY
2955, 3nayB, 0.7468, 2.84, 0.276, 278, 250, PDK1 IN COMPLEX WITH INHIBITOR MP6
2956, 2w5aA, 0.7468, 2.90, 0.285, 267, 253, HUMAN NEK2 KINASE ADP-BOUND
2957, 2ckeD, 0.7468, 2.89, 0.264, 300, 250, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
2958, 5x2aC, 0.7467, 2.60, 0.215, 303, 247, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R IN COMPLEX WITH SKLB(3)
2959, 5orlA, 0.7467, 2.70, 0.290, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2960, 5dwrA, 0.7467, 2.60, 0.264, 273, 246, IDENTIFICATION OF N-(4-((1R3S5S)-3-AMINO-5-METHYLCYCLOHEXYL)PYRIDIN- 3-YL)-6-(26-DIFLUOROPHENYL)-5-FLUOROPICOLINAMIDE (PIM447) A POTENT AND SELECTIVE PROVIRAL INSERTION SITE OF MOLONEY MURINE LEUKEMIA (PIM) 12 AND 3 KINASE INHIBITOR IN CLINICAL TRIALS FOR HEMATOLOGICAL MALIGNANCIES
2961, 4yuqB, 0.7467, 2.69, 0.310, 462, 245, CDPK1 FROM EIMERIA TENELLA IN COMPLEX WITH INHIBITOR UW1354
2962, 4cffC, 0.7467, 2.77, 0.290, 422, 248, STRUCTURE OF FULL LENGTH HUMAN AMPK IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR A THIENOPYRIDONE DERIVATIVE (A-769662)
2963, 4cfeC, 0.7467, 2.76, 0.290, 403, 248, STRUCTURE OF FULL LENGTH HUMAN AMPK IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR A BENZIMIDAZOLE DERIVATIVE (991)
2964, 3pvuA, 0.7467, 3.11, 0.267, 609, 255, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND A SELECTIVE KINASE INHIBITOR (CMPD101)
2965, 3cy2A, 0.7467, 2.58, 0.268, 271, 246, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A BETA CARBOLINE LIGAND II
2966, 1yxuD, 0.7467, 2.56, 0.264, 273, 246, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
2967, 5n50A, 0.7466, 2.54, 0.268, 273, 246, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUS PEPTIDE AND FRAGMENT LIKE MOLECULE 2-(4-CHLOROPHENYL) SULFANYLACETOHYDRAZIDE
2968, 5dt4A, 0.7466, 2.62, 0.306, 259, 245, AURORA A KINASE IN COMPLEX WITH AA35 AND ATP IN SPACE GROUP P6122
2969, 4zy6B, 0.7466, 2.81, 0.310, 280, 252, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
2970, 4wsqA, 0.7466, 2.74, 0.243, 317, 247, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2971, 4qmzA, 0.7466, 2.89, 0.279, 286, 251, MST3 IN COMPLEX WITH SUNITINIB
2972, 4qmuA, 0.7466, 2.91, 0.279, 286, 251, MST3 IN COMPLEX WITH JNJ-7706621 4-({5-AMINO-1-[(26-DIFLUOROPHENYL) CARBONYL]-1H-124-TRIAZOL-3-YL}AMINO)BENZENESULFONAMIDE
2973, 4l9iA, 0.7466, 3.22, 0.266, 504, 256, BOVINE G PROTEIN COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH PAROXETINE
2974, 3q52A, 0.7466, 2.85, 0.298, 292, 252, STRUCTURE OF PHOSPHORYLATED PAK1 KINASE DOMAIN
2975, 3cy3A, 0.7466, 2.50, 0.269, 270, 245, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND THE JNK INHIBITOR V
2976, 3c0hA, 0.7466, 3.13, 0.290, 300, 252, CASK CAM-KINASE DOMAIN- AMPPNP COMPLEX P1 FORM
2977, 2ckeC, 0.7466, 2.90, 0.264, 300, 250, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
2978, 2ckeA, 0.7466, 2.90, 0.264, 301, 250, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
2979, 5n4nA, 0.7465, 2.54, 0.268, 273, 246, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUS PEPTIDE AND FRAGMENT LIKE MOLECULE 34-DIMETHYL-5-(1H-124-TRIAZOL- 3-YL)THIOPHENE-2-CARBONITRILE
2980, 3uojB, 0.7465, 2.51, 0.307, 263, 244, AURORA A IN COMPLEX WITH RPM1715
2981, 3uojA, 0.7465, 2.51, 0.307, 263, 244, AURORA A IN COMPLEX WITH RPM1715
2982, 3nczD, 0.7465, 3.22, 0.264, 397, 258, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT 2H-ISOQUINOLIN-1-ONE INHIBITOR
2983, 2gs7B, 0.7465, 2.89, 0.212, 288, 250, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
2984, 1yxtA, 0.7465, 2.67, 0.263, 274, 247, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMPPNP
2985, 5n4yA, 0.7464, 2.55, 0.268, 273, 246, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUS PEPTIDE AND FRAGMENT LIKE MOLECULE 25-DIHYDRO-1H-ISOTHIOCHROMENO[3 4-D]PYRAZOL-3-ONE
2986, 5iisA, 0.7464, 2.52, 0.269, 273, 245, DESIGN SYNTHESIS AND STRUCTURE ACTIVITY RELATIONSHIP OF POTENT PAN- PIM KINASE INHIBITORS DERIVED FROM THE PYRIDYL-AMIDE SCAFFOLD
2987, 4n6zA, 0.7464, 2.53, 0.269, 272, 245, PIM1 COMPLEXED WITH A PYRIDYLCARBOXAMIDE
2988, 4i6bA, 0.7464, 2.95, 0.245, 285, 253, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
2989, 3uo6B, 0.7464, 2.48, 0.311, 264, 244, AURORA A IN COMPLEX WITH YL5-083
2990, 3uo6A, 0.7464, 2.48, 0.311, 264, 244, AURORA A IN COMPLEX WITH YL5-083
2991, 3c4eC, 0.7464, 2.55, 0.264, 272, 246, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
2992, 1yxsA, 0.7464, 2.64, 0.263, 274, 247, CRYSTAL STRUCTURE OF KINASE PIM1 WITH P123M MUTATION
2993, 6c2yA, 0.7463, 3.09, 0.269, 617, 253, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG257142 
2994, 5xzwB, 0.7463, 2.24, 0.326, 379, 239, CRYSTAL STRUCTURE OF RAD53 1-466
2995, 5kziA, 0.7463, 2.57, 0.264, 273, 246, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH AN IMIDAZOPYRIDAZINE INHIBITOR.
2996, 4qmvA, 0.7463, 2.88, 0.279, 288, 251, MST3 IN COMPLEX WITH PF-03814735 N-{2-[(1S4R)-6-{[4- (CYCLOBUTYLAMINO)-5-(TRIFLUOROMETHYL)PYRIMIDIN-2-YL]AMINO}-1234- TETRAHYDRO-14-EPIMINONAPHTHALEN-9-YL]-2-OXOETHYL}ACETAMIDE
2997, 4k1bA, 0.7463, 2.55, 0.268, 273, 246, STRUCTURE OF PIM-1 KINASE BOUND TO N-(5-(2-FLUOROPHENYL)-1H-PYRROLO[2 3-B]PYRIDIN-3-YL)-5-((((3R4R)-3-FLUOROPIPERIDIN-4-YL)METHYL)AMINO) PYRAZOLO[15-A]PYRIMIDINE-3-CARBOXAMIDE
2998, 3f2aA, 0.7463, 2.63, 0.267, 276, 247, CRYSTAL STRUCTURE OF HUMAN PIM-1 IN COMPLEX WITH DAPPA
2999, 2x4fB, 0.7463, 2.70, 0.278, 288, 248, THE CRYSTAL STRUCTURE OF THE HUMAN MYOSIN LIGHT CHAIN KINASE LOC340156.
3000, 2jiuB, 0.7463, 3.12, 0.180, 309, 256, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION IN COMPLEX WITH AEE788
3001, 4m13A, 0.7462, 2.88, 0.223, 264, 251, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 8 [4- (CARBAMOYLAMINO)-1-(7-PROPOXYNAPHTHALEN-1-YL)-1H-PYRAZOLE-3- CARBOXAMIDE]
3002, 4eqcA, 0.7462, 2.92, 0.308, 296, 253, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN IN COMPLEX WITH FRAX597 INHIBITOR
3003, 3uodA, 0.7462, 2.85, 0.305, 266, 249, AURORA A IN COMPLEX WITH RPM1693
3004, 3c4eA, 0.7461, 2.55, 0.264, 273, 246, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
3005, 1yhwA, 0.7461, 3.07, 0.298, 293, 255, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH ONE POINT MUTATIONS (K299R)
3006, 5li9A, 0.7460, 2.74, 0.293, 329, 249, STRUCTURE OF A NUCLEOTIDE-BOUND FORM OF PKCIOTA CORE KINASE DOMAIN
3007, 5ebzD, 0.7460, 3.40, 0.234, 655, 261, CRYSTAL STRUCTURE OF HUMAN IKK1
3008, 4yzbA, 0.7460, 2.71, 0.296, 466, 247, CDPK1 FROM EIMERIA TENELLA IN COMPLEX WITH INHIBITOR UW1521
3009, 3unzB, 0.7460, 2.48, 0.311, 263, 244, AURORA A IN COMPLEX WITH RPM1679
3010, 3unzA, 0.7460, 2.48, 0.311, 263, 244, AURORA A IN COMPLEX WITH RPM1679
3011, 3d14A, 0.7460, 2.36, 0.288, 262, 243, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240->ARG MET302- >LEU) IN COMPLEX WITH 1-{5-[2-(THIENO[32-D]PYRIMIDIN-4-YLAMINO)- ETHYL]- THIAZOL-2-YL}-3-(3-TRIFLUOROMETHYL-PHENYL)-UREA
3012, 3bwfA, 0.7460, 2.55, 0.264, 273, 246, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH AN OSMIUM COMPOUND
3013, 2yabB, 0.7460, 2.90, 0.280, 299, 250, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH AMP
3014, 2xizA, 0.7460, 2.60, 0.268, 273, 246, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-3 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
3015, 1ywvA, 0.7460, 2.64, 0.267, 274, 247, CRYSTAL STRUCTURES OF PROTO-ONCOGENE KINASE PIM1: A TARGET OF ABERRANT SOMATIC HYPERMUTATIONS IN DIFFUSE LARGE CELL LYMPHOMA
3016, 5isoC, 0.7459, 2.74, 0.290, 429, 248, STRUCTURE OF FULL LENGTH HUMAN AMPK (NON-PHOSPHORYLATED AT T-LOOP) IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR A BENZIMIDAZOLE DERIVATIVE (991)
3017, 5isoA, 0.7459, 2.69, 0.286, 453, 248, STRUCTURE OF FULL LENGTH HUMAN AMPK (NON-PHOSPHORYLATED AT T-LOOP) IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR A BENZIMIDAZOLE DERIVATIVE (991)
3018, 5auzA, 0.7459, 2.64, 0.278, 274, 245, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH GENISTEIN.
3019, 4cffA, 0.7459, 2.78, 0.290, 424, 248, STRUCTURE OF FULL LENGTH HUMAN AMPK IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR A THIENOPYRIDONE DERIVATIVE (A-769662)
3020, 3c0hB, 0.7459, 3.12, 0.290, 300, 252, CASK CAM-KINASE DOMAIN- AMPPNP COMPLEX P1 FORM
3021, 2xj2A, 0.7459, 2.61, 0.268, 273, 246, PROTEIN KINASE PIM-1 IN COMPLEX WITH SMALL MOLECULE INHIBITOR
3022, 2w1cA, 0.7459, 2.68, 0.304, 261, 247, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
3023, 1jktA, 0.7459, 2.71, 0.286, 276, 248, TETRAGONAL CRYSTAL FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
3024, 5toeA, 0.7458, 2.66, 0.267, 272, 247, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
3025, 4i6fA, 0.7458, 2.88, 0.246, 285, 252, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
3026, 4ae6A, 0.7458, 3.02, 0.276, 319, 254, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT CALPHA 2
3027, 2yaaB, 0.7458, 2.91, 0.276, 299, 250, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH ATP
3028, 2phkA, 0.7458, 2.73, 0.291, 277, 247, THE CRYSTAL STRUCTURE OF A PHOSPHORYLASE KINASE PEPTIDE SUBSTRATE COMPLEX: KINASE SUBSTRATE RECOGNITION
3029, 2o63A, 0.7458, 2.64, 0.263, 274, 247, CRYSTAL STRUCTURE OF PIM1 WITH MYRICETIN
3030, 5kgkA, 0.7457, 2.55, 0.268, 273, 246, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 3-(4-METHOXYPHENYL)-1~{H}- PYRAZOL-5-AMINE
3031, 3qd4A, 0.7457, 2.56, 0.276, 276, 246, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 11- DIMETHYLETHYL{(3R5R)-1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4- PYRIMIDINYL]-5-METHYL-3-PIPERIDINYL}CARBAMATE
3032, 3q5iA, 0.7457, 2.77, 0.312, 470, 247, CRYSTAL STRUCTURE OF PBANKA_031420
3033, 3nayA, 0.7457, 2.84, 0.276, 278, 250, PDK1 IN COMPLEX WITH INHIBITOR MP6
3034, 3kexB, 0.7457, 2.84, 0.195, 283, 251, CRYSTAL STRUCTURE OF THE CATALYTICALLY INACTIVE KINASE DOMAIN OF THE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3)
3035, 2a2aA, 0.7457, 2.91, 0.264, 304, 250, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
3036, 1eh4A, 0.7457, 3.06, 0.188, 293, 255, BINARY COMPLEX OF CASEIN KINASE-1 FROM S. POMBE WITH AN ATP COMPETITIVE INHIBITOR IC261
3037, 5vuaB, 0.7456, 2.52, 0.265, 270, 245, PIM1 KINASE IN COMPLEX WITH A BENZOFURANONE INHIBITOR
3038, 5auuA, 0.7456, 2.65, 0.265, 274, 245, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH LUTEOLIN.
3039, 4qmnA, 0.7456, 2.91, 0.279, 283, 251, MST3 IN COMPLEX WITH BOSUTINIB
3040, 4mbjA, 0.7456, 2.83, 0.209, 269, 249, HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH AN IMIDAZOPYRIDINE-BASED INHIBITOR
3041, 4btjA, 0.7456, 3.27, 0.191, 292, 256, TTBK1 IN COMPLEX WITH ATP
3042, 3bgzA, 0.7456, 2.52, 0.269, 267, 245, HUMAN PIM-1 KINASE IN COMPLEX WITH DIPHENYL INDOLE INHIBITOR VX3
3043, 2yaaA, 0.7456, 2.90, 0.272, 300, 250, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH ATP
3044, 6cpfA, 0.7455, 2.43, 0.300, 259, 243, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO AMPPCP IN AN ACTIVE CONFORMATION 
3045, 6b1uA, 0.7455, 2.79, 0.286, 441, 248, STRUCTURE OF FULL-LENGTH HUMAN AMPK (A2B1G1) IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR SC4 
3046, 4i5pA, 0.7455, 2.89, 0.246, 284, 252, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
3047, 3up2A, 0.7455, 2.79, 0.305, 266, 249, AURORA A IN COMPLEX WITH RPM1686
3048, 3qd0A, 0.7455, 2.59, 0.285, 274, 246, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH (2R5S)- 1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4-PYRIMIDINYL]-6-METHYL-N- PHENYL-3-PIPERIDINECARBOXAMIDE
3049, 6g4zA, 0.7454, 2.79, 0.249, 322, 249, CRYSTAL STRUCTURE OF HUMAN NF-KAPPAB INDUCING KINASE (NIK) IN COMPLEX WITH COMPOUND 2F 
3050, 5c1qB, 0.7454, 2.54, 0.272, 273, 246, SERINE/THREONINE-PROTEIN KINASE PIM-1
3051, 4xhkB, 0.7454, 2.52, 0.269, 269, 245, PIM1 KINASE IN COMPLEX WITH COMPOUND 1S
3052, 3u4wA, 0.7454, 2.97, 0.254, 275, 252, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC4B
3053, 3c4eB, 0.7454, 2.57, 0.264, 273, 246, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
3054, 2yabA, 0.7454, 2.91, 0.272, 299, 250, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH AMP
3055, 2xj1A, 0.7454, 2.62, 0.268, 273, 246, PROTEIN KINASE PIM-1 IN COMPLEX WITH SMALL MOLECULE INIBITOR
3056, 2jiuA, 0.7454, 2.91, 0.215, 303, 251, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION IN COMPLEX WITH AEE788
3057, 1yhvA, 0.7454, 3.07, 0.298, 293, 255, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH TWO POINT MUTATIONS (K299R T423E)
3058, 6fu5B, 0.7453, 2.80, 0.206, 286, 252, STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH THE INHIBITOR CSLP18 
3059, 5n5lA, 0.7453, 2.52, 0.269, 271, 245, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUSPEPTIDE AND [2-OXO-2-(1H-PYRROL-2-YL)ETHYL] 5-BROMO-1H- INDOLE-3-CARBOXYLATE
3060, 5he3A, 0.7453, 3.19, 0.267, 623, 255, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224411
3061, 5drdA, 0.7453, 2.68, 0.306, 259, 245, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P6122
3062, 2ckeB, 0.7453, 2.94, 0.264, 300, 250, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
3063, 2a2aD, 0.7453, 2.90, 0.264, 303, 250, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
3064, 5t18A, 0.7452, 2.80, 0.202, 261, 248, CRYSTAL STRUCTURE OF BRUTON AGAMMABULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-986142 AKA (2S)-6-FLUORO-5-[3-(8-FLUORO-1-METHYL-24-DIOXO- 1234-TETRAHYDROQUINAZOLIN-3-YL)-2-METHYLPHENYL]-2-(2- HYDROXYPROPAN-2-YL)-2349-TETRAHYDRO-1H-CARBAZOLE-8-CARBOXAMIDE
3065, 5o91A, 0.7452, 2.66, 0.300, 266, 250, CRYSTAL STRUCTURE OF HUMAN MPS1 (TTK) C604W MUTANT IN COMPLEX WITH CPD-5
3066, 5fetA, 0.7452, 2.88, 0.271, 802, 251, CRYSTAL STRUCTURE OF PVX_084705 IN PRESENCE OF COMPOUND 2
3067, 4qmlA, 0.7452, 2.82, 0.269, 280, 249, MST3 IN COMPLEX WITH AMP-PNP
3068, 4i94B, 0.7452, 2.94, 0.167, 297, 252, STRUCTURE OF BSK8 IN COMPLEX WITH AMP-PNP
3069, 4e4xA, 0.7452, 2.86, 0.209, 267, 249, CRYSTAL STRUCTURE OF B-RAF KINASE DOMAIN IN COMPLEX WITH A DIHYDROPYRIDO[23-D]PYRIMIDINONE-BASED INHIBITOR
3070, 4btjB, 0.7452, 3.12, 0.191, 293, 256, TTBK1 IN COMPLEX WITH ATP
3071, 2xiyA, 0.7452, 2.63, 0.268, 273, 246, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-2 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
3072, 2a2aC, 0.7452, 2.92, 0.264, 303, 250, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
3073, 1cmkE, 0.7452, 2.89, 0.278, 348, 252, CRYSTAL STRUCTURES OF THE MYRISTYLATED CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE REVEAL OPEN AND CLOSED CONFORMATIONS
3074, 4cfeA, 0.7451, 2.78, 0.290, 425, 248, STRUCTURE OF FULL LENGTH HUMAN AMPK IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR A BENZIMIDAZOLE DERIVATIVE (991)
3075, 3nczC, 0.7451, 3.16, 0.266, 389, 256, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT 2H-ISOQUINOLIN-1-ONE INHIBITOR
3076, 3m11A, 0.7451, 2.49, 0.309, 256, 243, CRYSTAL STRUCTURE OF AURORA A KINASE COMPLEXED WITH INHIBITOR
3077, 3dj7A, 0.7451, 2.43, 0.300, 257, 243, CRYSTAL STRUCTURE OF THE MOUSE AURORA-A CATALYTIC DOMAIN (ASN186->GLY LYS240->ARG MET302->LEU) IN COMPLEX WITH COMPOUND 130.
3078, 3bgqA, 0.7451, 2.55, 0.269, 272, 245, HUMAN PIM-1 KINASE IN COMPLEX WITH AN TRIAZOLO PYRIDAZINE INHIBITOR VX2
3079, 6aydA, 0.7450, 2.55, 0.268, 272, 246, PIM1 COMPLEXED WITH N-(6-(4-HYDROXYPHENYL)-1H-INDAZOL-3-YL) CYCLOPROPANECARBOXAMIDE
3080, 5hvuB, 0.7450, 2.81, 0.271, 394, 251, RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH A PYRIDINE THIAZOLE PIPERIDINE INHIBITOR
3081, 4n6yA, 0.7450, 2.50, 0.269, 273, 245, PIM1 COMPLEXED WITH A PHENYLCARBOXAMIDE
3082, 4bzoA, 0.7450, 2.54, 0.269, 272, 245, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH A PYRROLO- PYRAZINONE INHIBITOR
3083, 4bznA, 0.7450, 2.54, 0.265, 272, 245, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH A PYRROLO(12-A) PYRAZINONE INHIBITOR
3084, 4at3A, 0.7450, 3.08, 0.230, 289, 256, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH CPD5N
3085, 4wsqB, 0.7449, 2.75, 0.243, 310, 247, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
3086, 4qmqA, 0.7449, 2.95, 0.274, 289, 252, MST3 IN COMPLEX WITH CP-673451
3087, 5vjaA, 0.7448, 2.75, 0.270, 266, 248, CRYSTAL STRUCTURE OF HUMAN ZIPPER-INTERACTING PROTEIN KINASE (ZIPK; ALIAS DAPK3) IN COMPLEX WITH A PYRAZOLO[3;4-D]PYRIMIDINONE LIGAND (HS38) 
3088, 5eymB, 0.7448, 2.42, 0.258, 292, 244, MEK1 IN COMPLEX WITH BI 847325
3089, 4m0zA, 0.7448, 2.87, 0.227, 264, 251, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 5 {4- (CARBAMOYLAMINO)-1-(7-METHOXYNAPHTHALEN-1-YL)-1H-PYRAZOLE-3- CARBOXAMIDE}
3090, 4a7cA, 0.7448, 2.53, 0.269, 273, 245, CRYSTAL STRUCTURE OF PIM1 KINASE WITH ETP46546
3091, 1z9xB, 0.7448, 2.93, 0.268, 303, 250, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 3 MONOMERS IN THE ASYMMETRIC UNIT
3092, 5uzjA, 0.7447, 3.05, 0.260, 387, 254, CRYSTAL STRUCTURE OF ROCK1 BOUND TO AN AMINOPYRIDINE INHIBITOR
3093, 5eymA, 0.7447, 2.43, 0.258, 292, 244, MEK1 IN COMPLEX WITH BI 847325
3094, 5dosA, 0.7447, 2.65, 0.306, 259, 245, AURORA A KINASE IN COMPLEX WITH AA35 AND ATP IN SPACE GROUP P6122
3095, 5dfpA, 0.7447, 2.93, 0.308, 292, 253, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND FRAX1036
3096, 4m12A, 0.7447, 2.91, 0.223, 264, 251, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 7 [4- (CARBAMOYLAMINO)-1-(7-ETHOXYNAPHTHALEN-1-YL)-1H-PYRAZOLE-3- CARBOXAMIDE]
3097, 4i92A, 0.7447, 2.93, 0.170, 289, 253, STRUCTURE OF THE BSK8 KINASE DOMAIN
3098, 4c57B, 0.7447, 3.09, 0.262, 308, 256, STRUCTURE OF GAK KINASE IN COMPLEX WITH A NANOBODY
3099, 2vz6A, 0.7447, 2.92, 0.309, 291, 249, STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE TYPE II ALPHA (CAMK2A) IN COMPLEX WITH INDIRUBIN E804
3100, 1z9xA, 0.7447, 2.93, 0.268, 303, 250, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 3 MONOMERS IN THE ASYMMETRIC UNIT
3101, 4jbpA, 0.7446, 2.46, 0.300, 255, 243, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
3102, 2bcjA, 0.7446, 3.18, 0.267, 624, 255, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH GALPHA-Q AND GBETAGAMMA SUBUNITS
3103, 5kggA, 0.7445, 2.59, 0.268, 273, 246, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 2-(5-CHLORANYL-1~{H}-INDOL- 3-YL)ETHANAMINE
3104, 4txcA, 0.7445, 2.74, 0.263, 276, 247, CRYSTAL STRUCTURE OF DAPK1 KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
3105, 3lijA, 0.7445, 2.77, 0.325, 465, 246, CRYSTAL STRUCTURE OF FULL LENGTH CPCDPK3 (CGD5_820) IN COMPLEX WITH CA2+ AND AMPPNP
3106, 2dwbA, 0.7445, 2.66, 0.310, 259, 245, AURORA-A KINASE COMPLEXED WITH AMPPNP
3107, 5n5mA, 0.7444, 2.52, 0.269, 272, 245, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUSPEPTIDE AND (R)-3-(2-((ISOQUINOLIN-5-YLMETHYL)(METHYL) CARBAMOYL)PHENYL)PYRROLIDIN-1-IUM
3108, 5gtyA, 0.7444, 2.79, 0.217, 300, 249, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
3109, 4zhxA, 0.7444, 2.81, 0.286, 408, 248, NOVEL BINDING SITE FOR ALLOSTERIC ACTIVATION OF AMPK
3110, 4a07A, 0.7444, 2.88, 0.284, 282, 250, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC ACTIVATOR PS171 BOUND TO THE PIF-POCKET
3111, 3mfuA, 0.7444, 3.08, 0.287, 302, 251, CASK-4M CAM KINASE DOMAIN AMPPNP-MN2+
3112, 4ysjB, 0.7443, 2.74, 0.311, 462, 244, CALCIUM-DEPENDENT PROTEIN KINASE FROM EIMERIA TENELLA IN COMPLEX WITH ADP
3113, 4qmtA, 0.7443, 2.96, 0.279, 284, 251, MST3 IN COMPLEX WITH HESPERADIN
3114, 2o65A, 0.7443, 2.65, 0.263, 274, 247, CRYSTAL STRUCTURE OF PIM1 WITH PENTAHYDROXYFLAVONE
3115, 1ad5A, 0.7443, 2.53, 0.234, 437, 244, SRC FAMILY KINASE HCK-AMP-PNP COMPLEX
3116, 5texA, 0.7442, 2.68, 0.267, 274, 247, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
3117, 5gtyD, 0.7442, 2.79, 0.214, 297, 248, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
3118, 4fl3A, 0.7442, 2.46, 0.216, 538, 245, STRUCTURAL AND BIOPHYSICAL CHARACTERIZATION OF THE SYK ACTIVATION SWITCH
3119, 3r21A, 0.7442, 2.59, 0.306, 254, 245, DESIGN SYNTHESIS AND BIOLOGICAL EVALUATION OF PYRAZOLOPYRIDINE- SULFONAMIDES AS POTENT MULTIPLE-MITOTIC KINASE (MMK) INHIBITORS (PART I)
3120, 3bgpA, 0.7442, 2.54, 0.269, 272, 245, HUMAN PIM-1 COMPLEXED WITH A BENZOISOXAZOLE INHIBITOR VX1
3121, 2objA, 0.7442, 2.55, 0.269, 272, 245, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH INHIBITOR
3122, 5dewB, 0.7441, 2.84, 0.310, 281, 252, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND 5
3123, 4rpvA, 0.7441, 2.56, 0.272, 273, 246, CO-CRYSTAL STRUCTURE OF PIM1 WITH COMPOUND 3
3124, 4rc4A, 0.7441, 2.54, 0.269, 272, 245, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
3125, 4lm5A, 0.7441, 2.56, 0.265, 264, 245, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH 2-{4-[(3-AMINOPROPYL) AMINO]QUINAZOLIN-2-YL}PHENOL (RESULTING FROM DISPLACEMENT OF SKF86002)
3126, 4btmB, 0.7441, 3.02, 0.184, 293, 255, TTBK1 IN COMPLEX WITH INHIBITOR
3127, 3we8A, 0.7441, 2.59, 0.264, 273, 246, PIM-1 KINASE IN COMPLEX WITH RUTHENIUM-BASED INHIBITOR
3128, 3f69B, 0.7441, 2.62, 0.269, 282, 245, CRYSTAL STRUCTURE OF THE MYCOBACTERIUM TUBERCULOSIS PKNB MUTANT KINASE DOMAIN IN COMPLEX WITH KT5720
3129, 2wtkB, 0.7441, 2.89, 0.241, 311, 253, STRUCTURE OF THE HETEROTRIMERIC LKB1-STRADALPHA-MO25ALPHA COMPLEX
3130, 4o0tB, 0.7440, 2.89, 0.302, 280, 252, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
3131, 3mftA, 0.7440, 3.12, 0.294, 302, 252, CASK-4M CAM KINASE DOMAIN MN2+
3132, 3cikA, 0.7440, 3.20, 0.267, 619, 255, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS
3133, 1xwsA, 0.7440, 2.56, 0.268, 273, 246, CRYSTAL STRUCTURE OF THE HUMAN PIM1 KINASE DOMAIN
3134, 5yu9B, 0.7439, 2.79, 0.211, 295, 247, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH IBRUTINIB
3135, 5autA, 0.7439, 2.65, 0.269, 274, 245, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH ANS.
3136, 3twjD, 0.7439, 3.02, 0.261, 395, 253, RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1447
3137, 3dcvA, 0.7439, 2.57, 0.269, 273, 245, CRYSTAL STRUCTURE OF HUMAN PIM1 KINASE COMPLEXED WITH 4-(4- HYDROXY-3-METHYL-PHENYL)-6-PHENYLPYRIMIDIN-2(1H)-ONE
3138, 2yakA, 0.7439, 2.71, 0.267, 277, 247, STRUCTURE OF DEATH-ASSOCIATED PROTEIN KINASE 1 (DAPK1) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OSV)
3139, 2w4kA, 0.7438, 2.96, 0.268, 301, 250, X-RAY STRUCTURE OF A DAP-KINASE 2-302
3140, 2f57B, 0.7438, 3.16, 0.281, 299, 253, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 5
3141, 5ugaA, 0.7437, 2.87, 0.213, 283, 249, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN (L858R T790M V948R) IN COMPLEX WITH 4-(4-{[2-{[(3S)-1-ACETYLPYRROLIDIN-3-YL]AMINO}-9- (PROPAN-2-YL)-9H-PURIN-6-YL]AMINO}PHENYL)-1-METHYLPIPERAZIN-1-IUM
3142, 5gtyE, 0.7437, 2.80, 0.214, 297, 248, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
3143, 3lmgA, 0.7437, 2.63, 0.206, 268, 247, CRYSTAL STRUCTURE OF THE ERBB3 KINASE DOMAIN IN COMPLEX WITH AMP-PNP
3144, 2w5bA, 0.7437, 3.07, 0.282, 271, 255, HUMAN NEK2 KINASE ATPGAMMAS-BOUND
3145, 2clqA, 0.7437, 2.88, 0.291, 263, 247, STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 2 5
3146, 2bziB, 0.7437, 2.54, 0.265, 272, 245, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU2
3147, 4zhxC, 0.7436, 2.79, 0.286, 452, 248, NOVEL BINDING SITE FOR ALLOSTERIC ACTIVATION OF AMPK
3148, 3d2iA, 0.7436, 2.44, 0.300, 255, 243, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240- >ARG MET302->LEU) IN COMPLEX WITH 1-{5-[2-(1-METHYL-1H- PYRAZOLO[43-D]PYRIMIDIN-7-YLAMINO)-ETHYL]-THIAZOL-2-YL}-3- (3-TRIFLUOROMETHYL-PHENYL)-UREA
3149, 2wtkC, 0.7436, 2.98, 0.277, 285, 253, STRUCTURE OF THE HETEROTRIMERIC LKB1-STRADALPHA-MO25ALPHA COMPLEX
3150, 6g4yA, 0.7435, 2.80, 0.249, 322, 249, CRYSTAL STRUCTURE OF HUMAN NF-KAPPAB INDUCING KINASE (NIK) IN COMPLEX WITH COMPOUND 1A 
3151, 5mrdA, 0.7435, 2.95, 0.283, 283, 251, HUMAN PDK1-PKCIOTA KINASE CHIMERA IN COMPLEX WITH ALLOSTERIC COMPOUND PS267 BOUND TO THE PIF-POCKET
3152, 4o0rA, 0.7435, 3.01, 0.296, 293, 253, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
3153, 4i21B, 0.7435, 3.28, 0.202, 302, 257, CRYSTAL STRUCTURE OF L858R + T790M EGFR KINASE DOMAIN IN COMPLEX WITH MIG6 PEPTIDE
3154, 4btmA, 0.7435, 3.21, 0.192, 292, 255, TTBK1 IN COMPLEX WITH INHIBITOR
3155, 1ad5B, 0.7435, 2.54, 0.234, 437, 244, SRC FAMILY KINASE HCK-AMP-PNP COMPLEX
3156, 6gt1C, 0.7434, 2.46, 0.324, 257, 241, NEK7 BOUND TO PURINE INHIBITOR 
3157, 4q2aA, 0.7434, 2.90, 0.253, 271, 249, WNK1: A CHLORIDE SENSOR VIA AUTOPHOSPHORYLATION
3158, 4lmuA, 0.7434, 2.57, 0.273, 265, 245, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH THE INHIBITOR QUERCETIN (RESULTING FROM DISPLACEMENT OF SKF86002)
3159, 4enxA, 0.7434, 2.51, 0.266, 266, 244, CRYSTAL STRUCTURE OF PIM-1 KINASE IN COMPLEX WITH INHIBITOR (2E5Z)-2- (2-CHLOROPHENYLIMINO)-5-(4-HYDROXY-3-NITROBENZYLIDENE)THIAZOLIDIN-4- ONE
3160, 3nyxA, 0.7434, 3.10, 0.222, 287, 252, NON-PHOSPHORYLATED TYK2 JH1 DOMAIN WITH QUINOLINE-THIADIAZOLE- THIOPHENE INHIBITOR
3161, 2a2aB, 0.7434, 2.96, 0.264, 303, 250, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
3162, 6b1uC, 0.7433, 2.79, 0.286, 459, 248, STRUCTURE OF FULL-LENGTH HUMAN AMPK (A2B1G1) IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR SC4 
3163, 5yu9A, 0.7433, 2.64, 0.215, 302, 247, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH IBRUTINIB
3164, 4j8nC, 0.7433, 2.78, 0.302, 266, 248, AURORA A KINASE APO
3165, 4j8nB, 0.7433, 2.78, 0.302, 266, 248, AURORA A KINASE APO
3166, 4i41A, 0.7433, 2.55, 0.269, 272, 245, CRYSTAL STRUCTURE OF HUMAN SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE
3167, 4eheA, 0.7433, 2.65, 0.215, 266, 246, B-RAF KINASE DOMAIN IN COMPLEX WITH AN AMINOTHIENOPYRIMIDINE-BASED INHIBITOR
3168, 1yhsA, 0.7433, 2.51, 0.270, 267, 244, CRYSTAL STRUCTURE OF PIM-1 BOUND TO STAUROSPORINE
3169, 6g4zB, 0.7432, 2.77, 0.250, 325, 248, CRYSTAL STRUCTURE OF HUMAN NF-KAPPAB INDUCING KINASE (NIK) IN COMPLEX WITH COMPOUND 2F 
3170, 5dr9A, 0.7432, 2.53, 0.307, 257, 244, AURORA A KINASE IN COMPLEX WITH AA29 AND JNJ-7706621 IN SPACE GROUP P6122
3171, 5bmmA, 0.7432, 2.90, 0.244, 275, 250, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC25B
3172, 3c0iA, 0.7432, 3.18, 0.283, 298, 251, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P212121 FORM
3173, 2wtkE, 0.7432, 2.89, 0.246, 308, 252, STRUCTURE OF THE HETEROTRIMERIC LKB1-STRADALPHA-MO25ALPHA COMPLEX
3174, 6g4yB, 0.7431, 2.80, 0.249, 328, 249, CRYSTAL STRUCTURE OF HUMAN NF-KAPPAB INDUCING KINASE (NIK) IN COMPLEX WITH COMPOUND 1A 
3175, 5gtyB, 0.7431, 2.94, 0.208, 299, 250, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
3176, 5ezvA, 0.7431, 2.77, 0.279, 441, 247, X-RAY CRYSTAL STRUCTURE OF AMP-ACTIVATED PROTEIN KINASE ALPHA-2/ALPHA- 1 RIM CHIMAERA (ALPHA-2(1-347)/ALPHA-1(349-401)/ALPHA-2(397-END) BETA-1 GAMMA-1) CO-CRYSTALLIZED WITH C2 (5-(5-HYDROXYL-ISOXAZOL-3- YL)-FURAN-2-PHOSPHONIC ACID)
3177, 4yhjA, 0.7431, 3.18, 0.275, 501, 255, STRUCTURE AND FUNCTION OF THE HYPERTENSION VARIANT A486V OF G PROTEIN- COUPLED RECEPTOR KINASE 4 (GRK4)
3178, 4rc2A, 0.7431, 2.57, 0.269, 272, 245, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
3179, 4j8nD, 0.7431, 2.78, 0.302, 265, 248, AURORA A KINASE APO
3180, 4j8nA, 0.7431, 2.78, 0.302, 266, 248, AURORA A KINASE APO
3181, 2wzjB, 0.7431, 2.89, 0.305, 310, 249, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
3182, 1j3hB, 0.7431, 2.83, 0.275, 327, 251, CRYSTAL STRUCTURE OF APOENZYME CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
3183, 4tndA, 0.7430, 3.23, 0.281, 529, 256, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 5 IN COMPLEX WITH AMP-PNP
3184, 4debA, 0.7430, 2.77, 0.306, 264, 248, AURORA A IN COMPLEX WITH RK2-17-01
3185, 2x6dA, 0.7430, 2.62, 0.299, 255, 244, AURORA-A BOUND TO AN INHIBITOR
3186, 1ctpE, 0.7430, 2.93, 0.282, 332, 252, STRUCTURE OF THE MAMMALIAN CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE AND AN INHIBITOR PEPTIDE DISPLAYS AN OPEN CONFORMATION
3187, 3gt8C, 0.7429, 2.85, 0.210, 296, 248, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
3188, 2xixA, 0.7429, 2.62, 0.269, 272, 245, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-1 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
3189, 5fbnC, 0.7428, 2.70, 0.198, 256, 247, BTK KINASE DOMAIN WITH INHIBITOR 1
3190, 5drbA, 0.7428, 2.90, 0.253, 273, 249, CRYSTAL STRUCTURE OF WNK1 IN COMPLEX WITH WNK463
3191, 5ar7B, 0.7428, 2.84, 0.219, 278, 251, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIARYL UREA
3192, 4ysjA, 0.7428, 2.77, 0.316, 459, 244, CALCIUM-DEPENDENT PROTEIN KINASE FROM EIMERIA TENELLA IN COMPLEX WITH ADP
3193, 4i94A, 0.7428, 3.13, 0.165, 297, 254, STRUCTURE OF BSK8 IN COMPLEX WITH AMP-PNP
3194, 4dn5A, 0.7428, 2.78, 0.262, 331, 248, CRYSTAL STRUCTURE OF NF-KB-INDUCING KINASE (NIK)
3195, 3vs3A, 0.7428, 2.54, 0.251, 434, 243, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[TRANS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)- 7H-PYRROLO[23-D]PYRIMIDIN-4-AMINE
3196, 2hckA, 0.7428, 2.55, 0.234, 437, 244, SRC FAMILY KINASE HCK-QUERCETIN COMPLEX
3197, 4rgjA, 0.7427, 2.82, 0.308, 463, 250, APO CRYSTAL STRUCTURE OF CDPK4 FROM PLASMODIUM FALCIPARUM PF3D7_0717500
3198, 4qmwA, 0.7427, 2.97, 0.279, 286, 251, MST3 IN COMPLEX WITH PP-121 1-CYCLOPENTYL-3-(1H-PYRROLO[23- B]PYRIDIN-5-YL)-1H-PYRAZOLO[34-D]PYRIMIDIN-4-AMINE
3199, 3vs4A, 0.7427, 2.58, 0.250, 429, 244, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 5-(4-PHENOXYPHENYL)-7-(TETRAHYDRO-2H-PYRAN-4-YL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
3200, 5vucB, 0.7426, 2.54, 0.266, 269, 244, PIM1 KINASE IN COMPLEX WITH A BENZOFURANONE INHIBITOR
3201, 4m14A, 0.7426, 2.80, 0.228, 263, 250, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 9 [4- (CARBAMOYLAMINO)-1-[7-(PROPAN-2-YLOXY)NAPHTHALEN-1-YL]-1H-PYRAZOLE-3- CARBOXAMIDE]
3202, 4dhfA, 0.7426, 2.71, 0.306, 258, 245, STRUCTURE OF AURORA A MUTANT BOUND TO BIOGENIDEC CPD 15
3203, 3gt8B, 0.7426, 2.83, 0.198, 292, 247, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
3204, 5vubB, 0.7425, 2.54, 0.266, 269, 244, PIM1 KINASE IN COMPLEX WITH A BENZOFURANONE INHIBITOR
3205, 4tl0A, 0.7425, 2.96, 0.272, 300, 250, CRYSTAL STRUCTURE OF DEATH-ASSOCIATED PROTEIN KINASE 1 WITH A CRUCIAL PHOSPHOMIMICKING MUTATION
3206, 4nttA, 0.7425, 3.09, 0.272, 339, 254, STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE BOUND TO ADP AND ONE MAGNESIUM ION
3207, 1xr1A, 0.7425, 2.70, 0.267, 277, 247, CRYSTAL STRUCTURE OF HPIM-1 KINASE IN COMPLEX WITH AMP-PNP AT 2.1 A RESOLUTION
3208, 5u94A, 0.7424, 2.54, 0.257, 263, 245, CRYSTAL STRUCTURE OF THE MYCOBACTERIUM TUBERCULOSIS PASTA KINASE PKNB IN COMPLEX WITH THE POTENTIAL THERAPUTIC KINASE INHIBITOR GSK690693.
3209, 5bmmB, 0.7424, 2.90, 0.244, 275, 250, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC25B
3210, 4o0wA, 0.7424, 2.61, 0.302, 259, 245, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
3211, 4ejnA, 0.7424, 2.79, 0.278, 376, 248, CRYSTAL STRUCTURE OF AUTOINHIBITED FORM OF AKT1 IN COMPLEX WITH N-(4- (5-(3-ACETAMIDOPHENYL)-2-(2-AMINOPYRIDIN-3-YL)-3H-IMIDAZO[45- B]PYRIDIN-3-YL)BENZYL)-3-FLUOROBENZAMIDE
3212, 3zhpC, 0.7424, 3.08, 0.272, 272, 254, HUMAN MST3 (STK24) IN COMPLEX WITH MO25BETA
3213, 2ya9A, 0.7424, 2.96, 0.276, 299, 250, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2
3214, 1yi3A, 0.7424, 2.52, 0.270, 267, 244, CRYSTAL STRUCTURE OF PIM-1 BOUND TO LY294002
3215, 6e4tA, 0.7423, 2.84, 0.310, 361, 248, STRUCTURE OF AMPK BOUND TO ACTIVATOR 
3216, 5t5tA, 0.7423, 2.83, 0.306, 368, 248, AMPK BOUND TO ALLOSTERIC ACTIVATOR
3217, 5ar3A, 0.7423, 2.81, 0.219, 279, 251, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH AMP-PCP
3218, 4yzbB, 0.7423, 2.91, 0.296, 464, 247, CDPK1 FROM EIMERIA TENELLA IN COMPLEX WITH INHIBITOR UW1521
3219, 4rixC, 0.7423, 2.98, 0.194, 275, 252, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
3220, 4ae9A, 0.7423, 3.01, 0.277, 321, 253, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT C ALPHA 2
3221, 5dr6A, 0.7422, 2.56, 0.307, 257, 244, AURORA A KINASE IN COMPLEX WITH AA30 AND JNJ-7706621 IN SPACE GROUP P6122
3222, 4dhfB, 0.7422, 2.68, 0.310, 258, 245, STRUCTURE OF AURORA A MUTANT BOUND TO BIOGENIDEC CPD 15
3223, 3vs6B, 0.7422, 2.53, 0.251, 434, 243, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR TERT-BUTYL {4-[4-AMINO-1-(PROPAN-2-YL)-1H-PYRAZOLO[34- D]PYRIMIDIN-3-YL]-2-METHOXYPHENYL}CARBAMATE
3224, 3h0zA, 0.7422, 2.26, 0.300, 248, 240, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
3225, 6e4wA, 0.7421, 2.84, 0.310, 361, 248, STRUCTURE OF AMPK BOUND TO ACTIVATOR 
3226, 6cpeA, 0.7421, 2.43, 0.298, 256, 242, STRUCTURE OF APO; DEPHOSPHORYLATED AURORA A (122-403) IN AN ACTIVE CONFORMATION 
3227, 5o13A, 0.7421, 2.53, 0.266, 270, 244, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL-MOLECULE INHIBITOR
3228, 5m53A, 0.7421, 2.21, 0.285, 255, 239, NEK2 BOUND TO ARYLAMINOPURINE INHIBITOR 11
3229, 3jy0A, 0.7421, 2.76, 0.263, 275, 247, DISCOVERY OF 3H-BENZO[45]THIENO[32-D]PYRIMIDIN-4-ONES AS POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS
3230, 2vz6B, 0.7421, 2.95, 0.312, 294, 250, STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE TYPE II ALPHA (CAMK2A) IN COMPLEX WITH INDIRUBIN E804
3231, 5vjaD, 0.7420, 2.68, 0.278, 261, 245, CRYSTAL STRUCTURE OF HUMAN ZIPPER-INTERACTING PROTEIN KINASE (ZIPK; ALIAS DAPK3) IN COMPLEX WITH A PYRAZOLO[3;4-D]PYRIMIDINONE LIGAND (HS38) 
3232, 4zs0A, 0.7420, 2.61, 0.309, 257, 243, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO SB-6-OH
3233, 4cfhA, 0.7420, 2.72, 0.316, 401, 247, STRUCTURE OF AN ACTIVE FORM OF MAMMALIAN AMPK
3234, 3mfsA, 0.7420, 3.01, 0.281, 303, 249, CASK-4M CAM KINASE DOMAIN AMPPNP
3235, 3lmgB, 0.7420, 2.66, 0.206, 268, 247, CRYSTAL STRUCTURE OF THE ERBB3 KINASE DOMAIN IN COMPLEX WITH AMP-PNP
3236, 3fxzA, 0.7420, 2.97, 0.308, 292, 253, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH RUTHENIUM COMPLEX LAMBDA-FL172
3237, 3fmeA, 0.7420, 2.99, 0.248, 268, 250, CRYSTAL STRUCTURE OF HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (MEK6) ACTIVATED MUTANT (S207D T211D)
3238, 5wnhC, 0.7419, 3.15, 0.269, 388, 253, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
3239, 5imeB, 0.7419, 2.81, 0.309, 280, 249, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 (PAK1) IN COMPLEX WITH COMPOUND 9
3240, 2bikB, 0.7419, 2.54, 0.265, 272, 245, HUMAN PIM1 PHOSPHORYLATED ON SER261
3241, 5xgnA, 0.7418, 3.04, 0.223, 302, 251, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/C797S IN COMPLEX WITH GO6976
3242, 5wngC, 0.7418, 3.04, 0.274, 387, 252, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
3243, 5j7bA, 0.7418, 2.82, 0.231, 277, 251, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE GSK583 COMPLEX
3244, 5bq0A, 0.7418, 2.76, 0.197, 265, 249, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-824171 AKA 6-[(3R)-3-(4-TERT-BU TYLBENZAMIDO) PIPERIDIN-1-YL]-2-{[4-(MORPHOLINE-4-CARBONYL) PHENYL]AMINO}PYRIDINE- 3-CARBOXAMIDE
3245, 4xi2A, 0.7418, 3.00, 0.203, 421, 251, CRYSTAL STRUCTURE OF AN AUTO-INHIBITED FORM OF BRUTON S TRYROSINE KINASE
3246, 4riyC, 0.7418, 2.76, 0.201, 275, 249, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
3247, 3mfrA, 0.7418, 3.15, 0.287, 302, 251, CASK-4M CAM KINASE DOMAIN NATIVE
3248, 1xjdA, 0.7418, 2.72, 0.283, 280, 247, CRYSTAL STRUCTURE OF PKC-THETA COMPLEXED WITH STAUROSPORINE AT 2A RESOLUTION
3249, 5t8qA, 0.7417, 2.87, 0.256, 323, 250, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO ARYL PYRROLE FRAGMENT 17
3250, 5obrA, 0.7417, 2.53, 0.313, 255, 243, AURORA A KINASE IN COMPLEX WITH 2-(3-CHLORO-5-FLUOROPHENYL)QUINOLINE- 4-CARBOXYLIC ACID AND JNJ-7706621
3251, 5hu3A, 0.7417, 2.67, 0.311, 266, 244, DROSOPHILA CAMKII-D136N IN COMPLEX WITH A PHOSPHORYLATED FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/ADP
3252, 5eakA, 0.7417, 2.50, 0.307, 305, 244, OPTIMIZATION OF MICROTUBULE AFFINITY REGULATING KINASE (MARK) INHIBITORS WITH IMPROVED PHYSICAL PROPERTIES
3253, 4medA, 0.7417, 2.57, 0.269, 272, 245, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH THIORIDAZINE DERIVATIVES
3254, 3twjB, 0.7417, 3.09, 0.269, 395, 253, RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1447
3255, 2xruA, 0.7417, 2.48, 0.300, 253, 243, AURORA-A T288E COMPLEXED WITH PHA-828300
3256, 1zwsC, 0.7417, 2.89, 0.269, 278, 249, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
3257, 1wvwA, 0.7417, 2.79, 0.283, 275, 247, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
3258, 4qfsA, 0.7416, 2.84, 0.310, 361, 248, STRUCTURE OF AMPK IN COMPLEX WITH BR2-A769662CORE ACTIVATOR AND STAUROSPORINE INHIBITOR
3259, 3o7lD, 0.7416, 3.09, 0.272, 333, 254, CRYSTAL STRUCTURE OF PHOSPHOLAMBAN (1-19):PKA C-SUBUNIT:AMP-PNP:MG2+ COMPLEX
3260, 2r4bA, 0.7416, 2.94, 0.222, 292, 248, ERBB4 KINASE DOMAIN COMPLEXED WITH A THIENOPYRIMIDINE INHIBITOR
3261, 5t8oA, 0.7415, 2.93, 0.244, 324, 250, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO IMIDAZOBENZOXEPIN COMPOUND 3
3262, 5n4oA, 0.7415, 2.52, 0.270, 271, 244, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUSPEPTIDE AND FRAGMENT LIKE MOLEKULE (E)-3-(P-TOLYL)ACRYLIC ACID
3263, 5ezvC, 0.7415, 2.83, 0.286, 440, 248, X-RAY CRYSTAL STRUCTURE OF AMP-ACTIVATED PROTEIN KINASE ALPHA-2/ALPHA- 1 RIM CHIMAERA (ALPHA-2(1-347)/ALPHA-1(349-401)/ALPHA-2(397-END) BETA-1 GAMMA-1) CO-CRYSTALLIZED WITH C2 (5-(5-HYDROXYL-ISOXAZOL-3- YL)-FURAN-2-PHOSPHONIC ACID)
3264, 4lqpA, 0.7415, 2.88, 0.274, 383, 252, CRYSTAL STRUCTURE OF THE CBK1(T743E)-MOB2 KINASE-COACTIVATOR COMPLEX IN CRYSTAL FORM A
3265, 3uo4A, 0.7415, 2.84, 0.305, 266, 249, AURORA A IN COMPLEX WITH RPM1680
3266, 3ikaA, 0.7415, 3.09, 0.218, 310, 252, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M MUTANT COVALENTLY BINDING TO WZ4002
3267, 3d15A, 0.7415, 2.45, 0.302, 256, 242, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240->ARG MET302- >LEU) IN COMPLEX WITH 1-(3-CHLORO-PHENYL)-3-{5-[2-(THIENO[32- D]PYRIMIDIN-4-YLAMINO)- ETHYL]-THIAZOL-2-YL}-UREA [SNS-314]
3268, 6e4uA, 0.7414, 2.84, 0.302, 365, 248, STRUCTURE OF AMPK BOUND TO ACTIVATOR 
3269, 5wnfC, 0.7414, 3.12, 0.266, 386, 252, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
3270, 5wneC, 0.7414, 3.03, 0.267, 384, 251, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
3271, 5vcwA, 0.7414, 2.56, 0.307, 285, 244, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH PELITINIB
3272, 5hg7A, 0.7414, 2.87, 0.218, 280, 248, EGFR (L858R T790M V948R) IN COMPLEX WITH 1-{(3R4R)-3-[5-CHLORO-2- (1-METHYL-1H-PYRAZOL-4-YLAMINO)-7H-PYRROLO[23-D]PYRIMIDIN-4- YLOXYMETHYL]-4-METHOXY-PYRROLIDIN-1-YL}PROPENONE (PF-06459988)
3273, 5gnkA, 0.7414, 2.67, 0.229, 277, 245, CRYSTAL STRUCTURE OF EGFR 696-988 T790M IN COMPLEX WITH LXX-6-34
3274, 4iaaA, 0.7414, 2.56, 0.269, 272, 245, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH THIORIDAZINE
3275, 2pmnX, 0.7414, 3.33, 0.217, 340, 258, CRYSTAL STRUCTURE OF PFPK7 IN COMPLEX WITH AN ATP-SITE INHIBITOR
3276, 5t8qB, 0.7413, 2.93, 0.248, 328, 250, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO ARYL PYRROLE FRAGMENT 17
3277, 5kq5A, 0.7413, 2.85, 0.302, 362, 248, AMPK BOUND TO ALLOSTERIC ACTIVATOR
3278, 4ehgA, 0.7412, 2.43, 0.215, 262, 242, B-RAF KINASE DOMAIN IN COMPLEX WITH AN AMINOPYRIDIMINE-BASED INHIBITOR
3279, 3vs2B, 0.7412, 2.50, 0.252, 433, 242, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[CIS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)-7H- PYRROLO[23-D]PYRIMIDIN-4-AMINE
3280, 3up7A, 0.7412, 2.79, 0.308, 264, 247, AURORA A IN COMPLEX WITH YL1-038-09
3281, 3otuA, 0.7412, 2.97, 0.277, 276, 249, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR JS30
3282, 2jitB, 0.7412, 3.17, 0.180, 312, 255, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION
3283, 1ym7A, 0.7412, 3.19, 0.256, 608, 254, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
3284, 5t8oB, 0.7411, 2.86, 0.249, 328, 249, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO IMIDAZOBENZOXEPIN COMPOUND 3
3285, 4lg4C, 0.7411, 3.19, 0.283, 288, 258, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
3286, 4dn5B, 0.7411, 2.88, 0.257, 330, 249, CRYSTAL STRUCTURE OF NF-KB-INDUCING KINASE (NIK)
3287, 2rfeC, 0.7411, 2.51, 0.230, 262, 244, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE EGFR KINASE DOMAIN AND A MIG6 PEPTIDE
3288, 2pmoX, 0.7411, 3.35, 0.221, 340, 258, CRYSTAL STRUCTURE OF PFPK7 IN COMPLEX WITH HYMENIALDISINE
3289, 2pmlX, 0.7411, 3.36, 0.221, 340, 258, CRYSTAL STRUCTURE OF PFPK7 IN COMPLEX WITH AN ATP ANALOGUE
3290, 2hckB, 0.7411, 2.56, 0.238, 437, 244, SRC FAMILY KINASE HCK-QUERCETIN COMPLEX
3291, 2c3iB, 0.7411, 2.54, 0.262, 266, 244, CRYSTAL STRUCTURE OF HUMAN PIM1 IN COMPLEX WITH IMIDAZOPYRIDAZIN I
3292, 1zwsB, 0.7411, 2.89, 0.269, 278, 249, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
3293, 5dpvA, 0.7410, 2.58, 0.307, 257, 244, AURORA A KINASE IN COMPLEX WITH AA35 AND JNJ-7706621 IN SPACE GROUP P6122
3294, 4lqsA, 0.7410, 2.94, 0.271, 372, 251, CRYSTAL STRUCTURE OF THE CBK1-MOB2 KINASE-COACTIVATOR COMPLEX
3295, 4j8mA, 0.7410, 2.81, 0.293, 265, 249, AURORA A IN COMPLEX WITH CD532
3296, 3vs6A, 0.7410, 2.48, 0.244, 434, 242, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR TERT-BUTYL {4-[4-AMINO-1-(PROPAN-2-YL)-1H-PYRAZOLO[34- D]PYRIMIDIN-3-YL]-2-METHOXYPHENYL}CARBAMATE
3297, 3pscA, 0.7410, 3.23, 0.267, 614, 255, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS
3298, 3bhhB, 0.7410, 2.89, 0.315, 289, 248, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
3299, 2wzjF, 0.7410, 2.92, 0.305, 310, 249, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
3300, 1zwsD, 0.7410, 2.89, 0.269, 278, 249, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
3301, 1yi4A, 0.7410, 2.54, 0.275, 267, 244, STRUCTURE OF PIM-1 BOUND TO ADENOSINE
3302, 4riwC, 0.7409, 2.72, 0.197, 275, 249, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
3303, 4d28B, 0.7409, 2.84, 0.320, 277, 250, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.11 AT5G35410
3304, 3c4yA, 0.7409, 3.16, 0.270, 478, 256, CRYSTAL STRUCTURE OF APO FORM OF G PROTEIN COUPLED RECEPTOR KINASE 1 AT 7.51A
3305, 1wvyA, 0.7409, 2.60, 0.273, 273, 245, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
3306, 6gt1D, 0.7408, 2.41, 0.331, 260, 239, NEK7 BOUND TO PURINE INHIBITOR 
3307, 5vloA, 0.7408, 2.87, 0.304, 290, 247, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
3308, 4zjjC, 0.7408, 2.76, 0.286, 276, 248, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
3309, 4ynzB, 0.7408, 2.50, 0.290, 323, 245, STRUCTURE OF THE N-TERMINAL DOMAIN OF SAD
3310, 4jbqA, 0.7407, 2.59, 0.311, 257, 244, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
3311, 3umwA, 0.7407, 2.57, 0.275, 264, 244, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH INHIBITOR (Z)-2-[(1H- INDAZOL-3-YL)METHYLENE]-6-METHOXY-7-(PIPERAZIN-1-YLMETHYL)BENZOFURAN- 3(2H)-ONE
3312, 2z7sA, 0.7407, 1.95, 0.323, 256, 235, CRYSTAL STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF HUMAN RSK1 BOUND TO PURVALNOL A
3313, 6b2eA, 0.7406, 2.83, 0.290, 442, 248, STRUCTURE OF FULL LENGTH HUMAN AMPK (A2B2G1) IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR SC4. 
3314, 5tvtA, 0.7406, 2.52, 0.321, 321, 243, STRUCTURE OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE
3315, 5t8pB, 0.7406, 3.05, 0.254, 328, 252, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO BENZOXEPIN COMPOUND 2
3316, 3vrzB, 0.7406, 2.50, 0.252, 430, 242, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-BENZYLUREA
3317, 3vryA, 0.7406, 2.57, 0.251, 428, 243, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23-D]PYRIMIDIN-7-YL- CYCLOPENTANE
3318, 3a99A, 0.7406, 2.68, 0.268, 273, 246, STRUCTURE OF PIM-1 KINASE CRYSTALLIZED IN THE PRESENCE OF P27KIP1 CARBOXY-TERMINAL PEPTIDE
3319, 2qnjB, 0.7406, 2.90, 0.317, 322, 252, KINASE AND UBIQUITIN-ASSOCIATED DOMAINS OF MARK3/PAR-1
3320, 2fumD, 0.7406, 2.36, 0.260, 258, 242, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
3321, 5t8pA, 0.7405, 3.06, 0.254, 327, 252, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO BENZOXEPIN COMPOUND 2
3322, 4qfrA, 0.7405, 2.86, 0.302, 361, 248, STRUCTURE OF AMPK IN COMPLEX WITH CL-A769662 ACTIVATOR AND STAUROSPORINE INHIBITOR
3323, 4i5mA, 0.7405, 2.75, 0.242, 273, 248, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
3324, 3uixA, 0.7405, 2.56, 0.266, 266, 244, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
3325, 3gt8D, 0.7405, 2.87, 0.206, 295, 247, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
3326, 3fdnA, 0.7405, 2.66, 0.302, 261, 245, STRUCTURE-BASED DRUG DESIGN OF NOVEL AURORA KINASE A INHIBITORS: STRUCTURE BASIS FOR POTENCY AND SPECIFICITY
3327, 1ym7C, 0.7405, 3.15, 0.264, 607, 254, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
3328, 5dt0A, 0.7404, 2.64, 0.307, 259, 244, AURORA A KINASE IN COMPLEX WITH JNJ-7706621 IN SPACE GROUP P6122
3329, 5cnnA, 0.7404, 2.89, 0.213, 300, 249, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN MUTANT I682Q
3330, 4qfgA, 0.7404, 2.87, 0.310, 365, 248, STRUCTURE OF AMPK IN COMPLEX WITH STAUROSPORINE INHIBITOR AND IN THE ABSENCE OF A SYNTHETIC ACTIVATOR
3331, 4k2rA, 0.7404, 2.89, 0.222, 551, 248, STRUCTURAL BASIS FOR ACTIVATION OF ZAP-70 BY PHOSPHORYLATION OF THE SH2-KINASE LINKER
3332, 4c0tA, 0.7404, 3.28, 0.272, 290, 257, CANDIDA ALBICANS PKH KINASE DOMAIN
3333, 3vs4B, 0.7404, 2.57, 0.251, 434, 243, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 5-(4-PHENOXYPHENYL)-7-(TETRAHYDRO-2H-PYRAN-4-YL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
3334, 3tv4A, 0.7404, 2.58, 0.205, 264, 244, HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH AN BROMOPYRIDINE BENZAMIDE INHIBITOR
3335, 3a7jA, 0.7404, 2.99, 0.272, 286, 250, HUMAN MST3 KINASE IN COMPLEX WITH MNADP
3336, 2y7jB, 0.7404, 2.82, 0.287, 281, 247, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
3337, 2xngA, 0.7404, 2.52, 0.310, 253, 242, STRUCTURE OF AURORA-A BOUND TO A SELECTIVE IMIDAZOPYRAZINE INHIBITOR
3338, 5u6yK, 0.7403, 3.10, 0.311, 459, 251, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
3339, 4uv0A, 0.7403, 2.98, 0.276, 300, 250, STRUCTURE OF A SEMISYNTHETIC PHOSPHORYLATED DAPK
3340, 5x5oA, 0.7402, 2.99, 0.254, 291, 248, CRYSTAL STRUCTURE OF ZAK IN COMPLEX WITH COMPOUND D2829
3341, 5gtyF, 0.7402, 2.83, 0.210, 297, 248, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
3342, 5ap7A, 0.7402, 2.36, 0.305, 263, 243, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
3343, 1zwsH, 0.7402, 2.90, 0.269, 278, 249, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
3344, 1zwsF, 0.7402, 2.89, 0.269, 278, 249, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
3345, 1ym7D, 0.7402, 3.16, 0.264, 599, 254, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
3346, 5fbnD, 0.7401, 2.64, 0.200, 255, 245, BTK KINASE DOMAIN WITH INHIBITOR 1
3347, 4rc3A, 0.7401, 2.56, 0.270, 271, 244, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
3348, 3zhpD, 0.7401, 3.00, 0.269, 264, 253, HUMAN MST3 (STK24) IN COMPLEX WITH MO25BETA
3349, 2ya9B, 0.7401, 2.99, 0.272, 299, 250, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2
3350, 1ym7B, 0.7401, 3.16, 0.264, 608, 254, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
3351, 5hznG, 0.7400, 3.08, 0.213, 296, 253, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
3352, 5g1xA, 0.7400, 2.90, 0.308, 262, 247, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH N-MYC
3353, 4enyA, 0.7400, 2.51, 0.267, 261, 243, CRYSTAL STRUCTURE OF PIM-1 KINASE IN COMPLEX WITH (2E5Z)-2-(2- CHLOROPHENYLIMINO)-5-(4-HYDROXY-3-METHOXYBENZYLIDENE)THIAZOLIDIN-4- ONE
3354, 3k5uA, 0.7400, 2.64, 0.316, 260, 244, IDENTIFICATION SAR STUDIES AND X-RAY COCRYSTAL ANALYSIS OF A NOVEL FURANO-PYRIMIDINE AURORA KINASE A INHIBITOR
3355, 3genA, 0.7400, 2.87, 0.198, 264, 248, THE 1.6 A CRYSTAL STRUCTURE OF HUMAN BRUTON S TYROSINE KINASE BOUND TO A PYRROLOPYRIMIDINE-CONTAINING COMPOUND
3356, 5u6bA, 0.7399, 2.50, 0.221, 270, 244, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
3357, 5hznC, 0.7399, 3.08, 0.213, 296, 253, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
3358, 5aaeA, 0.7399, 2.46, 0.310, 252, 242, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14D)
3359, 3vryB, 0.7399, 2.57, 0.251, 434, 243, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23-D]PYRIMIDIN-7-YL- CYCLOPENTANE
3360, 3t9iA, 0.7399, 2.62, 0.269, 273, 245, PIM1 COMPLEXED WITH A NOVEL 36-DISUBSTITUTED INDOLE AT 2.6 ANG RESOLUTION
3361, 3gt8A, 0.7399, 2.64, 0.200, 300, 245, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
3362, 1mruB, 0.7399, 2.41, 0.252, 271, 242, INTRACELLULAR SER/THR PROTEIN KINASE DOMAIN OF MYCOBACTERIUM TUBERCULOSIS PKNB.
3363, 5aadA, 0.7398, 2.39, 0.299, 252, 241, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (7A)
3364, 3r22A, 0.7398, 2.51, 0.306, 255, 242, DESIGN SYNTHESIS AND BIOLOGICAL EVALUATION OF PYRAZOLOPYRIDINE- SULFONAMIDES AS POTENT MULTIPLE-MITOTIC KINASE (MMK) INHIBITORS (PART I)
3365, 5xgnB, 0.7397, 3.17, 0.188, 308, 255, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/C797S IN COMPLEX WITH GO6976
3366, 4rz7A, 0.7397, 2.94, 0.274, 801, 252, CRYSTAL STRUCTURE OF PVX_084705 WITH BOUND PCI32765
3367, 4o0rB, 0.7397, 2.90, 0.304, 282, 250, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
3368, 4idvC, 0.7397, 2.99, 0.255, 335, 251, CRYSTAL STRUCTURE OF NIK WITH COMPOUND 4-{3-[2-AMINO-5-(2- METHOXYETHOXY)PYRIMIDIN-4-YL]-1H-INDOL-5-YL}-2-METHYLBUT-3-YN-2-OL (13V)
3369, 3gniB, 0.7397, 2.72, 0.246, 304, 248, STRUCTURE OF STRAD AND MO25
3370, 2wzjC, 0.7397, 2.94, 0.305, 310, 249, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
3371, 6fu5A, 0.7396, 2.84, 0.220, 282, 250, STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH THE INHIBITOR CSLP18 
3372, 5m5aA, 0.7396, 2.24, 0.326, 315, 239, CRYSTAL STRUCTURE OF MELK IN COMPLEX WITH AN INHIBITOR
3373, 5cnoB, 0.7396, 2.87, 0.213, 302, 249, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN MUTANT V924R
3374, 4rblA, 0.7396, 2.56, 0.270, 271, 244, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
3375, 4mk0A, 0.7396, 3.19, 0.268, 631, 254, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH A A RATIONALLY DESIGNED PAROXETINE DERIVATIVE
3376, 4gu6A, 0.7396, 3.08, 0.243, 271, 255, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH N-{3-[(5-CYANO- 2-PHENYL-1H-PYRROLO[23-B]PYRIDIN-4-YLAMINO)- METHYL]-PYRIDIN-2-YL}- N-METHYL-METHANESULFONAMIDE
3377, 4g3eB, 0.7396, 2.86, 0.253, 325, 249, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO A 6-ALKYNYLINDOLINE (CMP1)
3378, 3utoB, 0.7396, 3.15, 0.256, 566, 254, TWITCHIN KINASE REGION FROM C.ELEGANS (FN31-NL-KIN-CRD-IG26)
3379, 2x0gA, 0.7396, 2.96, 0.279, 318, 251, X-RAY STRUCTURE OF A DAP-KINASE CALMODULIN COMPLEX
3380, 5d9hA, 0.7395, 3.10, 0.260, 290, 250, CRYSTAL STRUCTURE OF SPAK (STK39) DIMER IN THE BASAL ACTIVITY STATE
3381, 4otwA, 0.7395, 2.66, 0.202, 272, 247, HER3 PSEUDOKINASE DOMAIN BOUND TO BOSUTINIB
3382, 4idvB, 0.7395, 2.97, 0.255, 335, 251, CRYSTAL STRUCTURE OF NIK WITH COMPOUND 4-{3-[2-AMINO-5-(2- METHOXYETHOXY)PYRIMIDIN-4-YL]-1H-INDOL-5-YL}-2-METHYLBUT-3-YN-2-OL (13V)
3383, 2wzjD, 0.7395, 2.93, 0.305, 313, 249, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
3384, 5u6bC, 0.7394, 2.45, 0.230, 270, 243, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
3385, 5jebA, 0.7394, 3.18, 0.216, 299, 255, CRYSTAL STRUCTURE OF EGFR TYROSINE KINASE DOMAIN WITH NOVEL INHIBITOR OF ACTIVE STATE OF HER2
3386, 4idvA, 0.7394, 2.98, 0.255, 335, 251, CRYSTAL STRUCTURE OF NIK WITH COMPOUND 4-{3-[2-AMINO-5-(2- METHOXYETHOXY)PYRIMIDIN-4-YL]-1H-INDOL-5-YL}-2-METHYLBUT-3-YN-2-OL (13V)
3387, 3w2rA, 0.7394, 2.85, 0.202, 297, 248, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH COMPOUND 4
3388, 3vs2A, 0.7394, 2.55, 0.252, 430, 242, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[CIS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)-7H- PYRROLO[23-D]PYRIMIDIN-4-AMINE
3389, 3aloA, 0.7394, 3.13, 0.244, 289, 250, CRYSTAL STRUCTURE OF HUMAN NON-PHOSPHORYLATED MKK4 KINASE DOMAIN TERNARY COMPLEX WITH AMP-PNP AND P38 PEPTIDE
3390, 4ntsB, 0.7393, 3.12, 0.272, 341, 254, APO STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
3391, 4g3fA, 0.7393, 2.92, 0.256, 312, 250, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO A 2-(AMINOTHIAZOLY)PHENOL (CMP2)
3392, 5vcyA, 0.7392, 2.60, 0.299, 296, 244, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH BOSUTINIB
3393, 5ig1B, 0.7392, 3.05, 0.276, 304, 250, CRYSTAL STRUCTURE OF S. ROSETTA CAMKII KINASE DOMAIN
3394, 4usfB, 0.7392, 2.91, 0.283, 285, 251, HUMAN SLK WITH SB-440719
3395, 2np8A, 0.7392, 2.46, 0.302, 256, 242, STRUCTURAL BASIS FOR THE INHIBITION OF AURORA A KINASE BY A NOVEL CLASS OF HIGH AFFINITY DISUBSTITUTED PYRIMIDINE INHIBITORS
3396, 5u6yC, 0.7391, 3.03, 0.312, 459, 250, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
3397, 5hznE, 0.7391, 3.00, 0.214, 296, 252, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
3398, 5hznA, 0.7391, 3.00, 0.214, 296, 252, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
3399, 4c8bB, 0.7391, 2.90, 0.211, 281, 251, STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH PONATINIB
3400, 2gdoA, 0.7391, 2.96, 0.284, 269, 250, 4-(AMINOALKYLAMINO)-3-BENZIMIDAZOLE-QUINOLINONES AS POTENT CHK1 INHIBITORS
3401, 1zwsG, 0.7391, 2.91, 0.269, 278, 249, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
3402, 1eh4B, 0.7391, 3.10, 0.181, 293, 254, BINARY COMPLEX OF CASEIN KINASE-1 FROM S. POMBE WITH AN ATP COMPETITIVE INHIBITOR IC261
3403, 5ufuA, 0.7390, 2.89, 0.302, 368, 248, STRUCTURE OF AMPK BOUND TO ACTIVATOR
3404, 5ig1A, 0.7390, 2.99, 0.284, 300, 250, CRYSTAL STRUCTURE OF S. ROSETTA CAMKII KINASE DOMAIN
3405, 4ewhA, 0.7390, 3.00, 0.256, 274, 250, CO-CRYSTAL STRUCTURE OF ACK1 WITH INHIBITOR
3406, 4dedA, 0.7390, 2.98, 0.305, 265, 249, AURORA A IN COMPLEX WITH YL1-038-21
3407, 3vs5B, 0.7390, 2.46, 0.245, 427, 241, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-(1-METHYLPIPERIDIN-4-YL)-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
3408, 3d5xA, 0.7390, 2.57, 0.270, 279, 244, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH WORTMANNIN.
3409, 4euuB, 0.7389, 3.18, 0.239, 307, 255, STRUCTURE OF BX-795 COMPLEXED WITH HUMAN TBK1 KINASE DOMAIN PHOSPHORYLATED ON SER172
3410, 2r4bB, 0.7389, 2.93, 0.223, 291, 247, ERBB4 KINASE DOMAIN COMPLEXED WITH A THIENOPYRIMIDINE INHIBITOR
3411, 2c0oB, 0.7389, 2.45, 0.253, 433, 241, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-770041
3412, 1ol5A, 0.7389, 2.72, 0.311, 263, 244, STRUCTURE OF AURORA-A 122-403 PHOSPHORYLATED ON THR287 THR288 AND BOUND TO TPX2 1-43
3413, 5wg4A, 0.7388, 3.12, 0.274, 621, 252, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG257284
3414, 5cf5B, 0.7388, 3.04, 0.257, 294, 253, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 7-[(DIMETHYL-13-THIAZOL-2-YL)AMINO]-10-ETHYL-3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.026] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
3415, 4iw0A, 0.7388, 3.32, 0.241, 647, 257, CRYSTAL STRUCTURE AND MECHANISM OF ACTIVATION OF TBK1
3416, 2a27C, 0.7388, 3.01, 0.264, 303, 250, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
3417, 1zwsA, 0.7388, 2.92, 0.269, 278, 249, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
3418, 3fe3B, 0.7387, 3.12, 0.315, 317, 254, CRYSTAL STRUCTURE OF THE KINASE MARK3/PAR-1: T211A-S215A DOUBLE MUTANT
3419, 5hznF, 0.7386, 3.10, 0.213, 296, 253, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
3420, 5hznB, 0.7386, 3.10, 0.213, 296, 253, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
3421, 5ar5B, 0.7386, 2.79, 0.225, 279, 249, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BENZIMIDAZOLE
3422, 4twcA, 0.7386, 3.19, 0.177, 293, 254, 2-BENZAMIDO-N-(1H-BENZO[D]IMIDAZOL-2-YL)THIAZOLE-4- CARBOXAMIDE DERIVATIVES AS POTENT INHIBITORS OF CK1D/E
3423, 4tw9A, 0.7386, 3.17, 0.173, 290, 254, DIFLUORO-DIOXOLO-BENZOIMIDAZOL-BENZAMIDES AS POTENT INHIBITORS OF CK1DELTA AND EPSILON WITH NANOMOLAR INHIBITORY ACTIVITY ON CANCER CELL PROLIFERATION
3424, 4nfnA, 0.7386, 3.06, 0.181, 293, 254, HUMAN TAU TUBULIN KINASE 1 (TTBK1) COMPLEXED WITH 3-({5-[(4-AMINO-4- METHYLPIPERIDIN-1-YL)METHYL]PYRROLO[21-F][124]TRIAZIN-4-YL}AMINO)- 5-BROMOPHENOL
3425, 4g3cB, 0.7386, 3.07, 0.254, 327, 252, CRYSTAL STRUCTURE OF APO MURINE NF-KAPPAB INDUCING KINASE (NIK)
3426, 2y7jC, 0.7386, 2.83, 0.291, 284, 247, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
3427, 2a27E, 0.7386, 3.01, 0.264, 303, 250, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
3428, 2a27A, 0.7386, 3.02, 0.264, 304, 250, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
3429, 5gjfA, 0.7385, 2.98, 0.285, 298, 249, CRYSTAL STRUCTURE OF HUMAN TAK1/TAB1 FUSION PROTEIN IN COMPLEX WITH LIGAND 3
3430, 5es1A, 0.7385, 2.33, 0.324, 304, 241, CRYSTAL STRUCTURE OF MICROTUBULE AFFINITY-REGULATING KINASE 4 CATALYTIC DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE INHIBITOR
3431, 5deyA, 0.7385, 2.97, 0.306, 295, 252, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND G-5555
3432, 4zimB, 0.7385, 3.05, 0.257, 294, 253, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH A 9H-CARBAZOLE-1- CARBOXAMIDE INHIBITOR
3433, 5u6yI, 0.7384, 3.07, 0.312, 459, 250, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
3434, 4o0uA, 0.7384, 2.71, 0.301, 259, 246, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
3435, 4g3gA, 0.7384, 2.93, 0.256, 312, 250, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) V408L BOUND TO A 2-(AMINOTHIAZOLYL)PHENOL (CMP3)
3436, 6ccfA, 0.7383, 2.72, 0.287, 260, 244, CRYSTAL STRUCTURE OF THE HUMAN CAMKK1A IN COMPLEX WITH HESPERADIN
3437, 5oneA, 0.7383, 2.70, 0.306, 257, 245, CRYSTAL STRUCTURE OF AURORA-A IN COMPLEX WITH FMF-03-145-1 (COMPOUND 2)
3438, 5hg9A, 0.7383, 2.94, 0.214, 280, 248, EGFR (L858R T790M V948R) IN COMPLEX WITH 1-[(3R4R)-3-[({2-[(1- METHYL-1H-PYRAZOL-4-YL)AMINO]-7H-PYRROLO[23-D]PYRIMIDIN-4-YL}OXY) METHYL]-4-(TRIFLUOROMETHYL)PYRROLIDIN-1-YL]PROP-2-EN-1-ONE
3439, 3vs5A, 0.7383, 2.55, 0.252, 429, 242, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-(1-METHYLPIPERIDIN-4-YL)-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
3440, 2c0tB, 0.7383, 2.54, 0.252, 429, 242, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-641359
3441, 1csnA, 0.7383, 3.15, 0.187, 293, 252, BINARY COMPLEX OF CASEIN KINASE-1 WITH MGATP
3442, 4uy9A, 0.7382, 2.89, 0.281, 313, 249, STRUCTURE OF MLK1 KINASE DOMAIN WITH LEUCINE ZIPPER 1
3443, 4i22A, 0.7382, 2.71, 0.211, 297, 246, STRUCTURE OF THE MONOMERIC (V948R)GEFITINIB/ERLOTINIB RESISTANT DOUBLE MUTANT (L858R+T790M) EGFR KINASE DOMAIN CO-CRYSTALLIZED WITH GEFITINIB
3444, 3fy0A, 0.7382, 3.07, 0.307, 292, 254, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH RUTHENIUM COMPLEX DW1
3445, 2a27H, 0.7382, 3.01, 0.264, 304, 250, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
3446, 2a27F, 0.7382, 3.01, 0.264, 303, 250, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
3447, 5vioB, 0.7381, 3.10, 0.289, 271, 249, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 13)
3448, 4hnfB, 0.7381, 3.17, 0.173, 290, 254, CRYSTAL STRUCTURE OF CK1D IN COMPLEX WITH PF4800567
3449, 4euuA, 0.7381, 3.28, 0.238, 307, 256, STRUCTURE OF BX-795 COMPLEXED WITH HUMAN TBK1 KINASE DOMAIN PHOSPHORYLATED ON SER172
3450, 4byiA, 0.7381, 2.47, 0.310, 254, 242, AURORA A KINASE BOUND TO A HIGHLY SELECTIVE IMIDAZOPYRIDINE INHIBITOR
3451, 2cgxA, 0.7381, 3.13, 0.270, 265, 252, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
3452, 2c0iA, 0.7381, 2.56, 0.252, 433, 242, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-420983
3453, 5vd1A, 0.7380, 2.59, 0.300, 295, 243, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH PHA- 848125
3454, 5j5tA, 0.7380, 2.84, 0.286, 297, 248, GLK CO-CRYSTAL STRUCTURE WITH AMINOPYRROLOPYRIMIDINE INHIBITOR
3455, 4zjjD, 0.7380, 2.87, 0.288, 274, 250, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
3456, 4kikB, 0.7380, 3.46, 0.282, 648, 259, HUMAN IKB KINASE BETA
3457, 5wg3A, 0.7379, 3.14, 0.274, 618, 252, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG258748
3458, 5aagA, 0.7379, 2.51, 0.310, 253, 242, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14B)
3459, 4ewhB, 0.7379, 2.93, 0.257, 273, 249, CO-CRYSTAL STRUCTURE OF ACK1 WITH INHIBITOR
3460, 3vs0B, 0.7379, 2.56, 0.252, 433, 242, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR N-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL) PHENYL]BENZAMIDE
3461, 3vrzA, 0.7379, 2.48, 0.253, 429, 241, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-BENZYLUREA
3462, 3v5wA, 0.7379, 3.20, 0.276, 623, 254, HUMAN G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH SOLUBLE GBETAGAMMA SUBUNITS AND PAROXETINE
3463, 3ppzA, 0.7379, 2.88, 0.236, 264, 246, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
3464, 2z7qA, 0.7379, 1.94, 0.321, 255, 234, CRYSTAL STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF HUMAN RSK-1 BOUND TO AMP-PCP
3465, 2y7jA, 0.7379, 2.83, 0.291, 284, 247, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
3466, 2c0tA, 0.7379, 2.57, 0.252, 427, 242, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-641359
3467, 2a27G, 0.7379, 3.02, 0.264, 303, 250, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
3468, 2a27D, 0.7379, 3.02, 0.264, 304, 250, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
3469, 3vs0A, 0.7378, 2.49, 0.245, 428, 241, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR N-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL) PHENYL]BENZAMIDE
3470, 5d9hB, 0.7377, 2.99, 0.262, 293, 248, CRYSTAL STRUCTURE OF SPAK (STK39) DIMER IN THE BASAL ACTIVITY STATE
3471, 4ythA, 0.7376, 2.94, 0.235, 287, 251, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASES
3472, 2ydiA, 0.7376, 3.07, 0.271, 279, 251, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
3473, 2cgvA, 0.7376, 3.12, 0.286, 264, 252, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
3474, 2a27B, 0.7376, 3.03, 0.264, 303, 250, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
3475, 1yvjA, 0.7376, 3.10, 0.249, 288, 253, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN IN COMPLEX WITH A STAUROSPORINE ANALOGUE
3476, 5hznH, 0.7375, 3.12, 0.213, 303, 253, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
3477, 4wo5A, 0.7375, 2.74, 0.198, 266, 247, CRYSTAL STRUCTURE OF A BRAF KINASE DOMAIN MONOMER
3478, 4i24A, 0.7375, 2.74, 0.212, 295, 245, STRUCTURE OF T790M EGFR KINASE DOMAIN CO-CRYSTALLIZED WITH DACOMITINIB
3479, 2c0oA, 0.7375, 2.49, 0.245, 433, 241, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-770041
3480, 2c0iB, 0.7375, 2.56, 0.252, 433, 242, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-420983
3481, 5hznD, 0.7374, 3.13, 0.213, 304, 253, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
3482, 2y0aA, 0.7374, 3.11, 0.267, 300, 251, STRUCTURE OF DAPK1 CONSTRUCT RESIDUES 1-304
3483, 3mygA, 0.7373, 2.40, 0.300, 252, 240, AURORA A KINASE COMPLEXED WITH SCH 1473759
3484, 2csnA, 0.7373, 3.22, 0.182, 293, 253, BINARY COMPLEX OF CASEIN KINASE-1 WITH CKI7
3485, 5w4wC, 0.7372, 3.21, 0.173, 284, 254, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
3486, 3e63A, 0.7372, 3.23, 0.256, 290, 254, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
3487, 5ng0B, 0.7371, 3.15, 0.214, 282, 252, STRUCTURE OF RIP2K(L294F) WITH BOUND AMPPCP
3488, 5cf4B, 0.7371, 3.05, 0.257, 291, 253, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
3489, 4rzvB, 0.7371, 2.79, 0.198, 271, 248, CRYSTAL STRUCTURE OF THE BRAF (R509H) KINASE DOMAIN MONOMER BOUND TO VEMURAFENIB
3490, 4g3eA, 0.7371, 2.88, 0.254, 314, 248, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO A 6-ALKYNYLINDOLINE (CMP1)
3491, 3bbtB, 0.7370, 2.50, 0.227, 274, 242, CRYSTAL STRUCTURE OF THE ERBB4 KINASE IN COMPLEX WITH LAPATINIB
3492, 5vcxA, 0.7369, 2.72, 0.307, 287, 244, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN (UNTREATED) IN COMPLEX WITH SARACATINIB
3493, 5hibA, 0.7369, 3.25, 0.212, 314, 255, EGFR KINASE DOMAIN MUTANT TMLR WITH A PYRAZOLOPYRIMIDINE INHIBITOR
3494, 4umtA, 0.7369, 2.57, 0.318, 316, 242, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
3495, 4prjA, 0.7369, 2.42, 0.312, 251, 240, AURORA A KINASE DOMAIN WITH COMPOUND 2 (N-[1-(3-CYANOBENZYL)-1H- PYRAZOL-4-YL]-6-(1H-PYRAZOL-4-YL)-1H-INDAZOLE-3-CARBOXAMIDE)
3496, 4nfmA, 0.7369, 3.15, 0.188, 293, 255, HUMAN TAU TUBULIN KINASE 1 (TTBK1)
3497, 4czuD, 0.7368, 3.22, 0.297, 302, 256, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.23 AT1G30270 T190D MUTANT
3498, 3bhhA, 0.7368, 2.90, 0.316, 289, 247, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
3499, 5vilB, 0.7367, 3.14, 0.289, 271, 249, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 6)
3500, 5twlA, 0.7367, 2.54, 0.318, 319, 242, STRUCTURE OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE
3501, 5ar3B, 0.7367, 2.89, 0.217, 276, 249, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH AMP-PCP
3502, 4bicA, 0.7367, 2.70, 0.292, 260, 243, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3503, 3bkbA, 0.7367, 3.01, 0.241, 373, 249, CRYSTAL STRUCTURE OF HUMAN FELINE SARCOMA VIRAL ONCOGENE HOMOLOGUE (V- FES)
3504, 2w1gA, 0.7367, 2.60, 0.309, 254, 243, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
3505, 2vn9B, 0.7367, 2.95, 0.312, 301, 250, CRYSTAL STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II DELTA ISOFORM 1 CAMKD
3506, 6b2qB, 0.7366, 2.51, 0.264, 266, 242, DUAL INHIBITION OF THE ESSENTIAL PROTEIN KINASES A AND B IN MYCOBACTERIUM TUBERCULOSIS
3507, 4l53A, 0.7366, 2.78, 0.301, 296, 246, CRYSTAL STRUCTURE OF (1R4R)-4-{4-[7-AMINO-2-(123-BENZOTHIADIAZOL-7- YL)-3-CHLOROFURO[23-C]PYRIDIN-4-YL]-1H-PYRAZOL-1-YL}CYCLOHEXAN-1-OL BOUND TO TAK1-TAB1
3508, 3q32B, 0.7366, 3.07, 0.257, 294, 253, STRUCTURE OF JANUS KINASE 2 WITH A PYRROLOTRIAZINE INHIBITOR
3509, 2brnA, 0.7366, 3.16, 0.271, 268, 251, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
3510, 1ckjA, 0.7366, 3.12, 0.189, 296, 254, CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317 COMPLEX WITH BOUND TUNGSTATE
3511, 5ug9A, 0.7365, 2.96, 0.214, 280, 248, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN (L858R T790M V948R) IN COMPLEX WITH A COVALENT INHIBITOR N-[(3R4R)-4-FLUORO-1-{6-[(3- METHOXY-1-METHYL-1H-PYRAZOL-4-YL)AMINO]-9-(PROPAN-2-YL)-9H-PURIN-2- YL}PYRROLIDIN-3-YL]PROPANAMIDE
3512, 4u42B, 0.7365, 2.35, 0.253, 265, 241, MAP4K4 T181E MUTANT BOUND TO INHIBITOR COMPOUND 1
3513, 3ha6A, 0.7365, 2.74, 0.307, 263, 244, CRYSTAL STRUCTURE OF AURORA A IN COMPLEX WITH TPX2 AND COMPOUND 10
3514, 3bbwA, 0.7365, 2.51, 0.227, 268, 242, CRYSTAL STRUCTURE OF THE ERBB4 KINASE IN ITS INACTIVE CONFORMATION
3515, 2clqB, 0.7365, 2.68, 0.292, 259, 243, STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 2 5
3516, 6ccfB, 0.7364, 2.78, 0.294, 262, 245, CRYSTAL STRUCTURE OF THE HUMAN CAMKK1A IN COMPLEX WITH HESPERADIN
3517, 5vczA, 0.7364, 2.61, 0.300, 294, 243, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH BOSUTINIB ISOMER
3518, 5ukkA, 0.7364, 3.22, 0.264, 613, 254, HUMAN GRK2 IN COMPLEX WITH HUMAN G-BETA-GAMMA SUBUNITS AND CCG211998 (14AK)
3519, 2evaA, 0.7364, 2.80, 0.298, 295, 245, STRUCTURAL BASIS FOR THE INTERACTION OF TAK1 KINASE WITH ITS ACTIVATING PROTEIN TAB1
3520, 2cguA, 0.7364, 3.08, 0.287, 263, 251, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
3521, 1zysA, 0.7364, 3.01, 0.272, 271, 250, CO-CRYSTAL STRUCTURE OF CHECKPOINT KINASE CHK1 WITH A PYRROLO-PYRIDINE INHIBITOR
3522, 5u6yL, 0.7363, 2.96, 0.315, 459, 248, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
3523, 5u6yJ, 0.7363, 2.96, 0.315, 459, 248, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
3524, 5u6yH, 0.7363, 2.96, 0.315, 459, 248, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
3525, 5u6yG, 0.7363, 2.96, 0.315, 459, 248, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
3526, 5u6yF, 0.7363, 2.96, 0.315, 459, 248, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
3527, 5u6yE, 0.7363, 2.96, 0.315, 459, 248, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
3528, 5u6yD, 0.7363, 2.96, 0.315, 459, 248, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
3529, 5u6yB, 0.7363, 2.96, 0.315, 459, 248, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
3530, 5u6yA, 0.7363, 2.96, 0.315, 459, 248, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
3531, 5l8lA, 0.7363, 2.92, 0.305, 263, 249, AURORA-A KINASE DOMAIN IN COMPLEX WITH VNAR-D01 (CRYSTAL FORM 1)
3532, 5aafA, 0.7363, 2.56, 0.310, 254, 242, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14A)
3533, 4twcB, 0.7363, 3.18, 0.173, 292, 254, 2-BENZAMIDO-N-(1H-BENZO[D]IMIDAZOL-2-YL)THIAZOLE-4- CARBOXAMIDE DERIVATIVES AS POTENT INHIBITORS OF CK1D/E
3534, 3h0yA, 0.7363, 2.39, 0.308, 250, 240, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
3535, 3bbwB, 0.7363, 2.51, 0.227, 275, 242, CRYSTAL STRUCTURE OF THE ERBB4 KINASE IN ITS INACTIVE CONFORMATION
3536, 2x4fA, 0.7363, 2.71, 0.265, 289, 245, THE CRYSTAL STRUCTURE OF THE HUMAN MYOSIN LIGHT CHAIN KINASE LOC340156.
3537, 2w1fA, 0.7363, 2.60, 0.309, 253, 243, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
3538, 1ia8A, 0.7363, 3.12, 0.271, 272, 251, THE 1.7 A CRYSTAL STRUCTURE OF HUMAN CELL CYCLE CHECKPOINT KINASE CHK1
3539, 5uklA, 0.7362, 3.16, 0.269, 630, 253, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG222886 (14BD)
3540, 5jgaA, 0.7362, 2.76, 0.295, 296, 244, CRYSTAL STRUCTURE OF HUMAN TAK1/TAB1 FUSION PROTEIN IN COMPLEX WITH LIGAND 11C
3541, 3iecB, 0.7362, 2.83, 0.314, 313, 245, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
3542, 3c4yB, 0.7362, 2.85, 0.263, 466, 247, CRYSTAL STRUCTURE OF APO FORM OF G PROTEIN COUPLED RECEPTOR KINASE 1 AT 7.51A
3543, 2hxlA, 0.7362, 3.04, 0.272, 272, 250, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 1
3544, 5wg5A, 0.7361, 3.22, 0.274, 617, 252, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224061
3545, 5ug8A, 0.7361, 2.96, 0.214, 280, 248, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN (L858R T790M V948R) IN COMPLEX WITH A COVALENT INHIBITOR N-[(3R4R)-4-FLUORO-1-{6-[(1- METHYL-1H-PYRAZOL-4-YL)AMINO]-9-(PROPAN-2-YL)-9H-PURIN-2- YL}PYRROLIDIN-3-YL]PROPANAMIDE
3546, 4w9wA, 0.7361, 2.86, 0.259, 306, 247, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH SMALL MOLECULE AZD-7762
3547, 4gs6A, 0.7361, 2.64, 0.296, 294, 243, IRREVERSIBLE INHIBITION OF TAK1 KINASE BY 5Z-7-OXOZEAENOL
3548, 4d0xA, 0.7361, 3.22, 0.252, 291, 254, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
3549, 3e62A, 0.7361, 3.22, 0.244, 291, 254, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
3550, 1ckiA, 0.7361, 3.10, 0.189, 292, 254, RECOMBINANT CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317
3551, 5vioD, 0.7360, 2.93, 0.296, 271, 247, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 13)
3552, 5u6cA, 0.7360, 2.66, 0.222, 272, 243, CRYSTAL STRUCTURE OF THE MER KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
3553, 5k00A, 0.7360, 2.38, 0.333, 311, 240, MELK IN COMPLEX WITH NVS-MELK5
3554, 4lgdB, 0.7360, 3.30, 0.285, 350, 260, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
3555, 3utoA, 0.7360, 3.13, 0.257, 559, 253, TWITCHIN KINASE REGION FROM C.ELEGANS (FN31-NL-KIN-CRD-IG26)
3556, 2vn9A, 0.7360, 2.95, 0.312, 301, 250, CRYSTAL STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II DELTA ISOFORM 1 CAMKD
3557, 2hxqA, 0.7360, 3.04, 0.272, 272, 250, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 2
3558, 1o6yA, 0.7360, 2.50, 0.252, 260, 242, CATALYTIC DOMAIN OF PKNB KINASE FROM MYCOBACTERIUM TUBERCULOSIS
3559, 5kbqA, 0.7359, 3.20, 0.303, 289, 254, PAK1 IN COMPLEX WITH BIS-ANILINO PYRIMIDINE INHIBITOR
3560, 4wd5A, 0.7359, 3.04, 0.220, 307, 250, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH QL-X138
3561, 4umqA, 0.7359, 2.53, 0.322, 314, 242, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
3562, 3uzpA, 0.7359, 3.22, 0.169, 292, 254, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P21 CRYSTAL FORM
3563, 3pp0A, 0.7359, 2.87, 0.214, 286, 248, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN HER2 (ERBB2).
3564, 5x17A, 0.7358, 3.35, 0.184, 290, 255, CRYSTAL STRUCTURE OF MURINE CK1D IN COMPLEX WITH ADP
3565, 5v24B, 0.7358, 2.89, 0.286, 263, 245, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
3566, 5mzlA, 0.7358, 2.52, 0.264, 269, 242, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUSPEPTIDE AND FRAGMENT LIKE MOLEKULE N-QUINOLIN-5-YLPYRIDINE- 3-CARBOXAMIDE
3567, 4ztrA, 0.7358, 2.33, 0.308, 249, 240, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO FK1141
3568, 4gfmA, 0.7358, 3.00, 0.259, 289, 251, JAK2 KINASE (JH1 DOMAIN) WITH 26-DICHLORO-N-(2-OXO-25- DIHYDROPYRIDIN-4-YL)BENZAMIDE
3569, 4d28D, 0.7358, 2.73, 0.310, 271, 245, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.11 AT5G35410
3570, 1zwsE, 0.7358, 2.94, 0.269, 278, 249, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
3571, 5ukmA, 0.7357, 3.22, 0.272, 621, 254, BOVINE GRK2 IN COMPLEX WITH HUMAN GBETAGAMMA SUBUNITS AND CCG258208 (14AS)
3572, 5o23A, 0.7357, 2.88, 0.242, 269, 248, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED APO STATE
3573, 4aqcB, 0.7357, 3.08, 0.257, 295, 253, TRIAZOLOPYRIDINE-BASED INHIBITOR OF JANUS KINASE 2
3574, 3j4rE, 0.7357, 3.09, 0.261, 325, 253, PSEUDO-ATOMIC MODEL OF THE AKAP18-PKA COMPLEX IN A LINEAR CONFORMATION DERIVED FROM ELECTRON MICROSCOPY
3575, 3j4rD, 0.7357, 3.09, 0.261, 325, 253, PSEUDO-ATOMIC MODEL OF THE AKAP18-PKA COMPLEX IN A LINEAR CONFORMATION DERIVED FROM ELECTRON MICROSCOPY
3576, 3j4qE, 0.7357, 3.09, 0.261, 325, 253, PSEUDO-ATOMIC MODEL OF THE AKAP18-PKA COMPLEX IN A BENT CONFORMATION DERIVED FROM ELECTRON MICROSCOPY
3577, 3j4qD, 0.7357, 3.09, 0.261, 325, 253, PSEUDO-ATOMIC MODEL OF THE AKAP18-PKA COMPLEX IN A BENT CONFORMATION DERIVED FROM ELECTRON MICROSCOPY
3578, 3e64A, 0.7357, 3.23, 0.244, 291, 254, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
3579, 2wzjA, 0.7357, 2.88, 0.306, 310, 248, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
3580, 1kobA, 0.7357, 3.02, 0.266, 352, 252, TWITCHIN KINASE FRAGMENT (APLYSIA) AUTOREGULATED PROTEIN KINASE DOMAIN
3581, 5maiA, 0.7356, 2.11, 0.325, 312, 237, CRYSTAL STRUCTURE OF MELK IN COMPLEX WITH AN INHIBITOR
3582, 4wd5B, 0.7356, 3.09, 0.182, 304, 253, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH QL-X138
3583, 4hyiA, 0.7356, 3.07, 0.271, 269, 251, X-RAY CRYSTAL STRUCTURE OF COMPOUND 40 BOUND TO HUMAN CHK1 KINASE DOMAIN
3584, 3repA, 0.7356, 2.77, 0.170, 268, 247, CRYSTAL STRUCTURE OF THE ILK/ALPHA-PARVIN CORE COMPLEX (MNATP)
3585, 3kmwA, 0.7356, 2.76, 0.170, 268, 247, CRYSTAL STRUCTURE OF THE ILK/ALPHA-PARVIN CORE COMPLEX (MGATP)
3586, 1kobB, 0.7356, 3.23, 0.252, 352, 254, TWITCHIN KINASE FRAGMENT (APLYSIA) AUTOREGULATED PROTEIN KINASE DOMAIN
3587, 5ugcA, 0.7355, 2.97, 0.214, 280, 248, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN (L858R T790M V948R) IN COMPLEX WITH A COVALENT INHIBITOR N-[(3R4R)-4-FLUORO-1-{6-[(3- METHOXY-1-METHYL-1H-PYRAZOL-4-YL)AMINO]-9-METHYL-9H-PURIN-2- YL}PYRROLIDIN-3-YL]PROPANAMIDE
3588, 5gjgA, 0.7355, 2.67, 0.296, 289, 243, CRYSTAL STRUCTURE OF HUMAN TAK1/TAB1 FUSION PROTEIN IN COMPLEX WITH LIGAND 4
3589, 4ztsA, 0.7355, 2.38, 0.308, 249, 240, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO FK1142
3590, 4idvD, 0.7355, 2.96, 0.260, 335, 250, CRYSTAL STRUCTURE OF NIK WITH COMPOUND 4-{3-[2-AMINO-5-(2- METHOXYETHOXY)PYRIMIDIN-4-YL]-1H-INDOL-5-YL}-2-METHYLBUT-3-YN-2-OL (13V)
3591, 1wmkD, 0.7355, 3.11, 0.263, 314, 251, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
3592, 1wmkB, 0.7355, 3.11, 0.263, 314, 251, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
3593, 1mruA, 0.7354, 2.57, 0.259, 269, 243, INTRACELLULAR SER/THR PROTEIN KINASE DOMAIN OF MYCOBACTERIUM TUBERCULOSIS PKNB.
3594, 5vilD, 0.7353, 2.96, 0.289, 271, 246, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 6)
3595, 5te0A, 0.7353, 2.88, 0.243, 316, 247, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH BIBF 1120
3596, 5ng2B, 0.7353, 2.82, 0.214, 278, 248, STRUCTURE OF RIP2K(D146N) WITH BOUND STAUROSPORINE
3597, 5cf6A, 0.7353, 2.98, 0.263, 285, 251, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-[(2S)-23-DIHYDROXYPROPYL]-3-METHYL-7-(METHYLAMINO)-35810- TETRAAZATRICYCLO [7.3.0.026]DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
3598, 4umrA, 0.7353, 2.52, 0.322, 313, 242, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
3599, 3q32A, 0.7353, 3.01, 0.262, 291, 252, STRUCTURE OF JANUS KINASE 2 WITH A PYRROLOTRIAZINE INHIBITOR
3600, 3hmpA, 0.7353, 2.54, 0.298, 258, 245, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH A QUINAZOLIN LIGAND COMPOUND 4
3601, 2x8dA, 0.7353, 3.11, 0.271, 279, 251, DISCOVERY OF A NOVEL CLASS OF TRIAZOLONES AS CHECKPOINT KINASE INHIBITORS - HIT TO LEAD EXPLORATION
3602, 2w1eA, 0.7353, 2.59, 0.309, 252, 243, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
3603, 1wmkG, 0.7353, 3.11, 0.263, 313, 251, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
3604, 1wmkF, 0.7353, 3.11, 0.263, 303, 251, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
3605, 1wmkE, 0.7353, 3.11, 0.263, 313, 251, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
3606, 1wmkC, 0.7353, 3.11, 0.263, 303, 251, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
3607, 1wmkA, 0.7353, 3.11, 0.263, 303, 251, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
3608, 5oktA, 0.7352, 3.21, 0.169, 285, 254, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH IWP-2 
3609, 4uy9B, 0.7352, 2.91, 0.281, 315, 249, STRUCTURE OF MLK1 KINASE DOMAIN WITH LEUCINE ZIPPER 1
3610, 4rwkA, 0.7352, 3.34, 0.245, 308, 257, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) IN COMPLEX WITH N-{3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H- PYRAZOL-5-YL}-4-[(3R5S)-35-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE (AZD4547)
3611, 1wmkH, 0.7352, 3.11, 0.263, 304, 251, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
3612, 5tq3B, 0.7351, 2.93, 0.257, 285, 249, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
3613, 5lwnA, 0.7351, 3.13, 0.234, 290, 252, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 5 (FM409)
3614, 4ludB, 0.7351, 2.51, 0.253, 409, 241, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH THE FLUORESCENT COMPOUND SKF86002
3615, 4fg8B, 0.7351, 2.65, 0.286, 268, 241, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-315 IN COMPLEX WITH ATP
3616, 4e26A, 0.7351, 2.85, 0.206, 270, 247, BRAF IN COMPLEX WITH AN ORGANIC INHIBITOR 7898734
3617, 4d28A, 0.7351, 2.86, 0.302, 274, 248, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.11 AT5G35410
3618, 3iecD, 0.7351, 2.78, 0.313, 311, 243, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
3619, 2cgwA, 0.7351, 3.00, 0.269, 262, 249, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
3620, 5ih5A, 0.7350, 3.23, 0.180, 286, 255, HUMAN CASEIN KINASE 1 ISOFORM DELTA (KINASE DOMAIN) IN COMPLEX WITH EPIBLASTIN A
3621, 4ysmB, 0.7350, 3.06, 0.308, 475, 250, CALCIUM-DEPENDENT PROTEIN KINASE FROM EIMERIA TENELLA
3622, 2c6dA, 0.7350, 2.65, 0.307, 254, 244, AURORA A KINASE ACTIVATED MUTANT (T287D) IN COMPLEX WITH ADPNP
3623, 6b2pA, 0.7349, 2.38, 0.267, 255, 240, DUAL INHIBITION OF THE ESSENTIAL PROTEIN KINASES A AND B IN MYCOBACTERIUM TUBERCULOSIS
3624, 4usfA, 0.7349, 3.12, 0.270, 277, 252, HUMAN SLK WITH SB-440719
3625, 2qvsE, 0.7349, 3.15, 0.261, 323, 253, CRYSTAL STRUCTURE OF TYPE IIA HOLOENZYME OF CAMP-DEPENDENT PROTEIN KINASE
3626, 2jivB, 0.7349, 2.79, 0.224, 272, 246, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION IN COMPEX WITH HKI-272
3627, 2chlA, 0.7349, 3.40, 0.206, 298, 257, STRUCTURE OF CASEIN KINASE 1 GAMMA 3
3628, 1zltA, 0.7349, 3.09, 0.268, 272, 250, CRYSTAL STRUCTURE OF CHK1 COMPLEXED WITH A HYMENALDISINE ANALOG
3629, 5dewA, 0.7348, 3.03, 0.306, 295, 252, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND 5
3630, 4g5pB, 0.7348, 3.20, 0.190, 303, 253, CRYSTAL STRUCTURE OF EGFR KINASE T790M IN COMPLEX WITH BIBW2992
3631, 3vbwA, 0.7348, 2.57, 0.264, 264, 242, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
3632, 3a7gB, 0.7348, 2.98, 0.276, 290, 250, HUMAN MST3 KINASE
3633, 6gl9A, 0.7347, 3.30, 0.232, 292, 254, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 10 (FM475) 
3634, 4zy4A, 0.7347, 2.99, 0.284, 288, 250, CRYSTAL STRUCTURE OF P21 ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 4
3635, 4zjvA, 0.7347, 2.92, 0.210, 282, 248, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH MITOGEN- INDUCIBLE GENE 6 PROTEIN
3636, 3zzeA, 0.7347, 3.29, 0.222, 286, 252, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH N - ((3Z)-4-CHLORO-7-METHYL-2-OXO-12-DIHYDRO-3H-INDOL-3- YLIDENE)-2-(4-HYDROXYPHENYL)PROPANOHYDRAZIDE
3637, 3uytC, 0.7347, 3.21, 0.169, 286, 254, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
3638, 3rcdC, 0.7347, 2.68, 0.197, 281, 244, HER2 KINASE DOMAIN COMPLEXED WITH TAK-285
3639, 3rcdA, 0.7347, 2.68, 0.197, 281, 244, HER2 KINASE DOMAIN COMPLEXED WITH TAK-285
3640, 3f69A, 0.7347, 2.57, 0.270, 270, 241, CRYSTAL STRUCTURE OF THE MYCOBACTERIUM TUBERCULOSIS PKNB MUTANT KINASE DOMAIN IN COMPLEX WITH KT5720
3641, 1koaA, 0.7347, 3.21, 0.249, 447, 253, TWITCHIN KINASE FRAGMENT (C.ELEGANS) AUTOREGULATED PROTEIN KINASE AND IMMUNOGLOBULIN DOMAINS
3642, 5v5nA, 0.7346, 2.80, 0.295, 294, 244, CRYSTAL STRUCTURE OF TAKINIB BOUND TO TAK1
3643, 5ar4A, 0.7346, 2.78, 0.231, 274, 247, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH SB-203580
3644, 4wnpD, 0.7346, 2.83, 0.295, 272, 244, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
3645, 3q4zB, 0.7346, 2.93, 0.301, 279, 249, STRUCTURE OF UNPHOSPHORYLATED PAK1 KINASE DOMAIN
3646, 5mahA, 0.7345, 2.41, 0.322, 316, 239, CRYSTAL STRUCTURE OF MELK IN COMPLEX WITH AN INHIBITOR
3647, 3iecC, 0.7345, 2.78, 0.313, 311, 243, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
3648, 5vcvA, 0.7344, 2.65, 0.300, 287, 243, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH DASATINIB
3649, 5o11A, 0.7344, 2.55, 0.269, 268, 242, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL-MOLECULE INHIBITOR
3650, 5ih9A, 0.7344, 2.44, 0.329, 308, 240, MELK IN COMPLEX WITH NVS-MELK8A
3651, 4c3rA, 0.7344, 2.68, 0.313, 252, 243, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO AMPPCP
3652, 4bbeC, 0.7344, 3.10, 0.262, 288, 252, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
3653, 3vs1A, 0.7344, 2.60, 0.252, 424, 242, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-PHENYLUREA
3654, 3pjcA, 0.7344, 3.04, 0.252, 286, 250, CRYSTAL STRUCTURE OF JAK3 COMPLEXED WITH A POTENT ATP SITE INHIBITOR SHOWING HIGH SELECTIVITY WITHIN THE JANUS KINASE FAMILY
3655, 3h0zC, 0.7344, 2.15, 0.305, 246, 236, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
3656, 2f57A, 0.7344, 3.21, 0.269, 297, 253, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 5
3657, 1omwA, 0.7344, 3.21, 0.268, 614, 254, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN G PROTEIN-COUPLED RECEPTOR KINASE 2 AND HETEROTRIMERIC G PROTEIN BETA 1 AND GAMMA 2 SUBUNITS
3658, 5w5oM, 0.7343, 2.77, 0.223, 276, 247, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3659, 4g3dA, 0.7343, 2.96, 0.254, 324, 248, CRYSTAL STRUCTURE OF HUMAN NF-KAPPAB INDUCING KINASE (NIK)
3660, 4g3cA, 0.7343, 2.98, 0.253, 315, 249, CRYSTAL STRUCTURE OF APO MURINE NF-KAPPAB INDUCING KINASE (NIK)
3661, 3ndmA, 0.7343, 3.01, 0.270, 383, 248, CRYSTAL STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT ISOQUINOLONE DERIVATIVE
3662, 2wzjE, 0.7343, 2.99, 0.305, 310, 249, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
3663, 5ng0A, 0.7342, 2.73, 0.215, 274, 246, STRUCTURE OF RIP2K(L294F) WITH BOUND AMPPCP
3664, 5lwmA, 0.7342, 3.34, 0.231, 290, 255, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 4 (FM381)
3665, 5jgbA, 0.7342, 2.80, 0.290, 295, 245, CRYSTAL STRUCTURE OF HUMAN TAK1/TAB1 FUSION PROTEIN IN COMPLEX WITH LIGAND 10
3666, 4xhgA, 0.7342, 3.35, 0.183, 357, 257, STRUCTURE OF C. GLABRATA HRR25 BOUND TO ADP (FORMATE CONDITION)
3667, 3vs1B, 0.7342, 2.54, 0.245, 433, 241, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-PHENYLUREA
3668, 5oopA, 0.7341, 2.94, 0.282, 261, 248, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMP-PNP
3669, 4lqqA, 0.7341, 2.91, 0.280, 388, 250, CRYSTAL STRUCTURE OF THE CBK1(T743E)-MOB2 KINASE-COACTIVATOR COMPLEX IN CRYSTAL FORM B
3670, 4kbkB, 0.7341, 3.25, 0.173, 289, 254, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
3671, 2xzsA, 0.7341, 3.06, 0.276, 301, 250, DEATH ASSOCIATED PROTEIN KINASE 1 RESIDUES 1-312
3672, 5vioC, 0.7340, 3.07, 0.291, 271, 247, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 13)
3673, 5vcwB, 0.7340, 2.67, 0.296, 285, 243, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH PELITINIB
3674, 5cf5A, 0.7340, 2.99, 0.267, 287, 251, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 7-[(DIMETHYL-13-THIAZOL-2-YL)AMINO]-10-ETHYL-3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.026] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
3675, 4tw9B, 0.7340, 3.22, 0.169, 289, 254, DIFLUORO-DIOXOLO-BENZOIMIDAZOL-BENZAMIDES AS POTENT INHIBITORS OF CK1DELTA AND EPSILON WITH NANOMOLAR INHIBITORY ACTIVITY ON CANCER CELL PROLIFERATION
3676, 3krrA, 0.7340, 3.24, 0.252, 291, 254, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT QUINOXALINE ATP SITE INHIBITOR
3677, 3eqrA, 0.7340, 3.05, 0.256, 270, 250, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T74
3678, 5tq3A, 0.7339, 3.09, 0.252, 282, 250, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
3679, 5jznA, 0.7339, 2.78, 0.299, 268, 244, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH NVP-TAE684
3680, 4rwiA, 0.7339, 3.48, 0.239, 305, 259, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) APO
3681, 3ikaB, 0.7339, 3.30, 0.176, 310, 255, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M MUTANT COVALENTLY BINDING TO WZ4002
3682, 2v7oA, 0.7339, 2.94, 0.319, 305, 248, CRYSTAL STRUCTURE OF HUMAN CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE II GAMMA
3683, 2br1A, 0.7339, 3.18, 0.271, 272, 251, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
3684, 2aypA, 0.7339, 2.89, 0.286, 268, 248, CRYSTAL STRUCTURE OF CHK1 WITH AN INDOL INHIBITOR
3685, 6gl9B, 0.7338, 3.13, 0.235, 291, 251, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 10 (FM475) 
3686, 4lgdD, 0.7338, 3.33, 0.285, 338, 260, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
3687, 5vilC, 0.7337, 3.11, 0.290, 271, 248, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 6)
3688, 5j79B, 0.7337, 2.84, 0.222, 277, 248, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE COMPOUND 3 COMPLEX
3689, 5cf6B, 0.7337, 3.02, 0.259, 290, 251, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-[(2S)-23-DIHYDROXYPROPYL]-3-METHYL-7-(METHYLAMINO)-35810- TETRAAZATRICYCLO [7.3.0.026]DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
3690, 5ap1A, 0.7337, 2.98, 0.292, 268, 250, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
3691, 5uyjA, 0.7336, 2.85, 0.289, 281, 246, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B
3692, 5uoxA, 0.7336, 2.90, 0.286, 263, 245, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
3693, 5ih6A, 0.7336, 3.22, 0.177, 286, 254, HUMAN CASEIN KINASE 1 ISOFORM DELTA (KINASE DOMAIN) IN COMPLEX WITH EPIBLASTIN A DERIVATIVE
3694, 5gtyC, 0.7336, 2.87, 0.207, 295, 246, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
3695, 4g5pA, 0.7336, 3.00, 0.225, 299, 249, CRYSTAL STRUCTURE OF EGFR KINASE T790M IN COMPLEX WITH BIBW2992
3696, 4bbeB, 0.7336, 3.12, 0.262, 288, 252, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
3697, 3js2A, 0.7336, 3.51, 0.232, 295, 259, CRYSTAL STRUCTURE OF MINIMAL KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH 5-(2-THIENYL) NICOTINIC ACID
3698, 1k2pA, 0.7336, 2.83, 0.203, 258, 246, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE DOMAIN
3699, 5vilA, 0.7335, 3.03, 0.283, 271, 247, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 6)
3700, 4i21A, 0.7335, 3.11, 0.203, 290, 251, CRYSTAL STRUCTURE OF L858R + T790M EGFR KINASE DOMAIN IN COMPLEX WITH MIG6 PEPTIDE
3701, 3umxA, 0.7335, 2.58, 0.277, 261, 242, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH INHIBITOR (Z)-2-[(1H- INDOL-3-YL)METHYLENE]-7-(AZEPAN-1-YLMETHYL)-6-HYDROXYBENZOFURAN- 3(2H)-ONE
3702, 5n93A, 0.7334, 2.77, 0.293, 259, 246, TTK KINASE DOMAIN IN COMPLEX WITH TC-MPS1-12
3703, 5jgdA, 0.7334, 2.98, 0.293, 295, 246, CRYSTAL STRUCTURE OF HUMAN TAK1/TAB1 FUSION PROTEIN IN COMPLEX WITH LIGAND 12
3704, 4useA, 0.7334, 2.86, 0.313, 286, 246, HUMAN STK10 (LOK) WITH SB-633825
3705, 4f08B, 0.7334, 3.20, 0.256, 288, 254, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
3706, 4e4mD, 0.7334, 3.12, 0.270, 296, 252, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
3707, 6bkuA, 0.7333, 2.82, 0.290, 267, 245, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B BOUND TO GSK650394
3708, 5op7A, 0.7333, 2.84, 0.272, 261, 246, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIMIDINE LRRK2 INHIBITOR
3709, 4umuA, 0.7333, 2.64, 0.318, 316, 242, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
3710, 4qo9B, 0.7333, 3.03, 0.269, 285, 249, MST3 IN COMPLEX WITH DANUSERTIB
3711, 2ywpA, 0.7333, 3.02, 0.278, 269, 248, CRYSTAL STRUCTURE OF CHK1 WITH A UREA INHIBITOR
3712, 6b2qC, 0.7332, 2.44, 0.267, 264, 240, DUAL INHIBITION OF THE ESSENTIAL PROTEIN KINASES A AND B IN MYCOBACTERIUM TUBERCULOSIS
3713, 5jrqA, 0.7332, 2.58, 0.215, 258, 242, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-6-VEM
3714, 4zloA, 0.7332, 2.70, 0.293, 277, 246, SERINE/THREONINE-PROTEIN KINASE PAK1 COMPLEXED WITH A DIBENZODIAZEPINE: IDENTIFICATION OF AN ALLOSTERIC SITE ON PAK1
3715, 4wnpA, 0.7332, 2.86, 0.294, 273, 245, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
3716, 4gmyA, 0.7332, 3.19, 0.253, 298, 253, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH 26-DICHLORO-N-{2- [(CYCLOPROPYLCARBONYL)AMINO]PYRIDIN-4-YL}BENZAMIDE
3717, 3uytA, 0.7332, 3.09, 0.171, 287, 251, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
3718, 3fe3A, 0.7332, 3.16, 0.303, 317, 254, CRYSTAL STRUCTURE OF THE KINASE MARK3/PAR-1: T211A-S215A DOUBLE MUTANT
3719, 5kkrB, 0.7330, 2.87, 0.201, 272, 244, KSR2:MEK1 COMPLEX BOUND TO THE SMALL MOLECULE APS-2-79
3720, 4ytiA, 0.7330, 2.96, 0.252, 284, 250, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASE
3721, 4w9xA, 0.7330, 2.86, 0.260, 300, 246, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH BARICITINIB
3722, 4aqcA, 0.7330, 3.07, 0.270, 289, 252, TRIAZOLOPYRIDINE-BASED INHIBITOR OF JANUS KINASE 2
3723, 2e9oA, 0.7330, 3.08, 0.289, 269, 249, STRUCTURE OF H-CHK1 COMPLEXED WITH AA582939
3724, 5vioA, 0.7329, 2.95, 0.293, 271, 246, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 13)
3725, 4wnpC, 0.7329, 2.84, 0.295, 271, 244, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
3726, 4e4mB, 0.7329, 3.13, 0.270, 296, 252, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
3727, 3ppjB, 0.7329, 2.62, 0.193, 264, 243, HUMAN B-RAF KINASE IN COMPLEX WITH A FUROPYRIDINE INHIBITOR
3728, 2brbA, 0.7329, 3.18, 0.271, 272, 251, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
3729, 5oq5A, 0.7328, 3.01, 0.277, 265, 249, STRUCTURE OF CHK1 8-PT. MUTANT COMPLEX WITH AMINOPYRIMIDO- BENZODIAZEPINONE LRRK2 INHIBITOR
3730, 4jiaA, 0.7328, 3.28, 0.248, 298, 254, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 9
3731, 4czuA, 0.7328, 3.23, 0.303, 297, 254, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.23 AT1G30270 T190D MUTANT
3732, 3qc4A, 0.7328, 3.04, 0.283, 276, 251, PDK1 IN COMPLEX WITH DFG-OUT INHIBITOR XXX
3733, 3cblA, 0.7328, 3.17, 0.240, 356, 250, CRYSTAL STRUCTURE OF HUMAN FELINE SARCOMA VIRAL ONCOGENE HOMOLOGUE (V- FES) IN COMPLEX WITH STAUROSPORINE AND A CONSENSUS PEPTIDE
3734, 5v19B, 0.7327, 2.93, 0.294, 260, 245, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
3735, 5oorA, 0.7327, 2.91, 0.283, 273, 247, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH STAUROSPORINE
3736, 5ei6A, 0.7327, 2.78, 0.294, 264, 248, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
3737, 4f08A, 0.7327, 3.22, 0.256, 288, 254, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
3738, 3p1aA, 0.7327, 2.58, 0.289, 281, 242, STRUCTURE OF HUMAN MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE- SPECIFIC CDC2-INHIBITORY KINASE MYT1 (PKMYT1)
3739, 6es0A, 0.7326, 3.04, 0.218, 288, 252, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH THE ACTIVATION LOOP TARGETING INHIBITOR CS-R35
3740, 5tq5A, 0.7326, 2.98, 0.257, 291, 249, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
3741, 5jznB, 0.7326, 2.58, 0.290, 266, 241, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH NVP-TAE684
3742, 5ar2A, 0.7326, 2.80, 0.223, 277, 247, RIP2 KINASE CATALYTIC DOMAIN (1 - 310)
3743, 4e4mE, 0.7326, 3.29, 0.260, 296, 254, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
3744, 4d0wA, 0.7326, 3.00, 0.260, 289, 250, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
3745, 2zmcA, 0.7326, 2.64, 0.291, 260, 247, CRYSTAL STRUCTURE OF HUMAN MITOTIC CHECKPOINT KINASE MPS1 CATALYTIC DOMAIN APO FORM
3746, 1u59A, 0.7326, 3.18, 0.233, 282, 253, CRYSTAL STRUCTURE OF THE ZAP-70 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
3747, 5aepA, 0.7325, 2.99, 0.260, 287, 250, NOVEL PYRROLE CARBOXAMIDE INHIBITORS OF JAK2 AS POTENTIAL TREATMENT OF MYELOPROLIFERATIVE DISORDERS
3748, 4e6qA, 0.7325, 3.32, 0.267, 296, 255, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 12
3749, 3sv0A, 0.7325, 3.32, 0.194, 294, 253, CRYSTAL STRUCTURE OF CASEIN KINASE-1 LIKE PROTEIN IN PLANT
3750, 3ppkB, 0.7325, 2.63, 0.193, 264, 243, HUMAN B-RAF KINASE IN COMPLEX WITH A NON-OXIME FUROPYRIDINE INHIBITOR
3751, 3a4pA, 0.7325, 3.10, 0.223, 285, 251, HUMAN C-MET KINASE DOMAIN COMPLEXED WITH 6-BENZYLOXYQUINOLINE INHIBITOR
3752, 2w1iB, 0.7325, 3.23, 0.258, 284, 252, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
3753, 2e9uA, 0.7325, 3.10, 0.289, 269, 249, STRUCTURE OF H-CHK1 COMPLEXED WITH A780125
3754, 6babC, 0.7324, 2.86, 0.302, 284, 245, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
3755, 5zwjA, 0.7324, 2.55, 0.220, 267, 241, CRYSTAL STRUCTURE OF EGFR 675-1022 T790M/C797S/V948R IN COMPLEX WITH EAI045 
3756, 4zsaA, 0.7324, 3.41, 0.233, 289, 257, CRYSTAL STRUCTURE OF FGFR1 KINASE DOMAIN IN COMPLEX WITH 7N
3757, 4ysmA, 0.7324, 3.10, 0.308, 475, 250, CALCIUM-DEPENDENT PROTEIN KINASE FROM EIMERIA TENELLA
3758, 4bbeD, 0.7324, 3.12, 0.262, 288, 252, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
3759, 4bbeA, 0.7324, 3.13, 0.262, 288, 252, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
3760, 3uysC, 0.7324, 3.20, 0.174, 286, 253, CRYSTAL STRUCTURE OF APO HUMAN CK1D
3761, 3oroA, 0.7324, 2.96, 0.253, 272, 245, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 4)
3762, 3e5aA, 0.7324, 2.92, 0.309, 264, 246, CRYSTAL STRUCTURE OF AURORA A IN COMPLEX WITH VX-680 AND TPX2
3763, 5x17B, 0.7323, 3.22, 0.174, 289, 253, CRYSTAL STRUCTURE OF MURINE CK1D IN COMPLEX WITH ADP
3764, 5w5oO, 0.7323, 2.80, 0.223, 276, 247, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3765, 5oktB, 0.7323, 3.04, 0.171, 281, 251, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH IWP-2 
3766, 4hyhA, 0.7323, 2.79, 0.276, 263, 246, X-RAY CRYSTAL STRUCTURE OF COMPOUND 39 BOUND TO HUMAN CHK1 KINASE DOMAIN
3767, 2z2wA, 0.7323, 2.53, 0.217, 260, 240, HUMAND WEE1 KINASE COMPLEXED WITH INHIBITOR PF0335770
3768, 2y7jD, 0.7323, 2.85, 0.289, 281, 246, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
3769, 5ikwA, 0.7322, 2.92, 0.259, 297, 247, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
3770, 5eakB, 0.7322, 2.50, 0.320, 300, 241, OPTIMIZATION OF MICROTUBULE AFFINITY REGULATING KINASE (MARK) INHIBITORS WITH IMPROVED PHYSICAL PROPERTIES
3771, 4b0gA, 0.7322, 2.48, 0.305, 247, 239, COMPLEX OF AURORA-A BOUND TO AN IMIDAZOPYRIDINE-BASED INHIBITOR
3772, 5vd3A, 0.7321, 2.63, 0.306, 293, 242, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN (DE-PHOSPHORYLATED) IN COMPLEX WITH SARACATINIB
3773, 5n51A, 0.7321, 2.53, 0.266, 268, 241, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUS PEPTIDE AND FRAGMENT LIKE MOLECULE 34-DIBROMOTHIOPHENE-2-CARBOXYLIC ACID
3774, 5ih4A, 0.7321, 3.28, 0.180, 286, 255, HUMAN CASEIN KINASE 1 ISOFORM DELTA APO (KINASE DOMAIN)
3775, 4bicB, 0.7321, 2.73, 0.296, 259, 243, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3776, 2gs6A, 0.7321, 3.17, 0.202, 311, 252, CRYSTAL STRUCTURE OF THE ACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AN ATP ANALOG-PEPTIDE CONJUGATE
3777, 2g2fA, 0.7321, 3.28, 0.239, 275, 251, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
3778, 2e9nA, 0.7321, 2.91, 0.275, 269, 247, STRUCTURE OF H-CHK1 COMPLEXED WITH A767085
3779, 1ckjB, 0.7321, 3.31, 0.188, 293, 255, CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317 COMPLEX WITH BOUND TUNGSTATE
3780, 5vd0A, 0.7320, 2.68, 0.300, 293, 243, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH MK1775
3781, 5tq8A, 0.7320, 2.93, 0.254, 291, 248, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
3782, 4e4mA, 0.7320, 3.22, 0.261, 296, 253, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
3783, 2w1dA, 0.7320, 2.62, 0.310, 251, 242, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
3784, 2c3kA, 0.7320, 3.07, 0.289, 262, 249, IDENTIFICATION OF A BURIED POCKET FOR POTENT AND SELECTIVE INHIBITION OF CHK1: PREDICTION AND VERIFICATION
3785, 5u6bB, 0.7319, 3.16, 0.227, 291, 251, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
3786, 5n52A, 0.7319, 2.53, 0.266, 268, 241, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUS PEPTIDE AND FRAGMENT LIKE MOLECULE (E)-3-(23-DIMETHOXYPHENYL)ACRYLIC ACID
3787, 5mafA, 0.7319, 2.47, 0.322, 315, 239, CRYSTAL STRUCTURE OF MELK IN COMPLEX WITH AN INHIBITOR
3788, 4zjvB, 0.7319, 3.07, 0.209, 273, 249, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH MITOGEN- INDUCIBLE GENE 6 PROTEIN
3789, 4aoiA, 0.7319, 3.29, 0.223, 289, 251, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH 4-( 3-((1H- PYRROLO(23-B)PYRIDIN-3-YL)METHYL)-(124)TRIAZOLO( 43-B)(124) TRIAZIN-6-YL)BENZONITRILE
3790, 5uv4A, 0.7318, 3.22, 0.167, 290, 252, CRYSTAL STRUCTURE OF MAIZE SIRK1 (SUCROSE-INDUCED RECEPTOR KINASE 1) KINASE DOMAIN BOUND TO AMP-PNP
3791, 4lrmA, 0.7318, 3.27, 0.216, 307, 255, EGFR D770_N771INSNPG IN COMPLEX WITH PD168393
3792, 4ji9B, 0.7318, 3.05, 0.259, 288, 251, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH TG101209
3793, 4cztA, 0.7318, 3.25, 0.303, 294, 254, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.23 AT1G30270
3794, 3c4fA, 0.7318, 3.55, 0.239, 290, 259, FGFR TYROSINE KINASE DOMAIN IN COMPLEX WITH 3-(3- METHOXYBENZYL)-7-AZAINDOLE
3795, 6babB, 0.7317, 2.86, 0.307, 285, 244, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
3796, 4kbaC, 0.7317, 3.23, 0.174, 277, 253, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
3797, 4g3dB, 0.7317, 2.97, 0.255, 318, 247, CRYSTAL STRUCTURE OF HUMAN NF-KAPPAB INDUCING KINASE (NIK)
3798, 4cztD, 0.7317, 3.25, 0.302, 302, 255, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.23 AT1G30270
3799, 3sxsA, 0.7317, 2.78, 0.220, 264, 246, CRYSTAL STRUCTURE OF BMX NON-RECEPTOR TYROSINE KINASE COMPLEXED WITH PP2
3800, 3i6uA, 0.7317, 2.83, 0.305, 390, 243, STRUCTURE AND ACTIVATION MECHANISM OF THE CHK2 DNA-DAMAGE CHECKPOINT KINASE
3801, 2brmA, 0.7317, 3.09, 0.273, 263, 249, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
3802, 1tkiB, 0.7317, 3.33, 0.227, 321, 255, AUTOINHIBITED SERINE KINASE DOMAIN OF THE GIANT MUSCLE PROTEIN TITIN
3803, 5w5oP, 0.7316, 2.76, 0.220, 275, 245, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3804, 3vs7A, 0.7316, 2.54, 0.258, 432, 240, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR 1-CYCLOPENTYL-3-(1H-PYRROLO[23-B]PYRIDIN-5-YL)-1H- PYRAZOLO[34-D]PYRIMIDIN-4-AMINE
3805, 3psdB, 0.7316, 2.65, 0.198, 264, 243, NON-OXIME PYRAZOLE BASED INHIBITORS OF B-RAF KINASE
3806, 3hztA, 0.7316, 2.82, 0.327, 421, 248, CRYSTAL STRUCTURE OF TOXOPLASMA GONDII CDPK3 TGME49_105860
3807, 2j4zB, 0.7316, 2.95, 0.302, 269, 248, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-680626
3808, 1tkiA, 0.7316, 3.33, 0.227, 321, 255, AUTOINHIBITED SERINE KINASE DOMAIN OF THE GIANT MUSCLE PROTEIN TITIN
3809, 6cmjB, 0.7315, 2.84, 0.297, 284, 246, HUMAN CAMKK2 WITH GSK650393
3810, 5j79A, 0.7315, 3.15, 0.224, 283, 250, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE COMPOUND 3 COMPLEX
3811, 4ynzA, 0.7315, 2.42, 0.295, 313, 241, STRUCTURE OF THE N-TERMINAL DOMAIN OF SAD
3812, 2bzkB, 0.7315, 2.56, 0.261, 268, 241, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH AMPPNP AND PIMTIDE
3813, 6cmjA, 0.7314, 2.88, 0.301, 285, 246, HUMAN CAMKK2 WITH GSK650393
3814, 4zegA, 0.7314, 2.81, 0.293, 260, 246, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE INHIBITOR
3815, 3dlsD, 0.7314, 3.04, 0.258, 284, 248, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
3816, 2hakF, 0.7314, 3.11, 0.306, 318, 252, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
3817, 1x8bA, 0.7314, 2.67, 0.220, 259, 241, STRUCTURE OF HUMAN WEE1A KINASE: KINASE DOMAIN COMPLEXED WITH INHIBITOR PD0407824
3818, 5uy6A, 0.7313, 2.84, 0.290, 282, 245, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B
3819, 4zimA, 0.7313, 3.07, 0.271, 285, 251, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH A 9H-CARBAZOLE-1- CARBOXAMIDE INHIBITOR
3820, 4kb8C, 0.7313, 3.24, 0.174, 277, 253, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
3821, 4ehgB, 0.7313, 2.48, 0.208, 260, 240, B-RAF KINASE DOMAIN IN COMPLEX WITH AN AMINOPYRIDIMINE-BASED INHIBITOR
3822, 3eyhA, 0.7313, 3.18, 0.255, 285, 251, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
3823, 2w1iA, 0.7313, 3.25, 0.262, 284, 252, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
3824, 5w5oJ, 0.7312, 2.80, 0.224, 275, 246, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3825, 5gjdA, 0.7312, 2.86, 0.287, 292, 247, CRYSTAL STRUCTURE OF HUMAN TAK1/TAB1 FUSION PROTEIN IN COMPLEX WITH LIGAND 2
3826, 4f09A, 0.7312, 3.32, 0.235, 288, 255, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
3827, 3vapA, 0.7312, 2.56, 0.312, 249, 240, SYNTHESIS AND SAR STUDIES OF IMIDAZO-[12-A]-PYRAZINE AURORA KINASE INHIBITORS WITH IMPROVED OFF TARGET KINASE SELECTIVITY
3828, 3qc4B, 0.7312, 3.00, 0.293, 278, 249, PDK1 IN COMPLEX WITH DFG-OUT INHIBITOR XXX
3829, 3cd3A, 0.7312, 3.16, 0.241, 352, 249, CRYSTAL STRUCTURE OF PHOSPHORYLATED HUMAN FELINE SARCOMA VIRAL ONCOGENE HOMOLOGUE (V-FES) IN COMPLEX WITH STAUROSPORINE AND A CONSENSUS PEPTIDE
3830, 2w5hA, 0.7312, 3.01, 0.276, 265, 250, HUMAN NEK2 KINASE APO
3831, 5w5oB, 0.7311, 2.80, 0.224, 275, 246, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3832, 4riyD, 0.7311, 3.06, 0.217, 297, 249, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
3833, 4qyeA, 0.7311, 2.99, 0.271, 271, 247, CHK1 KINASE DOMAIN IN COMPLEX WITH DIARYLPYRAZINE COMPOUND 1
3834, 4ivaA, 0.7311, 3.15, 0.253, 290, 253, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR TRANS-4-[(8AS)- 2-[(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(8AH)- YL]CYCLOHEXANECARBONITRILE
3835, 4fg9B, 0.7311, 2.81, 0.282, 279, 241, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-320 IN COMPLEX WITH ATP
3836, 3d4qA, 0.7311, 2.65, 0.198, 264, 243, PYRAZOLE-BASED INHIBITORS OF B-RAF KINASE
3837, 3a7hB, 0.7311, 3.04, 0.276, 290, 250, HUMAN MST3 KINASE IN COMPLEX WITH ATP
3838, 6glbA, 0.7310, 3.10, 0.237, 288, 249, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 20 (FM484) 
3839, 6bqpA, 0.7310, 2.83, 0.294, 263, 245, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH CRENOLANIB
3840, 5ew8A, 0.7310, 3.51, 0.240, 291, 258, FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH JNJ-4275693
3841, 4rzvA, 0.7310, 2.69, 0.213, 261, 244, CRYSTAL STRUCTURE OF THE BRAF (R509H) KINASE DOMAIN MONOMER BOUND TO VEMURAFENIB
3842, 4riwD, 0.7310, 3.06, 0.217, 297, 249, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
3843, 3zclA, 0.7310, 3.30, 0.223, 289, 251, X-RAY STRUCTURE OF C-MET KINASE IN COMPLEX WITH INHIBITOR ( S)-3-(1-(1H-PYRROLO(23-B)PYRIDIN-3-YL)ETHYL)-N-ISOPROPYL-( 124)TRIAZOLO(43-B)PYRIDAZIN-6-AMINE
3844, 3psbB, 0.7310, 2.66, 0.198, 264, 243, FURO[23-C]PYRIDINE-BASED INDANONE OXIMES AS POTENT AND SELECTIVE B- RAF INHIBITORS
3845, 3omvA, 0.7310, 2.63, 0.189, 264, 243, CRYSTAL STRUCTURE OF C-RAF (RAF-1)
3846, 3d4qB, 0.7310, 2.65, 0.193, 264, 243, PYRAZOLE-BASED INHIBITORS OF B-RAF KINASE
3847, 3a7gA, 0.7310, 3.17, 0.287, 289, 251, HUMAN MST3 KINASE
3848, 2e9vA, 0.7310, 2.85, 0.276, 268, 246, STRUCTURE OF H-CHK1 COMPLEXED WITH A859017
3849, 1ckiB, 0.7310, 3.19, 0.178, 286, 253, RECOMBINANT CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317
3850, 5op2A, 0.7309, 2.97, 0.289, 263, 249, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
3851, 5lohB, 0.7309, 2.59, 0.312, 250, 240, KINASE DOMAIN OF HUMAN GREATWALL
3852, 4wnoA, 0.7309, 2.92, 0.294, 272, 245, STRUCTURE OF ULK1 BOUND TO AN INHIBITOR
3853, 4l3pA, 0.7309, 2.80, 0.303, 295, 244, CRYSTAL STRUCTURE OF 2-(1-BENZOTHIOPHEN-7-YL)-4-[1-(PIPERIDIN-4-YL)- 1H-PYRAZOL-4-YL]FURO[23-C]PYRIDIN-7-AMINE BOUND TO TAK1-TAB1
3854, 3zbxA, 0.7309, 3.30, 0.223, 282, 251, X-RAY STRUCTURE OF C-MET KINASE IN COMPLEX WITH INHIBITOR 6- ((6-(4-FLUOROPHENYL)-(124)TRIAZOLO(43-B)(124)TRIAZIN- 3-YL)METHYL)QUINOLINE.
3855, 3eqpB, 0.7309, 3.02, 0.253, 270, 249, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T95
3856, 2broA, 0.7309, 3.15, 0.272, 272, 250, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
3857, 6bl8A, 0.7308, 3.21, 0.236, 270, 250, PREDICTING THE CONFORMATIONAL VARIABILITY OF ABL TYROSINE KINASE USING MOLECULAR DYNAMICS SIMULATIONS AND MARKOV STATE MODELS
3858, 5jsmA, 0.7308, 2.78, 0.212, 265, 245, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
3859, 3eqrB, 0.7308, 2.88, 0.260, 271, 246, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T74
3860, 2j4zA, 0.7308, 2.76, 0.306, 263, 245, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-680626
3861, 6glaB, 0.7307, 3.30, 0.234, 286, 252, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 11 (FM481) 
3862, 4xv9A, 0.7307, 2.78, 0.207, 261, 242, B-RAF KINASE DOMAIN IN COMPLEX WITH PLX5568
3863, 4lqmA, 0.7307, 3.29, 0.198, 305, 253, EGFR L858R IN COMPLEX WITH PD168393
3864, 3tt0A, 0.7307, 3.49, 0.239, 305, 259, CO-STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN WITH 3-(26-DICHLORO-35-DIMETHOXY-PHENYL)-1-{6-[4-(4-ETHYL-PIPERAZIN-1- YL)-PHENYLAMINO]-PYRIMIDIN-4-YL}-1-METHYL-UREA (BGJ398)
3865, 3q6wA, 0.7307, 3.22, 0.222, 297, 252, STRUCTURE OF DUALLY-PHOSPHORYLATED MET RECEPTOR KINASE IN COMPLEX WITH AN MK-2461 ANALOG WITH SPECIFICITY FOR THE ACTIVATED RECEPTOR
3866, 3cqeA, 0.7307, 2.63, 0.232, 258, 241, WEE1 KINASE COMPLEX WITH INHIBITOR PD074291
3867, 3c4fB, 0.7307, 3.47, 0.225, 290, 258, FGFR TYROSINE KINASE DOMAIN IN COMPLEX WITH 3-(3- METHOXYBENZYL)-7-AZAINDOLE
3868, 6bleA, 0.7306, 2.84, 0.294, 265, 245, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH CP673451
3869, 5w5oL, 0.7306, 2.84, 0.215, 275, 246, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3870, 5opuA, 0.7306, 2.83, 0.282, 261, 245, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIDINE LRRK2 INHIBITOR
3871, 4btkA, 0.7306, 3.11, 0.187, 287, 252, TTBK1 IN COMPLEX WITH INHIBITOR
3872, 4bbfD, 0.7306, 3.15, 0.262, 288, 252, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
3873, 3rhkA, 0.7306, 2.96, 0.210, 298, 248, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF C-MET KINASE IN COMPLEX WITH ARQ 197
3874, 3nlbA, 0.7306, 3.01, 0.287, 261, 247, NOVEL KINASE PROFILE HIGHLIGHTS THE TEMPORAL BASIS OF CONTEXT DEPENDENT CHECKPOINT PATHWAYS TO CELL DEATH
3875, 2jitA, 0.7306, 2.89, 0.202, 299, 247, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION
3876, 2jiiB, 0.7306, 3.47, 0.143, 326, 258, STRUCTURE OF VACCINIA RELATED KINASE 3
3877, 6glaA, 0.7305, 3.31, 0.234, 288, 252, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 11 (FM481) 
3878, 6cz4A, 0.7305, 2.79, 0.260, 257, 246, STRUCTURE OF THE PTK6 KINASE DOMAIN BOUND TO A TYPE II INHIBITOR 2- {[(3R;4S)-3-FLUORO-1-{[4-(TRIFLUOROMETHOXY)PHENYL]ACETYL}PIPERIDIN-4- YL]OXY}-5-(1-METHYL-1H-IMIDAZOL-4-YL)PYRIDINE-3-CARBOXAMIDE 
3879, 5w5oH, 0.7305, 2.80, 0.224, 275, 246, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3880, 5w4wD, 0.7305, 3.11, 0.176, 287, 250, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
3881, 5n9sA, 0.7305, 2.62, 0.302, 259, 245, TTK KINASE DOMAIN IN COMPLEX WITH BAY 1161909
3882, 4bbfC, 0.7305, 3.17, 0.266, 288, 252, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
3883, 2j0jA, 0.7305, 2.73, 0.244, 611, 246, CRYSTAL STRUCTURE OF A FRAGMENT OF FOCAL ADHESION KINASE CONTAINING THE FERM AND KINASE DOMAINS.
3884, 1fgiA, 0.7305, 3.49, 0.240, 283, 258, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU5402 INHIBITOR
3885, 5ugbA, 0.7304, 3.28, 0.209, 307, 253, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN IN COMPLEX WITH 4-(4-{[2- {[(3S)-1-ACETYLPYRROLIDIN-3-YL]AMINO}-9-(PROPAN-2-YL)-9H-PURIN-6- YL]AMINO}PHENYL)-1-METHYLPIPERAZIN-1-IUM
3886, 5jzjA, 0.7304, 2.68, 0.290, 271, 241, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH AMPPN
3887, 4c4eA, 0.7304, 2.51, 0.300, 256, 243, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
3888, 3uytD, 0.7304, 2.99, 0.175, 268, 251, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
3889, 6glbB, 0.7303, 3.11, 0.237, 288, 249, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 20 (FM484) 
3890, 4wnpB, 0.7303, 2.89, 0.298, 272, 245, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
3891, 4li5A, 0.7303, 3.11, 0.221, 306, 249, EGFR-K IN COMPLEX WITH N-[3-[[5-CHLORO-4-(1H-INDOL-3-YL)PYRIMIDIN-2- YL]AMINO]-4-METHOXY-PHENYL] PROP-2-ENAMIDE
3892, 4lgdA, 0.7303, 3.38, 0.285, 350, 260, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
3893, 3uztA, 0.7303, 3.08, 0.271, 586, 247, STRUCTURE OF THE C13.18 RNA APTAMER IN COMPLEX WITH G PROTEIN-COUPLED RECEPTOR KINASE 2
3894, 3a61A, 0.7303, 2.19, 0.318, 254, 236, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED P70S6K1 (FORM II)
3895, 5o12A, 0.7302, 2.54, 0.262, 264, 240, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL-MOLECULE INHIBITOR
3896, 5cf8B, 0.7302, 3.04, 0.260, 288, 250, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
3897, 4zogA, 0.7302, 3.28, 0.228, 269, 250, VX-680/MK-0457 BINDS TO HUMAN ABL1 ALSO IN INACTIVE DFG CONFORMATIONS.
3898, 4h58B, 0.7302, 2.87, 0.200, 262, 245, BRAF IN COMPLEX WITH COMPOUND 3
3899, 4bbfA, 0.7302, 3.16, 0.262, 288, 252, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
3900, 5w5oF, 0.7301, 2.81, 0.224, 275, 246, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3901, 5w5oE, 0.7301, 2.79, 0.224, 275, 246, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3902, 5u6bD, 0.7301, 3.05, 0.221, 291, 249, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
3903, 5mqvC, 0.7301, 3.24, 0.181, 288, 254, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
3904, 5d41A, 0.7301, 2.77, 0.209, 300, 244, EGFR KINASE DOMAIN IN COMPLEX WITH MUTANT SELECTIVE ALLOSTERIC INHIBITOR
3905, 3zxzA, 0.7301, 3.14, 0.229, 289, 249, X-RAY STRUCTURE OF PF-04217903 BOUND TO THE KINASE DOMAIN OF C-MET
3906, 3r7oA, 0.7301, 3.24, 0.226, 299, 252, STRUCTURE OF DUALLY PHOSPHORYLATED C-MET RECEPTOR KINASE IN COMPLEX WITH AN MK-2461 ANALOG
3907, 3iecA, 0.7301, 2.83, 0.313, 311, 243, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
3908, 3eqpA, 0.7301, 2.92, 0.255, 268, 247, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T95
3909, 5w5oK, 0.7300, 2.77, 0.220, 275, 245, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3910, 5w5oA, 0.7300, 2.80, 0.224, 275, 246, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3911, 4neuA, 0.7300, 3.16, 0.212, 286, 255, X-RAY STRUCTURE OF RECEPTOR INTERACTING PROTEIN 1 (RIP1)KINASE DOMAIN WITH A 1-AMINOISOQUINOLINE INHIBITOR
3912, 4ji9A, 0.7300, 3.02, 0.268, 284, 250, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH TG101209
3913, 3ma3A, 0.7300, 2.57, 0.266, 266, 241, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A NAPHTHO-DIFURAN LIGAND
3914, 3ky2A, 0.7300, 3.39, 0.246, 307, 256, CRYSTAL STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN
3915, 4g16A, 0.7299, 3.34, 0.199, 302, 256, CRYSTAL STRUCTURE OF CK1G3 WITH 2-[(4-{[3-(TRIFLUOROMETHYL)PYRIDIN2- YL]OXY}PHENYL)AMINO]-1H-BENZIMIDAZOLE-6-CARBONITRILE
3916, 3zosA, 0.7299, 3.37, 0.207, 301, 256, STRUCTURE OF THE DDR1 KINASE DOMAIN IN COMPLEX WITH PONATINIB
3917, 3zc5A, 0.7299, 3.20, 0.232, 289, 250, X-RAY STRUCTURE OF C-MET KINASE IN COMPLEX WITH INHIBITOR ( S)-6-(1-(6-(1-METHYL-1H-PYRAZOL-4-YL)-(124)TRIAZOLO(43- B)PYRIDAZIN-3-YL)ETHYL)QUINOLINE.
3918, 5n87A, 0.7298, 2.46, 0.298, 255, 242, TTK KINASE DOMAIN IN COMPLEX WITH NTRC 0066-0
3919, 5fqdF, 0.7298, 3.33, 0.186, 294, 253, STRUCTURAL BASIS OF LENALIDOMIDE INDUCED CK1A DEGRADATION BY THE CRL4CRBN UBIQUITIN LIGASE
3920, 4e6qB, 0.7298, 3.34, 0.243, 296, 255, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 12
3921, 3iokA, 0.7298, 3.01, 0.261, 285, 249, 2-AMINOPYRAZOLO[15-A]PYRIMIDINES AS POTENT AND SELECTIVE INHIBITORS OF JAK2
3922, 6cd6D, 0.7297, 2.88, 0.286, 267, 245, CRYSTAL STRUCTURE OF THE HUMAN CAMKK1A IN COMPLEX WITH GSK650394
3923, 5uorB, 0.7297, 2.94, 0.291, 262, 244, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
3924, 5lohA, 0.7297, 2.49, 0.311, 248, 238, KINASE DOMAIN OF HUMAN GREATWALL
3925, 5e8xA, 0.7297, 3.20, 0.208, 304, 250, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249FS280T Y282FS287NA350CL352F) IN COMPLEX WITH STAUROSPORINE
3926, 4lg4A, 0.7297, 3.51, 0.281, 289, 260, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
3927, 4jnwA, 0.7297, 3.35, 0.227, 320, 255, BACTERIALLY EXPRESSED TITIN KINASE
3928, 3rzfA, 0.7297, 3.19, 0.276, 541, 254, CRYSTAL STRUCTURE OF INHIBITOR OF KAPPAB KINASE BETA (I4122)
3929, 5fqdC, 0.7296, 3.43, 0.189, 294, 254, STRUCTURAL BASIS OF LENALIDOMIDE INDUCED CK1A DEGRADATION BY THE CRL4CRBN UBIQUITIN LIGASE
3930, 4deiA, 0.7296, 3.20, 0.223, 287, 251, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH TRIAZOLOPYRIDINONE INHIBITOR 24
3931, 4bhnA, 0.7296, 2.82, 0.298, 256, 242, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3932, 3priB, 0.7296, 2.72, 0.198, 264, 243, CRYSTAL STRUCTURE OF HUMAN B-RAF KINASE IN COMPLEX WITH A NON-OXIME FUROPYRIDINE INHIBITOR
3933, 2vwiD, 0.7296, 2.88, 0.262, 284, 244, STRUCTURE OF THE OSR1 KINASE A HYPERTENSION DRUG TARGET
3934, 2iztA, 0.7296, 3.32, 0.200, 296, 255, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
3935, 1lufA, 0.7296, 2.98, 0.230, 275, 248, CRYSTAL STRUCTURE OF THE MUSK TYROSINE KINASE: INSIGHTS INTO RECEPTOR AUTOREGULATION
3936, 6groA, 0.7295, 3.16, 0.198, 293, 253, HUMAN CSNK1G3 BOUND TO SB-223133 
3937, 5up3A, 0.7295, 2.85, 0.296, 258, 243, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
3938, 5n84A, 0.7295, 2.55, 0.305, 256, 243, TTK KINASE DOMAIN IN COMPLEX WITH MPS-BAY2B
3939, 4ytfA, 0.7295, 3.00, 0.249, 283, 249, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASES
3940, 4uwcA, 0.7295, 3.57, 0.232, 300, 259, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P3
3941, 4tksA, 0.7295, 3.22, 0.202, 307, 252, NATIVE-SAD PHASING FOR HUMAN EGFR KINASE DOMAIN.
3942, 4rixD, 0.7295, 3.10, 0.217, 297, 249, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
3943, 4g17A, 0.7295, 3.34, 0.199, 302, 256, CRYSTAL STRUCTURE OF CK1G3 WITH 2-[(4-TERT-BUTYLPHENYL)AMINO]-1H- BENZIMIDAZOLE-6-CARBONITRILE
3944, 4cqgA, 0.7295, 2.57, 0.326, 313, 239, THE CRYSTAL STRUCTURE OF MPK38 IN COMPLEX WITH OTSSP167 AN ORALLY-ADMINISTRATIVE MELK SELECTIVE INHIBITOR
3945, 4c8bA, 0.7295, 2.81, 0.207, 279, 246, STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH PONATINIB
3946, 4bbfB, 0.7295, 3.08, 0.267, 288, 251, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
3947, 3ppzB, 0.7295, 2.65, 0.233, 264, 240, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
3948, 3kckA, 0.7295, 3.00, 0.249, 285, 249, A NOVEL CHEMOTYPE OF KINASE INHIBITORS
3949, 3is5E, 0.7295, 1.99, 0.306, 252, 232, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
3950, 1py5A, 0.7295, 3.04, 0.222, 301, 248, CRYSTAL STRUCTURE OF TGF-BETA RECEPTOR I KINASE WITH INHIBITOR
3951, 1j3hA, 0.7295, 2.91, 0.257, 329, 249, CRYSTAL STRUCTURE OF APOENZYME CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
3952, 6fckA, 0.7294, 3.13, 0.280, 269, 250, CHK1 KINASE IN COMPLEX WITH COMPOUND 13
3953, 5w5oI, 0.7294, 2.82, 0.224, 275, 246, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3954, 5w5oD, 0.7294, 2.82, 0.224, 275, 246, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3955, 4r1vA, 0.7294, 3.07, 0.217, 289, 249, IDENTIFICATION AND OPTIMIZATION OF PYRIDAZINONES AS POTENT AND SELECTIVE C-MET KINASE INHIBITORS
3956, 4lrmC, 0.7294, 3.05, 0.217, 293, 249, EGFR D770_N771INSNPG IN COMPLEX WITH PD168393
3957, 4lg4F, 0.7294, 2.83, 0.301, 276, 249, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
3958, 4l52A, 0.7294, 2.84, 0.302, 295, 245, CRYSTAL STRUCTURE OF 1-(4-{4-[7-AMINO-2-(123-BENZOTHIADIAZOL-7-YL) FURO[23-C]PYRIDIN-4-YL]-1H-PYRAZOL-1-YL}PIPERIDIN-1-YL)ETHAN-1-ONE BOUND TO TAK1-TAB1
3959, 4bl1A, 0.7294, 2.48, 0.324, 312, 238, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE (MELK) IN COMPLEX WITH AMP-PNP
3960, 3tjcB, 0.7294, 3.20, 0.258, 287, 252, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 8
3961, 3qd2B, 0.7294, 2.74, 0.246, 271, 240, CRSYTAL STRUCTURE OF MOUSE PERK KINASE DOMAIN
3962, 3priA, 0.7294, 2.70, 0.193, 264, 243, CRYSTAL STRUCTURE OF HUMAN B-RAF KINASE IN COMPLEX WITH A NON-OXIME FUROPYRIDINE INHIBITOR
3963, 3omvB, 0.7294, 2.69, 0.189, 264, 243, CRYSTAL STRUCTURE OF C-RAF (RAF-1)
3964, 3dlsA, 0.7294, 3.02, 0.258, 285, 248, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
3965, 1p4fA, 0.7294, 2.70, 0.261, 269, 241, DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN WITH BOUND INHIBITOR FRAGMENT
3966, 6d1zA, 0.7293, 3.02, 0.225, 290, 249, CRYSTAL STRUCTURE OF TYROSINE-PROTEIN KINASE RECEPTOR IN COMPLEX WITH 5-(4-FLUOROPHENYL)THIENO[2;3-D]PYRIMIDIN-4(3H)-ONE INHIBITOR 
3967, 5w5oC, 0.7293, 2.79, 0.220, 275, 245, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3968, 5op5A, 0.7293, 2.81, 0.275, 259, 244, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIMIDINE LRRK2 INHIBITOR
3969, 5o49A, 0.7293, 3.53, 0.240, 289, 258, HUMAN FGF IN COMPLEX WITH A COVALENT INHIBITOR
3970, 4hgsA, 0.7293, 3.33, 0.203, 302, 256, CRYSTAL STRUCTURE OF CK1GS WITH COMPOUND 13
3971, 4hglA, 0.7293, 3.29, 0.180, 302, 255, CRYSTAL STRUCTURE OF CK1G3 WITH COMPOUND 1
3972, 4bfmA, 0.7293, 2.59, 0.331, 313, 239, THE CRYSTAL STRUCTURE OF MOUSE PK38
3973, 4at4A, 0.7293, 3.23, 0.224, 292, 254, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH EX429
3974, 3gqiA, 0.7293, 3.28, 0.238, 304, 252, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
3975, 2wgjA, 0.7293, 3.32, 0.223, 289, 251, X-RAY STRUCTURE OF PF-02341066 BOUND TO THE KINASE DOMAIN OF C-MET
3976, 5opbA, 0.7292, 2.98, 0.289, 262, 249, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH INDAZOLE LRRK2 INHIBITOR
3977, 5l3aA, 0.7292, 3.14, 0.263, 290, 251, FRAGMENT-BASED DISCOVERY OF 6-ARYLINDAZOLE JAK INHIBITORS
3978, 4rwjA, 0.7292, 3.35, 0.242, 307, 256, CRYSTAL STRUCTURE OF FGFR1 (C488A C584S) IN COMPLEX WITH AZD4547 (N- {3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE)
3979, 4rvkA, 0.7292, 2.99, 0.287, 264, 247, CHK1 KINASE DOMAIN WITH DIAZACARBAZOLE COMPOUND 8: N-[3-(6-CYANO-9H- PYRROLO[23-B:54-C ]DIPYRIDIN-3-YL)PHENYL]ACETAMIDE
3980, 4ftiA, 0.7292, 3.03, 0.271, 270, 247, CRYSTAL STRUCTURE OF THE CHK1
3981, 4bc6A, 0.7292, 2.92, 0.317, 285, 246, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 BOUND TO NOVEL BOSUTINIB ISOFORM 1 PREVIOUSLY THOUGHT TO BE BOSUTINIB
3982, 3zosB, 0.7292, 3.35, 0.203, 303, 256, STRUCTURE OF THE DDR1 KINASE DOMAIN IN COMPLEX WITH PONATINIB
3983, 3bi6A, 0.7292, 2.58, 0.217, 258, 240, WEE1 KINASE COMPLEX WITH INHIBITOR PD352396
3984, 1rw8A, 0.7292, 3.01, 0.222, 301, 248, CRYSTAL STRUCTURE OF TGF-BETA RECEPTOR I KINASE WITH ATP SITE INHIBITOR
3985, 6cd6C, 0.7291, 2.82, 0.283, 265, 244, CRYSTAL STRUCTURE OF THE HUMAN CAMKK1A IN COMPLEX WITH GSK650394
3986, 4uwcB, 0.7291, 3.51, 0.229, 301, 258, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P3
3987, 4rioA, 0.7291, 3.16, 0.239, 285, 251, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRIDAZINE CARBOXAMIDE INHIBITOR
3988, 2b7aB, 0.7291, 3.21, 0.258, 287, 252, THE STRUCTURAL BASIS OF JANUS KINASE 2 INHIBITION BY A POTENT AND SPECIFIC PAN-JANUS KINASE INHIBITOR
3989, 5eydA, 0.7290, 3.19, 0.229, 289, 249, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH AMG 337
3990, 5ci7A, 0.7290, 2.86, 0.296, 276, 243, STRUCTURE OF ULK1 BOUND TO A SELECTIVE INHIBITOR
3991, 4ft3A, 0.7290, 2.84, 0.275, 269, 244, CRYSTAL STRUCTURE OF THE CHK1
3992, 4fsnA, 0.7290, 3.04, 0.283, 270, 247, CRYSTAL STRUCTURE OF THE CHK1
3993, 3oriB, 0.7290, 2.78, 0.263, 267, 243, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 1)
3994, 3js2B, 0.7290, 3.43, 0.233, 291, 257, CRYSTAL STRUCTURE OF MINIMAL KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH 5-(2-THIENYL) NICOTINIC ACID
3995, 3cr0A, 0.7290, 2.54, 0.218, 257, 239, WEE1 KINASE COMPLEX WITH INHIBITOR PD259_809
3996, 5w5oG, 0.7289, 2.83, 0.224, 275, 246, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3997, 5ng2A, 0.7289, 2.72, 0.209, 274, 244, STRUCTURE OF RIP2K(D146N) WITH BOUND STAUROSPORINE
3998, 5cf4A, 0.7289, 3.03, 0.268, 283, 250, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
3999, 4p7eB, 0.7289, 3.12, 0.259, 285, 251, TRIAZOLOPYRIDINE COMPOUNDS AS SELECTIVE JAK1 INHIBITORS: FROM HIT IDENTIFICATION TO GLPG0634
4000, 4aszA, 0.7289, 3.20, 0.217, 289, 253, CRYSTAL STRUCTURE OF APO TRKB KINASE DOMAIN
4001, 3dakB, 0.7289, 3.08, 0.262, 278, 244, CRYSTAL STRUCTURE OF DOMAIN-SWAPPED OSR1 KINASE DOMAIN
4002, 3bbtD, 0.7289, 2.66, 0.224, 259, 241, CRYSTAL STRUCTURE OF THE ERBB4 KINASE IN COMPLEX WITH LAPATINIB
4003, 2yexA, 0.7289, 3.12, 0.280, 269, 250, SYNTHESIS AND EVALUATION OF TRIAZOLONES AS CHECKPOINT KINASE 1 INHIBITORS
4004, 2wd1A, 0.7289, 3.04, 0.218, 289, 248, HUMAN C-MET KINASE IN COMPLEX WITH AZAINDOLE INHIBITOR
4005, 2jiiA, 0.7289, 3.46, 0.148, 321, 257, STRUCTURE OF VACCINIA RELATED KINASE 3
4006, 5vi9A, 0.7288, 3.24, 0.276, 306, 250, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH THE PKI PEPTIDE AND AMINOBENZOTHIAZOLE BASED INHIBITORS
4007, 5mqvF, 0.7288, 3.31, 0.185, 286, 254, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
4008, 5kbqB, 0.7288, 2.74, 0.299, 273, 244, PAK1 IN COMPLEX WITH BIS-ANILINO PYRIMIDINE INHIBITOR
4009, 5ar7A, 0.7288, 3.20, 0.229, 278, 253, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIARYL UREA
4010, 3skcA, 0.7288, 2.53, 0.204, 260, 240, HUMAN B-RAF KINASE IN COMPLEX WITH AN AMIDE LINKED PYRAZOLOPYRIDINE INHIBITOR
4011, 6cd6B, 0.7287, 2.91, 0.290, 266, 245, CRYSTAL STRUCTURE OF THE HUMAN CAMKK1A IN COMPLEX WITH GSK650394
4012, 6b2qA, 0.7287, 2.42, 0.269, 261, 238, DUAL INHIBITION OF THE ESSENTIAL PROTEIN KINASES A AND B IN MYCOBACTERIUM TUBERCULOSIS
4013, 5ootA, 0.7287, 2.95, 0.280, 260, 246, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMINOPYRIMIDO- BENZODIAZEPINONE LRRK2 INHIBITOR
4014, 5ihcA, 0.7287, 2.18, 0.323, 305, 235, MELK IN COMPLEX WITH NVS-MELK12B
4015, 5ih8A, 0.7287, 2.48, 0.324, 306, 238, MELK IN COMPLEX WITH NVS-MELK1
4016, 5eh0A, 0.7287, 2.67, 0.299, 258, 244, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
4017, 4rvmA, 0.7287, 3.00, 0.287, 264, 247, CHK1 KINASE DOMAIN WITH DIAZACARBAZOLE COMPOUND 19
4018, 4qyhB, 0.7287, 3.00, 0.287, 264, 247, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE GNE-783
4019, 4bkyA, 0.7287, 2.47, 0.324, 311, 238, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE (MELK) IN COMPLEX WITH PYRROLOPYRAZOLE INHIBITOR
4020, 3oriA, 0.7287, 2.72, 0.264, 267, 242, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 1)
4021, 3bprA, 0.7287, 2.42, 0.223, 261, 238, CRYSTAL STRUCTURE OF CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE- PROTEIN KINASE MER IN COMPLEX WITH INHIBITOR C52
4022, 2bdwB, 0.7287, 3.14, 0.323, 309, 251, CRYSTAL STRUCTURE OF THE AUTO-INHIBITED KINASE DOMAIN OF CALCIUM/CALMODULIN ACTIVATED KINASE II
4023, 6d20A, 0.7286, 3.04, 0.225, 296, 249, CRYSTAL STRUCTURE OF TYROSINE-PROTEIN KINASE RECEPTOR IN COMPLEX WITH 5-(4-FLUOROPHENYL)THIENO[2;3-D]PYRIMIDIN-4(3H)-ONE AND 5-{[2;4- DICHLORO-5-(PYRIDIN-2-YL)BENZENE-1-CARBONYL]AMINO}-N-(2-HYDROXY-2- METHYLPROPYL)-1-PHENYL-1H-PYRAZOLE-3-CARBOXAMIDE INHIBITORS 
4024, 4qrcA, 0.7286, 3.44, 0.242, 297, 256, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 4 IN COMPLEX WITH PONATINIB
4025, 4ap7A, 0.7286, 3.15, 0.229, 289, 249, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH 4-( (6-(4- FLUOROPHENYL)-(124)TRIAZOLO(43-B)(124)TRIAZIN-3-YL)METHYL) PHENOL
4026, 3dlsF, 0.7286, 3.09, 0.258, 281, 248, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
4027, 3dlsE, 0.7286, 3.08, 0.258, 282, 248, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
4028, 1iasA, 0.7286, 3.29, 0.213, 330, 249, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
4029, 6fc8A, 0.7285, 3.09, 0.273, 269, 249, CHK1 KINASE IN COMPLEX WITH COMPOUND 13
4030, 4ytcA, 0.7285, 3.01, 0.249, 284, 249, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASE
4031, 4jnwB, 0.7285, 3.37, 0.227, 321, 255, BACTERIALLY EXPRESSED TITIN KINASE
4032, 4bibA, 0.7285, 2.74, 0.296, 254, 240, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
4033, 2xzsB, 0.7285, 3.19, 0.267, 293, 251, DEATH ASSOCIATED PROTEIN KINASE 1 RESIDUES 1-312
4034, 2fumC, 0.7285, 2.44, 0.265, 254, 238, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
4035, 5w4wB, 0.7284, 3.33, 0.173, 291, 255, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
4036, 5bpyB, 0.7284, 2.63, 0.204, 247, 240, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-824171 AKA 6-[(3R)-3-(4-TERT-BU TYLBENZAMIDO) PIPERIDIN-1-YL]-2-{[4-(MORPHOLINE-4-CARBONYL) PHENYL]AMINO}PYRIDINE- 3-CARBOXAMIDE
4037, 4ybkA, 0.7284, 2.73, 0.255, 266, 243, C-HELIX-OUT DASATINIB ANALOG CRYSTALLIZED WITH C-SRC KINASE
4038, 4qo9A, 0.7284, 3.12, 0.281, 280, 249, MST3 IN COMPLEX WITH DANUSERTIB
4039, 4iwoA, 0.7284, 3.04, 0.253, 629, 249, CRYSTAL STRUCTURE AND MECHANISM OF ACTIVATION OF TBK1
4040, 4i93A, 0.7284, 2.92, 0.181, 281, 248, STRUCTURE OF THE BSK8 KINASE DOMAIN (SEMET LABELED)
4041, 4h58A, 0.7284, 2.68, 0.194, 263, 242, BRAF IN COMPLEX WITH COMPOUND 3
4042, 4gl9B, 0.7284, 3.06, 0.265, 280, 249, CRYSTAL STRUCTURE OF INHIBITORY PROTEIN SOCS3 IN COMPLEX WITH JAK2 KINASE DOMAIN AND FRAGMENT OF GP130 INTRACELLULAR DOMAIN
4043, 4bibB, 0.7284, 2.75, 0.289, 258, 242, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
4044, 3tkiA, 0.7284, 3.09, 0.286, 272, 248, CRYSTAL STRUCTURE OF CHK1 IN COMPLEX WITH INHIBITOR S25
4045, 1b6cD, 0.7284, 3.16, 0.222, 326, 248, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
4046, 5hesA, 0.7283, 2.72, 0.253, 287, 241, HUMAN LEUCINE ZIPPER- AND STERILE ALPHA MOTIF-CONTAINING KINASE (ZAK MLT HCCS-4 MRK AZK MLTK) IN COMPLEX WITH VEMURAFENIB
4047, 4cnhB, 0.7283, 3.22, 0.199, 293, 251, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 3-((1R)-1-(5-FLUORO-2- METHOXYPHENYL)ETHOXY)-5-(1-METHYL-1H-123-TRIAZOL-5-YL) PYRIDIN-2-AMINE
4048, 3vs7B, 0.7283, 2.53, 0.247, 426, 239, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR 1-CYCLOPENTYL-3-(1H-PYRROLO[23-B]PYRIDIN-5-YL)-1H- PYRAZOLO[34-D]PYRIMIDIN-4-AMINE
4049, 3f66B, 0.7283, 3.11, 0.226, 269, 248, HUMAN C-MET KINASE IN COMPLEX WITH QUINOXALINE INHIBITOR
4050, 3brbB, 0.7283, 2.61, 0.224, 271, 241, CRYSTAL STRUCTURE OF CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE- PROTEIN KINASE MER IN COMPLEX WITH ADP
4051, 2c3lA, 0.7283, 3.05, 0.287, 265, 247, IDENTIFICATION OF A BURIED POCKET FOR POTENT AND SELECTIVE INHIBITION OF CHK1: PREDICTION AND VERIFICATION
4052, 5nxcL, 0.7282, 2.63, 0.234, 274, 239, LIM DOMAIN KINASE 1 (LIMK1) IN COMPLEX WITH PF-00477736
4053, 5e8wA, 0.7282, 3.25, 0.208, 303, 250, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH STAUROSPORINE
4054, 4tn6A, 0.7282, 3.27, 0.179, 292, 252, CK1D IN COMPLEX WITH INHIBITOR
4055, 4jjrA, 0.7282, 2.94, 0.178, 284, 247, A P21 CRYSTAL FORM OF MAMMALIAN CASEIN KINASE 1 DELTA
4056, 3nz0A, 0.7282, 3.01, 0.231, 285, 247, NON-PHOSPHORYLATED TYK2 KINASE WITH CMP6
4057, 1muoA, 0.7282, 2.74, 0.305, 251, 243, CRYSTAL STRUCTURE OF AURORA-2 AN ONCOGENIC SERINE- THREONINE KINASE
4058, 5w4wA, 0.7281, 3.34, 0.176, 291, 255, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
4059, 5e8uA, 0.7281, 3.22, 0.212, 306, 250, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249FS280T Y282FS287NA350CL352F)
4060, 4x3fB, 0.7281, 2.50, 0.273, 278, 242, CRYSTAL STRUCTURE OF THE INTRACELLULAR DOMAIN OF THE M. TUBERCULOSIS SER/THR KINASE PKNA
4061, 4qygB, 0.7281, 3.02, 0.291, 264, 247, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE COMPOUND 14
4062, 4o6lB, 0.7281, 2.50, 0.293, 256, 242, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 401498 (N- [(1R)-1-(2-CHLOROPHENYL)PROPYL]-3-{4-[(1-METHYLPIPERIDIN-4-YL) OXY]PHENYL}-1H-INDAZOLE-5-CARBOXAMIDE)
4063, 2wqnA, 0.7281, 2.54, 0.326, 259, 239, STRUCTURE OF ADP-BOUND HUMAN NEK7
4064, 5wr7A, 0.7280, 3.01, 0.221, 301, 249, CRYSTAL STRUCTURE OF TRK-A COMPLEXED WITH A SELECTIVE INHIBITOR CH7057288
4065, 4wo5B, 0.7280, 2.63, 0.199, 257, 241, CRYSTAL STRUCTURE OF A BRAF KINASE DOMAIN MONOMER
4066, 4hgeB, 0.7280, 3.04, 0.256, 288, 250, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 8
4067, 3dlsC, 0.7280, 2.92, 0.252, 281, 246, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
4068, 2xneA, 0.7280, 2.48, 0.301, 246, 239, STRUCTURE OF AURORA-A BOUND TO AN IMIDAZOPYRAZINE INHIBITOR
4069, 2izsA, 0.7280, 3.34, 0.176, 298, 255, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
4070, 5vndB, 0.7279, 3.61, 0.224, 295, 259, CRYSTAL STRUCTURE OF FGFR1-Y563C (FGFR4 SURROGATE) COVALENTLY BOUND TO H3B-6527
4071, 2e9vB, 0.7279, 2.93, 0.276, 268, 246, STRUCTURE OF H-CHK1 COMPLEXED WITH A859017
4072, 1fotA, 0.7279, 3.14, 0.254, 299, 252, STRUCTURE OF THE UNLIGANDED CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT FROM SACCHAROMYCES CEREVISIAE
4073, 6dkiA, 0.7278, 2.91, 0.219, 279, 247, CRYSTAL STRUCTURE OF TRK-A IN COMPLEX WITH THE PAN-TRK KINASE INHIBITOR; COMPOUND 19. 
4074, 4riyA, 0.7278, 2.65, 0.206, 269, 243, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
4075, 3lzbB, 0.7278, 2.71, 0.215, 265, 242, EGFR KINASE DOMAIN COMPLEXED WITH AN IMIDAZO[21-B]THIAZOLE INHIBITOR
4076, 4xcuA, 0.7277, 3.21, 0.246, 288, 252, CRYSTAL STRUCTURE OF FGFR4 WITH AN IRREVERSIBLE INHIBITOR
4077, 4uwbA, 0.7277, 3.68, 0.235, 299, 260, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P5
4078, 4e3cD, 0.7277, 3.42, 0.268, 624, 257, X-RAY CRYSTAL STRUCTURE OF HUMAN IKK2 IN AN ACTIVE CONFORMATION
4079, 4bidB, 0.7277, 2.77, 0.289, 258, 242, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
4080, 4qygA, 0.7276, 3.04, 0.291, 264, 247, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE COMPOUND 14
4081, 4czuC, 0.7276, 3.42, 0.302, 281, 255, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.23 AT1G30270 T190D MUTANT
4082, 3rhxA, 0.7276, 3.56, 0.240, 289, 258, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR1 KINASE IN COMPLEX WITH ARQ 069
4083, 3q4uD, 0.7276, 3.09, 0.243, 299, 247, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
4084, 3jy9A, 0.7276, 2.98, 0.250, 282, 248, JANUS KINASE 2 INHIBITORS
4085, 2wtwA, 0.7276, 2.69, 0.311, 256, 244, AURORA-A INHIBITOR STRUCTURE (2ND CRYSTAL FORM)
4086, 3q4uB, 0.7275, 3.01, 0.244, 300, 246, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
4087, 3kulB, 0.7275, 2.71, 0.180, 271, 244, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 8 (EPHA8)
4088, 3fupB, 0.7275, 3.22, 0.258, 287, 252, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
4089, 3dbqA, 0.7275, 2.73, 0.298, 259, 245, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN
4090, 2ghgA, 0.7275, 3.02, 0.274, 269, 248, H-CHK1 COMPLEXED WITH A431994
4091, 6cqhB, 0.7274, 3.49, 0.159, 316, 258, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A N- PROPYNYL-N-ETHYL-DIHYDROPTERIDINE INHIBITOR
4092, 5p9lA, 0.7274, 2.64, 0.195, 252, 241, BTK1 IN COMPLEX WITH CC 292
4093, 5am7A, 0.7274, 3.46, 0.239, 294, 255, FGFR1 MUTANT WITH AN INHIBITOR
4094, 5am6A, 0.7274, 3.45, 0.239, 295, 255, NATIVE FGFR1 WITH AN INHIBITOR
4095, 4rixA, 0.7274, 2.76, 0.205, 269, 244, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
4096, 3ppjA, 0.7274, 2.62, 0.195, 262, 241, HUMAN B-RAF KINASE IN COMPLEX WITH A FUROPYRIDINE INHIBITOR
4097, 3dakA, 0.7274, 3.19, 0.261, 279, 245, CRYSTAL STRUCTURE OF DOMAIN-SWAPPED OSR1 KINASE DOMAIN
4098, 2yerA, 0.7274, 3.08, 0.281, 268, 249, SYNTHESIS AND EVALUATION OF TRIAZOLONES AS CHECKPOINT KINASE 1 INHIBITORS
4099, 5o4aA, 0.7273, 3.58, 0.240, 290, 258, HUMAN FGF IN COMPLEX WITH A COVALENT INHIBITOR
4100, 5cf8A, 0.7273, 3.01, 0.269, 285, 249, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
4101, 4iwdA, 0.7273, 3.29, 0.226, 299, 252, STRUCTURE OF DUALLY PHOSPHORYLATED C-MET RECEPTOR KINASE IN COMPLEX WITH AN MK-8033 ANALOG
4102, 3o96A, 0.7273, 2.69, 0.284, 367, 243, CRYSTAL STRUCTURE OF HUMAN AKT1 WITH AN ALLOSTERIC INHIBITOR
4103, 3c4cA, 0.7273, 2.66, 0.207, 258, 241, B-RAF KINASE IN COMPLEX WITH PLX4720
4104, 2j50B, 0.7273, 2.63, 0.311, 249, 241, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-739358
4105, 2j50A, 0.7273, 2.63, 0.311, 249, 241, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-739358
4106, 2hy0A, 0.7273, 3.08, 0.271, 272, 247, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 22
4107, 5x2kA, 0.7272, 3.26, 0.209, 314, 253, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH WZ4003
4108, 5n7vA, 0.7272, 2.78, 0.293, 260, 246, TTK KINASE DOMAIN IN COMPLEX WITH MPI-0479605
4109, 5em8A, 0.7272, 3.33, 0.206, 303, 253, EGFR KINASE DOMAIN WITH PYRIDONE COMPOUND 13: 4-[(2-METHOXYPHENYL) AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-2-OXIDANYLIDENE-1~{H}- PYRIDINE-3-CARBOXAMIDE
4110, 5a46B, 0.7272, 3.60, 0.236, 297, 259, FGFR1 IN COMPLEX WITH DOVITINIB
4111, 4xyfA, 0.7272, 3.36, 0.223, 290, 251, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH (S)-5-(8-FLUORO-3-(1-(3-(2- METHOXYETHOXY)QUINOLIN-6-YL)ETHYL)-[124]TRIAZOLO[43-A]PYRIDIN-6- YL)-3-METHYLISOXAZOLE
4112, 3a7hA, 0.7272, 3.18, 0.276, 289, 250, HUMAN MST3 KINASE IN COMPLEX WITH ATP
4113, 2j7tA, 0.7272, 2.71, 0.322, 285, 242, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 BOUND TO SU11274
4114, 2izuA, 0.7272, 3.33, 0.201, 297, 254, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
4115, 2in6A, 0.7272, 2.59, 0.230, 256, 239, WEE1 KINASE COMPLEX WITH INHIBITOR PD311839
4116, 3vquA, 0.7271, 2.88, 0.293, 258, 246, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 4- [(4-AMINO-5-CYANO-6-ETHOXYPYRIDIN-2- YL)AMINO]BENZAMIDE
4117, 1z9xC, 0.7271, 3.15, 0.255, 303, 251, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 3 MONOMERS IN THE ASYMMETRIC UNIT
4118, 6cd6A, 0.7270, 2.84, 0.287, 264, 244, CRYSTAL STRUCTURE OF THE HUMAN CAMKK1A IN COMPLEX WITH GSK650394
4119, 5l2qA, 0.7270, 3.04, 0.198, 293, 247, SERINE/THREONINE-PROTEIN KINASE 40 (STK40) KINASE HOMOLOGY DOMAIN
4120, 5eycA, 0.7270, 3.19, 0.222, 288, 248, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH NAPHTHYRIDINONE INHIBITOR 5
4121, 5ap4A, 0.7270, 2.69, 0.300, 257, 243, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4122, 4qyhA, 0.7270, 2.99, 0.276, 264, 246, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE GNE-783
4123, 4ft7A, 0.7270, 3.03, 0.272, 270, 246, CRYSTAL STRUCTURE OF THE CHK1
4124, 3uzpB, 0.7270, 3.00, 0.171, 284, 246, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P21 CRYSTAL FORM
4125, 3d94A, 0.7270, 3.28, 0.212, 288, 250, CRYSTAL STRUCTURE OF THE INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE IN COMPLEX WITH PQIP
4126, 2zmdA, 0.7270, 2.68, 0.297, 259, 246, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN T686A MUTANT IN COMPLEX WITH SP600125 INHIBITOR
4127, 2hogA, 0.7270, 3.13, 0.286, 272, 248, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 20
4128, 1iasB, 0.7270, 3.07, 0.211, 324, 247, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
4129, 5kvtA, 0.7269, 3.05, 0.223, 287, 251, THE STRUCTURE OF TRKA KINASE DOMAIN BOUND TO THE INHIBITOR ENTRECTINIB
4130, 4lrmE, 0.7269, 3.08, 0.213, 290, 249, EGFR D770_N771INSNPG IN COMPLEX WITH PD168393
4131, 4dehA, 0.7269, 3.13, 0.222, 286, 248, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH TRIAZOLOPYRIDINONE INHIBITOR 3
4132, 3eygA, 0.7269, 3.06, 0.262, 280, 248, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
4133, 1b6cB, 0.7269, 3.20, 0.222, 326, 248, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
4134, 5x18A, 0.7268, 3.45, 0.191, 294, 256, CRYSTAL STRUCTURE OF CASEIN KINASE I HOMOLOG 1
4135, 5oq7A, 0.7268, 2.95, 0.296, 259, 247, STRUCTURE OF CHK1 8-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
4136, 5hcxA, 0.7268, 3.07, 0.197, 298, 249, EGFR KINASE DOMAIN MUTANT TMLR WITH AZABENZIMIDAZOLE COMPOUND 7
4137, 5ew8B, 0.7268, 3.56, 0.236, 290, 258, FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH JNJ-4275693
4138, 5ehlA, 0.7268, 2.56, 0.309, 258, 243, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
4139, 4tygA, 0.7268, 3.40, 0.254, 293, 256, STRUCTURAL ANALYSIS OF THE HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE
4140, 3qa8D, 0.7268, 3.22, 0.295, 622, 254, CRYSTAL STRUCTURE OF INHIBITOR OF KAPPA B KINASE BETA
4141, 1gzoA, 0.7268, 2.54, 0.293, 271, 239, STRUCTURE OF PROTEIN KINASE B UNPHOSPHORYLATED
4142, 4kb8A, 0.7267, 3.00, 0.181, 265, 249, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
4143, 2b7aA, 0.7267, 3.10, 0.272, 284, 250, THE STRUCTURAL BASIS OF JANUS KINASE 2 INHIBITION BY A POTENT AND SPECIFIC PAN-JANUS KINASE INHIBITOR
4144, 1u4dB, 0.7267, 2.72, 0.264, 262, 242, STRUCTURE OF THE ACK1 KINASE DOMAIN BOUND TO DEBROMOHYMENIALDISINE
4145, 1iasE, 0.7267, 3.25, 0.214, 330, 248, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
4146, 5ttvA, 0.7266, 3.27, 0.255, 280, 251, JAK3 WITH COVALENT INHIBITOR 6
4147, 5f1zA, 0.7266, 2.83, 0.238, 281, 244, STRUCTURE OF TYK2 WITH INHIBITOR 16: 3-AZANYL-5-[(2~{S})-3- METHYLBUTAN-2-YL]-7-[1-METHYL-5-(2-OXIDANYLPROPAN-2-YL)PYRAZOL-3-YL]- 1~{H}-PYRAZOLO[43-C]PYRIDIN-4-ONE
4148, 4qyfA, 0.7266, 2.98, 0.272, 269, 246, CHK1 KINASE DOMAIN IN COMPLEX WITH AMINOPYRAZINE COMPOUND 13
4149, 4bi0A, 0.7266, 2.48, 0.307, 254, 241, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
4150, 3qa8E, 0.7266, 3.23, 0.295, 622, 254, CRYSTAL STRUCTURE OF INHIBITOR OF KAPPA B KINASE BETA
4151, 3ppkA, 0.7266, 2.63, 0.203, 262, 241, HUMAN B-RAF KINASE IN COMPLEX WITH A NON-OXIME FUROPYRIDINE INHIBITOR
4152, 2x6eA, 0.7266, 2.51, 0.311, 249, 238, AURORA-A BOUND TO AN INHIBITOR
4153, 5ap6A, 0.7265, 2.94, 0.298, 262, 248, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4154, 4ntsA, 0.7265, 3.25, 0.250, 341, 252, APO STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
4155, 4hgeA, 0.7265, 3.08, 0.272, 284, 250, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 8
4156, 4gl9D, 0.7265, 3.09, 0.257, 282, 249, CRYSTAL STRUCTURE OF INHIBITORY PROTEIN SOCS3 IN COMPLEX WITH JAK2 KINASE DOMAIN AND FRAGMENT OF GP130 INTRACELLULAR DOMAIN
4157, 3tjcA, 0.7265, 3.10, 0.272, 284, 250, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 8
4158, 3qa8C, 0.7265, 3.23, 0.295, 622, 254, CRYSTAL STRUCTURE OF INHIBITOR OF KAPPA B KINASE BETA
4159, 3io7A, 0.7265, 2.98, 0.250, 282, 248, 2-AMINOPYRAZOLO[15-A]PYRIMIDINES AS POTENT AND SELECTIVE INHIBITORS OF JAK2
4160, 2j5fA, 0.7265, 3.29, 0.198, 308, 252, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR 34-JAB
4161, 5l2qB, 0.7264, 3.12, 0.185, 282, 249, SERINE/THREONINE-PROTEIN KINASE 40 (STK40) KINASE HOMOLOGY DOMAIN
4162, 5cenA, 0.7264, 3.08, 0.278, 281, 245, CRYSTAL STRUCTURE OF DLK (KINASE DOMAIN)
4163, 4zy5A, 0.7264, 2.82, 0.303, 283, 244, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 17
4164, 4ymjB, 0.7264, 3.07, 0.230, 275, 248, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
4165, 4uwbB, 0.7264, 3.49, 0.233, 299, 257, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P5
4166, 4py1A, 0.7264, 3.30, 0.237, 289, 253, CRYSTAL STRUCTURE OF TYK2 IN COMPLEX WITH COMPOUND 15 6-((25- DIMETHOXYPHENYL)THIO)-3-(1-METHYL-1H-PYRAZOL-4-YL)-[124]TRIAZOLO[4 3-B]PYRIDAZINE
4167, 3kfaB, 0.7264, 3.23, 0.230, 284, 252, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
4168, 3kfaA, 0.7264, 3.23, 0.230, 284, 252, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
4169, 3fupA, 0.7264, 3.33, 0.265, 284, 253, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
4170, 2x9fA, 0.7264, 2.84, 0.220, 265, 246, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4171, 2hz0A, 0.7264, 3.21, 0.224, 265, 250, ABL KINASE DOMAIN IN COMPLEX WITH NVP-AEG082
4172, 2g15A, 0.7264, 3.22, 0.207, 301, 251, STRUCTURAL CHARACTERIZATION OF AUTOINHIBITED C-MET KINASE
4173, 6fdzU, 0.7263, 3.01, 0.347, 265, 248, UNC-51-LIKE KINASE 3 (ULK3) IN COMPLEX WITH MOMELOTINIB 
4174, 5vdkA, 0.7263, 2.74, 0.250, 260, 240, CRYSTAL STRUCTURE OF HUMAN WEE2 KINASE DOMAIN IN COMPLEX WITH MK1775
4175, 5usyA, 0.7263, 3.32, 0.259, 287, 251, JAK2 JH1 IN COMPLEX WITH JNJ-7706621
4176, 5opvA, 0.7263, 2.90, 0.275, 261, 244, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIDINE LRRK2 INHIBITOR
4177, 5gtzA, 0.7263, 3.36, 0.213, 317, 253, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH JTS-1-39
4178, 4riwA, 0.7263, 2.65, 0.202, 269, 243, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
4179, 4bidA, 0.7263, 2.84, 0.295, 254, 241, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
4180, 3wyxA, 0.7263, 2.80, 0.294, 258, 245, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 6- ((3-(CYANOMETHOXY)-4-(1-METHYL-1H-PYRAZOL-4-YL)PHENYL)AMINO)-2- (CYCLOHEXYLAMINO)NICOTINONITRILE
4181, 3tacA, 0.7263, 3.28, 0.302, 324, 252, CRYSTAL STRUCTURE OF THE LIPRIN-ALPHA/CASK COMPLEX
4182, 3lcdA, 0.7263, 3.03, 0.234, 290, 248, INHIBITOR BOUND TO A DFG-IN STRUCTURE OF THE KINASE DOMAIN OF CSF-1R
4183, 1zycD, 0.7263, 2.85, 0.266, 256, 244, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: WILD- TYPE IN APO FORM.
4184, 5vd7A, 0.7262, 2.84, 0.226, 261, 243, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH RAC-IV- 098 A MK1775 ANALOGUE
4185, 5ehoA, 0.7262, 2.82, 0.294, 258, 245, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
4186, 5e90A, 0.7262, 3.31, 0.213, 303, 249, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249F S280T Y282FS287NA350CL352F) IN COMPLEX WITH 3-AMINO-6- [4-(2- HYDROXYETHYL)PHENYL]-N-[4-(MORPHOLIN-4-YL)PYRIDIN-3-YL]PYRAZINE-2- CARBOXAMIDE
4187, 4ftuA, 0.7262, 3.08, 0.287, 270, 247, CRYSTAL STRUCTURE OF THE CHK1
4188, 4e6dB, 0.7262, 3.08, 0.264, 286, 250, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 7
4189, 3qa8H, 0.7262, 3.28, 0.290, 541, 255, CRYSTAL STRUCTURE OF INHIBITOR OF KAPPA B KINASE BETA
4190, 2z8cA, 0.7262, 3.28, 0.211, 297, 251, PHOSPHORYLATED INSULIN RECEPTOR TYROSINE KINASE IN COMPLEX WITH (4-{[5-CARBAMOYL-4-(3-METHYLANILINO)PYRIMIDIN-2- YL]AMINO}PHENYL)ACETIC ACID
4191, 5jzjB, 0.7261, 2.66, 0.289, 261, 239, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH AMPPN
4192, 4z16B, 0.7261, 3.13, 0.254, 276, 248, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
4193, 4x7nA, 0.7261, 2.83, 0.270, 259, 241, CO-CRYSTAL STRUCTURE OF PERK BOUND TO 4-[2-AMINO-4-METHYL-3-(2- METHYLQUINOLIN-6-YL)BENZOYL]-1-METHYL-25-DIPHENYL-12-DIHYDRO-3H- PYRAZOL-3-ONE INHIBITOR
4194, 4bieA, 0.7261, 2.74, 0.296, 257, 240, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
4195, 4asxB, 0.7261, 3.23, 0.225, 307, 249, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DIHYDRO-BAUERINE C
4196, 3qa8A, 0.7261, 3.23, 0.291, 622, 254, CRYSTAL STRUCTURE OF INHIBITOR OF KAPPA B KINASE BETA
4197, 3psbA, 0.7261, 2.64, 0.199, 262, 241, FURO[23-C]PYRIDINE-BASED INDANONE OXIMES AS POTENT AND SELECTIVE B- RAF INHIBITORS
4198, 2g2hA, 0.7261, 3.40, 0.242, 272, 252, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
4199, 1nvsA, 0.7261, 3.05, 0.287, 264, 247, THE COMPLEX STRUCTURE OF CHECKPOINT KINASE CHK1/SB218078
4200, 1nvqA, 0.7261, 3.05, 0.287, 264, 247, THE COMPLEX STRUCTURE OF CHECKPOINT KINASE CHK1/UCN-01
4201, 1gznA, 0.7261, 2.56, 0.293, 271, 239, STRUCTURE OF PKB KINASE DOMAIN
4202, 5vndA, 0.7260, 3.56, 0.236, 302, 258, CRYSTAL STRUCTURE OF FGFR1-Y563C (FGFR4 SURROGATE) COVALENTLY BOUND TO H3B-6527
4203, 5tozA, 0.7260, 3.15, 0.253, 278, 249, JAK3 WITH COVALENT INHIBITOR PF-06651600
4204, 5canA, 0.7260, 3.07, 0.201, 301, 249, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 27
4205, 4iebA, 0.7260, 3.03, 0.301, 472, 246, CRYSTAL STRUCTURE OF A GLY128MET MUTANT OF THE TOXOPLASMA CDPK TGME49_101440
4206, 4hvgA, 0.7260, 3.20, 0.244, 281, 250, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-2-HYDROXY-12-DIMETHYL-PROPYL)- AMIDE
4207, 3qa8B, 0.7260, 3.24, 0.295, 622, 254, CRYSTAL STRUCTURE OF INHIBITOR OF KAPPA B KINASE BETA
4208, 1zy5A, 0.7260, 3.00, 0.276, 271, 246, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: R794G HYPERACTIVATING MUTANT COMPLEXED WITH AMPPNP.
4209, 1iasD, 0.7260, 3.28, 0.210, 330, 248, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
4210, 1gzkA, 0.7260, 2.55, 0.293, 271, 239, MOLECULAR MECHANISM FOR THE REGULATION OF PROTEIN KINASE B/ AKT BY HYDROPHOBIC MOTIF PHOSPHORYLATION
4211, 5walA, 0.7259, 3.16, 0.227, 286, 251, IDENTIFICATION OF AN IMIDAZOPYRIDINE SCAFFOLD TO GENERATE POTENT AND SELECTIVE TYK2 INHIBITORS THAT DEMONSTRATE ACTIVITY IN AN IN VIVO PSORIASIS MODEL
4212, 5opsA, 0.7259, 2.83, 0.284, 258, 243, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIDINE LRRK2 INHIBITOR
4213, 4byjA, 0.7259, 2.35, 0.314, 246, 236, AURORA A KINASE BOUND TO A HIGHLY SELECTIVE IMIDAZOPYRIDINE INHIBITOR
4214, 2x8eA, 0.7259, 2.89, 0.269, 259, 245, DISCOVERY OF A NOVEL CLASS OF TRIAZOLONES AS CHECKPOINT KINASE INHIBITORS - HIT TO LEAD EXPLORATION
4215, 5w5oN, 0.7258, 2.74, 0.222, 272, 243, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
4216, 5i3oA, 0.7258, 3.02, 0.259, 302, 247, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
4217, 5ap0A, 0.7258, 2.43, 0.304, 254, 240, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4218, 4zogB, 0.7258, 3.31, 0.223, 268, 251, VX-680/MK-0457 BINDS TO HUMAN ABL1 ALSO IN INACTIVE DFG CONFORMATIONS.
4219, 4kikA, 0.7258, 3.50, 0.264, 618, 254, HUMAN IKB KINASE BETA
4220, 3rvgA, 0.7258, 2.96, 0.263, 285, 247, CRYSTALS STRUCTURE OF JAK2 WITH A 1-AMINO-5H-PYRIDO[43-B]INDOL-4- CARBOXAMIDE INHIBITOR
4221, 3mvjB, 0.7258, 3.22, 0.243, 320, 251, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
4222, 3f66A, 0.7258, 3.12, 0.216, 288, 250, HUMAN C-MET KINASE IN COMPLEX WITH QUINOXALINE INHIBITOR
4223, 3f3zA, 0.7258, 2.99, 0.275, 271, 247, CRYSTAL STRUCTURE OF CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840 IN PRESENCE OF INDIRUBIN E804
4224, 2welA, 0.7258, 3.07, 0.317, 304, 249, CRYSTAL STRUCTURE OF SU6656-BOUND CALCIUM/CALMODULIN- DEPENDENT PROTEIN KINASE II DELTA IN COMPLEX WITH CALMODULIN
4225, 1b6cH, 0.7258, 3.12, 0.223, 326, 247, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
4226, 6b16A, 0.7257, 2.89, 0.301, 285, 246, P21-ACTIVATED KINASE 1 IN COMPLEX WITH A 4-AZAINDOLE INHIBITOR
4227, 5x28A, 0.7257, 3.10, 0.205, 310, 249, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH SKLB(6)
4228, 5vd4A, 0.7257, 2.83, 0.222, 261, 243, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH RAC-IV- 016 A MK1775 ANALOUGUE
4229, 3oriD, 0.7257, 2.79, 0.260, 267, 242, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 1)
4230, 1iasC, 0.7257, 3.19, 0.219, 330, 247, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
4231, 5wnlA, 0.7256, 2.59, 0.208, 262, 240, CRYSTAL STRUCTURE OF MURINE RECEPTOR-INTERACTING PROTEIN 4 (RIPK4) D143N BOUND TO STAUROSPORINE 
4232, 5oq8A, 0.7256, 2.96, 0.279, 261, 247, STRUCTURE OF CHK1 12-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
4233, 5mqvA, 0.7256, 3.23, 0.183, 286, 252, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
4234, 5hicA, 0.7256, 3.08, 0.197, 302, 249, EGFR KINASE DOMAIN MUTANT TMLR WITH A IMIDAZOPYRIDINYL- AMINOPYRIMIDINE INHIBITOR
4235, 5e8sA, 0.7256, 3.25, 0.214, 301, 248, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (WT)
4236, 4bggB, 0.7256, 2.84, 0.243, 293, 243, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
4237, 3d2kA, 0.7256, 2.39, 0.297, 245, 236, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240- >ARG MET302->LEU) IN COMPLEX WITH [7-(2-{2-[3-(3-CHLORO- PHENYL)-UREIDO]-THIAZOL-5-YL}-ETHYLAMINO)-PYRAZOLO[43- D]PYRIMIDIN-1-YL]-ACETIC ACID
4238, 2x9eA, 0.7256, 2.41, 0.301, 253, 239, HUMAN MPS1 IN COMPLEX WITH NMS-P715
4239, 2wkmA, 0.7256, 3.13, 0.228, 286, 250, X-RAY STRUCTURE OF PHA-00665752 BOUND TO THE KINASE DOMAIN OF C-MET
4240, 2izrA, 0.7256, 3.34, 0.177, 298, 254, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
4241, 6gipA, 0.7255, 2.90, 0.242, 296, 244, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH A QUINAZOLINONE BASED ALK2 INHIBITOR WITH A 2; 5-DIMETHYL CORE. 
4242, 6d8eA, 0.7255, 3.32, 0.206, 304, 252, DISCOVERY OF A HIGHLY POTENT AND BROADLY EFFECTIVE EGFR AND HER2 EXON 20 INSERTION MUTANT INHIBITOR 
4243, 4ymjA, 0.7255, 3.11, 0.234, 270, 248, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
4244, 4p7eA, 0.7255, 3.11, 0.272, 281, 250, TRIAZOLOPYRIDINE COMPOUNDS AS SELECTIVE JAK1 INHIBITORS: FROM HIT IDENTIFICATION TO GLPG0634
4245, 4czuB, 0.7255, 3.33, 0.300, 287, 253, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.23 AT1G30270 T190D MUTANT
4246, 3qa8G, 0.7255, 3.30, 0.290, 541, 255, CRYSTAL STRUCTURE OF INHIBITOR OF KAPPA B KINASE BETA
4247, 3oriC, 0.7255, 2.79, 0.260, 267, 242, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 1)
4248, 2qnjA, 0.7255, 3.03, 0.320, 318, 250, KINASE AND UBIQUITIN-ASSOCIATED DOMAINS OF MARK3/PAR-1
4249, 3qa8F, 0.7254, 3.25, 0.295, 622, 254, CRYSTAL STRUCTURE OF INHIBITOR OF KAPPA B KINASE BETA
4250, 3ormA, 0.7254, 2.72, 0.257, 266, 241, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN D76A MUTANT
4251, 3kcfC, 0.7254, 3.33, 0.209, 330, 249, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
4252, 2v7aA, 0.7254, 3.29, 0.228, 269, 250, CRYSTAL STRUCTURE OF THE T315I ABL MUTANT IN COMPLEX WITH THE INHIBITOR PHA-739358
4253, 6brcA, 0.7253, 2.86, 0.292, 265, 243, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH AP26113-ANALOG (ALK-IN-1)
4254, 6bqqA, 0.7253, 2.85, 0.288, 271, 243, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH BI2526
4255, 5i4nA, 0.7253, 2.95, 0.206, 275, 247, CRYSTAL STRUCTURE OF THE E596A V617F MUTANT JAK2 PSEUDOKINASE DOMAIN BOUND TO MG-ATP
4256, 5calA, 0.7253, 3.08, 0.197, 300, 249, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 24
4257, 4x7kA, 0.7253, 2.85, 0.270, 260, 241, CO-CRYSTAL STRUCTURE OF PERK BOUND TO 4-{2-AMINO-3-[5-FLUORO-2- (METHYLAMINO)QUINAZOLIN-6-YL]-4-METHYLBENZOYL}-1-METHYL-25-DIPHENYL- 12-DIHYDRO-3H-PYRAZOL-3-ONE INHIBITOR
4258, 4bkjB, 0.7253, 3.22, 0.190, 297, 253, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH IMATINIB
4259, 3p86A, 0.7253, 2.36, 0.228, 250, 237, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN MUTANT D676N IN COMPLEX WITH STAUROSPORINE
4260, 3nczB, 0.7253, 2.91, 0.265, 379, 245, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT 2H-ISOQUINOLIN-1-ONE INHIBITOR
4261, 3hx4A, 0.7253, 2.95, 0.303, 467, 244, CRYSTAL STRUCTURE OF CDPK1 OF TOXOPLASMA GONDII TGME49_101440 IN PRESENCE OF CALCIUM
4262, 3dakC, 0.7253, 3.05, 0.255, 281, 243, CRYSTAL STRUCTURE OF DOMAIN-SWAPPED OSR1 KINASE DOMAIN
4263, 6bbvA, 0.7252, 3.02, 0.241, 289, 249, CRYSTAL STRUCTURE OF JAK2 IN COMPLEX WITH COMPOUND 25
4264, 6b2qD, 0.7252, 2.48, 0.273, 259, 238, DUAL INHIBITION OF THE ESSENTIAL PROTEIN KINASES A AND B IN MYCOBACTERIUM TUBERCULOSIS
4265, 5vd8A, 0.7252, 2.85, 0.226, 260, 243, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH RAC-IV- 099 A MK1775 ANALOGUE
4266, 5na0A, 0.7252, 2.42, 0.300, 253, 240, TTK KINASE DOMAIN IN COMPLEX WITH A PEG-LINKED PYRIMIDO-INDOLIZINE
4267, 5i3rA, 0.7252, 3.03, 0.259, 302, 247, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
4268, 5capA, 0.7252, 3.07, 0.201, 303, 249, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 30
4269, 4e3cF, 0.7252, 3.47, 0.265, 624, 257, X-RAY CRYSTAL STRUCTURE OF HUMAN IKK2 IN AN ACTIVE CONFORMATION
4270, 3psdA, 0.7252, 2.66, 0.199, 262, 241, NON-OXIME PYRAZOLE BASED INHIBITORS OF B-RAF KINASE
4271, 3hmoA, 0.7252, 2.53, 0.302, 257, 242, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH THE INHIBITOR STAUROSPORINE
4272, 3dajA, 0.7252, 2.32, 0.305, 245, 236, CRYSTAL STRUCTURE OF AURORA A COMPLEXED WITH AN INHIBITOR DISCOVERED THROUGH SITE-DIRECTED DYNAMIC TETHERING
4273, 2j5eA, 0.7252, 3.29, 0.198, 309, 252, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR 13-JAB
4274, 2fb8A, 0.7252, 2.72, 0.202, 259, 242, STRUCTURE OF THE B-RAF KINASE DOMAIN BOUND TO SB-590885
4275, 2c6eA, 0.7252, 2.59, 0.306, 251, 242, AURORA A KINASE ACTIVATED MUTANT (T287D) IN COMPLEX WITH A 5-AMINOPYRIMIDINYL QUINAZOLINE INHIBITOR
4276, 5hcyA, 0.7251, 3.09, 0.197, 302, 249, EGFR KINASE DOMAIN MUTANT TMLR WITH 3-CARBOXAMIDE AZAINDOLE COMPOUND 13
4277, 4l7sA, 0.7251, 2.56, 0.226, 250, 239, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH AN AMINOBENZOTHIAZOLE INHIBITOR
4278, 4j96B, 0.7251, 3.35, 0.236, 305, 250, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659M MUTATION IDENTIFIED IN CERVICAL CANCER.
4279, 4gj3A, 0.7251, 3.32, 0.230, 288, 252, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-4-CYANO-N-[2-({[(1R2R)-2- FLUOROCYCLOPROPYL]CARBONYL}AMINO)PYRIDIN-4-YL]BENZAMIDE
4280, 4gj2A, 0.7251, 3.24, 0.231, 288, 251, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-N-[2-({[(1R2R)-2- FLUOROCYCLOPROPYL]CARBONYL}AMINO)PYRIDIN-4-YL]BENZAMIDE
4281, 4ft9A, 0.7251, 3.02, 0.269, 270, 245, CRYSTAL STRUCTURE OF THE CHK1
4282, 4bggA, 0.7251, 2.84, 0.243, 296, 243, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
4283, 3lzbA, 0.7251, 2.60, 0.216, 265, 241, EGFR KINASE DOMAIN COMPLEXED WITH AN IMIDAZO[21-B]THIAZOLE INHIBITOR
4284, 1vjyA, 0.7251, 3.08, 0.198, 299, 247, CRYSTAL STRUCTURE OF A NAPHTHYRIDINE INHIBITOR OF HUMAN TGF- BETA TYPE I RECEPTOR
4285, 6b8yA, 0.7250, 3.32, 0.208, 304, 250, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH N-(3- FLUOROPYRIDIN-4-YL)-2-[6-(TRIFLUOROMETHYL)PYRIDIN-2-YL]-7H-PYRROLO[2 3-D]PYRIMIDIN-4-AMINE
4286, 5vd9A, 0.7250, 2.90, 0.222, 261, 243, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH RAC-IV- 097 A MK1775 ANALOGUE
4287, 5hczA, 0.7250, 3.08, 0.197, 300, 249, EGFR KINASE DOMAIN MUTANT TMLR WITH 3-AZETIDINYL AZAINDAZOLE COMPOUND 21
4288, 5a46A, 0.7250, 3.49, 0.242, 289, 256, FGFR1 IN COMPLEX WITH DOVITINIB
4289, 4lueA, 0.7250, 2.52, 0.257, 422, 237, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH 7-[TRANS-4-(4- METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE (RESULTING FROM DISPLACEMENT OF SKF86002)
4290, 1zycC, 0.7250, 3.04, 0.263, 271, 247, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: WILD- TYPE IN APO FORM.
4291, 1k2pB, 0.7250, 3.03, 0.203, 258, 246, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE DOMAIN
4292, 5twzA, 0.7249, 2.45, 0.325, 313, 237, STRUCTURE OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE
4293, 4x7lA, 0.7249, 2.86, 0.270, 260, 241, CO-CRYSTAL STRUCTURE OF PERK BOUND TO 4-{2-AMINO-4-METHYL-3-[2- (METHYLAMINO)-13-BENZOTHIAZOL-6-YL]BENZOYL}-1-METHYL-25-DIPHENYL-1 2-DIHYDRO-3H-PYRAZOL-3-ONE INHIBITOR
4294, 4x2nA, 0.7249, 3.28, 0.209, 303, 249, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
4295, 4o91A, 0.7249, 2.81, 0.291, 293, 244, CRYSTAL STRUCTURE OF TYPE II INHIBITOR NG25 BOUND TO TAK1-TAB1
4296, 4iwqA, 0.7249, 3.13, 0.245, 626, 249, CRYSTAL STRUCTURE AND MECHANISM OF ACTIVATION OF TBK1
4297, 3faaE, 0.7249, 3.30, 0.214, 330, 248, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A 2- AMINOIMIDAZOLE INHIBITOR
4298, 3dlsB, 0.7249, 2.92, 0.253, 280, 245, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
4299, 2qu5A, 0.7249, 2.88, 0.232, 292, 246, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZIMIDAZOLE INHIBITOR
4300, 2qohB, 0.7249, 3.36, 0.231, 281, 251, CRYSTAL STRUCTURE OF ABL KINASE BOUND WITH PPY-A
4301, 5wevA, 0.7248, 3.12, 0.257, 293, 249, IDENTIFICATION OF AN IMIDAZOPYRIDINE SCAFFOLD TO GENERATE POTENT AND SELECTIVE TYK2 INHIBITORS THAT DEMONSTRATE ACTIVITY IN AN IN VIVO PSORIASIS MODEL
4302, 4kbkC, 0.7248, 3.25, 0.175, 280, 251, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
4303, 3vw6A, 0.7248, 2.74, 0.296, 255, 240, CRYSTAL STRUCTURE OF HUMAN APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) WITH IMIDAZOPYRIDINE INHIBITOR
4304, 3rcdB, 0.7248, 2.79, 0.202, 271, 243, HER2 KINASE DOMAIN COMPLEXED WITH TAK-285
4305, 3q4uC, 0.7248, 2.88, 0.242, 296, 244, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
4306, 3lpbA, 0.7248, 3.08, 0.265, 278, 249, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT 28-DIARYL- QUINOXALINE INHIBITOR
4307, 3lcsA, 0.7248, 3.29, 0.186, 304, 253, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
4308, 3kcfD, 0.7248, 3.38, 0.209, 330, 249, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
4309, 5vd5A, 0.7247, 2.90, 0.222, 260, 243, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH RAC-IV- 050 A MK1775 ANALOUGUE
4310, 5usyB, 0.7247, 3.24, 0.272, 287, 250, JAK2 JH1 IN COMPLEX WITH JNJ-7706621
4311, 5nadA, 0.7247, 2.75, 0.292, 256, 243, TTK KINASE DOMAIN IN COMPLEX WITH BAY 1217389
4312, 4gihA, 0.7247, 3.24, 0.231, 288, 251, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-N-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}BENZAMIDE
4313, 4e3cC, 0.7247, 3.47, 0.268, 624, 257, X-RAY CRYSTAL STRUCTURE OF HUMAN IKK2 IN AN ACTIVE CONFORMATION
4314, 3ue4A, 0.7247, 3.33, 0.240, 270, 250, STRUCTURAL AND SPECTROSCOPIC ANALYSIS OF THE KINASE INHIBITOR BOSUTINIB BINDING TO THE ABL TYROSINE KINASE DOMAIN
4315, 3tjdB, 0.7247, 3.26, 0.258, 287, 252, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 19
4316, 3q4tA, 0.7247, 3.20, 0.230, 305, 248, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DORSOMORPHIN
4317, 3prfA, 0.7247, 2.70, 0.199, 262, 241, CRYSTAL STRUCTURE OF HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH A NON- OXIME FUROPYRIDINE INHIBITOR
4318, 3lw0A, 0.7247, 3.13, 0.209, 292, 249, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
4319, 2wotA, 0.7247, 3.34, 0.217, 303, 249, ALK5 IN COMPLEX WITH 4-((56-DIMETHYL-2-(2-PYRIDYL)-3- PYRIDYL)OXY)-N-(345-TRIMETHOXYPHENYL)PYRIDIN-2-AMINE
4320, 4fsrA, 0.7246, 3.01, 0.269, 269, 245, CRYSTAL STRUCTURE OF THE CHK1
4321, 4e3cB, 0.7246, 3.39, 0.273, 632, 256, X-RAY CRYSTAL STRUCTURE OF HUMAN IKK2 IN AN ACTIVE CONFORMATION
4322, 3rcdD, 0.7246, 2.79, 0.202, 271, 243, HER2 KINASE DOMAIN COMPLEXED WITH TAK-285
4323, 3lw0C, 0.7246, 3.13, 0.209, 292, 249, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
4324, 5de2A, 0.7245, 2.70, 0.339, 267, 242, STRUCTURAL MECHANISM OF NEK7 ACTIVATION BY NEK9-INDUCED DIMERISATION
4325, 4qpsC, 0.7245, 2.81, 0.243, 276, 243, CRYSTAL STRUCTURE OF JAK3 COMPLEXED TO N-[3-(6-PHENYLAMINO-PYRAZIN-2- YL)-3H-BENZOIMIDAZOL-5-YL]-ACRYLAMIDE
4326, 4js8A, 0.7245, 2.82, 0.294, 259, 245, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 401348
4327, 3lxnA, 0.7245, 3.27, 0.235, 287, 251, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
4328, 3lw0D, 0.7245, 3.13, 0.209, 292, 249, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
4329, 3hkoA, 0.7245, 2.99, 0.282, 319, 248, CRYSTAL STRUCTURE OF A CDPK KINASE DOMAIN FROM CRYPTOSPORIDIUM PARVUM CGD7_40
4330, 1nvrA, 0.7245, 3.07, 0.287, 264, 247, THE COMPLEX STRUCTURE OF CHECKPOINT KINASE CHK1/STAUROSPORINE
4331, 5op4A, 0.7244, 2.84, 0.280, 259, 243, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMINOPYRIMIDINE LRRK2 INHIBITOR
4332, 5grnA, 0.7244, 3.20, 0.198, 285, 252, CRYSTAL STRUCTURE OF PDGFRA IN COMPLEX WITH WQ-C-159
4333, 5em7A, 0.7244, 3.12, 0.197, 300, 249, EGFR KINASE DOMAIN MUTANT TMLR WITH PYRIDONE COMPOUND 13: 4-[(2- METHOXYPHENYL)AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-2- OXIDANYLIDENE-1~{H}-PYRIDINE-3-CARBOXAMIDE
4334, 4umpD, 0.7244, 2.83, 0.321, 321, 243, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
4335, 4e3cA, 0.7244, 3.39, 0.259, 624, 255, X-RAY CRYSTAL STRUCTURE OF HUMAN IKK2 IN AN ACTIVE CONFORMATION
4336, 3w1fA, 0.7244, 2.89, 0.297, 259, 246, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 5-(5- ETHOXY-6-(1-METHYL-1H-PYRAZOL-4-YL)-1H-INDAZOL-3-YL)-2- METHYLBENZENESULFONAMIDE
4337, 3lxlA, 0.7244, 3.24, 0.256, 281, 250, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
4338, 3kcfB, 0.7244, 3.11, 0.203, 324, 246, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
4339, 3kcfA, 0.7244, 3.26, 0.214, 328, 248, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
4340, 3brbA, 0.7244, 2.42, 0.224, 260, 237, CRYSTAL STRUCTURE OF CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE- PROTEIN KINASE MER IN COMPLEX WITH ADP
4341, 5usqA, 0.7243, 3.26, 0.214, 299, 248, ALK-5 KINASE INHIBITOR COMPLEX
4342, 5ljjA, 0.7243, 2.96, 0.297, 264, 246, CRYSTAL STRUCTURE OF HUMAN MPS1 (TTK) IN COMPLEX WITH REVERSINE
4343, 5jsmB, 0.7243, 2.87, 0.217, 263, 244, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
4344, 4nt4A, 0.7243, 3.26, 0.202, 300, 252, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF GILGAMESH ISOFORM I FROM DROSOPHILA MELANOGASTER
4345, 3lw0B, 0.7243, 3.13, 0.209, 292, 249, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
4346, 3dakD, 0.7243, 3.09, 0.259, 284, 243, CRYSTAL STRUCTURE OF DOMAIN-SWAPPED OSR1 KINASE DOMAIN
4347, 2c30A, 0.7243, 3.39, 0.251, 289, 251, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 6
4348, 5l8kA, 0.7242, 3.18, 0.305, 266, 249, AURORA-A KINASE DOMAIN IN COMPLEX WITH VNAR-D01 (CRYSTAL FORM 2)
4349, 5jsmD, 0.7242, 2.92, 0.217, 259, 244, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
4350, 5imeA, 0.7242, 2.91, 0.284, 280, 243, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 (PAK1) IN COMPLEX WITH COMPOUND 9
4351, 4gl9C, 0.7242, 3.11, 0.249, 282, 249, CRYSTAL STRUCTURE OF INHIBITORY PROTEIN SOCS3 IN COMPLEX WITH JAK2 KINASE DOMAIN AND FRAGMENT OF GP130 INTRACELLULAR DOMAIN
4352, 4e26B, 0.7242, 2.79, 0.210, 264, 243, BRAF IN COMPLEX WITH AN ORGANIC INHIBITOR 7898734
4353, 3q4cA, 0.7242, 2.75, 0.194, 264, 242, CRYSTAL STRUCTURE OF WILD TYPE BRAF KINASE DOMAIN IN COMPLEX WITH ORGANOMETALLIC INHIBITOR CNS292
4354, 3faaA, 0.7242, 3.25, 0.214, 328, 248, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A 2- AMINOIMIDAZOLE INHIBITOR
4355, 1zycB, 0.7242, 2.94, 0.266, 254, 244, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: WILD- TYPE IN APO FORM.
4356, 5ehyA, 0.7241, 2.50, 0.307, 255, 241, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
4357, 5e8zA, 0.7241, 3.35, 0.213, 303, 249, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH 3- AMINO-6-[4-(2-HYDROXYETHYL)PHENYL]-N-[4-(MORPHOLIN-4-YL)PYRIDIN-3- YL]PYRAZINE-2-CARBOXAMIDE
4358, 5e8tA, 0.7241, 3.33, 0.213, 302, 249, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D)
4359, 4yhtB, 0.7241, 2.68, 0.203, 258, 241, BRAF COMPLEXED WITH AN INHIBITOR
4360, 4rj7A, 0.7241, 3.01, 0.198, 295, 247, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 1
4361, 4rixB, 0.7241, 2.82, 0.210, 293, 243, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
4362, 3u6iA, 0.7241, 2.92, 0.216, 281, 245, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH PYRAZOLONE INHIBITOR 58A
4363, 2rf9B, 0.7241, 2.89, 0.213, 269, 244, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE EGFR KINASE DOMAIN AND A MIG6 PEPTIDE
4364, 5xdkA, 0.7240, 3.37, 0.213, 307, 253, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH CO-1686
4365, 5oprA, 0.7240, 2.85, 0.276, 258, 243, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMINOPYRIDINE LRRK2 INHIBITOR
4366, 4yhtA, 0.7240, 2.61, 0.204, 256, 240, BRAF COMPLEXED WITH AN INHIBITOR
4367, 4x2fA, 0.7240, 3.29, 0.209, 303, 249, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
4368, 4u0iA, 0.7240, 3.09, 0.213, 297, 249, CRYSTAL STRUCTURE OF KIT IN COMPLEX WITH PONATINIB
4369, 4e20A, 0.7240, 3.34, 0.239, 282, 251, STRUCTURE OF MOUSE TYK-2 COMPLEXED TO A 3-AMINOINDAZOLE INHIBITOR
4370, 3wzkA, 0.7240, 2.81, 0.286, 258, 245, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH N- CYCLOPROPYL-4-(8-((THIOPHEN-2-YLMETHYL)AMINO)IMIDAZO[12-A]PYRAZIN-3- YL)BENZAMIDE
4371, 3uytB, 0.7240, 3.13, 0.176, 286, 250, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
4372, 3kcfE, 0.7240, 3.46, 0.213, 330, 249, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
4373, 5k0kA, 0.7239, 2.48, 0.228, 260, 237, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE-PROTEIN KINASE MER IN COMPLEX WITH INHIBITOR UNC2434
4374, 4x2kA, 0.7239, 3.30, 0.209, 303, 249, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
4375, 4x2jA, 0.7239, 3.30, 0.209, 303, 249, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
4376, 4x2gA, 0.7239, 3.29, 0.213, 303, 249, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
4377, 4mkcA, 0.7239, 3.28, 0.187, 303, 252, CRYSTAL STRUCTURE OF ANAPLASTIC LYMPHOMA KINASE COMPLEXED WITH LDK378
4378, 3prfB, 0.7239, 2.71, 0.195, 262, 241, CRYSTAL STRUCTURE OF HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH A NON- OXIME FUROPYRIDINE INHIBITOR
4379, 3ot3A, 0.7239, 3.01, 0.286, 259, 245, X-RAY CRYSTAL STRUCTURE OF COMPOUND 22K BOUND TO HUMAN CHK1 KINASE DOMAIN
4380, 3hmiA, 0.7239, 3.23, 0.213, 268, 249, THE CRYSTAL STRUCTURE OF HUMAN ABL2 IN COMPLEX WITH 5-AMINO-3-{[4- (AMINOSULFONYL)PHENYL]AMINO}-N-(26-DIFLUOROPHENYL)-1H-124- TRIAZOLE-1-CARBOTHIOAMIDE
4381, 2wtvD, 0.7239, 3.14, 0.297, 262, 249, AURORA-A INHIBITOR STRUCTURE
4382, 5zv2A, 0.7238, 3.44, 0.234, 284, 256, FGFR-1 IN COMPLEX WITH LIGAND LENVATINIB 
4383, 5kz8A, 0.7238, 2.53, 0.308, 302, 240, MARK2 COMPLEX WITH 7-[(1S)-1-(4-FLUOROPHENYL)ETHYL]-55-DIMETHYL-2-(3- PYRIDYLAMINO)PYRROLO[23-D]PYRIMIDIN-6-ONE
4384, 4umpB, 0.7238, 2.80, 0.318, 324, 242, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
4385, 4u5jB, 0.7238, 2.72, 0.240, 267, 242, C-SRC IN COMPLEX WITH RUXOLITINIB
4386, 4o2pA, 0.7238, 2.81, 0.254, 265, 244, KINASE DOMAIN OF CSRC IN COMPLEX WITH A SUBSTITUTED PYRAZOLOPYRIMIDINE
4387, 4id7A, 0.7238, 2.91, 0.240, 268, 246, ACK1 KINASE IN COMPLEX WITH THE INHIBITOR CIS-3-[8-AMINO-1-(4- PHENOXYPHENYL)IMIDAZO[15-A]PYRAZIN-3-YL]CYCLOBUTANOL
4388, 3u6hA, 0.7238, 2.88, 0.217, 280, 244, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH PYRAZOLONE INHIBITOR 26
4389, 3lzbD, 0.7238, 2.69, 0.224, 261, 241, EGFR KINASE DOMAIN COMPLEXED WITH AN IMIDAZO[21-B]THIAZOLE INHIBITOR
4390, 3bprD, 0.7238, 2.41, 0.225, 259, 236, CRYSTAL STRUCTURE OF CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE- PROTEIN KINASE MER IN COMPLEX WITH INHIBITOR C52
4391, 2rf9A, 0.7238, 2.89, 0.212, 280, 245, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE EGFR KINASE DOMAIN AND A MIG6 PEPTIDE
4392, 5em6A, 0.7237, 3.11, 0.197, 301, 249, EGFR KINASE DOMAIN MUTANT TMLR WITH PYRIDONE COMPOUND 19: 4-[(2- AZANYLPYRIMIDIN-4-YL)AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]- 2-OXIDANYLIDENE-1~{H}-PYRIDINE-3-CARBOXAMIDE
4393, 4xhlA, 0.7237, 3.28, 0.153, 330, 249, STRUCTURE OF S. CEREVISIAE HRR25 1-394 (K38R MUTANT)
4394, 4mnfB, 0.7237, 2.66, 0.196, 257, 240, CRYSTAL STRUCTURE OF BRAF-V600E BOUND TO GDC0879
4395, 4aojA, 0.7237, 2.71, 0.226, 260, 243, HUMAN TRKA IN COMPLEX WITH THE INHIBITOR AZ-23
4396, 3lzbC, 0.7237, 2.64, 0.225, 259, 240, EGFR KINASE DOMAIN COMPLEXED WITH AN IMIDAZO[21-B]THIAZOLE INHIBITOR
4397, 2wtvB, 0.7237, 3.15, 0.301, 261, 249, AURORA-A INHIBITOR STRUCTURE
4398, 2wtvA, 0.7237, 3.15, 0.297, 262, 249, AURORA-A INHIBITOR STRUCTURE
4399, 1zy4A, 0.7237, 3.07, 0.275, 271, 247, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: R794G HYPERACTIVATING MUTANT IN APO FORM.
4400, 1zmwB, 0.7237, 2.74, 0.306, 302, 242, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: T208A/S212A INACTIVE DOUBLE MUTANT
4401, 1k9aA, 0.7237, 2.70, 0.224, 439, 241, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
4402, 5i3oB, 0.7236, 2.97, 0.260, 302, 246, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
4403, 4cztC, 0.7236, 3.49, 0.271, 286, 255, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.23 AT1G30270
4404, 4cztB, 0.7236, 3.51, 0.294, 286, 255, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.23 AT1G30270
4405, 3wyyA, 0.7236, 2.82, 0.290, 258, 245, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH (E)- 3-(4-((6-(((3S5S7S)-ADAMANTAN-1-YL)AMINO)-4-AMINO-5-CYANOPYRIDIN-2- YL)AMINO)-2-(CYANOMETHOXY)PHENYL)-N-(2-METHOXYETHYL)ACRYLAMIDE
4406, 3rhkB, 0.7236, 3.11, 0.205, 299, 249, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF C-MET KINASE IN COMPLEX WITH ARQ 197
4407, 2e9pA, 0.7236, 3.05, 0.275, 269, 247, STRUCTURE OF H-CHK1 COMPLEXED WITH A771129
4408, 6d1yA, 0.7235, 3.15, 0.224, 300, 250, CRYSTAL STRUCTURE OF TYROSINE-PROTEIN KINASE RECEPTOR IN COMPLEX WITH 2;4-DICHLORO-N-(3-METHYL-1-PHENYL-1H-PYRAZOL-5-YL)BENZAMIDE INHIBITOR 
4409, 5xp5A, 0.7235, 2.82, 0.247, 267, 243, C-SRC IN COMPLEX WITH ATP-CHF
4410, 5mqvB, 0.7235, 3.33, 0.182, 287, 253, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
4411, 5eobA, 0.7235, 3.42, 0.215, 288, 251, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
4412, 4rfmA, 0.7235, 2.60, 0.224, 249, 241, ITK KINASE DOMAIN IN COMPLEX WITH COMPOUND 1 N-{1-[(11-DIOXO-1-THIAN- 2-YL)(PHENYL)METHYL]-1H- PYRAZOL-4-YL}-55-DIFLUORO-5A-METHYL-1H4H 4AH5H5AH6H-CYCLOPROPA[F]INDAZOLE-3-CARBOXAMIDE
4413, 4e6dA, 0.7235, 3.09, 0.277, 286, 249, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 7
4414, 4ckrA, 0.7235, 3.33, 0.209, 295, 254, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH DDR1-IN-1
4415, 6eixA, 0.7234, 3.03, 0.241, 312, 245, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE Q207E MUTANT OF ACVR1 (ALK2) IN COMPLEX WITH A 2-AMINOPYRIDINE INHIBITOR K02288
4416, 5oq6A, 0.7234, 2.92, 0.279, 257, 244, STRUCTURE OF CHK1 12-PT. MUTANT COMPLEX WITH AMINOPYRIMIDO- BENZODIAZEPINONE LRRK2 INHIBITOR
4417, 5ia2A, 0.7234, 3.21, 0.187, 287, 251, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 66
4418, 5flfA, 0.7234, 3.38, 0.239, 296, 251, DISEASE LINKED MUTATION IN FGFR
4419, 5am7B, 0.7234, 3.36, 0.237, 287, 253, FGFR1 MUTANT WITH AN INHIBITOR
4420, 4u5jA, 0.7234, 2.91, 0.242, 267, 244, C-SRC IN COMPLEX WITH RUXOLITINIB
4421, 3qbnA, 0.7234, 2.61, 0.308, 250, 240, STRUCTURE OF HUMAN AURORA A IN COMPLEX WITH A DIAMINOPYRIMIDINE
4422, 2xvdA, 0.7234, 2.96, 0.230, 270, 248, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4423, 2wtvC, 0.7234, 3.16, 0.301, 261, 249, AURORA-A INHIBITOR STRUCTURE
4424, 2itpA, 0.7234, 3.32, 0.215, 305, 251, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AEE788
4425, 1k9aB, 0.7234, 2.72, 0.227, 441, 242, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
4426, 6c4dD, 0.7233, 3.03, 0.229, 266, 245, STRUCTURE BASED DESIGN OF RIP1 KINASE INHIBITORS
4427, 4x0mA, 0.7233, 3.29, 0.209, 303, 249, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
4428, 4tn6B, 0.7233, 3.39, 0.168, 285, 256, CK1D IN COMPLEX WITH INHIBITOR
4429, 4riyB, 0.7233, 2.84, 0.214, 293, 243, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
4430, 4qqtA, 0.7233, 3.43, 0.232, 283, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 TYROSINE KINASE DOMAIN
4431, 4pmmA, 0.7233, 3.17, 0.217, 285, 249, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR N-(3-CYCLOPROPYL- 1-PHENYL-1H-PYRAZOL-5-YL)-2-{4-[3-METHOXY-4-(4-METHYL-1H-IMIDAZOL-1- YL)PHENYL]-1H-123-TRIAZOL-1-YL}ACETAMIDE
4432, 3ii5A, 0.7233, 3.01, 0.207, 262, 246, THE COMPLEX OF WILD-TYPE B-RAF WITH PYRAZOLO PYRIMIDINE INHIBITOR
4433, 2jivA, 0.7233, 2.89, 0.221, 270, 244, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION IN COMPEX WITH HKI-272
4434, 6fekA, 0.7232, 3.26, 0.253, 294, 249, ONCOGENIC POINT MUTATION OF RET RECEPTOR TYROSINE KINASE
4435, 4ludA, 0.7232, 2.46, 0.254, 421, 236, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH THE FLUORESCENT COMPOUND SKF86002
4436, 4kbcA, 0.7232, 3.30, 0.172, 288, 250, CK1D IN COMPLEX WITH {4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDIN-2- YL}METHANOL INHIBITOR
4437, 4ft0A, 0.7232, 3.01, 0.290, 266, 245, CRYSTAL STRUCTURE OF THE CHK1
4438, 4c4fA, 0.7232, 2.46, 0.304, 254, 240, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
4439, 3zepD, 0.7232, 3.03, 0.262, 272, 244, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
4440, 2itxA, 0.7232, 3.40, 0.202, 307, 253, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AMP- PNP
4441, 5x26A, 0.7231, 3.03, 0.202, 302, 247, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH SKLB(3)
4442, 5vc6A, 0.7231, 2.88, 0.223, 259, 242, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH PHA- 848125
4443, 5ihaA, 0.7231, 2.38, 0.328, 303, 235, MELK IN COMPLEX WITH NVS-MELK8F
4444, 5eg3A, 0.7231, 3.28, 0.239, 301, 251, CRYSTAL STRUCTURE OF THE ACTIVATED FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN IN COMPLEX WITH THE CSH2 DOMAIN OF PHOSPHOLIPASE C GAMMA (PLCGAMMA)
4445, 4v05A, 0.7231, 3.43, 0.235, 287, 255, FGFR1 IN COMPLEX WITH AZD4547.
4446, 4fsuA, 0.7231, 3.03, 0.286, 260, 245, CRYSTAL STRUCTURE OF THE CHK1
4447, 3socA, 0.7231, 3.14, 0.223, 307, 247, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH A QUINAZOLIN
4448, 2y4iB, 0.7231, 2.94, 0.202, 265, 242, KSR2-MEK1 HETERODIMER
4449, 2v7aB, 0.7231, 3.32, 0.232, 268, 250, CRYSTAL STRUCTURE OF THE T315I ABL MUTANT IN COMPLEX WITH THE INHIBITOR PHA-739358
4450, 2dq7X, 0.7231, 2.91, 0.230, 262, 243, CRYSTAL STRUCTURE OF FYN KINASE DOMAIN COMPLEXED WITH STAUROSPORINE
4451, 1uwhA, 0.7231, 2.98, 0.196, 264, 245, THE COMPLEX OF WILD TYPE B-RAF AND BAY439006
4452, 1b6cF, 0.7231, 3.21, 0.222, 326, 248, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
4453, 5x27A, 0.7230, 3.02, 0.206, 302, 247, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH SKLB(5)
4454, 5oxgB, 0.7230, 2.87, 0.243, 296, 243, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
4455, 5ei8A, 0.7230, 2.81, 0.301, 261, 246, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
4456, 5csxA, 0.7230, 3.09, 0.203, 261, 246, CRYSTAL STRUCTURE OF B-RAF IN COMPLEX WITH BI 882370
4457, 4x7hA, 0.7230, 2.69, 0.273, 256, 238, CO-CRYSTAL STRUCTURE OF PERK BOUND TO N-{5-[(67-DIMETHOXYQUINOLIN-4- YL)OXY]PYRIDIN-2-YL}-1-METHYL-3-OXO-2-PHENYL-5-(PYRIDIN-4-YL)-23- DIHYDRO-1H-PYRAZOLE-4-CARBOXAMIDE INHIBITOR
4458, 4r3pA, 0.7230, 3.54, 0.208, 310, 255, CRYSTAL STRUCTURES OF EGFR IN COMPLEX WITH MIG6
4459, 4kbcB, 0.7230, 3.15, 0.192, 277, 250, CK1D IN COMPLEX WITH {4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDIN-2- YL}METHANOL INHIBITOR
4460, 4giiA, 0.7230, 3.26, 0.231, 289, 251, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-4-CYANO-N-{2- [(CYCLOPROPYLCARBONYL)AMINO]PYRIDIN-4-YL}BENZAMIDE
4461, 3d7uC, 0.7230, 2.59, 0.229, 257, 240, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
4462, 3d7uA, 0.7230, 2.59, 0.229, 257, 240, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
4463, 3cohB, 0.7230, 2.53, 0.310, 247, 239, CRYSTAL STRUCTURE OF AURORA-A IN COMPLEX WITH A PENTACYCLIC INHIBITOR
4464, 2fb8B, 0.7230, 2.75, 0.198, 259, 242, STRUCTURE OF THE B-RAF KINASE DOMAIN BOUND TO SB-590885
4465, 5oy6D, 0.7229, 3.12, 0.243, 292, 247, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
4466, 5oq7B, 0.7229, 2.82, 0.276, 256, 243, STRUCTURE OF CHK1 8-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
4467, 5mqvD, 0.7229, 3.31, 0.175, 287, 252, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
4468, 5i9yA, 0.7229, 3.16, 0.191, 287, 251, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH DASATINIB
4469, 5friA, 0.7229, 3.19, 0.215, 301, 247, ALK5 IN COMPLEX WITHA AN N-(4-ANILINO-2-PYRIDYL)ACETAMIDE INHIBITOR.
4470, 5f4nA, 0.7229, 2.79, 0.281, 258, 242, MULTI-PARAMETER LEAD OPTIMIZATION TO GIVE AN ORAL CHK1 INHIBITOR CLINICAL CANDIDATE: (R)-5-((4-((MORPHOLIN-2-YLMETHYL)AMINO)-5- (TRIFLUOROMETHYL)PYRIDIN-2-YL)AMINO)PYRAZINE-2-CARBONITRILE (CCT245737)
4471, 4j98B, 0.7229, 3.42, 0.240, 304, 250, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659Q MUTATION.
4472, 4hniA, 0.7229, 3.08, 0.194, 284, 247, CRYSTAL STRUCTURE OF CK1E IN COMPLEX WITH PF4800567
4473, 4bf2A, 0.7229, 2.68, 0.298, 253, 238, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
4474, 3tjdA, 0.7229, 3.14, 0.272, 284, 250, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 19
4475, 3p08B, 0.7229, 2.96, 0.192, 258, 245, CRYSTAL STRUCTURE OF THE HUMAN BTK KINASE DOMAIN
4476, 3bprC, 0.7229, 2.44, 0.225, 259, 236, CRYSTAL STRUCTURE OF CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE- PROTEIN KINASE MER IN COMPLEX WITH INHIBITOR C52
4477, 2pvfA, 0.7229, 3.23, 0.233, 285, 249, CRYSTAL STRUCTURE OF TYROSINE PHOSPHORYLATED ACTIVATED FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN IN COMPLEX WITH ATP ANALOG AND SUBSTRATE PEPTIDE
4478, 6bu6A, 0.7228, 3.49, 0.154, 322, 259, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
4479, 4qt1A, 0.7228, 2.93, 0.245, 277, 245, JAK3 KINASE DOMAIN IN COMPLEX WITH 1-[(3S)-1-ISOBUTYLSULFONYL-3- PIPERIDYL]-3-(5H-PYRROLO[23-B]PYRAZIN-2-YL)UREA
4480, 4fvrA, 0.7228, 2.96, 0.202, 274, 247, CRYSTAL STRUCTURE OF THE JAK2 PSEUDOKINASE DOMAIN MUTANT V617F (MG- ATP-BOUND FORM)
4481, 4bkjA, 0.7228, 3.25, 0.190, 295, 253, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH IMATINIB
4482, 3tkhA, 0.7228, 3.05, 0.290, 269, 245, CRYSTAL STRUCTURE OF CHK1 IN COMPLEX WITH INHIBITOR S01
4483, 2bujB, 0.7228, 3.10, 0.247, 286, 247, CRYSTAL STRUCTURE OF THE HUMAN SERINE-THREONINE KINASE 16 IN COMPLEX WITH STAUROSPORINE
4484, 2brgA, 0.7228, 2.97, 0.270, 257, 244, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
4485, 4uxlA, 0.7227, 2.86, 0.228, 288, 246, STRUCTURE OF HUMAN ROS1 KINASE DOMAIN IN COMPLEX WITH PF-06463922
4486, 4iwpA, 0.7227, 3.17, 0.245, 628, 249, CRYSTAL STRUCTURE AND MECHANISM OF ACTIVATION OF TBK1
4487, 4hvdA, 0.7227, 3.15, 0.246, 276, 248, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-122-TRIMETHYL-PROPYL)-AMIDE
4488, 3mpmA, 0.7227, 3.14, 0.220, 257, 250, LCK COMPLEXED WITH A PYRAZOLOPYRIMIDINE
4489, 3lpbB, 0.7227, 3.23, 0.261, 284, 249, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT 28-DIARYL- QUINOXALINE INHIBITOR
4490, 3l8pA, 0.7227, 2.70, 0.259, 292, 239, CRYSTAL STRUCTURE OF CYTOPLASMIC KINASE DOMAIN OF TIE2 COMPLEXED WITH INHIBITOR CEP11207
4491, 5tq4A, 0.7226, 3.05, 0.254, 290, 248, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
4492, 5oxgC, 0.7226, 2.94, 0.242, 301, 244, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
4493, 5caqA, 0.7226, 3.12, 0.197, 301, 249, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 33
4494, 4mnfA, 0.7226, 2.67, 0.204, 257, 240, CRYSTAL STRUCTURE OF BRAF-V600E BOUND TO GDC0879
4495, 4lg4E, 0.7226, 3.13, 0.280, 275, 250, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
4496, 4itjB, 0.7226, 3.45, 0.234, 276, 252, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-4
4497, 5cauA, 0.7225, 3.10, 0.202, 297, 248, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 41B
4498, 4xmoA, 0.7225, 3.37, 0.217, 289, 249, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH (R)-5-(8-FLUORO-3-(1- FLUORO-1-(3-METHOXYQUINOLIN-6-YL)ETHYL)-[124]TRIAZOLO[43- A]PYRIDIN-6-YL)-3-METHYLISOXAZOLE
4499, 4jq8A, 0.7225, 3.22, 0.217, 303, 249, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 4B
4500, 4i23A, 0.7225, 3.27, 0.208, 304, 250, CRYSTAL STRUCTURE OF THE WILD-TYPE EGFR KINASE DOMAIN IN COMPLEX WITH DACOMITINIB (SOAKED)
4501, 4hvhA, 0.7225, 3.15, 0.246, 278, 248, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((R)-2-HYDROXY-12-DIMETHYL-PROPYL
4502, 2i1mA, 0.7225, 3.28, 0.203, 311, 251, CFMS TYROSINE KINASE (TIE2 KID) IN COMPLEX WITH AN ARYLAMIDE INHIBITOR
4503, 5c8nA, 0.7224, 3.11, 0.197, 300, 249, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 23
4504, 5c8kA, 0.7224, 3.12, 0.197, 300, 249, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 1
4505, 4qqjA, 0.7224, 3.45, 0.240, 282, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE DOMAIN HARBORING THE V550L GATE-KEEPER MUTATION
4506, 4lrmB, 0.7224, 3.18, 0.221, 293, 249, EGFR D770_N771INSNPG IN COMPLEX WITH PD168393
4507, 4l7sB, 0.7224, 2.58, 0.222, 250, 239, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH AN AMINOBENZOTHIAZOLE INHIBITOR
4508, 3q4uA, 0.7224, 2.97, 0.242, 298, 244, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
4509, 3p9jA, 0.7224, 2.63, 0.318, 249, 239, AURORA A KINASE DOMAIN WITH PHTHALAZINONE PYRAZOLE INHIBITOR
4510, 3faaC, 0.7224, 3.40, 0.209, 330, 249, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A 2- AMINOIMIDAZOLE INHIBITOR
4511, 3cohA, 0.7224, 2.53, 0.310, 247, 239, CRYSTAL STRUCTURE OF AURORA-A IN COMPLEX WITH A PENTACYCLIC INHIBITOR
4512, 5wngB, 0.7223, 2.70, 0.282, 365, 241, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
4513, 5oxgD, 0.7223, 2.94, 0.242, 293, 244, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
4514, 5o49B, 0.7223, 3.48, 0.231, 286, 255, HUMAN FGF IN COMPLEX WITH A COVALENT INHIBITOR
4515, 4kbaB, 0.7223, 3.14, 0.177, 285, 248, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
4516, 4g9rA, 0.7223, 2.98, 0.213, 262, 244, B-RAF V600E KINASE DOMAIN BOUND TO A TYPE II DIHYDROQUINAZOLINE INHIBITOR
4517, 4bi1A, 0.7223, 2.44, 0.305, 252, 239, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
4518, 2x7oA, 0.7223, 3.26, 0.215, 330, 247, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH AN INDOLINONE INHIBITOR
4519, 1zmwA, 0.7223, 2.77, 0.314, 302, 242, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: T208A/S212A INACTIVE DOUBLE MUTANT
4520, 5ui0B, 0.7222, 3.51, 0.230, 304, 252, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING AN E565A/K659M DOUBLE GAIN-OF-FUNCTION MUTATION
4521, 5i3rB, 0.7222, 3.10, 0.259, 302, 247, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
4522, 4z55A, 0.7222, 3.29, 0.187, 294, 251, ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN COMPLEXED WITH PYRAZOLOPYRIMIDINE DERIVATIVE OF LDK378
4523, 4gl9A, 0.7222, 3.17, 0.257, 282, 249, CRYSTAL STRUCTURE OF INHIBITORY PROTEIN SOCS3 IN COMPLEX WITH JAK2 KINASE DOMAIN AND FRAGMENT OF GP130 INTRACELLULAR DOMAIN
4524, 4g9cB, 0.7222, 3.02, 0.204, 264, 245, HUMAN B-RAF KINASE DOMAIN BOUND TO A TYPE II PYRAZOLOPYRIDINE INHIBITOR
4525, 1t46A, 0.7222, 3.10, 0.221, 297, 249, STRUCTURAL BASIS FOR THE AUTOINHIBITION AND STI-571 INHIBITION OF C-KIT TYROSINE KINASE
4526, 6c4dA, 0.7221, 3.22, 0.227, 267, 247, STRUCTURE BASED DESIGN OF RIP1 KINASE INHIBITORS
4527, 5ttsA, 0.7221, 3.17, 0.258, 274, 248, JAK3 WITH COVALENT INHIBITOR 4
4528, 5oxgA, 0.7221, 2.91, 0.243, 293, 243, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
4529, 5nkgA, 0.7221, 3.23, 0.187, 292, 251, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3D
4530, 5mqvE, 0.7221, 3.31, 0.175, 287, 252, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
4531, 5flfD, 0.7221, 3.39, 0.244, 290, 250, DISEASE LINKED MUTATION IN FGFR
4532, 4ztqA, 0.7221, 2.54, 0.315, 247, 238, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO FK932
4533, 4mneB, 0.7221, 2.85, 0.198, 270, 242, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
4534, 4kbaA, 0.7221, 2.97, 0.182, 263, 247, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
4535, 3zfxI, 0.7221, 2.73, 0.222, 263, 243, CRYSTAL STRUCTURE OF EPHB1
4536, 3hmnA, 0.7221, 2.60, 0.302, 255, 242, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH ATP
4537, 2j6mA, 0.7221, 3.21, 0.217, 306, 249, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AEE788
4538, 1t45A, 0.7221, 3.13, 0.213, 331, 249, STRUCTURAL BASIS FOR THE AUTOINHIBITION AND STI-571 INHIBITION OF C- KIT TYROSINE KINASE
4539, 5k0xA, 0.7220, 2.46, 0.220, 258, 236, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE-PROTEIN KINASE MER IN COMPLEX WITH INHIBITOR UNC2541
4540, 5f20A, 0.7220, 2.90, 0.239, 274, 243, STRUCTURE OF TYK2 WITH INHIBITOR 4: 3-AZANYL-5-(2-METHYLPHENYL)-7-(1- METHYLPYRAZOL-3-YL)-1~{H}-PYRAZOLO[43-C]PYRIDIN-4-ONE
4541, 5casA, 0.7220, 3.10, 0.202, 299, 248, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 41A
4542, 4rwlB, 0.7220, 3.49, 0.227, 285, 255, CRYSTAL STRUCTURE OF FGFR1 (C488A C584C) IN COMPLEX WITH 6-(7-((1- AMINOCYCLOPROPYL) METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1- NAPHTHAMIDE (E3810)
4543, 4k33A, 0.7220, 3.34, 0.232, 293, 250, CRYSTAL STRUCTURE OF FGF RECEPTOR 3 (FGFR3) KINASE DOMAIN HARBORING THE K650E MUTATION A GAIN-OF-FUNCTION MUTATION RESPONSIBLE FOR THANATOPHORIC DYSPLASIA TYPE II AND SPERMATOCYTIC SEMINOMA
4544, 4gfgA, 0.7220, 2.96, 0.199, 277, 246, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH R9021
4545, 4e93A, 0.7220, 2.86, 0.235, 361, 243, CRYSTAL STRUCTURE OF HUMAN FELINE SARCOMA VIRAL ONCOGENE HOMOLOGUE (V- FES)IN COMPLEX WITH TAE684
4546, 4cd0A, 0.7220, 3.32, 0.187, 295, 251, STRUCTURE OF L1196M MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 2-(5-(6-AMINO-5-((R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)PYRIDIN-3-YL)-4-METHYLTHIAZOL-2-YL)PROPANE-12-DIOL
4547, 4bi2A, 0.7220, 2.49, 0.308, 253, 240, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
4548, 3wzuA, 0.7220, 2.78, 0.242, 270, 244, THE STRUCTURE OF MAP2K7 IN COMPLEX WITH 5Z-7-OXOZEAENOL
4549, 2g2hB, 0.7220, 3.37, 0.226, 272, 252, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
4550, 3wzjA, 0.7219, 2.77, 0.287, 257, 244, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 4-(6- (CYCLOHEXYLAMINO)-8-(((TETRAHYDRO-2H-PYRAN-4-YL)METHYL)AMINO) IMIDAZO[12-B]PYRIDAZIN-3-YL)-N-CYCLOPROPYLBENZAMIDE
4551, 2jfmA, 0.7219, 2.55, 0.269, 287, 238, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE (UNLIGANDED FORM)
4552, 1m52B, 0.7219, 3.40, 0.247, 272, 251, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH PD173955
4553, 5odtA, 0.7218, 2.93, 0.309, 258, 246, AURORA-A IN COMPLEX WITH TACC3
4554, 4lrmD, 0.7218, 3.15, 0.225, 289, 249, EGFR D770_N771INSNPG IN COMPLEX WITH PD168393
4555, 4ithB, 0.7218, 3.03, 0.228, 270, 246, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-1 ANALOG
4556, 4hniB, 0.7218, 3.02, 0.192, 284, 245, CRYSTAL STRUCTURE OF CK1E IN COMPLEX WITH PF4800567
4557, 4aojC, 0.7218, 2.77, 0.226, 261, 243, HUMAN TRKA IN COMPLEX WITH THE INHIBITOR AZ-23
4558, 3oy3B, 0.7218, 3.27, 0.230, 284, 252, CRYSTAL STRUCTURE OF ABL T315I MUTANT KINASE DOMAIN BOUND WITH A DFG- OUT INHIBITOR AP24589
4559, 3bceC, 0.7218, 2.97, 0.211, 286, 246, CRYSTAL STRUCTURE OF THE ERBB4 KINASE
4560, 1m52A, 0.7218, 3.27, 0.248, 271, 250, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH PD173955
4561, 6bu6D, 0.7217, 3.45, 0.153, 318, 255, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
4562, 6b4wA, 0.7217, 2.85, 0.294, 259, 245, TTK IN COMPLEX WITH INHIBITOR
4563, 5vc4A, 0.7217, 2.94, 0.222, 261, 243, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH BOSUTINIB-ISOMER
4564, 5a4cB, 0.7217, 3.54, 0.234, 286, 256, FGFR1 LIGAND COMPLEX
4565, 4jaiA, 0.7217, 2.58, 0.310, 249, 239, CRYSTAL STRUCTURE OF AURORA KINASE A IN COMPLEX WITH N-{4-[(6-OXO-56- DIHYDROBENZO[C][18]NAPHTHYRIDIN-1-YL)AMINO]PHENYL}BENZAMIDE
4566, 4fszA, 0.7217, 2.92, 0.259, 268, 243, CRYSTAL STRUCTURE OF THE CHK1
4567, 3oy3A, 0.7217, 3.19, 0.231, 284, 251, CRYSTAL STRUCTURE OF ABL T315I MUTANT KINASE DOMAIN BOUND WITH A DFG- OUT INHIBITOR AP24589
4568, 2ivsA, 0.7217, 3.32, 0.253, 284, 249, CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED RET TYROSINE KINASE DOMAIN
4569, 1uwhB, 0.7217, 3.00, 0.196, 264, 245, THE COMPLEX OF WILD TYPE B-RAF AND BAY439006
4570, 1rqqA, 0.7217, 3.33, 0.212, 294, 250, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH THE SH2 DOMAIN OF APS
4571, 5gmpA, 0.7216, 3.21, 0.201, 305, 249, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH XTF-262
4572, 4rj8A, 0.7216, 3.10, 0.202, 298, 248, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 8
4573, 4riwB, 0.7216, 2.84, 0.210, 293, 243, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
4574, 2x7oB, 0.7216, 3.28, 0.215, 330, 247, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH AN INDOLINONE INHIBITOR
4575, 2ptkA, 0.7216, 2.39, 0.247, 425, 235, CHICKEN SRC TYROSINE KINASE
4576, 5l2qD, 0.7215, 3.33, 0.197, 294, 249, SERINE/THREONINE-PROTEIN KINASE 40 (STK40) KINASE HOMOLOGY DOMAIN
4577, 5caoA, 0.7215, 3.07, 0.194, 300, 248, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 29
4578, 4pmpA, 0.7215, 3.06, 0.223, 280, 247, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR 1-CYCLOPROPYL-1- [3-(13-THIAZOL-2-YL)BENZYL]-3-[4-(TRIFLUOROMETHOXY)PHENYL]UREA
4579, 4jrvA, 0.7215, 3.24, 0.213, 300, 249, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 4C
4580, 4c4jA, 0.7215, 2.81, 0.294, 261, 245, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
4581, 4c3fA, 0.7215, 3.11, 0.217, 257, 249, STRUCTURE OF LCK IN COMPLEX WITH A COMPOUND DISCOVERED BY VIRTUAL FRAGMENT LINKING
4582, 4bggC, 0.7215, 2.87, 0.244, 279, 242, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
4583, 3lctA, 0.7215, 3.32, 0.186, 308, 253, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
4584, 3faaD, 0.7215, 3.32, 0.215, 330, 247, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A 2- AMINOIMIDAZOLE INHIBITOR
4585, 3faaB, 0.7215, 3.19, 0.215, 324, 247, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A 2- AMINOIMIDAZOLE INHIBITOR
4586, 2x7oD, 0.7215, 3.27, 0.215, 330, 247, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH AN INDOLINONE INHIBITOR
4587, 2r0iB, 0.7215, 2.47, 0.315, 300, 238, CRYSTAL STRUCTURE OF A KINASE MARK2/PAR-1 MUTANT
4588, 2c3jA, 0.7215, 3.00, 0.266, 257, 244, IDENTIFICATION OF A BURIED POCKET FOR POTENT AND SELECTIVE INHIBITION OF CHK1: PREDICTION AND VERIFICATION
4589, 1u4dA, 0.7215, 2.56, 0.256, 258, 238, STRUCTURE OF THE ACK1 KINASE DOMAIN BOUND TO DEBROMOHYMENIALDISINE
4590, 4uwyA, 0.7214, 3.41, 0.237, 296, 253, FGFR1 APO STRUCTURE
4591, 4hviA, 0.7214, 3.21, 0.258, 274, 248, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((R)-1-METHYL-2-OXO-2-PIPERIDIN-1-YL- ETHYL)-AMIDE
4592, 4gvjA, 0.7214, 3.41, 0.233, 290, 253, TYK2 (JH1) IN COMPLEX WITH ADENOSINE DI-PHOSPHATE
4593, 4ftjA, 0.7214, 2.97, 0.276, 266, 243, CRYSTAL STRUCTURE OF THE CHK1
4594, 4fk3A, 0.7214, 2.41, 0.212, 251, 236, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX3203
4595, 4degA, 0.7214, 3.04, 0.216, 286, 245, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH TRIAZOLOPYRIDAZINE INHIBITOR 2
4596, 3u51A, 0.7214, 2.58, 0.244, 256, 238, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC1
4597, 2j0kB, 0.7214, 2.62, 0.236, 612, 242, CRYSTAL STRUCTURE OF A FRAGMENT OF FOCAL ADHESION KINASE CONTAINING THE FERM AND KINASE DOMAINS.
4598, 2c6eB, 0.7214, 2.50, 0.312, 246, 237, AURORA A KINASE ACTIVATED MUTANT (T287D) IN COMPLEX WITH A 5-AMINOPYRIMIDINYL QUINAZOLINE INHIBITOR
4599, 1zydA, 0.7214, 3.02, 0.264, 270, 246, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: WILD- TYPE COMPLEXED WITH ATP.
4600, 4f0iB, 0.7213, 3.18, 0.224, 294, 250, CRYSTAL STRUCTURE OF APO TRKA
4601, 4dfyE, 0.7213, 3.05, 0.269, 312, 249, CRYSTAL STRUCTURE OF R194A MUTANT OF CAMP-DEPENDENT PROTEIN KINASE WITH UNPHOSPHORYLATED ACTIVATION LOOP
4602, 3w8qA, 0.7213, 2.67, 0.270, 318, 241, STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1)
4603, 3dk7B, 0.7213, 3.33, 0.237, 268, 249, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
4604, 3bprB, 0.7213, 2.30, 0.222, 256, 234, CRYSTAL STRUCTURE OF CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE- PROTEIN KINASE MER IN COMPLEX WITH INHIBITOR C52
4605, 2j0kA, 0.7213, 2.70, 0.244, 598, 242, CRYSTAL STRUCTURE OF A FRAGMENT OF FOCAL ADHESION KINASE CONTAINING THE FERM AND KINASE DOMAINS.
4606, 1xbcA, 0.7213, 3.05, 0.211, 268, 246, CRYSTAL STRUCTURE OF THE SYK TYROSINE KINASE DOMAIN WITH STAUROSPORIN
4607, 6ao5A, 0.7212, 2.31, 0.294, 321, 235, CRYSTAL STRUCTURE OF HUMAN MST2 IN COMPLEX WITH SAV1 SARAH DOMAIN
4608, 5y25A, 0.7212, 3.05, 0.198, 292, 248, EGFR KINASE DOMAIN MUTANT (T790M/L858R) WITH COVALENT LIGAND NS-062 
4609, 5jsmC, 0.7212, 2.64, 0.217, 262, 240, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
4610, 4bieB, 0.7212, 2.80, 0.299, 257, 241, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
4611, 4asxA, 0.7212, 2.89, 0.219, 310, 242, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DIHYDRO-BAUERINE C
4612, 3zfxH, 0.7212, 2.75, 0.218, 266, 243, CRYSTAL STRUCTURE OF EPHB1
4613, 3zepA, 0.7212, 3.03, 0.262, 274, 244, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
4614, 3w2qA, 0.7212, 3.38, 0.198, 307, 253, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH HKI-272
4615, 3w16A, 0.7212, 2.68, 0.318, 249, 239, STRUCTURE OF AURORA KINASE A COMPLEXED TO PYRAZOLE-AMINOQUINOLINE INHIBITOR III
4616, 2ydkA, 0.7212, 3.11, 0.268, 263, 246, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
4617, 2wqmA, 0.7212, 2.44, 0.335, 258, 236, STRUCTURE OF APO HUMAN NEK7
4618, 5tq6A, 0.7211, 3.16, 0.267, 274, 247, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
4619, 4c2vA, 0.7211, 3.00, 0.308, 270, 247, AURORA B KINASE IN COMPLEX WITH THE SPECIFIC INHIBITOR BARASERTIB
4620, 3g0fB, 0.7211, 3.18, 0.217, 293, 249, KIT KINASE DOMAIN MUTANT D816H IN COMPLEX WITH SUNITINIB
4621, 3bu6A, 0.7211, 3.36, 0.211, 294, 251, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH IRS2 KRLB PHOSPHOPEPTIDE
4622, 1y57A, 0.7211, 3.09, 0.252, 452, 246, STRUCTURE OF UNPHOSPHORYLATED C-SRC IN COMPLEX WITH AN INHIBITOR
4623, 1fmkA, 0.7211, 2.74, 0.249, 437, 241, CRYSTAL STRUCTURE OF HUMAN TYROSINE-PROTEIN KINASE C-SRC
4624, 5wnjA, 0.7210, 2.64, 0.209, 264, 239, CRYSTAL STRUCTURE OF MURINE RECEPTOR-INTERACTING PROTEIN KINASE 4 (RIPK4) D143N IN COMPLEX WITH LESTAURTINIB 
4625, 5ap3A, 0.7210, 2.52, 0.304, 253, 240, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4626, 4im2A, 0.7210, 2.98, 0.236, 618, 246, STRUCTURE OF TANK-BINDING KINASE 1
4627, 4fsyA, 0.7210, 3.03, 0.279, 267, 244, CRYSTAL STRUCTURE OF THE CHK1
4628, 3ik3B, 0.7210, 3.16, 0.224, 286, 250, AP24534 A PAN-BCR-ABL INHIBITOR FOR CHRONIC MYELOID LEUKEMIA POTENTLY INHIBITS THE T315I MUTANT AND OVERCOMES MUTATION-BASED RESISTANCE
4629, 3dkfA, 0.7210, 3.15, 0.230, 294, 248, STRUCTURE OF MET RECEPTOR TYROSINE KINASE IN COMPLEX WITH INHIBITOR SGX-523
4630, 4rj4A, 0.7209, 3.17, 0.197, 299, 249, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 6
4631, 4fg9A, 0.7209, 2.78, 0.278, 278, 237, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-320 IN COMPLEX WITH ATP
4632, 4cv8A, 0.7209, 2.65, 0.302, 255, 242, MPS1 KINASE WITH 3-AMINOPYRIDIN-2-ONE INHIBITORS
4633, 1m17A, 0.7209, 3.29, 0.204, 312, 250, EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE DOMAIN WITH 4-ANILINOQUINAZOLINE INHIBITOR ERLOTINIB
4634, 5ukfA, 0.7208, 3.50, 0.154, 322, 259, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO AN OXINDOLE INHIBITOR
4635, 5oy6B, 0.7208, 2.91, 0.243, 292, 243, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
4636, 5kmnA, 0.7208, 3.22, 0.228, 296, 250, TRKA JM-KINASE WITH 1-(2-METHYL-4-PHENYL-PYRIMIDIN-5-YL)-3-[[2- (TRIFLUOROMETHYL)PHENYL]METHYL]UREA
4637, 5e1eA, 0.7208, 3.14, 0.262, 279, 248, HUMAN JAK1 KINASE IN COMPLEX WITH COMPOUND 30 AT 2.30 ANGSTROMS RESOLUTION
4638, 4equB, 0.7208, 2.89, 0.322, 282, 242, HUMAN STK-10 (LOK) KINASE DOMAIN IN DFG-OUT CONFORMATION WITH INHIBITOR DSA-7
4639, 3q4cB, 0.7208, 2.82, 0.202, 264, 242, CRYSTAL STRUCTURE OF WILD TYPE BRAF KINASE DOMAIN IN COMPLEX WITH ORGANOMETALLIC INHIBITOR CNS292
4640, 3kulA, 0.7208, 2.68, 0.187, 267, 241, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 8 (EPHA8)
4641, 2qohA, 0.7208, 3.31, 0.222, 271, 248, CRYSTAL STRUCTURE OF ABL KINASE BOUND WITH PPY-A
4642, 6bruA, 0.7207, 3.52, 0.154, 322, 259, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A (S)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
4643, 5x3fB, 0.7207, 3.27, 0.255, 348, 251, CRYSTAL STRUCTURE OF THE YGJG-PROTEIN A-ZPA963-PKA CATALYTIC DOMAIN
4644, 5hx8A, 0.7207, 3.22, 0.256, 291, 250, JAK1 COMPLEX WITH 4-[(4-AMINOCYCLOHEXYL)AMINO]-3-(1H-BENZIMIDAZOL-2- YL)-1H-PYRIDIN-2-ONE
4645, 5cy3A, 0.7207, 3.03, 0.215, 276, 247, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT AND ORALLY BIOAVAILABLE BENZISOTHIAZOLE INHIBITOR
4646, 4x7jA, 0.7207, 2.81, 0.268, 257, 239, CO-CRYSTAL STRUCTURE OF PERK WITH 2-AMINO-N-[4-METHOXY-3- (TRIFLUOROMETHYL)PHENYL]-4-METHYL-3-[2-(METHYLAMINO)QUINAZOLIN-6- YL]BENZAMIDE INHIBITOR
4647, 4ll0A, 0.7207, 2.97, 0.196, 291, 245, EGFR L858R/T790M IN COMPLEX WITH PD168393
4648, 3q4zA, 0.7207, 2.86, 0.273, 282, 242, STRUCTURE OF UNPHOSPHORYLATED PAK1 KINASE DOMAIN
4649, 3fzrA, 0.7207, 2.79, 0.221, 261, 244, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH PF-431396
4650, 3ag9A, 0.7207, 3.39, 0.238, 323, 252, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1012
4651, 2wouA, 0.7207, 3.19, 0.215, 299, 246, ALK5 IN COMPLEX WITH 4-((4-((26-DIMETHYL-3-PYRIDYL)OXY)-2- PYRIDYL)AMINO)BENZENESULFONAMIDE
4652, 2itzA, 0.7207, 3.20, 0.201, 302, 249, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH IRESSA
4653, 1sykA, 0.7207, 3.21, 0.248, 348, 250, CRYSTAL STRUCTURE OF E230Q MUTANT OF CAMP-DEPENDENT PROTEIN KINASE REVEALS UNEXPECTED APOENZYME CONFORMATION
4654, 1ol6A, 0.7207, 2.42, 0.301, 245, 236, STRUCTURE OF UNPHOSPHORYLATED D274N MUTANT OF AURORA-A
4655, 6eimB, 0.7206, 2.86, 0.311, 295, 244, HUMAN STK10 BOUND TO GW683134A
4656, 5itaA, 0.7206, 2.38, 0.213, 250, 235, CRYSTAL STRUCTURE OF BRAF KINASE DOMAIN BOUND TO AZ-VEM
4657, 4jjrB, 0.7206, 3.22, 0.156, 283, 250, A P21 CRYSTAL FORM OF MAMMALIAN CASEIN KINASE 1 DELTA
4658, 3o50A, 0.7206, 2.44, 0.309, 246, 236, CRYSTAL STRUCTURE OF BENZAMIDE 9 BOUND TO AURORAA
4659, 3naxA, 0.7206, 2.91, 0.273, 278, 245, PDK1 IN COMPLEX WITH INHIBITOR MP7
4660, 3et7A, 0.7206, 2.78, 0.225, 261, 244, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH PF-2318841
4661, 2z60A, 0.7206, 3.50, 0.235, 281, 251, CRYSTAL STRUCTURE OF THE T315I MUTANT OF ABL KINASE BOUND WITH PPY-A
4662, 2x7oC, 0.7206, 3.28, 0.215, 330, 247, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH AN INDOLINONE INHIBITOR
4663, 3socB, 0.7205, 2.91, 0.215, 309, 242, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH A QUINAZOLIN
4664, 3op5A, 0.7205, 3.47, 0.151, 320, 258, HUMAN VACCINIA-RELATED KINASE 1
4665, 3bceB, 0.7205, 3.05, 0.207, 286, 246, CRYSTAL STRUCTURE OF THE ERBB4 KINASE
4666, 2j51A, 0.7205, 2.66, 0.268, 288, 239, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE BOUND TO 5- AMINO-3-((4-(AMINOSULFONYL)PHENYL)AMINO)-N-(26- DIFLUOROPHENYL)-1H-124-TRIAZOLE-1-CARBOTHIOAMIDE
4667, 2gs2A, 0.7205, 3.34, 0.210, 305, 252, CRYSTAL STRUCTURE OF THE ACTIVE EGFR KINASE DOMAIN
4668, 1rqqB, 0.7205, 3.30, 0.212, 294, 250, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH THE SH2 DOMAIN OF APS
4669, 5y5uA, 0.7204, 2.87, 0.209, 266, 244, CRYSTAL STRUCTURES OF SPLEEN TYROSINE KINASE IN COMPLEX WITH A NOVEL INHIBITOR 
4670, 5jfsA, 0.7204, 2.71, 0.224, 277, 241, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-00593174
4671, 4i6qA, 0.7204, 3.19, 0.258, 277, 248, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-PHENOXY-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-1-CYCLOPROPYL-ETHYL)-AMIDE
4672, 3tzmA, 0.7204, 3.00, 0.221, 295, 244, TGF-BETA RECEPTOR TYPE 1 IN COMPLEX WITH SB431542
4673, 3en4B, 0.7204, 2.90, 0.247, 266, 243, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP121 A MULTITARGETED KINASE INHIBITOR
4674, 3a4oX, 0.7204, 3.19, 0.210, 259, 248, LYN KINASE DOMAIN
4675, 2itoA, 0.7204, 3.15, 0.210, 303, 248, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH IRESSA
4676, 2fo0A, 0.7204, 3.49, 0.242, 465, 252, ORGANIZATION OF THE SH3-SH2 UNIT IN ACTIVE AND INACTIVE FORMS OF THE C-ABL TYROSINE KINASE
4677, 2f4jA, 0.7204, 3.32, 0.232, 287, 250, STRUCTURE OF THE KINASE DOMAIN OF AN IMATINIB-RESISTANT ABL MUTANT IN COMPLEX WITH THE AURORA KINASE INHIBITOR VX-680
4678, 6cnxA, 0.7203, 3.49, 0.155, 322, 258, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 (VRK1) BOUND TO AN N-PROPYNYL-N-ISOPENTYL-DIHYDROPTERIDIN INHIBITOR
4679, 5nkfA, 0.7203, 3.26, 0.187, 291, 251, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3B
4680, 4im0A, 0.7203, 2.99, 0.236, 619, 246, STRUCTURE OF TANK-BINDING KINASE 1
4681, 3o50B, 0.7203, 2.64, 0.301, 249, 239, CRYSTAL STRUCTURE OF BENZAMIDE 9 BOUND TO AURORAA
4682, 5kz8B, 0.7202, 2.52, 0.315, 300, 238, MARK2 COMPLEX WITH 7-[(1S)-1-(4-FLUOROPHENYL)ETHYL]-55-DIMETHYL-2-(3- PYRIDYLAMINO)PYRROLO[23-D]PYRIMIDIN-6-ONE
4683, 4mhaA, 0.7202, 2.48, 0.220, 256, 236, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE-PROTEIN KINASE MER IN COMPLEX WITH INHIBITOR UNC1817
4684, 4fvqA, 0.7202, 3.09, 0.198, 274, 248, CRYSTAL STRUCTURE OF THE JAK2 PSEUDOKINASE DOMAIN (MG-ATP-BOUND FORM)
4685, 3zfxA, 0.7202, 2.71, 0.219, 267, 242, CRYSTAL STRUCTURE OF EPHB1
4686, 3qgyB, 0.7202, 2.58, 0.214, 245, 238, CRYSTAL STRUCTURE OF ITK INHIBITOR COMPLEX
4687, 3oomA, 0.7202, 3.19, 0.243, 297, 247, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH THE IMIDAZO[12-B]PYRIDAZINE INHIBITOR K00507
4688, 2x7oE, 0.7202, 3.31, 0.215, 330, 247, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH AN INDOLINONE INHIBITOR
4689, 5k9iA, 0.7201, 2.59, 0.244, 258, 238, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH A COVALENT LYSINE PROBE
4690, 4kb8B, 0.7201, 3.08, 0.178, 285, 247, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
4691, 4hvsA, 0.7201, 3.18, 0.205, 326, 249, CRYSTAL STRUCTURE OF KIT KINASE DOMAIN WITH A SMALL MOLECULE INHIBITOR PLX647
4692, 4bhnB, 0.7201, 2.96, 0.298, 257, 242, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
4693, 3my0L, 0.7201, 3.02, 0.246, 296, 244, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4694, 3lxpA, 0.7201, 3.21, 0.242, 285, 248, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
4695, 3h10D, 0.7201, 2.88, 0.302, 255, 245, AURORA A INHIBITOR COMPLEX
4696, 2bvaB, 0.7201, 3.08, 0.249, 274, 245, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4
4697, 5vdaA, 0.7200, 2.93, 0.223, 259, 242, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH RAC-IV- 101 A MK1775 ANALOGUE
4698, 4rj6A, 0.7200, 3.12, 0.202, 297, 248, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 4
4699, 4jq7A, 0.7200, 3.27, 0.217, 303, 249, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 2A
4700, 1mryA, 0.7200, 2.48, 0.287, 270, 237, CRYSTAL STRUCTURE OF AN INACTIVE AKT2 KINASE DOMAIN
4701, 5ek7B, 0.7199, 3.09, 0.202, 286, 248, STRUCTURE OF THE AUTOINHIBITED EPHA2 JMS-KD
4702, 4zy6A, 0.7199, 2.98, 0.309, 284, 246, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
4703, 4l00A, 0.7199, 3.15, 0.225, 277, 249, CRYSTAL STRUCTURE OF THE APO JAK1 PSEUDOKINASE DOMAIN
4704, 4cv9A, 0.7199, 2.55, 0.304, 254, 240, MPS1 KINASE WITH 3-AMINOPYRIDIN-2-ONE INHIBITORS
4705, 4ckiA, 0.7199, 3.34, 0.253, 293, 249, CRYSTAL STRUCTURE OF ONCOGENIC RET TYROSINE KINASE M918T BOUND TO ADENOSINE
4706, 3mdyA, 0.7199, 3.33, 0.224, 320, 250, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B (BMPR1B) IN COMPLEX WITH FKBP12 AND LDN- 193189
4707, 3h9rA, 0.7199, 3.05, 0.235, 312, 243, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TYPE I ACTIVIN RECEPTOR (ACVR1) IN COMPLEX WITH FKBP12 AND DORSOMORPHIN
4708, 2rfsA, 0.7199, 3.06, 0.230, 264, 243, X-RAY STRUCTURE OF SU11274 BOUND TO C-MET
4709, 2gqgB, 0.7199, 3.22, 0.225, 276, 249, X-RAY CRYSTAL STRUCTURE OF DASATINIB (BMS-354825) BOUND TO ACTIVATED ABL KINASE DOMAIN
4710, 5ei2A, 0.7198, 2.70, 0.296, 256, 243, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
4711, 5c8mA, 0.7198, 3.16, 0.193, 302, 249, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 17
4712, 4xh0A, 0.7198, 3.32, 0.167, 350, 251, STRUCTURE OF C. GLABRATA HRR25 BOUND TO ADP (SO4 CONDITION)
4713, 4jr3A, 0.7198, 3.27, 0.213, 303, 249, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 3G
4714, 4fobA, 0.7198, 3.28, 0.187, 295, 251, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH ACYLIMINOBENZIMIDAZOLE INHIBITOR 1
4715, 3wzeA, 0.7198, 3.22, 0.204, 298, 250, KDR IN COMPLEX WITH LIGAND SORAFENIB
4716, 3w10A, 0.7198, 2.94, 0.293, 263, 246, AURORA KINASE A COMPLEXED TO PYRAZOLE AMINOQUINOLINE I
4717, 3vntA, 0.7198, 3.21, 0.204, 301, 250, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN VEGFR2 WITH A [1 3]THIAZOLO[54-B]PYRIDINE DERIVATIVE
4718, 1r0pA, 0.7198, 3.34, 0.229, 301, 249, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH THE MICROBIAL ALKALOID K-252A
4719, 6brcB, 0.7197, 2.98, 0.292, 260, 243, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH AP26113-ANALOG (ALK-IN-1)
4720, 5wijA, 0.7197, 3.09, 0.198, 274, 248, JAK2 PSEUDOKINASE IN COMPLEX WITH NU6140 
4721, 5v5yA, 0.7197, 2.90, 0.232, 259, 241, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH MK1775
4722, 5o26A, 0.7197, 3.06, 0.253, 271, 245, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A DIPHOSPHORYLATED STATE AND IN COMPLEX WITH AMP-PNP/MG2+
4723, 4kioC, 0.7197, 2.66, 0.225, 251, 240, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
4724, 4d2tA, 0.7197, 2.97, 0.313, 316, 243, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
4725, 4d1sA, 0.7197, 2.87, 0.254, 280, 244, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
4726, 3zfxD, 0.7197, 2.72, 0.219, 265, 242, CRYSTAL STRUCTURE OF EPHB1
4727, 3txoA, 0.7197, 2.73, 0.293, 317, 239, PKC ETA KINASE IN COMPLEX WITH A NAPHTHYRIDINE
4728, 3cekA, 0.7197, 2.63, 0.302, 256, 242, CRYSTAL STRUCTURE OF HUMAN DUAL SPECIFICITY PROTEIN KINASE (TTK)
4729, 2itqA, 0.7197, 3.24, 0.217, 300, 249, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AFN941
4730, 5tkxA, 0.7196, 3.67, 0.174, 315, 258, CRYSTAL STRUCTURE OF HUMAN VACCINIA-RELATED KINASE 2 (VRK-2) BOUND TO BI-D1870
4731, 5magA, 0.7196, 2.61, 0.324, 314, 238, CRYSTAL STRUCTURE OF MELK IN COMPLEX WITH AN INHIBITOR
4732, 5flfB, 0.7196, 3.44, 0.244, 292, 250, DISEASE LINKED MUTATION IN FGFR
4733, 5cavA, 0.7196, 3.24, 0.217, 306, 249, EGFR KINASE DOMAIN WITH COMPOUND 41A
4734, 4hnfA, 0.7196, 3.20, 0.176, 289, 250, CRYSTAL STRUCTURE OF CK1D IN COMPLEX WITH PF4800567
4735, 4cvaA, 0.7196, 2.53, 0.304, 254, 240, MPS1 KINASE WITH 3-AMINOPYRIDIN-2-ONE INHIBITORS
4736, 3q4tB, 0.7196, 2.90, 0.219, 308, 242, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DORSOMORPHIN
4737, 3lxkA, 0.7196, 3.22, 0.257, 279, 249, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
4738, 5vamB, 0.7195, 3.11, 0.216, 260, 245, BRAF IN COMPLEX WITH RAF709
4739, 5jfxA, 0.7195, 2.72, 0.224, 277, 241, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-06273340
4740, 4l01A, 0.7195, 3.16, 0.225, 274, 249, CRYSTAL STRUCTURE OF THE V658F APO JAK1 PSEUDOKINASE DOMAIN
4741, 4l00B, 0.7195, 3.19, 0.221, 278, 249, CRYSTAL STRUCTURE OF THE APO JAK1 PSEUDOKINASE DOMAIN
4742, 4fk3B, 0.7195, 2.75, 0.203, 257, 241, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX3203
4743, 4ae6B, 0.7195, 3.45, 0.238, 321, 252, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT CALPHA 2
4744, 3mtfB, 0.7195, 3.00, 0.242, 298, 244, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH A 2- AMINOPYRIDINE INHIBITOR
4745, 5tehB, 0.7194, 2.65, 0.238, 262, 239, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-156
4746, 4wnmA, 0.7194, 3.13, 0.215, 273, 247, SYK CATALYTIC DOMAIN IN COMPLEX WITH A POTENT TRIAZOLOPYRIDINE INHIBITOR
4747, 4asdA, 0.7194, 3.21, 0.204, 305, 250, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH SORAFENIB (BAY 43-9006)
4748, 4ag8A, 0.7194, 3.22, 0.204, 296, 250, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH AXITINIB (AG-013736) (N-METHYL-2-(3-((E)-2-PYRIDIN-2-YL-VINYL)-1H- INDAZOL-6- YLSULFANYL)-BENZAMIDE)
4749, 6drwA, 0.7193, 3.27, 0.262, 289, 248, JAK2 JH1 IN COMPLEX WITH JNJ-7706621 (CRYSTAL FORM 2) 
4750, 5winA, 0.7193, 3.10, 0.198, 274, 248, JAK2 PSEUDOKINASE IN COMPLEX WITH JNJ7706621 
4751, 4zsaB, 0.7193, 3.34, 0.230, 282, 252, CRYSTAL STRUCTURE OF FGFR1 KINASE DOMAIN IN COMPLEX WITH 7N
4752, 4e3cE, 0.7193, 3.40, 0.260, 624, 254, X-RAY CRYSTAL STRUCTURE OF HUMAN IKK2 IN AN ACTIVE CONFORMATION
4753, 3zc6B, 0.7193, 2.97, 0.263, 276, 243, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH AN INDAZOLE SUBSTITUTED PYRROLOPYRAZINE INHIBITOR
4754, 3zc6A, 0.7193, 3.01, 0.266, 277, 244, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH AN INDAZOLE SUBSTITUTED PYRROLOPYRAZINE INHIBITOR
4755, 3uysD, 0.7193, 3.12, 0.170, 284, 247, CRYSTAL STRUCTURE OF APO HUMAN CK1D
4756, 3u9nA, 0.7193, 2.92, 0.276, 257, 243, X-RAY CRYSTAL STRUCTURE OF COMPOUND 1 BOUND TO HUMAN CHK1 KINASE DOMAIN
4757, 5jfvA, 0.7192, 2.72, 0.224, 277, 241, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-05206283
4758, 5e1eB, 0.7192, 3.18, 0.257, 280, 249, HUMAN JAK1 KINASE IN COMPLEX WITH COMPOUND 30 AT 2.30 ANGSTROMS RESOLUTION
4759, 3dqwD, 0.7192, 3.19, 0.256, 276, 246, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
4760, 2j0mB, 0.7192, 2.71, 0.257, 257, 241, CRYSTAL STRUCTURE A TWO-CHAIN COMPLEX BETWEEN THE FERM AND KINASE DOMAINS OF FOCAL ADHESION KINASE.
4761, 1sykB, 0.7192, 3.23, 0.252, 323, 250, CRYSTAL STRUCTURE OF E230Q MUTANT OF CAMP-DEPENDENT PROTEIN KINASE REVEALS UNEXPECTED APOENZYME CONFORMATION
4762, 6bbuA, 0.7191, 3.23, 0.256, 279, 250, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH COMPOUND 25
4763, 5kmjA, 0.7191, 3.34, 0.233, 300, 249, TRKA JM-KINASE WITH {N}-(2-PYRIDYLMETHYL)-2-[2-(2-THIENYL)INDOL-1- YL]ACETAMIDE
4764, 5khwA, 0.7191, 3.09, 0.260, 276, 246, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH ADP
4765, 4v05B, 0.7191, 3.53, 0.227, 286, 255, FGFR1 IN COMPLEX WITH AZD4547.
4766, 4knbA, 0.7191, 2.98, 0.212, 273, 245, C-MET IN COMPLEX WITH OSI LIGAND
4767, 4j99C, 0.7191, 3.47, 0.224, 291, 250, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
4768, 3dk3B, 0.7191, 3.35, 0.229, 269, 249, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
4769, 2x2kA, 0.7191, 3.33, 0.253, 289, 249, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
4770, 2ivtA, 0.7191, 3.33, 0.253, 288, 249, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN
4771, 5uu1A, 0.7190, 3.51, 0.176, 315, 256, CRYSTAL STRUCTURE OF HUMAN VACCINIA-RELATED KINASE 2 (VRK-2) BOUND TO BI-D1870
4772, 5j9yA, 0.7190, 3.24, 0.217, 300, 249, EGFR-T790M IN COMPLEX WITH PYRAZOLOPYRIMIDINE INHIBITOR 1B
4773, 5i9xA, 0.7190, 3.15, 0.189, 284, 249, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH BOSUTINIB (SKI-606)
4774, 3u51B, 0.7190, 2.57, 0.245, 255, 237, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC1
4775, 3soaA, 0.7190, 3.12, 0.306, 436, 248, FULL-LENGTH HUMAN CAMKII
4776, 5kmkA, 0.7189, 3.21, 0.233, 304, 249, TRKA JM-KINASE WITH 2-FLUORO-{N}-[2-(4-FLUOROPHENYL)-6-METHYL-3- PYRIDYL]-4-(TRIFLUOROMETHYL)BENZAMIDE
4777, 4uzhA, 0.7189, 2.54, 0.308, 251, 237, SAR156497 AN EXQUISITELY SELECTIVE INHIBITOR OF AURORA KINASES
4778, 4i20A, 0.7189, 3.09, 0.202, 287, 248, CRYSTAL STRUCTURE OF MONOMERIC (V948R) PRIMARY ONCOGENIC MUTANT L858R EGFR KINASE DOMAIN
4779, 4bhzA, 0.7189, 2.45, 0.307, 251, 238, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
4780, 3ugcA, 0.7189, 3.09, 0.255, 274, 247, STRUCTURAL BASIS OF JAK2 INHIBITION BY THE TYPE II INHIBTOR NVP-BBT594
4781, 6dkgA, 0.7188, 3.07, 0.228, 276, 246, CRYSTAL STRUCTURE OF TRK-A IN COMPLEX WITH THE PAN-TRK KINASE INHIBITOR; COMPOUND 13B. 
4782, 6bl8B, 0.7188, 3.30, 0.242, 268, 248, PREDICTING THE CONFORMATIONAL VARIABILITY OF ABL TYROSINE KINASE USING MOLECULAR DYNAMICS SIMULATIONS AND MARKOV STATE MODELS
4783, 5nk1A, 0.7188, 3.24, 0.184, 284, 250, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1K
4784, 5k5xA, 0.7188, 3.30, 0.187, 345, 251, CRYSTAL STRUCTURE OF HUMAN PDGFRA
4785, 4fg8A, 0.7188, 2.36, 0.289, 263, 232, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-315 IN COMPLEX WITH ATP
4786, 3og7B, 0.7188, 2.79, 0.212, 254, 241, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX4032
4787, 2pwlA, 0.7188, 3.35, 0.233, 284, 249, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549H MUTATION RESPONSIBLE FOR CROUZON SYNDROME.
4788, 5cxhA, 0.7187, 3.10, 0.211, 277, 247, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT ORALLY BIOAVAILABLE THIAZOLE INHIBITOR
4789, 4gg7A, 0.7187, 3.05, 0.214, 278, 248, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
4790, 3my0M, 0.7187, 3.04, 0.241, 298, 245, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4791, 3l9pA, 0.7187, 3.35, 0.186, 303, 253, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
4792, 3gqlA, 0.7187, 3.22, 0.240, 287, 250, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
4793, 1snuB, 0.7187, 2.44, 0.226, 241, 235, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
4794, 5vc5A, 0.7186, 2.92, 0.226, 261, 243, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH PD- 166285
4795, 5tq7A, 0.7186, 3.07, 0.265, 275, 245, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
4796, 5hu9A, 0.7186, 3.21, 0.211, 266, 247, CRYSTAL STRUCTURE OF ABL1 IN COMPLEX WITH CHMFL-074
4797, 5g15A, 0.7186, 3.28, 0.260, 265, 246, STRUCTURE AURORA A (122-403) BOUND TO ACTIVATING MONOBODY MB1 AND AMPPCP
4798, 4z16A, 0.7186, 3.02, 0.263, 271, 243, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
4799, 4hgtA, 0.7186, 3.16, 0.173, 283, 248, CRYSTAL STRUCTURE OF CK1D WITH COMPOUND 13
4800, 4bb4A, 0.7186, 2.90, 0.220, 265, 245, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4801, 3vf8A, 0.7186, 3.12, 0.211, 265, 246, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE SYK CATALYTIC DOMAIN WITH PYRAZOLYLBENZIMIDAZOLE INHIBITOR 416
4802, 2r0iA, 0.7186, 2.63, 0.314, 300, 239, CRYSTAL STRUCTURE OF A KINASE MARK2/PAR-1 MUTANT
4803, 2psqA, 0.7186, 3.50, 0.218, 287, 252, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED UNACTIVATED WILD TYPE FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN
4804, 2jflA, 0.7186, 2.48, 0.274, 286, 237, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE ( DIPHOSPHORYLATED FORM) BOUND TO 5- AMINO-3-((4-( AMINOSULFONYL)PHENYL)AMINO)-N-(26- DIFLUOROPHENYL)-1H-12 4-TRIAZOLE-1-CARBOTHIOAMIDE
4805, 5oy6C, 0.7185, 2.94, 0.243, 291, 243, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
4806, 5jrsB, 0.7185, 2.32, 0.210, 240, 233, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH 4-[2-FLUORO-3-(4-OXO -34-DIHYDROQUINAZOLIN-3-YL) PHENYL]-7-(2-HYDROXYPROPAN-2-Y L)-9H-CARBAZOLE-1-CARBOXAMIDE
4807, 4z16D, 0.7185, 3.05, 0.272, 271, 243, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
4808, 4focA, 0.7185, 3.37, 0.187, 296, 251, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH ACYLIMINOBENZIMIDAZOLE INHIBITOR 2
4809, 1uwjA, 0.7185, 3.13, 0.212, 264, 245, THE COMPLEX OF MUTANT V599E B-RAF AND BAY439006
4810, 6ginA, 0.7184, 3.00, 0.242, 296, 244, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH AN QUINAZOLINONE BASED ALK2 INHIBITOR WITH A 4-MORPHOLINOPHENYL SOLVENT ACCESSIBLE GROUP. 
4811, 5y8uA, 0.7184, 2.75, 0.241, 267, 241, CRYSTAL STRUCTURE OF THE C276S MUTANT OF MAP2K7
4812, 5nk6A, 0.7184, 3.17, 0.185, 284, 249, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2D
4813, 5edqA, 0.7184, 3.11, 0.206, 298, 248, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 15: ~{N}-(7- CHLORANYL-1~{H}-INDAZOL-3-YL)-77-DIMETHYL-2-(1~{H}-PYRAZOL-4-YL)- 5~{H}-FURO[34-D]PYRIMIDIN-4-AMINE
4814, 5czoB, 0.7184, 3.30, 0.173, 365, 249, STRUCTURE OF S. CEREVISIAE HRR25:MAM1 COMPLEX FORM 2
4815, 4k6zA, 0.7184, 3.18, 0.258, 279, 248, THE JAK1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 37
4816, 4itiA, 0.7184, 3.29, 0.222, 272, 248, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-3 ANALOG
4817, 4e5wB, 0.7184, 3.19, 0.261, 278, 249, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 26
4818, 3g0eA, 0.7184, 3.35, 0.215, 332, 251, KIT KINASE DOMAIN IN COMPLEX WITH SUNITINIB
4819, 2xa4B, 0.7184, 2.98, 0.270, 275, 244, INHIBITORS OF JAK2 KINASE DOMAIN
4820, 2hakE, 0.7184, 3.10, 0.307, 318, 251, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
4821, 5zv2B, 0.7183, 3.29, 0.223, 282, 251, FGFR-1 IN COMPLEX WITH LIGAND LENVATINIB 
4822, 2zvaA, 0.7183, 3.11, 0.234, 261, 248, LYN TYROSINE KINASE DOMAIN-DASATINIB COMPLEX
4823, 2xirA, 0.7183, 3.24, 0.208, 296, 250, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH PF-00337210 (N2-DIMETHYL-6-(7-(2-MORPHOLINOETHOXY) QUINOLIN-4-YLOXY)BENZOFURAN-3-CARBOXAMIDE)
4824, 2qluA, 0.7183, 3.36, 0.210, 297, 248, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE II KINASE DOMAIN FROM HUMAN
4825, 5x02A, 0.7182, 3.10, 0.210, 305, 248, CRYSTAL STRUCTURE OF THE FLT3 KINASE DOMAIN BOUND TO THE INHIBITOR FF- 10101
4826, 5ui0A, 0.7182, 3.44, 0.228, 301, 250, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING AN E565A/K659M DOUBLE GAIN-OF-FUNCTION MUTATION
4827, 5tq7B, 0.7182, 2.92, 0.263, 269, 243, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
4828, 5o4aB, 0.7182, 3.36, 0.230, 291, 252, HUMAN FGF IN COMPLEX WITH A COVALENT INHIBITOR
4829, 5nkbA, 0.7182, 3.26, 0.184, 285, 250, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 4A
4830, 5nk9A, 0.7182, 3.16, 0.185, 285, 249, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2E
4831, 5nk2A, 0.7182, 3.24, 0.184, 290, 250, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2B
4832, 5kmiA, 0.7182, 3.14, 0.226, 300, 248, TRKA JM-KINASE WITH 1-(9{H}-FLUOREN-9-YL)-3-(2-METHYL-4-PHENYL- PYRIMIDIN-5-YL)UREA
4833, 5k9iB, 0.7182, 2.73, 0.250, 262, 240, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH A COVALENT LYSINE PROBE
4834, 4jt3A, 0.7182, 2.57, 0.296, 254, 240, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 400740
4835, 3k5vA, 0.7182, 3.29, 0.224, 286, 250, STRUCTURE OF ABL KINASE IN COMPLEX WITH IMATINIB AND GNF-2
4836, 3fpqA, 0.7182, 3.08, 0.259, 262, 243, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF WNK1
4837, 5wo4A, 0.7181, 3.26, 0.256, 292, 250, JAK1 COMPLEXED WITH COMPOUND 28
4838, 4fvpA, 0.7181, 3.11, 0.202, 274, 248, CRYSTAL STRUCTURE OF THE JAK2 PSEUDOKINASE DOMAIN (APO FORM)
4839, 4fg7A, 0.7181, 2.38, 0.279, 250, 233, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-293 IN COMPLEX WITH ATP
4840, 3pa3A, 0.7181, 2.95, 0.280, 259, 243, X-RAY CRYSTAL STRUCTURE OF COMPOUND 70 BOUND TO HUMAN CHK1 KINASE DOMAIN
4841, 3bu3A, 0.7181, 3.33, 0.212, 294, 250, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH IRS2 KRLB PEPTIDE
4842, 2j0lA, 0.7181, 3.19, 0.233, 274, 249, CRYSTAL STRUCTURE OF A THE ACTIVE CONFORMATION OF THE KINASE DOMAIN OF FOCAL ADHESION KINASE WITH A PHOSPHORYLATED ACTIVATION LOOP.
4843, 1qpjA, 0.7181, 3.25, 0.235, 265, 247, CRYSTAL STRUCTURE OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH STAUROSPORINE.
4844, 5nk7A, 0.7180, 3.33, 0.187, 284, 251, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2A
4845, 5kmlA, 0.7180, 3.24, 0.224, 296, 250, TRKA JM-KINASE WITH 1-(5-METHYL-3-PHENYL-12-OXAZOL-4-YL)-3-[[2- (TRIFLUOROMETHYL)PHENYL]METHYL]UREA
4846, 5jh6A, 0.7180, 2.72, 0.293, 288, 239, CRYSTAL STRUCTURE OF TL10-92 BOUND TO TAK1-TAB1
4847, 4rwlA, 0.7180, 3.47, 0.225, 282, 253, CRYSTAL STRUCTURE OF FGFR1 (C488A C584C) IN COMPLEX WITH 6-(7-((1- AMINOCYCLOPROPYL) METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1- NAPHTHAMIDE (E3810)
4848, 4pdpB, 0.7180, 2.57, 0.314, 265, 236, CRYSTAL STRUCTURE OF RAD53 KINASE DOMAIN AND SCD2
4849, 4mneG, 0.7180, 2.76, 0.200, 259, 240, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
4850, 4d4sB, 0.7180, 2.89, 0.242, 260, 244, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4851, 3my0B, 0.7180, 3.05, 0.246, 295, 244, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4852, 3dk7A, 0.7180, 3.24, 0.239, 265, 247, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
4853, 2x8iA, 0.7180, 2.93, 0.272, 261, 243, DISCOVERY OF A NOVEL CLASS OF TRIAZOLONES AS CHECKPOINT KINASE INHIBITORS - HIT TO LEAD EXPLORATION
4854, 2hyyA, 0.7180, 2.99, 0.228, 263, 246, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
4855, 6cswB, 0.7179, 3.49, 0.154, 308, 254, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A N- METHYL-N-PROPYL-DIHYDROPTERIDINE INHIBITOR
4856, 5wimA, 0.7179, 3.12, 0.198, 274, 248, JAK2 PSEUDOKINASE IN COMPLEX WITH AT9283 
4857, 5wilA, 0.7179, 3.13, 0.198, 274, 248, JAK2 PSEUDOKINASE IN COMPLEX WITH AZD7762 
4858, 5nkcA, 0.7179, 3.25, 0.184, 286, 250, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2H
4859, 5jfwA, 0.7179, 2.74, 0.224, 277, 241, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-05247452
4860, 5hhwA, 0.7179, 3.07, 0.196, 306, 250, CRYSTAL STRUCTURE OF INSULIN RECEPTOR KINASE DOMAIN IN COMPLEX WITH CIS-(R)-7-(3-(AZETIDIN-1-YLMETHYL)CYCLOBUTYL)-5-(3-((TETRAHYDRO-2H- PYRAN-2-YL)METHOXY)PHENYL)-7H-PYRROLO[23-D]PYRIMIDIN-4-AMINE.
4861, 5b7vA, 0.7179, 3.37, 0.235, 282, 251, HUMAN FGFR1 KINASE IN COMPLEX WITH CH5183284
4862, 4rx7A, 0.7179, 3.17, 0.211, 272, 247, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT TRIAZINE INHIBITOR
4863, 4fk6B, 0.7179, 3.31, 0.254, 284, 252, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 72
4864, 4c02A, 0.7179, 3.18, 0.221, 313, 244, CRYSTAL STRUCTURE OF HUMAN ACVR1 (ALK2) IN COMPLEX WITH FKBP12.6 AND DORSOMORPHIN
4865, 2hziB, 0.7179, 3.33, 0.242, 264, 248, ABL KINASE DOMAIN IN COMPLEX WITH PD180970
4866, 6bu6B, 0.7178, 3.37, 0.142, 307, 253, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
4867, 5am6B, 0.7178, 3.03, 0.244, 280, 246, NATIVE FGFR1 WITH AN INHIBITOR
4868, 3rhxB, 0.7178, 3.36, 0.243, 275, 251, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR1 KINASE IN COMPLEX WITH ARQ 069
4869, 2itnA, 0.7178, 3.18, 0.214, 304, 248, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AMP-PNP
4870, 5cxzA, 0.7177, 3.03, 0.196, 269, 245, SYK CATALYTIC DOMAIN COMPLEXED WITH NAPHTHYRIDINE INHIBITOR
4871, 4z16C, 0.7177, 3.04, 0.263, 271, 243, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
4872, 4y85A, 0.7177, 2.94, 0.236, 307, 242, CRYSTAL STRUCTURE OF COT KINASE DOMAIN IN COMPLEX WITH 5-(5-(1H-INDOL- 3-YL)-1H-PYRROLO[23-B]PYRIDIN-3-YL)-134-OXADIAZOL-2-AMINE
4873, 4pmsA, 0.7177, 3.18, 0.226, 283, 248, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR 4-NAPHTHALEN-1-YL- 1-[(5-PHENYL-124-OXADIAZOL-3-YL)METHYL]-1H-PYRROLO[32-C]PYRIDINE- 2-CARBOXYLIC ACID
4874, 4p90A, 0.7177, 2.74, 0.310, 272, 239, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN PAK1 IN COMPLEX WITH COMPOUND 15
4875, 3g0fA, 0.7177, 3.25, 0.221, 291, 249, KIT KINASE DOMAIN MUTANT D816H IN COMPLEX WITH SUNITINIB
4876, 2pwlB, 0.7177, 3.36, 0.233, 286, 249, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549H MUTATION RESPONSIBLE FOR CROUZON SYNDROME.
4877, 2eb2A, 0.7177, 3.32, 0.208, 305, 250, CRYSTAL STRUCTURE OF MUTATED EGFR KINASE DOMAIN (G719S)
4878, 1xbaA, 0.7177, 3.13, 0.211, 266, 246, CRYSTAL STRUCTURE OF APO SYK TYROSINE KINASE DOMAIN
4879, 6cmmA, 0.7176, 3.40, 0.145, 318, 256, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A NN- DIPROPYNYL-DIHYDROPTERIDINE INHIBITOR
4880, 5ugxB, 0.7176, 3.25, 0.222, 282, 248, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A E565A/D650V DOUBLE GAIN-OF-FUNCTION MUTATION
4881, 5khwB, 0.7176, 3.09, 0.264, 276, 246, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH ADP
4882, 4xliA, 0.7176, 3.25, 0.228, 264, 246, CRYSTAL STRUCTURE OF ABL2/ARG KINASE IN COMPLEX WITH DASATINIB
4883, 4bkzA, 0.7176, 2.51, 0.323, 309, 235, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE (MELK) IN COMPLEX WITH A BENZODIPYRAZOLE INHIBITOR
4884, 3vo3A, 0.7176, 3.30, 0.211, 303, 251, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN VEGFR2 WITH IMIDAZO[1 2-B]PYRIDAZINE DERIVATIVE
4885, 3vhkA, 0.7176, 3.25, 0.208, 297, 250, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BACK POCKET BINDER
4886, 3bceA, 0.7176, 3.05, 0.211, 285, 246, CRYSTAL STRUCTURE OF THE ERBB4 KINASE
4887, 2xynA, 0.7176, 3.16, 0.220, 264, 246, HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680
4888, 5tq6B, 0.7175, 3.02, 0.275, 271, 244, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
4889, 5lmbA, 0.7175, 3.00, 0.212, 264, 245, HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR
4890, 5cziA, 0.7175, 3.44, 0.194, 310, 253, EGFR L858R MUTANT IN COMPLEX WITH A SHC PEPTIDE SUBSTRATE
4891, 4d2vC, 0.7175, 2.88, 0.322, 316, 242, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
4892, 4bf2B, 0.7175, 2.73, 0.307, 252, 238, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
4893, 3my0U, 0.7175, 2.92, 0.244, 285, 242, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4894, 3mtfA, 0.7175, 2.91, 0.240, 296, 242, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH A 2- AMINOPYRIDINE INHIBITOR
4895, 2yiyA, 0.7175, 3.01, 0.290, 293, 245, CRYSTAL STRUCTURE OF COMPOUND 8 BOUND TO TAK1-TAB
4896, 2ittA, 0.7175, 3.22, 0.218, 302, 248, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH AEE788
4897, 2hziA, 0.7175, 3.47, 0.235, 268, 251, ABL KINASE DOMAIN IN COMPLEX WITH PD180970
4898, 2c47D, 0.7175, 3.31, 0.202, 290, 252, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
4899, 1sm2A, 0.7175, 2.52, 0.233, 245, 236, CRYSTAL STRUCTURE OF THE PHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
4900, 4rj5A, 0.7174, 3.11, 0.198, 296, 247, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 5
4901, 4o6lA, 0.7174, 2.87, 0.296, 257, 243, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 401498 (N- [(1R)-1-(2-CHLOROPHENYL)PROPYL]-3-{4-[(1-METHYLPIPERIDIN-4-YL) OXY]PHENYL}-1H-INDAZOLE-5-CARBOXAMIDE)
4902, 4nk9B, 0.7174, 3.49, 0.229, 282, 253, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 1
4903, 3dqwC, 0.7174, 3.21, 0.256, 275, 246, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
4904, 2etmA, 0.7174, 3.00, 0.240, 262, 246, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN COMPLEXED WITH 7H-PYRROLO [23-D] PYRIMIDINE DERIVATIVE
4905, 1f3mC, 0.7174, 3.58, 0.297, 287, 256, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE PAK1
4906, 6c3eA, 0.7173, 3.12, 0.230, 258, 244, CRYSTAL STRUCTURE OF RIP1 KINASE BOUND TO INHIBITOR
4907, 5b2lA, 0.7173, 3.28, 0.228, 288, 254, A CRUCIAL ROLE OF CYS218 IN THE STABILIZATION OF AN UNPRECEDENTED AUTO-INHIBITION FORM OF MAP2K7
4908, 4k77A, 0.7173, 3.22, 0.253, 282, 249, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 6
4909, 3sdmG, 0.7173, 3.24, 0.276, 415, 246, STRUCTURE OF OLIGOMERIC KINASE/RNASE IRE1 IN COMPLEX WITH AN OLIGONUCLEOTIDE
4910, 3sdmF, 0.7173, 3.24, 0.276, 415, 246, STRUCTURE OF OLIGOMERIC KINASE/RNASE IRE1 IN COMPLEX WITH AN OLIGONUCLEOTIDE
4911, 3sdmE, 0.7173, 3.24, 0.276, 415, 246, STRUCTURE OF OLIGOMERIC KINASE/RNASE IRE1 IN COMPLEX WITH AN OLIGONUCLEOTIDE
4912, 3sdmD, 0.7173, 3.24, 0.276, 415, 246, STRUCTURE OF OLIGOMERIC KINASE/RNASE IRE1 IN COMPLEX WITH AN OLIGONUCLEOTIDE
4913, 3sdmC, 0.7173, 3.24, 0.276, 415, 246, STRUCTURE OF OLIGOMERIC KINASE/RNASE IRE1 IN COMPLEX WITH AN OLIGONUCLEOTIDE
4914, 3sdmB, 0.7173, 3.24, 0.276, 415, 246, STRUCTURE OF OLIGOMERIC KINASE/RNASE IRE1 IN COMPLEX WITH AN OLIGONUCLEOTIDE
4915, 3sdmA, 0.7173, 3.24, 0.276, 415, 246, STRUCTURE OF OLIGOMERIC KINASE/RNASE IRE1 IN COMPLEX WITH AN OLIGONUCLEOTIDE
4916, 3lauA, 0.7173, 2.52, 0.308, 251, 237, CRYSTAL STRUCTURE OF AURORA2 KINASE IN COMPLEX WITH A GSK3BETA INHIBITOR
4917, 3fbvB, 0.7173, 3.24, 0.276, 415, 246, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4918, 2zv2A, 0.7173, 2.81, 0.287, 256, 240, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE KINASE 2 BETA CAMKK2 KINASE DOMAIN IN COMPLEX WITH STO-609
4919, 2xa4A, 0.7173, 3.00, 0.275, 276, 244, INHIBITORS OF JAK2 KINASE DOMAIN
4920, 1uwjB, 0.7173, 3.16, 0.208, 263, 245, THE COMPLEX OF MUTANT V599E B-RAF AND BAY439006
4921, 1pkgA, 0.7173, 3.24, 0.243, 290, 247, STRUCTURE OF A C-KIT KINASE PRODUCT COMPLEX
4922, 1m14A, 0.7173, 3.22, 0.206, 307, 248, TYROSINE KINASE DOMAIN FROM EPIDERMAL GROWTH FACTOR RECEPTOR
4923, 5oy6A, 0.7172, 2.96, 0.243, 291, 243, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
4924, 5oktC, 0.7172, 3.21, 0.173, 285, 248, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH IWP-2 
4925, 5e8yA, 0.7172, 3.05, 0.238, 298, 244, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A) IN COMPLEX WITH STAUROSPORINE
4926, 4k77B, 0.7172, 3.23, 0.261, 280, 249, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 6
4927, 4g9cA, 0.7172, 2.82, 0.199, 265, 241, HUMAN B-RAF KINASE DOMAIN BOUND TO A TYPE II PYRAZOLOPYRIDINE INHIBITOR
4928, 4e5wA, 0.7172, 3.21, 0.257, 292, 249, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 26
4929, 3sdjK, 0.7172, 3.27, 0.285, 422, 246, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4930, 3sdjD, 0.7172, 3.26, 0.285, 422, 246, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4931, 3my0N, 0.7172, 3.02, 0.242, 300, 244, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4932, 3fbvM, 0.7172, 3.24, 0.276, 415, 246, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4933, 3fbvK, 0.7172, 3.25, 0.280, 422, 246, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4934, 3fbvA, 0.7172, 3.24, 0.276, 415, 246, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4935, 3ckwA, 0.7172, 2.74, 0.271, 255, 240, CRYSTAL STRUCTURE OF STERILE 20-LIKE KINASE 3 (MST3 STK24)
4936, 2x2lA, 0.7172, 3.36, 0.253, 287, 249, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
4937, 2wmrA, 0.7172, 2.95, 0.289, 254, 242, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4938, 2qhmA, 0.7172, 3.04, 0.263, 268, 243, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 2A
4939, 5wnkA, 0.7171, 2.63, 0.206, 263, 238, CRYSTAL STRUCTURE OF MURINE RECEPTOR-INTERACTING PROTEIN 4 (RIPK4) D143N BOUND TO TG100-115 
4940, 4tyiA, 0.7171, 3.05, 0.244, 277, 246, STRUCTURAL ANALYSIS OF THE HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 4
4941, 4f0iA, 0.7171, 3.09, 0.223, 284, 247, CRYSTAL STRUCTURE OF APO TRKA
4942, 4e4nB, 0.7171, 3.24, 0.261, 280, 249, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 49
4943, 3w2oA, 0.7171, 3.26, 0.191, 305, 251, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH TAK-285
4944, 3sdjN, 0.7171, 3.26, 0.276, 415, 246, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4945, 3sdjM, 0.7171, 3.26, 0.276, 415, 246, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4946, 3sdjG, 0.7171, 3.26, 0.276, 415, 246, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4947, 3sdjF, 0.7171, 3.26, 0.276, 415, 246, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4948, 3sdjB, 0.7171, 3.26, 0.276, 415, 246, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4949, 3sdjA, 0.7171, 3.26, 0.276, 415, 246, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4950, 3fbvL, 0.7171, 3.24, 0.276, 415, 246, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4951, 3fbvH, 0.7171, 3.24, 0.276, 415, 246, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4952, 3fbvG, 0.7171, 3.24, 0.276, 415, 246, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4953, 3fbvE, 0.7171, 3.24, 0.276, 415, 246, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4954, 2brhA, 0.7171, 2.91, 0.277, 257, 242, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
4955, 2b4sB, 0.7171, 3.36, 0.205, 294, 249, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN PTP1B AND THE INSULIN RECEPTOR TYROSINE KINASE
4956, 1pkgB, 0.7171, 2.95, 0.218, 277, 243, STRUCTURE OF A C-KIT KINASE PRODUCT COMPLEX
4957, 6ginB, 0.7170, 3.25, 0.223, 296, 247, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH AN QUINAZOLINONE BASED ALK2 INHIBITOR WITH A 4-MORPHOLINOPHENYL SOLVENT ACCESSIBLE GROUP. 
4958, 4d2pC, 0.7170, 2.80, 0.320, 316, 241, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
4959, 3sdjH, 0.7170, 3.26, 0.276, 415, 246, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4960, 3sdjE, 0.7170, 3.26, 0.276, 415, 246, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4961, 3sdjC, 0.7170, 3.26, 0.276, 415, 246, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4962, 3my0A, 0.7170, 3.03, 0.242, 296, 244, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4963, 3fbvN, 0.7170, 3.25, 0.276, 415, 246, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4964, 3fbvD, 0.7170, 3.25, 0.280, 422, 246, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4965, 3fbvC, 0.7170, 3.24, 0.276, 415, 246, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4966, 3beaA, 0.7170, 3.26, 0.204, 310, 250, CFMS TYROSINE KINASE (TIE2 KID) IN COMPLEX WITH A PYRIMIDINOPYRIDONE INHIBITOR
4967, 1oplB, 0.7170, 3.44, 0.236, 365, 250, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
4968, 5wnmA, 0.7169, 2.71, 0.205, 263, 239, CRYSTAL STRUCTURE OF MURINE RECEPTOR-INTERACTING PROTEIN 4 (RIPK4) D143N BOUND TO TOZASERTIB (VX-680) 
4969, 5flfC, 0.7169, 3.74, 0.241, 283, 253, DISEASE LINKED MUTATION IN FGFR
4970, 5czhA, 0.7169, 3.31, 0.199, 311, 251, EGFR L858R MUTANT IN COMPLEX WITH AN OPTIMAL PEPTIDE SUBSTRATE
4971, 3sdjL, 0.7169, 3.26, 0.276, 415, 246, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4972, 3pxkB, 0.7169, 2.79, 0.241, 258, 241, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH PYRROLO[23- D]THIAZOLE
4973, 3my0V, 0.7169, 2.98, 0.243, 282, 243, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4974, 3mdyC, 0.7169, 3.12, 0.215, 320, 246, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B (BMPR1B) IN COMPLEX WITH FKBP12 AND LDN- 193189
4975, 3h10A, 0.7169, 3.23, 0.306, 268, 248, AURORA A INHIBITOR COMPLEX
4976, 3fbvF, 0.7169, 3.25, 0.276, 415, 246, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4977, 5aaaA, 0.7168, 3.34, 0.192, 294, 250, STRUCTURE OF L1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
4978, 4d2wC, 0.7168, 2.67, 0.328, 313, 238, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
4979, 6gi6A, 0.7167, 3.24, 0.243, 298, 247, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH A QUINAZOLINONE BASED ALK2 INHIBITOR WITH A 5-METHYL CORE. 
4980, 6dd4B, 0.7167, 3.48, 0.161, 309, 254, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A N;N- DIPROPYL-DIHYDROPTERIDINE INHIBITOR 
4981, 5wikB, 0.7167, 3.14, 0.198, 274, 248, JAK2 PSEUDOKINASE IN COMPLEX WITH BI-D1870 
4982, 5c26A, 0.7167, 3.09, 0.199, 272, 246, CRYSTAL STRUCTURE OF SYK IN COMPLEX WITH COMPOUND 1
4983, 4nkaB, 0.7167, 3.47, 0.225, 287, 253, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 2
4984, 4c4iA, 0.7167, 2.56, 0.300, 253, 240, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
4985, 3zfxE, 0.7167, 2.74, 0.220, 262, 241, CRYSTAL STRUCTURE OF EPHB1
4986, 3hmmA, 0.7167, 2.90, 0.207, 293, 241, STRUCTURE OF ALK5 + GW855857
4987, 3bqrA, 0.7167, 2.67, 0.253, 275, 237, CRYSTAL STRUCTURE OF HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3) IN COMPLEX WITH AN IMIDAZO-PYRIDAZINE LIGAND
4988, 3b2tA, 0.7167, 3.32, 0.241, 288, 249, STRUCTURE OF PHOSPHOTRANSFERASE
4989, 2hyyB, 0.7167, 2.99, 0.224, 265, 246, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
4990, 1u54B, 0.7167, 2.82, 0.262, 261, 240, CRYSTAL STRUCTURES OF THE PHOSPHORYLATED AND UNPHOSPHORYLATED KINASE DOMAINS OF THE CDC42-ASSOCIATED TYROSINE KINASE ACK1 BOUND TO AMP-PCP
4991, 1sm2B, 0.7167, 2.54, 0.226, 241, 235, CRYSTAL STRUCTURE OF THE PHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
4992, 5xdlA, 0.7166, 3.11, 0.195, 292, 246, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH CO-1686
4993, 5t3qA, 0.7166, 2.85, 0.216, 278, 241, CRYSTAL STRUCTURE OF THE C-MET KINASE DOMAIN IN COMPLEX WITH A PYRAZOLONE INHIBITOR
4994, 4x3fC, 0.7166, 2.56, 0.279, 273, 240, CRYSTAL STRUCTURE OF THE INTRACELLULAR DOMAIN OF THE M. TUBERCULOSIS SER/THR KINASE PKNA
4995, 4i1zA, 0.7166, 3.13, 0.202, 287, 248, CRYSTAL STRUCTURE OF THE MONOMERIC (V948R) FORM OF THE GEFITINIB/ERLOTINIB RESISTANT EGFR KINASE DOMAIN L858R+T790M
4996, 4d2tD, 0.7166, 3.00, 0.321, 319, 243, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
4997, 4bggD, 0.7166, 2.93, 0.245, 286, 241, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
4998, 3en5B, 0.7166, 2.64, 0.248, 261, 238, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP494 A MULTITARGETED KINASE INHIBITOR
4999, 3clyA, 0.7166, 3.42, 0.244, 289, 250, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAINS TRAPPED IN TRANS-PHOSPHORYLATION REACTION
5000, 2vwiC, 0.7166, 2.65, 0.263, 270, 236, STRUCTURE OF THE OSR1 KINASE A HYPERTENSION DRUG TARGET
